



(86) Date de dépôt PCT/PCT Filing Date: 2011/04/08
(87) Date publication PCT/PCT Publication Date: 2011/10/20
(85) Entrée phase nationale/National Entry: 2012/10/10
(86) N° demande PCT/PCT Application No.: CA 2011/000394
(87) N° publication PCT/PCT Publication No.: 2011/127567
(30) Priorité/Priority: 2010/04/16 (US61/324,803)

(51) Cl.Int./Int.Cl. *C07D 495/04* (2006.01),
A61K 31/444 (2006.01), *A61P 27/02* (2006.01),
A61P 35/00 (2006.01)



(71) Demandeur/Applicant:
METHYLGENE INC., CA

(72) Inventeurs/Inventors:
RAEPEL, STEPHANE, CA;
RAEPEL, FRANCK, CA;
CLARIDGE, STEPHEN WILLIAM, CA;
ZHAN, LIJIE, CA;
GAUDETTE, FREDERIC, CA;
MANNION, MICHAEL, CA;
...

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : INHIBITEURS DE L'ACTIVITE PROTEINE TYROSINE KINASE

(54) Title: INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY



(57) Abrégé/Abstract:

Compounds that inhibit protein tyrosine kinase activity are disclosed, preferably of Formulae (II) and (III). In particular, said compounds inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides said compounds, compositions thereof and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.



(72) Inventeurs(suite)/Inventors(continued): SATO, NORIFUMI, JP; YUKI, YOHEI, JP; KISHIDA, MASASHI, JP;
VAISBURG, ARKADII, CA

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 October 2011 (20.10.2011)(10) International Publication Number
WO 2011/127567 A1

(51) International Patent Classification:

C07D 495/04 (2006.01) A61P 27/02 (2006.01)
A61K 31/444 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CA2011/000394

(22) International Filing Date:

8 April 2011 (08.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/324,803 16 April 2010 (16.04.2010) US

(71) Applicant (for all designated States except US):
METHYLGENE INC. [CA/CA]; 7210 Frederick-Banting,
Montréal, Québec H4S 2A1 (CA).



(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAEPPÉL, Stéphane** [CA/CA]; 2620 rue de l'Étrier, St. Lazare,
Québec J7T 3L8 (CA). **RAEPPÉL, Franck** [CA/CA]; 3194 rue Claude Jodoin, Montréal, Québec H1Y 3M2
(CA). **CLARIDGE, Stephen William** [CA/CA]; 443 Notre Dame East, Apt. 2, Montréal, Québec H2Y 1C9
(CA). **ZHAN, Lijie** [CA/CA]; 2540 Boulevard de la Côte Vertu, Montréal, Québec H4R 1P5 (CA). **GAUDETTE, Frédéric** [CA/CA]; 1683 rue Malherbe, Sherbrooke,
Québec J1N 0R1 (CA). **MANNION, Michael** [CA/CA]; 74 rue St. Cuthbert, Montréal, Québec H2W 1L5 (CA). **SATO, Norifumi** [JP/JP]; c/o Otsuka Pharmaceutical
Co., Ltd., 1-7-1 Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **YUKI, Yohei** [JP/JP]; c/o Otsuka Pharmaceutical
Co., Ltd., 1-7-1 Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).ka-shi, Osaka 541-0045 (JP). **KISHIDA, Masashi**
[JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1
Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).
VAISBURG, Arkadii [CA/CA]; 10 Riverwood Grove,
Kirkland, Québec H9J 2X2 (CA).(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.**; 40th floor, 40 King Street West, Toronto, Ontario
M5H 3Y2 (CA).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY



(57) Abstract: Compounds that inhibit protein tyrosine kinase activity are disclosed, preferably of Formulae (II) and (III). In particular, said compounds inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides said compounds, compositions thereof and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 307

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 307

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY**BACKGROUND OF THE INVENTION****Related Application**

5 This application claims the benefit of U.S. Provisional Application Serial Number 61/324,803, filed April 16, 2010. The entire teachings of the above-referenced application are incorporated herein by reference.

Field of the Invention

10 This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling.

15 Summary of the Related Art

 Tyrosine kinases may be classified as growth factor receptor (e.g. EGFR, PDGFR, FGFR and erbB2) or non-receptor (e.g. c-src and bcr-abl) kinases. The receptor type tyrosine kinases make up about 20 different subfamilies. The non-receptor type tyrosine kinases make up numerous subfamilies. These tyrosine kinases have diverse biological activity. Receptor
20 tyrosine kinases are large enzymes that span the cell membrane and possess an extracellular binding domain for growth factors, a transmembrane domain, and an intracellular portion that functions as a kinase to phosphorylate a specific tyrosine residue in proteins and hence to influence cell proliferation. Aberrant or inappropriate protein kinase activity can contribute to the rise of disease states associated with such aberrant kinase activity.

25 Angiogenesis is an important component of certain normal physiological processes such as embryogenesis and wound healing, but aberrant angiogenesis contributes to some pathological disorders and in particular to tumor growth. VEGF-A (vascular endothelial growth factor A) is a key factor promoting neovascularization (angiogenesis) of tumors. VEGF induces endothelial cell proliferation and migration by signaling through two high affinity
30 receptors, the fms-like tyrosine kinase receptor, Flt-1, and the kinase insert domain-containing receptor, KDR. These signaling responses are critically dependent upon receptor dimerization and activation of intrinsic receptor tyrosine kinase (RTK) activity. The binding of VEGF as a disulfide-linked homodimer stimulates receptor dimerization and activation of the RTK domain. The kinase autophosphorylates cytoplasmic receptor tyrosine residues, which then serve as
35 binding sites for molecules involved in the propagation of a signaling cascade. Although

multiple pathways are likely to be elucidated for both receptors, KDR signaling is most extensively studied, with a mitogenic response suggested to involve ERK-1 and ERK-2 mitogen-activated protein kinases.

Disruption of VEGF receptor signaling is a highly attractive therapeutic target in cancer,
5 as angiogenesis is a prerequisite for all solid tumor growth, and that the mature endothelium remains relatively quiescent (with the exception of the female reproductive system and wound healing). A number of experimental approaches to inhibiting VEGF signaling have been examined, including use of neutralizing antibodies, receptor antagonists, soluble receptors, antisense constructs and dominant-negative strategies.

10 Despite the attractiveness of anti-angiogenic therapy by VEGF inhibition alone, several issues may limit this approach. VEGF expression levels can themselves be elevated by numerous diverse stimuli and perhaps most importantly, the hypoxic state of tumors resulting from VEGFr inhibition, can lead to the induction of factors that themselves promote tumor invasion and metastasis thus, potentially undermining the impact of VEGF inhibitors as cancer
15 therapeutics.

The HGF (hepatocyte growth factor) and the HGF receptor, c-met, are implicated in the ability of tumor cells to undermine the activity of VEGF inhibition. HGF derived from either stromal fibroblasts surrounding tumor cells or expressed from the tumor itself has been suggested to play a critical role in tumor angiogenesis, invasion and metastasis. For example,
20 invasive growth of certain cancer cells is drastically enhanced by tumor-stromal interactions involving the HGF/c-Met (HGF receptor) pathway. HGF, which was originally identified as a potent mitogen for hepatocytes is primarily secreted from stromal cells, and the secreted HGF can promote motility and invasion of various cancer cells that express c-Met in a paracrine manner. Binding of HGF to c-Met leads to receptor phosphorylation and activation of
25 Ras/mitogen-activated protein kinase (MAPK) signaling pathway, thereby enhancing malignant behaviors of cancer cells. Moreover, stimulation of the HGF/c-met pathway itself can lead to the induction of VEGF expression, itself contributing directly to angiogenic activity.

Thus, anti-tumor anti-angiogenic strategies or approaches that target VEGF/VEGFr signaling or HGF/c-met signaling may represent improved cancer therapeutics.

30 Tyrosine kinases also contribute to the pathology of ophthalmic diseases, disorders and conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). Blindness from such diseases has been linked to anomalies in retinal neovascularization. The formation of new blood vessels is regulated by growth factors such as VEGF and HGF that activate receptor tyrosine kinases resulting in the initiation of signaling pathways leading to

plasma leakage into the macula, causing vision loss. Kinases are thus attractive targets for the treatment of eye diseases involving neovascularization.


Thus, there is a need to develop a strategy for controlling neovascularization of the eye and to develop a strategy for the treatment of ocular diseases.

5 Here we describe small molecules that are potent inhibitors of protein tyrosine kinase activity.

BRIEF SUMMARY OF THE INVENTION

The present invention provides new compounds and methods for treating a disease
 10 responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. In some embodiments the disease is a cell proliferative
 15 disease. In other embodiments, the disease is an ophthalmic disease. The compounds of the invention are inhibitors of kinase activity, such as protein tyrosine kinase activity, for example protein tyrosine kinase activity of growth factor receptors, or for example receptor type tyrosine kinase signaling.

In a first aspect, the invention provides compounds of Formula (I) that are useful as
 20 kinase inhibitors:



and N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein D, M, Z, Ar and G are as defined herein. Because compounds of the present invention
 25 are useful as kinase inhibitors they are, therefore, useful research tools for the study of the role of kinases in both normal and disease states. In some embodiments, the invention provides compounds that are useful as inhibitors of VEGF receptor signaling and, therefore, are useful research tools for the study of the role of VEGF in both normal and disease states.

In a second aspect, the invention provides compositions comprising a compound
 30 according to the present invention and a pharmaceutically acceptable carrier, excipient or diluent. For example, the invention provides compositions comprising a compound that is an

inhibitor of VEGF receptor signaling, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

In a third aspect, the invention provides a method of inhibiting kinase activity, for example protein tyrosine kinase, for example tyrosine kinase activity of a growth factor receptor, the method comprising contacting the kinase with a compound according to the present invention, or with a composition according to the present invention. In some embodiments of this aspect, the invention provides a method of inhibiting receptor type tyrosine kinase signaling, for example inhibiting VEGF receptor signaling. Inhibition can be in a cell or a multicellular organism. If in a cell, the method according to this aspect of the invention comprises contacting the cell with a compound according to the present invention, or with a composition according to the present invention. If in a multicellular organism, the method according to this aspect of the invention comprises administering to the organism a compound according to the present invention, or a composition according to the present invention. In some embodiments the organism is a mammal, for example a primate, for example a human.

In a fourth aspect, the invention provides a method of inhibiting angiogenesis, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount of a composition according to the present invention. In some embodiments of this aspect, the angiogenesis to be inhibited is involved in tumor growth. In some other embodiments the angiogenesis to be inhibited is retinal angiogenesis. In some embodiments of this aspect, the patient is a mammal, for example a primate, for example a human.

In a fifth aspect, the invention provides a method of treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the invention provides a method of treating a disease responsive to inhibition of receptor type tyrosine kinase signaling, for example a disease responsive to inhibition of VEGF receptor signaling, the method comprising administering to an organism in need thereof a therapeutically effective amount of a compound according to the present invention, or a composition according to the present invention. In some embodiments of this aspect, the organism is a mammal, for example a primate, for example a human.

In a sixth aspect, the invention provides a method of treating a cell proliferative disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount

of a composition according to the present invention. In some embodiments of this aspect, the cell proliferative disease is cancer. In some embodiments, the patient is a mammal, for example a primate, for example a human.

5 In a seventh aspect, the invention provides a method of treating an ophthalmic disease, disorder or condition, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount of a composition according to the present invention. In some embodiments of this aspect, the disease is caused by choroidal angiogenesis. In some
10 embodiments of this aspect, the patient is a mammal, for example a primate, for example a human.

In an eighth aspect, the invention provides for the use of a compound according to the present invention for or in the manufacture of a medicament to inhibit kinase activity, for example to inhibit protein tyrosine kinase activity, for example to inhibit protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the invention
15 provides for the use of a compound according to the present invention for or in the manufacture of a medicament to inhibit receptor type tyrosine kinase signaling, for example to inhibit VEGF receptor signaling. In some embodiments of this aspect, the invention provides for the use of a compound according to the present invention for or in the manufacture of a medicament to treat a disease responsive to inhibition of kinase activity. In some embodiments of this aspect, the
20 disease is responsive to inhibition of protein tyrosine kinase activity, for example inhibition of protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the disease is responsive to inhibition of receptor type tyrosine kinase signaling, for example VEGF receptor signaling. In some embodiments of this aspect, the disease is a cell proliferative disease, for example cancer. In some embodiments of this aspect, the disease is an
25 ophthalmic disease, disorder or condition. In some embodiments of this aspect, the ophthalmic disease, disorder or condition is caused by choroidal angiogenesis. In some embodiments of this aspect, the disease is age-related macular degeneration, diabetic retinopathy or retinal edema.

In a ninth aspect, the invention provides for the use of a compound according to the
30 present invention, or a composition thereof, to inhibit kinase activity, for example to inhibit receptor type tyrosine kinase activity, for example to inhibit protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the invention provides for the use of a compound according to the present invention, or a composition thereof, to inhibit receptor type tyrosine kinase signaling, for example to inhibit VEGF receptor signaling.

In a tenth aspect, the invention provides for the use of a compound according to the present invention, or a composition thereof, to treat a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor
5 receptors. In some embodiments of this aspect, the invention provides for the use of a compound according to the present invention, or a composition thereof, to treat a disease responsive to inhibition of receptor type tyrosine kinase signaling, for example a disease responsive to inhibition of VEGF receptor signaling. In some embodiments of this aspect, the disease is a cell proliferative disease, for example cancer. In some embodiments of this aspect,
10 the disease is an ophthalmic disease, disorder or condition. In some embodiments of this aspect, the ophthalmic disease, disorder or condition is caused by choroidal angiogenesis.

The foregoing merely summarizes some aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below.

15

DETAILED DESCRIPTION

The invention provides compounds, compositions and methods for inhibiting kinase activity, for example protein tyrosine kinase activity, for example receptor protein kinase activity, for example the VEGF receptor KDR. The invention also provides compounds,
20 compositions and methods for inhibiting angiogenesis, treating a disease responsive to inhibition of kinase activity, treating cell proliferative diseases and conditions and treating ophthalmic diseases, disorders and conditions. The patent and scientific literature referred to herein reflects knowledge that is available to those with skill in the art. The issued patents, published patent applications, and references that are cited herein are hereby incorporated by
25 reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of inconsistencies, the present disclosure will prevail.

For purposes of the present invention, the following definitions will be used (unless expressly stated otherwise):

For simplicity, chemical moieties are defined and referred to throughout primarily as
30 univalent chemical moieties (*e.g.*, alkyl, aryl, etc.). Nevertheless, such terms are also used to convey corresponding multivalent moieties under the appropriate structural circumstances clear to those skilled in the art. For example, while an “alkyl” moiety generally refers to a monovalent radical (*e.g.* CH₃-CH₂-), in certain circumstances a bivalent linking moiety can be “alkyl,” in which case those skilled in the art will understand the alkyl to be a divalent radical
35 (*e.g.*, -CH₂-CH₂-), which is equivalent to the term “alkylene.” Similarly, in circumstances in

which a divalent moiety is required and is stated as being “aryl,” those skilled in the art will understand that the term “aryl” refers to the corresponding divalent moiety, arylene. All atoms are understood to have their normal number of valences for bond formation (*i.e.*, 4 for carbon, 3 for nitrogen, 2 for oxygen, and 2, 4, or 6 for sulfur, depending on the oxidation state of the S).

5 On occasion a moiety may be defined, for example, as $(A)_a-B-$, wherein a is 0 or 1. In such instances, when a is 0 the moiety is $B-$ and when a is 1 the moiety is $A-B-$.

For simplicity, reference to a “ C_n-C_m ”heterocyclyl or “ C_n-C_m ”heteroaryl means a heterocyclyl or heteroaryl having from “ n ” to “ m ” annular atoms, where “ n ” and “ m ” are integers. Thus, for example, a C_5-C_6 heterocyclyl is a 5- or 6-membered ring having at least one
10 heteroatom, and includes pyrrolidinyl (C_5) and piperazinyl and piperidinyl (C_6); C_6 heteroaryl includes, for example, pyridyl and pyrimidyl.

The term “hydrocarbyl” refers to a straight, branched, or cyclic alkyl, alkenyl, or alkynyl, each as defined herein. A “ C_0 ” hydrocarbyl is used to refer to a covalent bond. Thus, “ C_0-C_3 hydrocarbyl” includes a covalent bond, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl,
15 propynyl, and cyclopropyl.

The term “alkyl” is intended to mean a straight chain or branched aliphatic group having from 1 to 12 carbon atoms, alternatively 1-8 carbon atoms, and alternatively 1-6 carbon atoms. In some embodiments, the alkyl group has 1-4 carbon atoms. In some embodiments, the alkyl groups have from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms and alternatively 2-6
20 carbon atoms. In some embodiments, the alkyl group has 2-4 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like. A “ C_0 ” alkyl (as in “ C_0-C_3 alkyl”) is a covalent bond.

The term “alkenyl” is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon double bonds, having from 2 to 12 carbon
25 atoms, alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms. In some embodiments, the alkenyl group has 2-4 carbon atoms. Examples alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

The term “alkynyl” is intended to mean an unsaturated straight chain or branched aliphatic group with one or more carbon-carbon triple bonds, having from 2 to 12 carbon atoms,
30 alternatively 2-8 carbon atoms, and alternatively 2-6 carbon atoms. In some embodiments, the alkynyl group has 2-4 carbon atoms. Examples of alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

The terms “alkylene,” “alkenylene,” or “alkynylene” as used herein are intended to mean an alkyl, alkenyl, or alkynyl group, respectively, as defined hereinabove, that is positioned
35 between and serves to connect two other chemical groups. Examples of alkylene groups

include, without limitation, methylene, ethylene, propylene, and butylene. Examples of alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene. Examples of alkynylene groups include, without limitation, ethynylene, propynylene, and butynylene.

5 The term “carbocycle” as employed herein is intended to mean a cycloalkyl or aryl moiety.

10 The term “cycloalkyl” is intended to mean a saturated, partially unsaturated or unsaturated mono-, bi-, tri- or poly-cyclic hydrocarbon group having about 3 to 15 carbons, alternatively having 3 to 12 carbons, alternatively 3 to 8 carbons, alternatively 3 to 6 carbons, and alternatively 5 or 6 carbons. In some embodiments, the cycloalkyl group is fused to an aryl, heteroaryl or heterocyclic group. Examples of cycloalkyl groups include, without limitation, cyclopenten-2-enone, cyclopenten-2-enol, cyclohex-2-enone, cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, etc.

15 The term “heteroalkyl” is intended to mean a saturated, partially unsaturated or unsaturated, straight chain or branched aliphatic group, wherein one or more carbon atoms in the group are independently replaced by a heteroatom selected from the group consisting of O, S, and N.

20 The term “aryl” is intended to mean a mono-, bi-, tri- or polycyclic aromatic moiety, comprising one to three aromatic rings. In some embodiments the aryl is a C₆-C₁₄aromatic moiety, alternatively the aryl group is a C₆-C₁₀aryl group, alternatively a C₆ aryl group. Examples of aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl.

25 The terms “aralkyl” or “arylalkyl” are intended to mean a group comprising an aryl group covalently linked to an alkyl group. If an aralkyl group is described as “optionally substituted”, it is intended that either or both of the aryl and alkyl moieties may independently be optionally substituted or unsubstituted. In some embodiments, the aralkyl group is (C₁-C₆)alk(C₆-C₁₀)aryl, including, without limitation, benzyl, phenethyl, and naphthylmethyl. For simplicity, when written as “arylalkyl” this term, and terms related thereto, is intended to indicate the order of groups in a compound as “aryl-alkyl”. Similarly, “alkyl-aryl” is intended to indicate the order of the groups in a compound as “alkyl-aryl”.

30 The terms “heterocyclyl”, “heterocyclic” or “heterocycle” are intended to mean a group which is a mono-, bi-, or polycyclic structure having from about 3 to about 14 atoms, alternatively 3 to 8 atoms, alternatively 4 to 7 atoms, alternatively 5 or 6 atoms wherein one or more atoms, for example 1 or 2 atoms, are independently selected from the group consisting of

N, O, and S, the remaining ring-constituting atoms being carbon atoms. The ring structure may be saturated, unsaturated or partially unsaturated. In some embodiments, the heterocyclic group is non-aromatic, in which case the group is also known as a heterocycloalkyl. In some embodiments the heterocyclyl is a spiro-heterocyclyl, such as 2,7-diazaspiro[4.4]nonane, 2,8-diazaspiro[5.5]undecane, 2,8-diazaspiro[4.5]decane, 2,7-diazaspiro[3.5]nonane, 2,6-diazaspiro[3.4]octane, 2-oxa-7-azaspiro[4.4]nonane, 2-oxa-8-azaspiro[5.5]undecane, 8-oxa-2-azaspiro[4.5]decane, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 1-oxa-7-azaspiro[4.4]nonane, 2-oxa-8-azaspiro[5.5]undecane, 2-oxa-8-azaspiro[4.5]decane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.4]octane. In a bicyclic or polycyclic structure, one or more rings may be aromatic; for example, one ring of a bicyclic heterocycle or one or two rings of a tricyclic heterocycle may be aromatic, as in indan and 9,10-dihydro anthracene. Examples of heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, morpholino, thienyl, pyridyl, 1,2,3-triazolyl, imidazolyl, isoxazolyl, pyrazolyl, piperazino, piperidyl, piperidino, morpholinyl, homopiperazinyl, homopiperazino, thiomorpholinyl, thiomorpholino, tetrahydropyrrolyl, and azepanyl. In some embodiments, the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the scope of this term are compounds where an annular O or S atom is adjacent to another O or S atom.

In some embodiments, the heterocyclic group is a heteroaryl group. As used herein, the term "heteroaryl" is intended to mean a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; having for example 6, 10, or 14 pi electrons shared in a cyclic array; and having, in addition to carbon atoms, between one or more heteroatoms independently selected from the group consisting of N, O, and S. For example, a heteroaryl group includes, without limitation, pyrimidinyl, pyridinyl, benzimidazolyl, thienyl, benzothiazolyl, benzofuranyl and indolinyl. Other examples of heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl, and isoxazolyl.

The terms "arylene," "heteroarylene," or "heterocyclylene" are intended to mean an aryl, heteroaryl, or heterocyclyl group, respectively, as defined hereinabove, that is positioned between and serves to connect two other chemical groups.

Examples of heterocyclyls and heteroaryls include, but are not limited to, azepinyl, azetidiny, acridinyl, azocinyl, benzidolyl, benzimidazolyl, benzofuranyl, benzofurazanyl,

benzofuryl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzothienyl,
 benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, benzoxazolyl,
 benzoxadiazolyl, benzopyranyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl,
 cinnolinyl, coumarinyl, decahydroquinolinyl, 1,3-dioxolane, 2H,6H-1,5,2-dithiazinyl,
 5 dihydrofuro[2,3-b]tetrahydrofuran, dihydroisoindolyl, dihydroquinazolyl (such as 3,4-
 dihydro-4-oxo-quinazolyl), furanyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-
 b]pyridinyl or furo[2,3-b]pyridinyl), furyl, furazanyl, hexahydrodiazepinyl, imidazolidinyl,
 imidazolyl, indazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-
 indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl,
 10 isothiazolidinyl, isothiazolyl, isoxazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl,
 naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, oxetanyl, 2-
 oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodiny, pyrimidinyl,
 phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl,
 15 phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl,
 pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
 pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl,
 pyrrolopyridyl, 2H-pyrrolyl, pyrrolyl, quinazolyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,
 quinuclidinyl, tetrahydro-1,1-dioxothienyl, tetrahydrofuranyl, tetrahydrofuryl,
 20 tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydropyranyl, tetrazolyl, thiazolidinyl, 6H-
 1,2,5-thiadiazinyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,
 1,3,4-thiadiazolyl), thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholuiyl sulfone,
 thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl,
 triazinyl, triazinylazepinyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-
 25 triazolyl), and xanthenyl.

The term “azolyl” as employed herein is intended to mean a five-membered saturated or
 unsaturated heterocyclic group containing two or more hetero-atoms, as ring atoms, selected
 from the group consisting of nitrogen, sulfur and oxygen, wherein at least one of the hetero-
 atoms is a nitrogen atom. Examples of azolyl groups include, but are not limited to, optionally
 30 substituted imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-
 thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, and 1,3,4-oxadiazolyl.

As employed herein, and unless stated otherwise, when a moiety (*e.g.*, alkyl, heteroalkyl,
 cycloalkyl, aryl, heteroaryl, heterocyclyl, etc.) is described as “optionally substituted” it is
 meant that the group optionally has from one to four, alternatively from one to three,
 35 alternatively one or two, independently selected non-hydrogen substituents. Suitable

substituents include, without limitation, halo, hydroxy, oxo (*e.g.*, an annular -CH- substituted with oxo is -C(O)-) nitro, halohydrocarbyl, hydrocarbyl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups.

Examples of substituents, which are themselves not further substituted (unless expressly stated otherwise) are:

- (a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino,
- (b) C₁-C₅alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C₁-C₈alkyl, C₂-C₈alkenyl, C₁-C₈alkoxy, C₁-C₈alkylamino, C₁-C₈alkoxycarbonyl, aryloxycarbonyl, C₂-C₈acyl, C₂-C₈acylamino, C₁-C₈alkylthio, arylalkylthio, arylthio, C₁-C₈alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C₁-C₈alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C₀-C₆N-alkyl carbamoyl, C₂-C₁₅N,N-dialkylcarbamoyl, C₃-C₇ cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C₃-C₇heterocycle, C₅-C₁₅heteroaryl or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; and

- (c) $-(CR^{32}R^{33})_s-NR^{30}R^{31}$,

wherein s is from 0 (in which case the nitrogen is directly bonded to the moiety that is substituted) to 6,

R³² and R³³ are each independently hydrogen, halo, hydroxyl or C₁-C₄alkyl, and

R³⁰ and R³¹ are each independently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl,

C₁-C₈heteroalkyl, C₂-C₈alkenyl, carboxamido, C₁-C₃alkyl-carboxamido,

carboxamido-C₁-C₃alkyl, amidino, C₂-C₈hydroxyalkyl, C₁-C₃alkylaryl, aryl-

C₁-C₃alkyl, C₁-C₃alkylheteroaryl, heteroaryl-C₁-C₃alkyl, C₁-

C₃alkylheterocyclyl, heterocyclyl-C₁-C₃alkyl C₁-C₃alkylcycloalkyl,

cycloalkyl-C₁-C₃alkyl, C₂-C₈alkoxy, C₂-C₈alkoxy-C₁-C₄alkyl, C₁-

C₈alkoxycarbonyl, aryloxycarbonyl, aryl-C₁-C₃alkoxycarbonyl,

heteroaryloxycarbonyl, heteroaryl-C₁-C₃alkoxycarbonyl, C₁-C₈acyl, C₀-

C₈alkyl-carbonyl, aryl-C₀-C₈alkyl-carbonyl, heteroaryl-C₀-C₈alkyl-carbonyl,

cycloalkyl-C₀-C₈alkyl-carbonyl, C₀-C₈alkyl-NH-carbonyl, aryl-C₀-C₈alkyl-

NH-carbonyl, heteroaryl-C₀-C₈alkyl-NH-carbonyl, cycloalkyl-C₀-C₈alkyl-

NH-carbonyl, C₀-C₈alkyl-O-carbonyl, aryl-C₀-C₈alkyl-O-carbonyl,

heteroaryl-C₀-C₈alkyl-O-carbonyl, cycloalkyl-C₀-C₈alkyl-O-carbonyl, C₁-C₈alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, heteroarylalkylsulfonyl, heteroarylsulfonyl, C₁-C₈alkyl-NH-sulfonyl, arylalkyl-NH-sulfonyl, aryl-NH-sulfonyl, heteroarylalkyl-NH-sulfonyl, heteroaryl-NH-sulfonyl aroyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; or

R³⁰ and R³¹ taken together with the N to which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with from 1 to 3 substituents selected from the group consisting of (a) above, a protecting group, and (X³⁰-Y³¹-), wherein said heterocyclyl may also be bridged (forming a bicyclic moiety with a methylene, ethylene or propylene bridge); wherein

X³⁰ is selected from the group consisting of C₁-C₈alkyl, C₂-C₈alkenyl-, C₂-C₈alkynyl-, -C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl, C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl, C₀-C₃alkyl-O-C₀-C₃alkyl-, HO-C₀-C₃alkyl-, C₀-C₄alkyl-N(R³⁰)-C₀-C₃alkyl-, N(R³⁰)(R³¹)-C₀-C₃alkyl-, N(R³⁰)(R³¹)-C₀-C₃alkenyl-, N(R³⁰)(R³¹)-C₀-C₃alkynyl-, (N(R³⁰)(R³¹))₂-C=N-, C₀-C₃alkyl-S(O)₀₋₂-C₀-C₃alkyl-, CF₃-C₀-C₃alkyl-, C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, wherein the aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted with from 1 to 3 substituents from (a); and

Y³¹ is selected from the group consisting of a direct bond, -O-, -N(R³⁰)-, -C(O)-, -O-C(O)-, -C(O)-O-, -N(R³⁰)-C(O)-, -C(O)-N(R³⁰)-, -N(R³⁰)-C(S)-, -C(S)-N(R³⁰)-, -N(R³⁰)-C(O)-N(R³¹)-, -N(R³⁰)-C(NR³⁰)-N(R³¹)-, -N(R³⁰)-C(NR³¹)-, -C(NR³¹)-N(R³⁰)-, -N(R³⁰)-C(S)-N(R³¹)-, -N(R³⁰)-C(O)-O-, -O-C(O)-N(R³¹)-, -N(R³⁰)-C(S)-O-, -O-C(S)-N(R³¹)-, -S(O)₀₋₂-, -SO₂N(R³¹)-, -N(R³¹)-SO₂- and -N(R³⁰)-SO₂N(R³¹)-.

A moiety that is substituted is one in which one or more (for example one to four, alternatively from one to three and alternatively one or two), hydrogens have been independently replaced with another chemical substituent. As a non-limiting example, substituted phenyls include 2-fluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-fluoro-3-propylphenyl. As another non-limiting example, substituted n-octyls include 2,4-

dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. Included within this definition are methylenes (-CH₂-) substituted with oxygen to form carbonyl (-CO-).

When there are two optional substituents bonded to adjacent atoms of a ring structure, such as for example a phenyl, thiophenyl, or pyridinyl, the substituents, together with the atoms to which they are bonded, optionally form a 5- or 6- membered cycloalkyl or heterocycle having 1, 2, or 3 annular heteroatoms.

In some embodiments, a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group is unsubstituted.

In some embodiments, a hydrocarbyl, heteroalkyl, heterocyclic and/or aryl group is substituted with from 1 to 3 independently selected substituents.

Examples of substituents on alkyl groups include, but are not limited to, hydroxyl, halogen (e.g., a single halogen substituent or multiple halo substituents; in the latter case, groups such as CF₃ or an alkyl group bearing Cl₃), oxo, cyano, nitro, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, -OR^a, -SR^a, -S(=O)R^e, -S(=O)₂R^e, -P(=O)₂R^e, -S(=O)₂OR^e, -P(=O)₂OR^e, -NR^bR^c, -NR^bS(=O)₂R^e, -NR^bP(=O)₂R^e, -S(=O)₂NR^bR^c, -P(=O)₂NR^bR^c, -C(=O)OR^e, -C(=O)R^a, -C(=O)NR^bR^c, -OC(=O)R^a, -OC(=O)NR^bR^c, -NR^bC(=O)OR^e, -NR^dC(=O)NR^bR^c, -NR^dS(=O)₂NR^bR^c, -NR^dP(=O)₂NR^bR^c, -NR^bC(=O)R^a or -NR^bP(=O)₂R^e, wherein R^a is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl; R^b, R^c and R^d are independently hydrogen, alkyl, cycloalkyl, heterocycle or aryl, or said R^b and R^c together with the N to which they are bonded optionally form a heterocycle; and R^e is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl. In the aforementioned exemplary substituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.

Examples of substituents on alkenyl and alkynyl groups include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents.

Examples of substituents on cycloalkyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents. Other examples of substituents include, but are not limited to, spiro-attached or fused cyclic substituents, for example, spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.

Examples of substituents on cycloalkenyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited as examples of alkyl substituents. Other examples of substituents include, but are not limited to, spiro-attached or

fused cyclic substituents, for examples spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.

5 Examples of substituents on aryl groups include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as those groups recited above as examples of alkyl substituents. Other examples of substituents include, but are not limited to, fused cyclic groups, such as fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted. Still other examples of substituents on aryl groups (phenyl, as a non-limiting example) include, but are not limited to, haloalkyl and those groups recited as examples of alkyl substituents.

15 Examples of substituents on heterocyclic groups include, but are not limited to, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, nitro, oxo (i.e., =O), cyano, alkyl, substituted alkyl, as well as those groups recited as examples of alkyl substituents. Other examples of substituents on heterocyclic groups include, but are not limited to, spiro-attached or fused cyclic substituents at any available point or points of attachment, for example spiro-attached cycloalkyl, spiro-attached cycloalkenyl, spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle and fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents can themselves be optionally substituted.

20 In some embodiments, a heterocyclic group is substituted on carbon, nitrogen and/or sulfur at one or more positions. Examples of substituents on nitrogen include, but are not limited to alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxy carbonyl, or aralkoxy carbonyl. Examples of substituents on sulfur include, but are not limited to, oxo and C₁₋₆alkyl. In some embodiments, nitrogen and sulfur heteroatoms may independently be optionally oxidized and nitrogen heteroatoms may independently be optionally quaternized.

30 In some embodiments, substituents on ring groups, such as aryl, heteroaryl, cycloalkyl and heterocyclyl, include halogen, alkoxy and/or alkyl.

 In some embodiments, substituents on alkyl groups include halogen and/or hydroxy.

 A "halohydrocarbyl" as employed herein is a hydrocarbyl moiety, in which from one to all hydrogens have been replaced with halo.


35 The term "halogen" or "halo" as employed herein refers to chlorine, bromine, fluorine, or iodine. As herein employed, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl

substituent. The term "acylamino" refers to an amide group attached at the nitrogen atom (*i.e.*, R-CO-NH-). The term "carbamoyl" refers to an amide group attached at the carbonyl carbon atom (*i.e.*, NH₂-CO-). The nitrogen atom of an acylamino or carbamoyl substituent is additionally optionally substituted. The term "sulfonamido" refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom. The term "amino" is meant to include NH₂, alkylamino, dialkylamino (wherein each alkyl may be the same or different), arylamino, and cyclic amino groups. The term "ureido" as employed herein refers to a substituted or unsubstituted urea moiety.

The term "radical" as used herein means a chemical moiety comprising one or more unpaired electrons.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from within one of the specified groups or from within the combination of all of the specified groups.

In addition, substituents on cyclic moieties (*i.e.*, cycloalkyl, heterocyclyl, aryl, heteroaryl) include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system. Substituents on cyclic moieties also include 5- to 6-membered mono- and 9- to 14-membered bi-cyclic moieties attached to the parent cyclic moiety by a covalent bond to form a bi- or tri-cyclic bi-ring system. For example, an optionally substituted phenyl includes, but is not limited to, the following:



An "unsubstituted" moiety (*e.g.*, unsubstituted cycloalkyl, unsubstituted heteroaryl, etc.) means a moiety as defined above that does not have any optional substituents.

A saturated, partially unsaturated or unsaturated three- to eight-membered carbocyclic ring is for example a four- to seven-membered, alternatively a five- or six-membered, saturated or unsaturated carbocyclic ring. Examples of saturated or unsaturated three- to eight-membered carbocyclic rings include phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

A saturated or unsaturated carbocyclic and heterocyclic group may condense with another saturated or heterocyclic group to form a bicyclic group, for example a saturated or unsaturated nine- to twelve-membered bicyclic carbocyclic or heterocyclic group. Bicyclic groups include naphthyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, 1,4-benzoxanyl, indanyl, indolyl, and 1,2,3,4-tetrahydronaphthyl.

When a carbocyclic or heterocyclic group is substituted by two C₁-C₆alkyl groups, the two alkyl groups may combine together to form an alkylene chain, for example a C₁-C₃alkylene chain. Carbocyclic or heterocyclic groups having this crosslinked structure include bicyclo[2.2.2]octanyl and norbornanyl.

5 The terms "kinase inhibitor" and "inhibitor of kinase activity", and the like, are used to identify a compound which is capable of interacting with a kinase and inhibiting its enzymatic activity.

 The term "inhibiting kinase enzymatic activity" and the like is used to mean reducing the ability of a kinase to transfer a phosphate group from a donor molecule, such as ATP, to a
10 specific target molecule (substrate). For example, the inhibition of kinase activity may be at least about 10%. In some embodiments of the invention, such reduction of kinase activity is at least about 25%, alternatively at least about 50%, alternatively at least about 75%, and alternatively at least about 90%. In other embodiments, kinase activity is reduced by at least 95% and alternatively by at least 99%. The IC₅₀ value is the concentration of kinase inhibitor
15 which reduces the activity of a kinase to 50% of the uninhibited enzyme.

 The terms "inhibitor of VEGF receptor signaling" is used to identify a compound having a structure as defined herein, which is capable of interacting with a VEGF receptor and inhibiting the activity of the VEGF receptor. In some embodiments, such reduction of activity is at least about 50%, alternatively at least about 75%, and alternatively at least about 90%. In
20 some embodiments, activity is reduced by at least 95% and alternatively by at least 99%.

 The term "inhibiting effective amount" is meant to denote a dosage sufficient to cause inhibition of kinase activity. The amount of a compound of the invention which constitutes an "inhibiting effective amount" will vary depending on the compound, the kinase, and the like. The inhibiting effective amount can be determined routinely by one of ordinary skill in the art.
25 The kinase may be in a cell, which in turn may be in a multicellular organism. The multicellular organism may be, for example, a plant, a fungus or an animal, for example a mammal and for example a human. The fungus may be infecting a plant or a mammal, for example a human, and could therefore be located in and/or on the plant or mammal.

 In an exemplary embodiment, such inhibition is specific, i.e., the kinase inhibitor reduces
30 the ability of a kinase to transfer a phosphate group from a donor molecule, such as ATP, to a specific target molecule (substrate) at a concentration that is lower than the concentration of the inhibitor that is required to produce another, unrelated biological effect. For example, the concentration of the inhibitor required for kinase inhibitory activity is at least 2-fold lower, alternatively at least 5-fold lower, alternatively at least 10-fold lower, and alternatively at least
35 20-fold lower than the concentration required to produce an unrelated biological effect.

Thus, the invention provides a method for inhibiting kinase enzymatic activity, comprising contacting the kinase with an inhibiting effective amount of a compound or composition according to the invention. In some embodiments, the kinase is in an organism. Thus, the invention provides a method for inhibiting kinase enzymatic activity in an organism,
5 comprising administering to the organism an inhibiting effective amount of a compound or composition according to the invention. In some embodiments, the organism is a mammal, for example a domesticated mammal. In some embodiments, the organism is a human.

The term "therapeutically effective amount" as employed herein is an amount of a compound of the invention, that when administered to a patient, elicits the desired therapeutic
10 effect. The therapeutic effect is dependent upon the disease being treated and the results desired. As such, the therapeutic effect can be treatment of a disease-state. Further, the therapeutic effect can be inhibition of kinase activity. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like.
15 The therapeutically effective amount can be determined routinely by one of ordinary skill in the art.

In some embodiments, the therapeutic effect is inhibition of angiogenesis. The phrase "inhibition of angiogenesis" is used to denote an ability of a compound according to the present invention to retard the growth of blood vessels, such as blood vessels contacted with the
20 inhibitor as compared to blood vessels not contacted. In some embodiments, angiogenesis is tumor angiogenesis. The phrase "tumor angiogenesis" is intended to mean the proliferation of blood vessels that penetrate into or otherwise contact a cancerous growth, such as a tumor. In some embodiments, angiogenesis is abnormal blood vessel formation in the eye.

In an exemplary embodiment, angiogenesis is retarded by at least 25% as compared to
25 angiogenesis of non-contacted blood vessels, alternatively at least 50%, alternatively at least 75%, alternatively at least 90%, alternatively at least 95%, and alternatively, at least 99%. Alternatively, angiogenesis is inhibited by 100% (i.e., the blood vessels do not increase in size or number). In some embodiments, the phrase "inhibition of angiogenesis" includes regression in the number or size of blood vessels, as compared to non-contacted blood vessels. Thus, a
30 compound according to the invention that inhibits angiogenesis may induce blood vessel growth retardation, blood vessel growth arrest, or induce regression of blood vessel growth.

Thus, the invention provides a method for inhibiting angiogenesis in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the animal is a
35 mammal, for example a domesticated mammal. In some embodiments, the animal is a human.

In some embodiments, the therapeutic effect is treatment of an ophthalmic disease, disorder or condition. The phrase "treatment of an ophthalmic disease, disorder or condition" is intended to mean the ability of a compound according to the present invention to treat (a) a disease disorder or condition caused by choroidal angiogenesis, including, without limitation, age-related macular degeneration, or (b) diabetic retinopathy or retinal edema. In some
5 embodiments the phrase "treatment of an ophthalmic disease, disorder or condition" is intended to mean the ability of a compound according to the present invention to treat an exudative and/or inflammatory ophthalmic disease, disorder or condition, a disorder related to impaired retinal vessel permeability and/or integrity, a disorder related to retinal microvessel rupture
10 leading to focal hemorrhage, a disease of the back of the eye, a retinal disease, or a disease of the front of the eye, or other ophthalmic disease, disorder or condition.

In some embodiments, the ophthalmic disease, disorder or condition includes but is not limited to Age Related Macular Degeneration (ARMD), exudative macular degeneration (also known as "wet" or neovascular age-related macular degeneration (wet-AMD), macular oedema,
15 aged disciform macular degeneration, cystoid macular oedema, palpebral oedema, retinal oedema, diabetic retinopathy, Acute Macular Neuroretinopathy, Central Serous Chorioretinopathy, chorioretinopathy, Choroidal Neovascularization, neovascular maculopathy, neovascular glaucoma, obstructive arterial and venous retinopathies (e.g. Retinal Venous Occlusion or Retinal Arterial Occlusion), Central Retinal Vein Occlusion, Disseminated
20 Intravascular Coagulopathy, Branch Retinal Vein Occlusion, Hypertensive Fundus Changes, Ocular Ischemic Syndrome, Retinal Arterial Microaneurysms, Coat's Disease, Parafoveal Telangiectasis, Hemi-Retinal Vein Occlusion, Papillophlebitis, Central Retinal Artery Occlusion, Branch Retinal Artery Occlusion, Carotid Artery Disease(CAD), Frosted Branch Angitis, Sickle Cell Retinopathy and other Hemoglobinopathies, Angioid Streaks, macular
25 oedema occurring as a result of aetiologies such as disease (e.g. Diabetic Macular Oedema), eye injury or eye surgery, retinal ischemia or degeneration produced for example by injury, trauma or tumours, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment,
30 corneal ulcer, conjunctival ulcer, chronic nummular keratitis, Thygeson keratitis, progressive Mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection or by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, and a symptom caused by an ocular inflammatory disease including itching, flare, oedema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare,

scleroedema, dermatitis, angioneurotic oedema, laryngeal oedema, glottic oedema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.

In some embodiments, the ophthalmic disease, disorder or condition is (a) a disease disorder or condition caused by choroidal angiogenesis, including, without limitation, age-related macular degeneration, or (b) diabetic retinopathy or retinal edema.

In some embodiments, the ophthalmic disease, disorder or condition includes but is not limited to age-related macular degeneration, diabetic retinopathy, retinal edema, retinal vein occlusion, neovascular glaucoma, retinopathy of prematurity, pigmentary retinal degeneration, uveitis, corneal neovascularization or proliferative vitreoretinopathy.

In some embodiments, the ophthalmic disease, disorder or condition is age-related macular degeneration, diabetic retinopathy or retinal edema.

Thus, the invention provides a method for treating an ophthalmic disease, disorder or condition in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the animal is a mammal, for example a domesticated mammal. In some embodiments, the animal is a human.

In some embodiments, the therapeutic effect is inhibition of retinal neovascularization. The phrase "inhibition of retinal neovascularization" is intended to mean the ability of a compound according to the present invention to retard the growth of blood vessels in the eye, for example new blood vessels originating from retinal veins, for example, to retard the growth of new blood vessels originating from retinal veins and extending along the inner (vitreal) surface of the retina.

In an exemplary embodiment, retinal neovascularization is retarded by at least 25% as compared to retinal neovascularization of non-contacted blood vessels, alternatively at least 50%, alternatively at least 75%, alternatively at least 90%, alternatively at least 95%, and alternatively, at least 99%. Alternatively, retinal neovascularization is inhibited by 100% (i.e., the blood vessels do not increase in size or number). In some embodiments, the phrase "inhibition of retinal neovascularization" includes regression in the number or size of blood vessels, as compared to non-contacted blood vessels. Thus, a compound according to the invention that inhibits retinal neovascularization may induce blood vessel growth retardation, blood vessel growth arrest, or induce regression of blood vessel growth.

Thus, the invention provides a method for inhibiting retinal neovascularization in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the

animal is a mammal, for example a domesticated mammal. In some embodiments, the animal is a human.

In some embodiments, the therapeutic effect is inhibition of cell proliferation. The phrase "inhibition of cell proliferation" is used to denote an ability of a compound according to the present invention to retard the growth of cells contacted with the inhibitor as compared to cells not contacted. An assessment of cell proliferation can be made by counting contacted and non-contacted cells using a Coulter Cell Counter (Coulter, Miami, Fla.) or a hemacytometer. Where the cells are in a solid growth (e.g., a solid tumor or organ), such an assessment of cell proliferation can be made by measuring the growth with calipers or comparing the size of the growth of contacted cells with non-contacted cells.

In an exemplary embodiment, growth of cells contacted with the inhibitor is retarded by at least 25% as compared to growth of non-contacted cells, alternatively at least 50%, alternatively at least 75%, alternatively at least 90%, alternatively at least 95%, and alternatively, at least 99%. Alternatively, cell proliferation is inhibited by 100% (i.e., the contacted cells do not increase in number). In some embodiments, the phrase "inhibition of cell proliferation" includes a reduction in the number or size of contacted cells, as compared to non-contacted cells. Thus, a compound according to the invention that inhibits cell proliferation in a contacted cell may induce the contacted cell to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., to apoptose), or to undergo necrotic cell death.

In some embodiments, the contacted cell is a neoplastic cell. The term "neoplastic cell" is used to denote a cell that shows aberrant cell growth. In some embodiments, the aberrant cell growth of a neoplastic cell is increased cell growth. A neoplastic cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth *in vitro*, a benign tumor cell that is incapable of metastasis *in vivo*, or a cancer cell that is capable of metastasis *in vivo* and that may recur after attempted removal. The term "tumorigenesis" is used to denote the induction of cell proliferation that leads to the development of a neoplastic growth.

In some embodiments, the contacted cell is in an animal. Thus, the invention provides a method for treating a cell proliferative disease or condition in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the animal is a mammal, for example a domesticated mammal. In some embodiments, the animal is a human.

The term "cell proliferative disease or condition" is meant to refer to any condition characterized by aberrant cell growth, such as abnormally increased cellular proliferation. Examples of such cell proliferative diseases or conditions amenable to inhibition and treatment include, but are not limited to, cancer. Examples of particular types of cancer include, but are

not limited to, breast cancer, lung cancer, colon cancer, rectal cancer, bladder cancer, prostate cancer, leukemia and renal cancer. In some embodiments, the invention provides a method for inhibiting neoplastic cell proliferation in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of a compound of the invention or a composition thereof.

The term "patient" as employed herein for the purposes of the present invention includes humans and other animals, for example mammals, and other organisms. Thus the compounds, compositions and methods of the present invention are applicable to both human therapy and veterinary applications. In some embodiments the patient is a mammal, for example a human.

The terms "treating", "treatment", or the like, as used herein cover the treatment of a disease-state in an organism, and includes at least one of: (i) preventing the disease-state from occurring, in particular, when such animal is predisposed to the disease-state but has not yet been diagnosed as having it; (ii) inhibiting the disease-state, i.e., partially or completely arresting its development; (iii) relieving the disease-state, i.e., causing regression of symptoms of the disease-state, or ameliorating a symptom of the disease; and (iv) reversal or regression of the disease-state, such as eliminating or curing of the disease. In some embodiments of the present invention the organism is an animal, for example a mammal, for example a primate, for example a human. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction, the severity of the condition, etc., may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art. In some embodiments, the terms "treating", "treatment", or the like, as used herein cover the treatment of a disease-state in an organism and includes at least one of (ii), (iii) and (iv) above.

Administration for non-ophthalmic diseases, disorders or conditions may be by any route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal. In some embodiments, compounds of the invention are administered intravenously in a hospital setting. In some embodiments, administration may be by the oral route.

Examples of routes of administration for ophthalmic diseases, disorders and conditions include but are not limited to, systemic, periocular, retrobulbar, intracanalicular, intravitreal injection, topical (for example, eye drops), subconjunctival injection, subtenon, transcleral, intracameral, subretinal, electroporation, and sustained-release implant. Other routes of administration, other injection sites or other forms of administration for ophthalmic situations will be known or contemplated by one skilled in the art and are intended to be within the scope of the present invention.

In some embodiments of the present invention, routes of administration for ophthalmic diseases, disorders and conditions include topical, subconjunctival injection, intravitreal injection, or other ocular routes, systemically, or other methods known to one skilled in the art to a patient following ocular surgery.

5 In some other embodiments of the present invention, routes of administration for ophthalmic diseases, disorders and conditions include topical, intravitreal, transcleral, periocular, conjunctival, subtenon, intracameral, subretinal, subconjunctival, retrobulbar, or intracanalicular.

10 In some embodiments of the present invention, routes of administration for ophthalmic diseases, disorders and conditions include topical administration (for example, eye drops), systemic administration (for example, oral or intravenous), subconjunctival injection, periocular injection, intravitreal injection, and surgical implant for local delivery.

15 In some embodiments of the present invention, routes of administration for ophthalmic diseases, disorders and conditions include intravitreal injection, periocular injection, and sustained-release implant for local delivery.

In some embodiments of the present invention, an intraocular injection may be into the vitreous (intravitreal), under the conjunctiva (subconjunctival), behind the eye (retrobulbar), into the sclera, under the Capsule of Tenon (sub-Tenon), or may be in a depot form.

20 In some embodiments of the present invention, administration is local, including without limitation, topical, intravitreal, periorbital, intraocular, and other local administration to the eye, the ocular and/or periocular tissues and spaces, including without limitation, via a delivery device.

The compounds of the present invention form salts which are also within the scope of this invention.

25 The term “salt(s)”, as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, when a compound of the present invention contains both a basic moiety, such as but not limited to a pyridine or imidazole, and an acidic moiety such as but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable
30 (i.e., non-toxic (exhibiting minimal or no undesired toxicological effects), physiologically acceptable) salts are preferred, although other salts are also useful, e.g., in isolation or purification steps which may be employed during preparation. Salts of the compounds of the invention may be formed, for example, by reacting a compound of the present invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the
35 salts precipitates or in an aqueous medium followed by lyophilization.

The compounds of the present invention which contain a basic moiety, such as but not limited to an amine or a pyridine or imidazole ring, may form salts with a variety of organic and inorganic acids. Examples of acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, hydroxyethanesulfonates (e.g., 2-hydroxyethanesulfonates), lactates, maleates, methanesulfonates, naphthalenesulfonates (e.g., 2-naphthalenesulfonates), nicotines, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g., 3-phenylpropionates), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates, tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

The compounds of the present invention which contain an acidic moiety, such as but not limited to a carboxylic acid, may form salts with a variety of organic and inorganic bases. Examples of basic salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl) ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glycamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.

As used herein, the term "pharmaceutically acceptable salts" is intended to mean salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to, salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid, p-toluenesulfonic acid and polygalacturonic acid. Other salts include pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula $--NR^+Z^-$, wherein R is

hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).

5 Another aspect of the invention provides compositions comprising a compound according to the present invention. For example, in some embodiments of the invention, a composition comprises a compound, or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug of a compound according to the present invention present in at least about 30% enantiomeric or diastereomeric excess. In some embodiments of the invention, the
10 compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present in at least about 50%, at least about 80%, or even at least about 90% enantiomeric or diastereomeric excess. In some embodiments of the invention, the compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present in at least about 95%, alternatively at least about 98% and alternatively at least about 99% enantiomeric or
15 diastereomeric excess. In other embodiments of the invention, a compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present as a substantially racemic mixture.

Some compounds of the invention may have chiral centers and/or geometric isomeric centers (E- and Z- isomers), and it is to be understood that the invention encompasses all such
20 optical, enantiomeric, diastereoisomeric and geometric isomers. The invention also comprises all tautomeric forms of the compounds disclosed herein. Where compounds of the invention include chiral centers, the invention encompasses the enantiomerically and/or diastereomerically pure isomers of such compounds, the enantiomerically and/or diastereomerically enriched mixtures of such compounds, and the racemic and scalemic mixtures of such compounds. For
25 example, a composition may include a mixture of enantiomers or diastereomers of a compound of Formula (I) in at least about 30% diastereomeric or enantiomeric excess. In some embodiments of the invention, the compound is present in at least about 50% enantiomeric or diastereomeric excess, in at least about 80% enantiomeric or diastereomeric excess, or even in at least about 90% enantiomeric or diastereomeric excess. In some embodiments of the
30 invention, the compound is present in at least about 95%, alternatively in at least about 98% enantiomeric or diastereomeric excess, and alternatively in at least about 99% enantiomeric or diastereomeric excess.

The chiral centers of the present invention may have the S or R configuration. The racemic forms can be resolved by physical methods, such as, for example, fractional
35 crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral

column chromatography. The individual optical isomers can be obtained either starting from chiral precursors/intermediates or from the racemates by any suitable method, including without limitation, conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.

5 The present invention also includes prodrugs of compounds of the invention. The term “prodrug” is intended to represent a compound covalently bonded to a carrier, which prodrug is capable of releasing the active ingredient when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs *in vivo*. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional
10 groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or *in vivo*. Prodrugs of compounds of the invention include compounds wherein a hydroxy, amino, carboxylic, or a similar group is modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy or amino functional
15 groups in compounds of the present invention), amides (e.g., trifluoroacetyl amino, acetyl amino, and the like), and the like.

 The compounds of the invention may be administered, for example, as is or as a prodrug, for example in the form of an *in vivo* hydrolyzable ester or *in vivo* hydrolyzable amide. An *in vivo* hydrolyzable ester of a compound of the invention containing a carboxy or hydroxy group
20 is, for example, a pharmaceutically acceptable ester which is hydrolyzed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁-C₆alkoxymethyl esters (e.g., methoxymethyl), C₁-C₆alkanoyloxymethyl esters (e.g., for example pivaloyloxymethyl), phthalidyl esters, C₃-C₈cycloalkoxycarbonyloxy-C₁-C₆alkyl esters (e.g., 1-cyclohexylcarbonyloxyethyl); 1,3-dioxolen-2-onylmethyl esters (e.g.,
25 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁-C₆alkoxycarbonyloxyethyl esters (e.g., 1-methoxycarbonyloxyethyl) and may be formed at any appropriate carboxy group in the compounds of this invention.

 An *in vivo* hydrolyzable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related
30 compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolyzable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(N,N-
35 dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), N,N-dialkylaminoacetyl and

carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring. A suitable value for an *in vivo* hydrolyzable amide of a compound of the invention containing a carboxy group is, for example, a *N*-C₁-C₆alkyl or *N,N*-di-C₁-C₆alkyl amide such as *N*-methyl,
5 *N*-ethyl, *N*-propyl, *N,N*-dimethyl, *N*-ethyl-*N*-methyl or *N,N*-diethyl amide.

Upon administration to a subject, the prodrug undergoes chemical conversion by metabolic or chemical processes to yield a compound of the present invention.


The present invention is also directed to solvates and hydrates of the compounds of the present invention. The term "solvate" refers to a molecular complex of a compound with one or
10 more solvent molecules in a stoichiometric or non-stoichiometric amount. A molecular complex of a compound or moiety of a compound and a solvent can be stabilized by non-covalent intra-molecular forces such as, for example, electrostatic forces, van der Waals forces, or hydrogen bonds. Those skilled in the art of organic chemistry will appreciate that many organic compounds can form such complexes with solvents in which they are obtained,
15 prepared or synthesized, or from which they are precipitated or crystallized. The term "hydrate" refers to a complex in which the one or more solvent molecules are water and includes monohydrates, hemi-hydrates, dihydrates, hexahydrates, and the like. The meaning of the words "solvate" and "hydrate" are well known to those skilled in the art. Techniques for the preparation of solvates are well established in the art (see, for example, Brittain, Polymorphism
20 in Pharmaceutical solids. Marcel Dekker, New York, 1999; Hilfiker, Polymorphism in the Pharmaceutical Industry, Wiley, Weinheim, Germany, 2006).

In some embodiments of this aspect, the solvent is an inorganic solvent (for example, water). In some embodiments of this aspect, the solvent is an organic solvent (such as, but not limited to, alcohols, such as, without limitation, methanol, ethanol, isopropanol, and the like,
25 acetic acid, ketones, esters, and the like). In certain embodiments, the solvent is one commonly used in the pharmaceutical art, is known to be innocuous to a recipient to which such solvate is administered (for example, water, ethanol, and the like) and in preferred embodiments, does not interfere with the biological activity of the solute.

30 Throughout the specification, embodiments of one or more chemical substituents are identified. Also encompassed are combinations of various embodiments. For example, the invention describes some embodiments of D in the compounds and describes some embodiments of group G. Thus, as an example, also contemplated as within the scope of the invention are compounds in which examples of D are as described and in which examples of
35 group G are as described.

Compounds

According to one aspect, the invention is directed to compounds having the Formula (I):




including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs
5 and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of an aromatic, heteroaromatic, cycloalkyl or
heterocyclic ring system, C₁-C₆alkyl-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C₁-
C₆alkyl-N(R⁶)-C(O)-, (R⁶)(R⁶)N-C(O)-O-heterocyclyl-C(O)-, heterocyclyl-C(O)-, PivO-
10 heterocyclyl-C(O)-, C₁-C₆alkyl-O-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-N(R⁶)-
heterocyclyl-C(O)-, (C₁-C₆alkyl)(Box)N-heterocyclyl-C(O)-, HO-heterocyclyl-C(O)-, HO-
C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-O-heterocyclyl-C(O)-, (R⁶)(R⁶)N-C₁-C₆alkyl-
N(R⁶)-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C(O)- and
15 (R⁶)(R⁶)N-heterocyclyl-C(O)-, wherein each of the aromatic, heteroaromatic, cycloalkyl
and heterocyclic groups is optionally substituted with 1 or more independently selected
R³⁸;

M is an optionally substituted fused heterocyclic moiety;

Z is selected from the group consisting of -O-, -S(O)₀₋₂- and -NR⁵-, wherein R⁵ is selected from
the group consisting of H, optionally substituted C₁-C₅alkyl, an optionally substituted (C₁-
20 C₅)acyl and C₁-C₆ alkyl-O-C(O), wherein C₁-C₆ alkyl is optionally substituted;

Ar is a group of the formula C,



C

wherein,

A⁴, A⁵, A⁶ and A⁷ are independently selected from the group consisting of N and -CH-, with the
25 proviso that no more than two of A⁴, A⁵, A⁶ and A⁷ can be N, wherein Ar is optionally
substituted; and

G is a group B-L-T, wherein

B is selected from the group consisting of a covalent bond, -N(R¹³)-, -N(SO₂R¹³)-, -O-, -
S(O)₀₋₂ and -C(=O)-;

L is selected from the group consisting of a covalent bond, $-C(=S)N(R^{13})-$, -

$C(=NR^{14})N(R^{13})-$, $-SO_2N(R^{13})-$, $-SO_2-$, $-C(=O)N(R^{13})-$, $-N(R^{13})-$, $-C(=O)C_{1-2}alkyl-$, $N(R^{13})-$, $-N(R^{13})C_{1-2}alkyl-C(=O)-$, $-C(=O)C_{0-1}alkyl-C(=O)N(R^{13})-$, $-C_{0-4}alkylene-$, $-C(=O)C_{0-1}alkyl-C(=O)OR^3-$, $-C(=NR^{14})-C_{0-1}alkyl-C(=O)-$, $-C(=O)-$, $-C(=O)C_{0-1}alkyl-$, $C(=O)-$ and an optionally substituted four to six-membered heterocyclyl containing between one and three annular heteroatoms including at least one nitrogen, wherein the alkyl and alkylene are optionally substituted; and

T is selected from the group consisting of $-H$, $-R^{13}$, $-C_{0-4}alkyl$, $-C_{0-4}alkyl-Q$, $-O-C_{0-4}alkyl-Q$, $-C_{0-4}alkyl-O-Q$, $-N(R^{13})C_{0-4}alkyl-Q$, $-SO_2C_{0-4}alkyl-Q$, $-C(=O)C_{0-4}alkyl-Q$, $-C_{0-4}alkyl-N(R^{13})Q$ and $-C(=O)N(R^{13})-C_{0-4}alkyl-Q$, wherein each $C_{0-4}alkyl$ is optionally substituted;

wherein

R^{38} is selected from the group consisting of $C_2-C_6alkynyl-heterocyclyl$, $H(O)C-$ and $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-$, $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$, $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, $C_1-C_6alkyl-S(O)_2-(CH_2)_2-N(A)-CH_2-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$, $HOOC-C_1-C_6alkyl-N(A)-CH_2-$, $(HOOC)(NR^9R^{10})-C_1-C_6alkyl-N(A)-CH_2-$, $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$, $cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$, $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$, $(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-heterocyclyl-CH_2-$, $NC-C_1-C_6alkyl-heterocyclyl-CH_2-$, $F_3C-C_1-C_6alkyl-heterocyclyl-CH_2-$, $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6alkyl-$, (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6alkyl-$,

$F-heterocyclyl-C_1-C_6alkyl-$,

$heteroaryl-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-$,

$R^{37}-C_1-C_6alkyl-O-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-$,

$R^{37}O-C(O)-C_1-C_6alkyl-O-heterocyclyl-C_1-C_6alkyl-$,

$R^{37}O-C(O)-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-$,

$heterocyclyl-C_1-C_6alkyl-O-aryl-N(R^6)-C_1-C_6alkyl-$,

(heteroaryl substituted with one or more C_1-C_6alkyl)- $N(R^6)-C_1-C_6alkyl-$,

$(C_1-C_6alkyl)_2N-C_1-C_6alkyl-aryl-N(R^6)-C_1-C_6alkyl-$,

$(C_1-C_6alkyl)_2N-C_1-C_6alkyl-C(O)-aryl-N(R^6)-C_1-C_6alkyl-$,

$heterocyclyl-C_1-C_6alkyl-O-aryl-N(R^6)-C_1-C_6alkyl-$,

$(R^6)_2N-heterocyclyl-C_1-C_6alkyl-$,

- $C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkylC(O)-O-C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $heteroaryl-C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
5 $C_1-C_6alkyl-S(O)_2-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-N(R^6)-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-heterocyclyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-N(R^6)-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
10 $(heterocyclyl\ optionally\ substituted\ with\ one\ or\ more\ C_1-C_6alkyl)-C_1-C_6alkyl-$,
 $(C_1-C_6alkyl)_2N-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C(O)-C_1-C_6alkyl-$,
15 $C_1-C_6alkyl-O-C(O)-C_1-C_6alkyl-heteroaryl-N(R^6)-C(O)-C_1-C_6alkyl-$,
 $(C_1-C_6alkyl)_2N-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $heteroaryl-C_1-C_6alkyl-N(R^6)-C(O)-C_1-C_6alkyl-$,
 $(Boc)(H)N-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
20 $Boc-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $Ac-O-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $(Boc)(H)N-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $NH_2-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
25 $(C_1-C_6alkyl)(H)N-C(O)-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $NH_2-heterocyclyl-C(O)-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-O-C_1-C_6alkyl-heterocyclyl-C(O)-$,
 $C_1-C_6alkyl-O-C(O)-N(R^6)-heterocyclyl-C(O)-$,
 $(R^6)(R^6)N-heterocyclyl-C(O)-$,
30 $(R^6)(R^6)N-heterocyclyl-C_1-C_6alkyl-$,
 $heterocyclyl-O-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-N(R^6)-C(O)-N(R^6)-heterocyclyl-C(O)-$,
 $(R^6)(R^6)N-C(O)-heterocyclyl-O-C_1-C_6alkyl-$,
 $C_2-C_6alkenyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$,
35 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-O-C_1-C_6alkyl-$,

- $R^{37}O-C_1-C_6alkyl-N(R^6)-heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-C_1-C_6alkyl-N(R^6)-heterocyclcyl-C_1-C_6alkyl-$,
halo- $C_1-C_6alkyl-heterocyclcyl-C_1-C_6alkyl-$,
halo- $C_1-C_6alkyl-N(R^6)-heterocyclcyl-C_1-C_6alkyl-$,
5 $R^{37}O-C(O)-C_1-C_6alkyl-N(R^6)-heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}-O-C(O)-C_1-C_6alkyl-N(R^6)-C(O)-N(R^6)-heterocyclcyl-C_1-C_6alkyl-$,
 $(C_1-C_6alkyl)(H)N-C(O)-heterocyclcyl-N[C_1-C_6alkyl-C(O)-OH]-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
HO- $C(O)-heterocyclcyl-C_1-C_6alkyl-$,
10 $C_1-C_6alkyl-heterocyclcyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_1-C_6alkyl-N(R^6)-CO-heterocyclcyl-C_1-C_6alkyl-$,
 $(C_1-C_6alkyl)(C_1-C_6alkyl)N-heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-[(C_1-C_6alkyl)(C_1-C_6alkyl)heterocyclcyl]-C_1-C_6alkyl-$,
15 $C_2-C_6alkenyl-C(O)-[(C_1-C_6alkyl)(C_1-C_6alkyl)heterocyclcyl]-C_1-C_6alkyl-$,
 $R^{37}-O-C_1-C_6alkyl-[(C_1-C_6alkyl)(C_1-C_6alkyl)heterocyclcyl]-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C_1-C_6alkyl-NR^6-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C_1-C_6alkyl-N[C(O)-NH-C_1-C_6alkyl]-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-O-C_1-C_6alkyl-N[C(O)-C_1-C_6alkyl]-C_1-C_6alkyl-$,
20 $C_1-C_6alkyl-O-C_1-C_6alkyl-[C(O)-C_1-C_6alkyl-OH]-C_1-C_6alkyl-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-heterocyclcyl-C_1-C_6alkyl-$,
spiro- $heterocyclcyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-spiro-heterocyclcyl-C_1-C_6alkyl-$,
25 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-heterocyclcyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $heterocyclcyl-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
30 $heterocyclcyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_2-C_6alkenyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $heterocyclcyl-C_2-C_8alkenyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_1-C_6alkyl-N(R^6)-C_1-C_6alkyl-C(O)-heterocyclcyl-C_1-C_6alkyl-$,
 $heterocyclcyl-C(O)-$,
35 $(R^6)(R^6)N-C(O)-heterocyclcyl-C_1-C_6alkyl-$,

- $R^{37}O-C(O)-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $C_2-C_6alkenyl-C(O)-O-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C(O)-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
5 $R^{37}O-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-(heterocyclyl)-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-$,
 $C_1-C_6alkyl-O-C(O)-N(R^6)-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$
10 $R^{37}O-(CH_2)_n[(CH_2)_iO]_x-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $HO-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-cycloalkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$
and
 $R^{37}O-(CH_2)_n[(CH_2)_iO]_x-C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl$;
15 A is selected from the group consisting of $-C(O)-C_1-C_6alkyl-N(R^{39})-C(O)-C_1-C_6alkyl-$
 $N(R^9)(R^{10})$, $-C(O)-N(R^{39})-C_1-C_6alkyl$, $-C(=NR^{37})-C_1-C_6alkyl$, $-C(O)-(CH_2)_n-S(O)_2-C_1-$
 C_6alkyl , $-C(O)-N(R^{39})-cycloalkyl$, $-C(O)-N(R^9)(R^{10})$, $(R^{37}O)(R^{37a}O)P(O)O-C_1-C_6alkyl-$
 $C(O)-$, $-C(=NR^{37})-H$ and $-C_1-C_6alkyl-CF_3$;
each R^6 is independently H or C_1-C_6alkyl ;
20 R^{37} is selected from the group consisting of H, C_1-C_6alkyl and $C_3-C_{10}cycloalkyl$;
 R^{37a} is selected from the group consisting of H, C_1-C_6alkyl and $C_3-C_{10}cycloalkyl$;
j is an integer ranging from 0 to 4, alternatively 0 to 2;
i is 2 or 3;
x is an integer ranging from 0 to 6, alternatively 2 or 3;
25 i1 is 2 or 3;
j1 is an integer ranging from 0 to 4, alternatively 1 or 2;
n is an integer ranging from 0 to 4;
 R^{39} is selected from the group consisting of H, -OH, C_1-C_6alkyl , $C_3-C_{10}cycloalkyl$, -
 $(CH_2)_{n2}(C_6-C_{10}aryl)$, $-(CH_2)_{n2}(C_5-C_{10}heteroaryl)$, $-(CH_2)_{n2}(5-10\text{ membered heterocyclyl})$, -
30 $(CH_2)_{n2}O(CH_2)_{i2}OR^{37}$ and $-(CH_2)_{n2}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
heterocyclyl moieties of the foregoing R^{39} groups are optionally substituted;
 R^9 is selected from the group consisting of H, -OH, C_1-C_6alkyl , $C_3-C_{10}cycloalkyl$, -
 $(CH_2)_{n3}(C_6-C_{10}aryl)$, $-(CH_2)_{n3}(C_5-C_{10}heteroaryl)$, $-(CH_2)_{n3}(5-10\text{ membered heterocyclyl})$, -
 $(CH_2)_{n3}O(CH_2)_{i3}OR^{37}$ and $-(CH_2)_{n3}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
35 heterocyclyl moieties of the foregoing R^9 groups are optionally substituted;

R^{10} is selected from the group consisting of H, -OH, C_1 - C_6 alkyl, C_3 - C_{10} cycloalkyl, -
 $(CH_2)_{n4}(C_6$ - C_{10} aryl), $-(CH_2)_{n4}(C_5$ - C_{10} heteroaryl), $-(CH_2)_{n4}(5$ -10 membered heterocyclyl), -
 $(CH_2)_{n4}O(CH_2)_{i4}OR^{37}$ and $-(CH_2)_{n4}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
heterocyclyl moieties of the foregoing R^{10} groups are optionally substituted;

5 $n2$ is an integer ranging from 0 to 6;

$i2$ is an integer ranging from 2 to 6;

$n3$ is an integer ranging from 0 to 6;

$i3$ is an integer ranging from 2 to 6;

$n4$ is an integer ranging from 0 to 6;

10 $i4$ is an integer ranging from 2 to 6;

R^2 at each occurrence is independently selected from the group consisting of -H, halogen,
trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -S(O)₂NR³R³, -C(O)OR³, -
C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, C_1 - C_4 alkoxy, C_1 - C_4
alkylthio, -O(CH₂)_naryl, -O(CH₂)_nheteroaryl, -(CH₂)₀₋₅(aryl), -(CH₂)₀₋₅(heteroaryl), C_1 - C_6
15 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, -CH₂(CH₂)₀₋₄-T², wherein T² is selected from the
group consisting of -OH, -OMe, -OEt, -NH₂, -NHMe, -NMe₂, -NH₂Et and -NEt₂, and
wherein the aryl, heteroaryl, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl are optionally
substituted; and

q is an integer from 0 to 4;

20 R^{13} is selected from the group consisting of -H, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -
S(O)₂NR³R³, -C(O)OR³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -
C(O)R³, -C(O)SR³, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, -O(CH₂)_{n5}aryl, -O(CH₂)_{n5}heteroaryl, -
(CH₂)_{n5}(aryl), -(CH₂)_{n5}(heteroaryl), C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, -
CH₂(CH₂)₀₋₄-T², an optionally substituted C_{1-4} alkylcarbonyl, and a saturated or
25 unsaturated three- to seven-membered cycloalkyl or heterocyclic group, wherein T² is
selected from the group consisting of -OH, -OMe, -OEt, -NH₂, -NHMe, -NMe₂, -NH₂Et
and -NEt₂, and wherein the aryl, heteroaryl, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, and C_2 - C_6 alkynyl
are optionally substituted;

two R^{13} , together with the atom or atoms to which they are attached, can combine to form a
30 heteroalicyclic optionally substituted with between one and four of R^{60} , wherein the
heteroalicyclic can have up to four annular heteroatoms, and the heteroalicyclic can have
an aryl or heteroaryl fused thereto, in which case the aryl or heteroaryl is optionally
substituted with an additional one to four of R^{60} ;

$n5$ is an integer ranging from 0 to 6

R^{60} is selected from the group consisting of -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -SO₂NR³R³, -CO₂R³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, an optionally substituted (C₁-C₆)alkyl, an optionally substituted aryl, an optionally substituted heteroarylalkyl and an optionally substituted arylalkyl;

5 two R^{60} , when attached to a non-aromatic carbon, can be oxo;

each R^3 is independently selected from the group consisting of -H and R^4 ;

R^4 is selected from the group consisting of a (C₁-C₆)alkyl, an aryl, a lower arylalkyl, a heterocyclyl and a lower heterocyclyl-alkyl, each of which is optionally substituted, or

R^3 and R^4 , taken together with a common nitrogen to which they are attached, form an

10 optionally substituted five- to seven-membered heterocyclyl, the optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from the group consisting of N, O, S and P;

R^{14} is selected from the group -H, -NO₂, -NH₂, -N(R³)R⁴, -CN, -OR³, an optionally substituted (C₁-C₆)alkyl, an optionally substituted heteroalicyclyl-alkyl, an optionally substituted aryl,

15 an optionally substituted arylalkyl and an optionally substituted heteroalicyclic,


Q is a three- to ten-membered ring system, optionally substituted with zero, one or more of R^{20} ;






















R^{20} is selected from the group consisting of -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -OCF₃, -NR³R⁴, -S(O)₀₋₂R³, -S(O)₂NR³R³, -C(O)OR³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)C(O)OR³, -C(O)R³, -C(O)SR³, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -O(CH₂)_{n6}aryl, -O(CH₂)_{n6}heteroaryl, -(CH₂)_{n6}(aryl), -(CH₂)_{n6}(heteroaryl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂(CH₂)₀₋₄-T², an optionally substituted C₁₋₄ alkylcarbonyl, C₁₋₄ alkoxy, an amino optionally substituted by C₁₋₄ alkyl optionally substituted by C₁₋₄ alkoxy, -(CH₂)_{n6}P(=O)(C₁-C₆alkyl)₂, a saturated or unsaturated three- to seven-membered cycloalkyl or heterocyclic group, -SiMe₃ and -SbF₅; and

25 n₆ is an integer ranging from 0 to 6.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is -aryl or -heteroaryl each of which is substituted with 1 or more R^{38} .



















In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is selected from the group consisting of



wherein the members of said group are substituted by 1 or more R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is selected from the group consisting of

wherein the members of said group are substituted with 1 or more R^{38} .

- 5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is selected from the group consisting of phenyl, pyridine, imidazole, pyrazole and tetrahydropyridine substituted with one R^{38} , wherein when D is imidazole said imidazole is further optionally substituted with one C_1 - C_6 alkyl.

- 10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is phenyl or pyridine substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} .

- 15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-$

C₆alkyl-heterocyclyl-CH₂-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(R³⁹)-C(O)-, R³⁷-O-C(O)-C₁-C₆alkyl-heterocyclyl-C(O)-, C₀-C₆alkyl-heterocyclyl-C₀-C₆alkyl-heterocyclyl-C(O)-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, NC-C₁-C₆alkyl-heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂- and N(R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is selected from the group consisting of R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(A)-(CH₂)_{jl}-, R³⁷O-C(O)-C₀-C₆alkyl-heterocyclyl-CH₂-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(R³⁹)-C(O)-, R³⁷-O-C(O)-C₁-C₆alkyl-heterocyclyl-C(O)-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, NC-C₁-C₆alkyl-heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂- and N(R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄- or R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(A)-(CH₂)_{jl}-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R³⁷O)(R^{37a}O)P(O)O-C₁-C₆alkyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, alternatively R³⁷O-(CH₂)₂-N(A)-(CH₂)₂-, alternatively R³⁷O-(CH₂)₂-N(A)-(CH₂)₂-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R³⁷O)(R^{37a}O)P(O)O-C₁-C₆alkyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₂-N(A)-(CH₂)₂-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R³⁷O)(R^{37a}O)P(O)O-C₁-C₆alkyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_2-$, and A is -C(O)-N(R^{39})-C₁-C₆alkyl.

5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is -C(O)-N(R^{39})-C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is -C(O)-H.

10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, and A is -C(O)-N(R^{39})-C₁-C₆alkyl,

15

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$.

20

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$.

25 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $C_0-C_6alkyl-heterocyclyl-C_0-C_6alkyl-heterocyclyl-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$.

30

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $NC-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $F_3C-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $N(R^9)(R^{10})N-C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-\text{heterocyclyl}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6\text{alkyl}-$, wherein the optional substituent is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, $C_1-C_6\text{alkyl}$, $-C(O)-C_1-C_6\text{alkyl}-OH$, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6\text{alkyl}$, $-S(O)_{0-2}-\text{cycloalkyl}$, $-S(O)_{0-2}-\text{heterocyclyl}$, $-S(O)_{0-2}-\text{aryl}$, $-S(O)_{0-2}-\text{heteroaryl}$, $-C(O)H$, $-C(O)-C_1-C_6\text{alkyl}$, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6\text{alkyl}-OH$, $-C_1-C_6\text{alkyl}-C(O)-OH$ and $-C_1-C_6\text{alkyl}-C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} and one $C_1-C_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} and one $C_1-C_6\text{alkyl}$, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} and one $C_1-C_6\text{alkyl}$, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$ or $-C(O)-N(R^{39})-\text{cycloalkyl}$.

In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} and one $C_1-C_6\text{alkyl}$, wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$ or $-C(O)-N(R^{39})-\text{cycloalkyl}$.

In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl, wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl.

5 In some embodiments of the first aspect, the compounds have the Formula I, wherein D is imidazole substituted with one R^{38} , wherein R^{38} is C_1 - C_6 alkyl- $C(O)-O-C_1$ - C_6 alkyl- $C(O)-(5$ to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is phenyl substituted with one R^{38} .

10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-N(R^{39})$ -cycloalkyl.

15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-N(R^{39})$ -cycloalkyl.

20 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is tetrahydropyridine substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_1$ - C_6 alkyl- $C(O)-$ or $R^{37}-O-C_1$ - C_6 alkyl- $O-C_1$ - C_6 alkyl- $C(O)-$.

25 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_1$ - C_6 alkyl- $C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}-O-C_1$ - C_6 alkyl- $O-C_1$ - C_6 alkyl- $C(O)-$.

30 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is cycloalkyl- $N(R^{39})-C(O)-O-C_1$ - C_6 alkyl- or $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein R^{38} is cycloalkyl- $N(R^{39})-C(O)-O-C_1-C_6$ alkyl- or $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl.

5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is cycloalkyl- $N(R^{39})-C(O)-O-C_1-C_6$ alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_2-$, and A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl.

15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, alternatively $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$, $MeO-(CH_2)_2-N(A)-CH_2-$ or $MeO-(CH_2)_2-N(A)-(CH_2)_2-$.

20 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is C_1-C_6 alkyl- $S(O)_2-(CH_2)_2-N(A)-CH_2-$, alternatively $CH_3-S(O)_2-(CH_2)_2-N(A)-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-CH_2-$.

25 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl- CH_2- , alternatively $R^{37}O-C(O)-C_1-C_6$ alkyl-heterocyclyl- CH_2- , alternatively $HO-C(O)-(CH_2)_2$ -piperazine- CH_2- , $EtO-C(O)$ -piperidine- CH_2- , $EtO-C(O)-CH_2$ -piperidine- CH_2- , $EtO-C(O)-CH_2$ -piperazine- CH_2- , $HO-C(O)$ -piperidine- CH_2- , $HO-C(O)-CH_2$ -piperidine- CH_2- $HO-C(O)-CH_2$ -piperazine- CH_2- , $(CH_3)_3C-O-C(O)$ -piperazine- CH_2- or $HO-C(O)$ -pyrrolidine- CH_2- .

30 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-C(O)-$.


35 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $R^{37}-O-C(O)-C_1-C_6$ alkyl-heterocyclyl- $C(O)-$, alternatively $CH_3-CH_2-O-C(O)-(CH_2)_2$ -piperazine- $C(O)-$ or $HO-C(O)-(CH_2)_2$ -piperazine- $C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $\text{HOOC-C}_1\text{-C}_6\text{alkyl-N(A)-CH}_2\text{-}$, alternatively $\text{HOOC-(CH}_2\text{)}_3\text{-N(A)-CH}_2\text{-}$.


In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $(\text{HOOC})(\text{NR}^9\text{R}^{10})\text{-C}_1\text{-C}_6\text{alkyl-N(A)-CH}_2\text{-}$, alternatively $(\text{HOOC})(\text{NH}_2)\text{CH-(CH}_2\text{)}_4\text{-N(A)-CH}_2\text{-}$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $\text{R}^{37}\text{O-C(O)-C}_1\text{-C}_6\text{alkyl-C(O)-}$, alternatively $\text{HO-C(O)-(CH}_2\text{)}_2\text{-C(O)-}$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein



R^{38} is $\text{R}^9(\text{R}^{10})\text{N-C}_1\text{-C}_6\text{alkyl-C(O)-heterocycl-CH}_2\text{-}$, alternatively




10 or



In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $\text{cycloalkyl-N(R}^{39})\text{-C(O)-O-C}_1\text{-C}_6\text{alkyl-}$, alternatively $\text{C}_3\text{cycloalkyl-NH-C(O)-O-(CH}_2\text{)}_2\text{-}$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $\text{R}^{37}\text{-O-C}_1\text{-C}_6\text{alkyl-O-C}_1\text{-C}_6\text{alkyl-C(O)-}$, alternatively $\text{MeO-(CH}_2\text{)}_2\text{-O-CH}_2\text{-C(O)-}$.

15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein




R^{38} is $(\text{R}^9)(\text{R}^{10})\text{N-C(O)-C}_1\text{-C}_6\text{alkyl-heterocycl-CH}_2\text{-}$, alternatively



or


In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$, alternatively



In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $NC-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$, alternatively $NC-(CH_2)_2\text{-piperazine}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $F_3C-C_1-C_6\text{alkyl}-\text{heterocyclyl}-CH_2-$, alternatively $F_3C-CH_2\text{-piperazine}-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-\text{heterocyclyl}-CH_2-$, alternatively




10

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$, wherein the heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$,




which is

or

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, which is



G is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G¹ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G² is CH or N;

G³ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G⁴ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G⁵ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G⁶ is CH or N;


G⁷ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

R^s is an optional substituent; and

R^{s1} is an optional substituent,


provided that two O atoms are not adjacent to each other.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



In some embodiments of the first aspect, the compounds have the Formula (I), wherein

R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



consisting of CH₂, O, NH, S, SO and SO₂; G¹ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂; and R^S is an optional substituent.

- 5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^S is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH, -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

- 15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R^{S1} is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH, -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

- 20 In some embodiments of the first aspect, the compounds have the Formula (I), wherein R³⁸ is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl-, wherein the optional substituent is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH and -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^{39})-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^9)(\text{R}^{10})$, alternatively $-\text{C}(\text{O})-\text{CH}_2-\text{NH}-\text{C}(\text{O})-\text{CH}(\text{NH}_2)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{O})-\text{CH}_2-\text{NH}-\text{C}(\text{O})-\text{CH}_2-\text{NH}_2$ or $-\text{C}(\text{O})-\text{CH}[\text{CH}(\text{CH}_3)_2]-\text{NH}-\text{C}(\text{O})-\text{CH}_2-\text{NH}_2$.

5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(\text{O})-\text{NH}-\text{CH}_2-\text{CH}_3$, $-\text{C}(\text{O})-\text{NH}-\text{CH}_3$, $-\text{C}(\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$ or $-\text{C}(\text{O})-\text{N}(\text{CH}_3)_2$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(=\text{NR}^{37})-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(=\text{NH})\text{H}$.

10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{S}(\text{O})_2-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(\text{O})-\text{CH}_2-\text{S}(\text{O})_2-\text{Me}$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{cycloalkyl}$, alternatively $-\text{C}(\text{O})-\text{NH}-\text{cyclopentyl}$ or $-\text{C}(\text{O})-\text{NH}-\text{C}_3\text{cycloalkyl}$.

15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^9)(\text{R}^{10})$, alternatively $-\text{C}(\text{O})-\text{NH}_2$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein A is $(\text{R}^{37}\text{O})(\text{R}^{37a}\text{O})\text{P}(\text{O})\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-$, alternatively $(\text{HO})_2\text{P}(\text{O})\text{O}-\text{CH}_2-\text{C}(\text{O})-$.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein

20 M is a structure selected from the group consisting of

wherein

* represents the point of attachment to D;

† represents the point of attachment to Z;

A¹ is selected from the group consisting of CH, -O-, -S-, -N(H)-, -N(C₁-C₆ alkyl)-, -N-(Y-aryl)-, -N-OMe, -NCH₂OMe and N-Bn;

5 Y is a bond or -(C(R^x)(H))_t-, wherein t is an integer from 1 to 6; and

R^x at each occurrence is independently selected from the group consisting of H and C₁-C₆ alkyl, wherein the C₁-C₆ alkyl is optionally substituted;

A² is selected from the group consisting of N and CR, wherein R is selected from the group consisting of -H, halogen, -CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -COOH and -C(O)Oalkyl, wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl and -C(O)Oalkyl are optionally substituted;


each A³ is independently selected from the group consisting of CH and N;

each R⁸⁰ is independently selected from the group consisting of H, halogen, NO₂, cyano, OR⁸³, N(R⁸³)₂, CO₂R⁸³, C(O)N(R⁸³)₂, SO₂R⁸³, SO₂N(R⁸³)₂, NR⁸³SO₂R⁸³, NR⁸³C(O)R⁸³, NR⁸³CO₂R⁸³, -CO(CH₂)₁R⁸³, -CONH(CH₂)₁R⁸³, alkylaminoalkyl, alkylaminoalkynyl, C₁-C₆alkyl, substituted C₁-C₆alkyl, C₃-C₇cycloalkyl, substituted C₃-C₇cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, hydroxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heterocycloalkyl, and substituted heterocycloalkyl; and

20 each R⁸³ is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heterocycloalkyl, and substituted heterocycloalkyl; or two R⁸³ taken together with the N atom to which they are attached form a heterocyclic ring.

In some embodiments of the first aspect, the compounds have the Formual (I), wherein

25 M is a structure selected from the group consisting of




wherein

J is CR⁸⁰ or N;

R^{82} is selected from the group consisting of H, C_1 - C_6 alkyl or substituted C_1 - C_6 alkyl, -Y-(aryl), -Y-(heteroaryl), -alkoxy and - CH_2OMe ;

wherein *, †, R^{80} and Y are as defined above.

In some embodiments of the first aspect, the compounds have the Formual (I), wherein M
5 is a structure selected from the group consisting of




wherein

† is as defined above; and

R^{22} is selected from the group consisting of -H, -C₁-C₆alkyl, -Y-aryl, alkoxy, -CH₂-O-Me and -Bn.

5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein M




In some embodiments of the first aspect, the compounds have the Formula (I), wherein Z is O.


10 In some embodiments of the first aspect, the compounds have the Formula (I), wherein Ar is selected from the group consisting of phenyl, pyrazine, pyridazine, pyrimidine and pyridine, wherein each of said phenyl, pyrazine, pyridazine, pyrimidine and pyridine are optionally substituted with between zero and four R^2 .

In some embodiments of the first aspect, the compound have the Formula (I), wherein Ar is phenyl, optionally substituted with between zero and four R^2 .

15 In some embodiments of the first aspect, the compounds have the Formula (I), wherein Ar is phenyl, substituted with between zero and four halo.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein G is selected from the group consisting of





wherein R^{13} , R^{14} , Q , R^3 and R^4 are as defined above;

W is S, O or NH;

any methylene group is independently optionally substituted with R^{25} , wherein

- 5 R^{25} is selected from the group consisting of halogen, trihalomethyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{OR}^3$, $-\text{NR}^3\text{R}^4$, $-\text{S}(\text{O})_{0-2}\text{R}^3$, $-\text{SO}_2\text{NR}^3\text{R}^3$, $-\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})\text{NR}^3\text{R}^3$, $-\text{N}(\text{R}^3)\text{SO}_2\text{R}^3$, $-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})\text{R}^3$, an optionally substituted aryl, an optionally substituted arylalkyl, an optionally substituted heteroarylalkyl, and an optionally substituted $(\text{C}_1\text{-C}_6)$ alkyl, two R^{25} , together with the carbon or carbons to which they are attached, can combine to form a
- 10 three- to seven-membered alicyclic or heteroalicyclic, and two R^{25} , on a single carbon can be oxo;

R^9 is selected from the group consisting of a C_{1-6} alkyl on which one or more hydrogen atoms are optionally substituted by $-\text{R}^{21}$, $-\text{T}^1\text{-R}^{15}$, or $-\text{NR}^{16}\text{R}^{17}$, a $-\text{N}(\text{R}^{18})(\text{R}^{19})$ moiety and a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group

15 which is optionally substituted by a C_{1-6} alkyl, a C_{1-6} alkoxy, a halogen atom, nitro, a trifluoromethyl, a C_{1-6} alkoxy carbonyl, cyano, a cyano C_{1-6} alkyl, a C_{1-6} alkylthio, a phenoxy, an acetyl, or a saturated or unsaturated five- or six-membered heterocyclyl ring wherein, when the three- to eight-membered carbocyclic or heterocyclic group is substituted by two C_{1-6} alkyl groups, the two alkyl groups may combine together to form

20 an alkylene chain, or the three- to eight-membered carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group,

wherein

T¹ is selected from the group consisting of -O-, -S- and -NH-;

R²¹ represents a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group;

5 R¹⁵, R¹⁶, and R¹⁷, which may be the same or different, represent a C₁₋₆ alkyl or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group; wherein the three- to eight-membered carbocyclic or heterocyclic group represented by R²¹, R¹⁵, R¹⁶, and R¹⁷ is optionally substituted by a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, nitro, a trifluoromethyl, a C₁₋₆ alkoxy carbonyl, a cyano, a cyano C₁₋₆ alkyl, a C₁₋₆ alkylthio, a
10 phenoxy, an acetyl, or a saturated or unsaturated five- or six-membered heterocyclyl ring; and wherein when the three- to eight-membered carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain; and wherein the three- to eight-membered carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated three- to
15 eight-membered carbocyclic or heterocyclic group; and

R¹⁸ and R¹⁹, which may be the same or different, represent (1) a hydrogen atom, (2) a C₁₋₆ alkyl which is optionally substituted by a C₁₋₆ alkoxy, a C₁₋₆ alkylthio, or a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group in which the three- to eight-membered carbocyclic or heterocyclic group is optionally substituted by a
20 C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, nitro, a trifluoromethyl, a C₁₋₆ alkoxy carbonyl, cyano, a cyano C₁₋₆ alkyl, a C₁₋₆ alkylthio, a phenoxy, an acetyl, or a saturated or unsaturated five- or six-membered heterocyclyl ring and wherein when the three- to eight-membered carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the three- to eight-
25 membered carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, or (3) a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group which is optionally substituted by a C₁₋₆ alkyl, a C₁₋₆ alkoxy, a halogen atom, nitro, a trifluoromethyl, a C₁₋₆ alkoxy carbonyl, cyano, a cyano C₁₋₆ alkyl, a C₁₋₆
30 alkylthio, a phenoxy, an acetyl, or a saturated or unsaturated five- or six-membered heterocyclyl ring and in which, when the three to eight-membered carbocyclic or heterocyclic group is substituted by two C₁₋₆ alkyl groups, the two alkyl groups may combine together to form an alkylene chain, or the three- to eight-membered carbocyclic or heterocyclic group may be a bicyclic group condensed with another saturated or
35 unsaturated three- to eight-membered carbocyclic or heterocyclic group;

X and X¹ are each independently selected from the group consisting of -H, halogen, cyano, nitro, C₁-C₆ alkyl, or

X and X¹ together with the atom to which they are attached form a C₃-C₄ cycloalkyl;

E is selected from the group consisting of -O-, -N(R¹³)-, -CH₂- and -S(O)₀₋₂-;

5 M is selected from the group consisting of -O-, -N(R¹³)-, -CH₂- and -C(=O)N(R¹³);























M¹ represents -C(R²⁶)(R²⁷)-, wherein





















R²⁶ and R²⁷ are independently selected from the group consisting of a hydrogen atom, a C₁₋₄ alkyl, a C₁₋₄ alkoxy and -N(R¹²), wherein

R¹² is a hydrogen atom or a C₁₋₄ alkyl; and







10 each V is independently selected from the group consisting of =N- and =C(H)-.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein G is selected from the group consisting of



















	
	
	
	
	
	
	
	
	
	
	






In some embodiments of the first aspect, the compounds have the Formula (I), wherein G is selected from the group consisting of


In some embodiments of the first aspect, the compounds have the Formula (I), wherein G is selected from the group consisting of


5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein G is selected from the group consisting of

		
 and		


In some embodiments of the first aspect, the compounds have the Formula (I), wherein




5 In some embodiments of the first aspect, the compounds have the Formula (I), wherein




In some embodiments of the first aspect, the compounds have the Formula (I), wherein




In some embodiments of the first aspect, the compounds have the Formula (I), wherein




In some embodiments of the first aspect, the compounds have the Formula (I), wherein



In some embodiments of the first aspect, the compounds have the Formula (I), wherein



In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is selected from the group consisting of



wherein P¹ is a five- to seven-membered ring, including the two shared carbon atoms of the aromatic ring to which P¹ is fused, and wherein P¹ optionally contains between one and three heteroatoms.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is selected from the group consisting of phenyl, naphthyl, 1,2, 3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolynyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolynyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, isoindolyl, indolynyl, isoindolynyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl, and oxadiazolyl; each optionally substituted with between one and four of R²⁰.


In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is phenyl or C₃cycloalkyl.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is phenyl substituted with one or two independently selected R²⁰.

In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is phenyl substituted with one R²⁰, wherein the R²⁰ is selected from the group consisting of -P(O)(Me)₂, -CH₃, F, -CF₃, -C(O)-NH₂, -S(O)₂CH₃, Cl, -OCF₃, -OMe, Br, -S(O)₂-NH₂, -COOCH₃, -C(O)NH(CH₃) and -C(O)N(CH₃)(CH₃).

In some embodiments of the first aspect, the compounds have the Formula (I), wherein Q is C₃cycloalkyl.

In some embodiments of the first aspect, the compounds of have the Formula (Ia),



wherein D, M, Z, Ar and G are as defined in Formula (I), except that

R^{38} is selected from the group consisting of $(R^{23})(R^{24})(O)P-C_1-C_6\text{alkyl-heterocyclyl}-C_1-C_6\text{alkyl-}$, (optionally substituted 7- or 8-membered heterocyclyl)- $C_1-C_6\text{alkyl-}$, (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6\text{alkyl-}$, (optionally substituted spiro-heterocyclyl)- $C_1-C_6\text{alkyl-}$, (optionally substituted bridged bicyclic ring system)- $C_1-C_6\text{alkyl-}$,
 5 (substituted piperazine)- $C_1-C_6\text{alkyl-}$, $(R^9)(R^{10})N-C_1-C_6\text{alkyl-C(O)-O-}C_1-C_6\text{alkyl-C(O)-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $C_1-C_6\text{alkyl-S(O)}_{0-2}-C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl-C(O)-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $R^{37}S(O)_{0-2}\text{-aryl-C(O)-O-}C_1-C_6\text{alkyl-C(O)-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $R^{37}O-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$,
 10 $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N(R}^{37})\text{-C(O)-}C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $R^{11}\text{-}C_1-C_6\text{alkyl-C(O)-piperazine-}C_1-C_6\text{alkyl-}$, $C_0-C_6\text{alkyl-(5 or 6-membered heterocyclyl)-}C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, (5-10-membered optionally substituted heterocyclyl)- $C_1-C_6\text{alkyl-O-}$ (oxo substituted 5 to 10-membered heterocyclyl)- $C_1-C_6\text{alkyl-}$, (5-10-membered optionally substituted heterocyclyl)- $C_1-C_6\text{alkyl-N(R}^1\text{)-(oxo substituted 5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, (5-10-membered optionally substituted heterocyclyl)- $C_1-C_6\text{alkyl-S(O)}_{0-2}\text{-(oxo substituted 5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $(R^{23})(R^{24})P(O)\text{-}C_1-C_6\text{alkyl-C(O)-}$, $(R^{23})(R^{24})(O)P\text{-}C_1-C_6\text{alkyl-N(R}^{37})\text{-}C_1-C_6\text{alkyl-}$, $(R^9)(R^{10})N\text{-C(H)(R}^{28})\text{-}$, $R^{29}O\text{-C(O)-C(H)(C(O)-OR}^{29a})\text{-O-}C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$, $R^{29}O\text{-C(O)-C(H)(C(O)-OR}^{29a})\text{-O-}C_1-C_6\text{alkyl-C(O)-(5 to 10-membered heterocyclyl)-}C_1-C_6\text{alkyl-}$ and (substituted piperidine)- $C_1-C_6\text{alkyl-}$;

wherein

R^1 is H or $C_1-C_6\text{alkyl}$;

R^{11} is -OH, -O- $C_1-C_6\text{alkyl}$, optionally substituted 5 to 10-membered heterocyclyl, or -O-(amino acid);

R^{23} is selected from the group consisting of H, -OH, $C_1-C_6\text{alkyl}$, $C_1-C_6\text{alkoxy}$, aryl, -O-aryl, cycloalkyl, -O-cycloalkyl, heteroaryl, -O-heteroaryl, 5 to 10-membered heterocyclyl, -O-(5 to 10-membered heterocyclyl), - $C_1-C_6\text{alkyl-aryl}$, -O- $C_1-C_6\text{alkyl-aryl}$, - $C_1-C_6\text{alkyl-heteroaryl}$, -O- $C_1-C_6\text{alkyl-heteroaryl}$, - $C_1-C_6\text{alkyl-cycloalkyl}$, -O- $C_1-C_6\text{alkyl-cycloalkyl}$, - $C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)}$ and -O- $C_1-C_6\text{alkyl-(5 to 10-membered heterocyclyl)}$;

R^{24} is selected from the group consisting of H, -OH, $C_1-C_6\text{alkyl}$, $C_1-C_6\text{alkoxy}$, aryl, -O-aryl, cycloalkyl, -O-cycloalkyl, heteroaryl, -O-heteroaryl, 5 to 10-membered heterocyclyl, -O-(5 to 10-membered heterocyclyl), - $C_1-C_6\text{alkyl-aryl}$, -O- $C_1-C_6\text{alkyl-aryl}$, - $C_1-C_6\text{alkyl-heteroaryl}$, -O- $C_1-C_6\text{alkyl-heteroaryl}$, - $C_1-C_6\text{alkyl-cycloalkyl}$, -O- $C_1-C_6\text{alkyl-cycloalkyl}$, -

C₁-C₆alkyl-(5 to 10-membered heterocyclyl) and -O-C₁-C₆alkyl-(5 to 10-membered heterocyclyl);

R²⁸ is selected from the group consisting of H, -CF₃, -CHF₂, -CH₂F, CN, optionally substituted C₁-C₆alkyl and C₃-C₆cycloalkyl;

5 R²⁹ is selected from the group consisting of H, C₁-C₆alkyl and a cation; and

R^{29a} is selected from the group consisting of H, C₁-C₆alkyl and a cation.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (R²³)(R²⁴)(O)P-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-.

10 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (R²³)(R²⁴)(O)P-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, wherein the heterocyclyl is a six-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (R²³)(R²⁴)(O)P-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, wherein the heterocyclyl is selected from the group consisting of tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidine, 15 tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, dioxanyl, oxathianyl, morpholinyl, dithianyl, piperazinyl, azathianyl, oxepanyl, thiepaneyl, azepanyl, dioxepanyl, oxathiepanyl, oxazepanyl, dithiepanyl, thiazepanyl and diazepanyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (R²³)(R²⁴)(O)P-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, wherein the heterocyclyl is selected 20 from the group consisting of piperidinyl, morpholinyl and piperazinyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 7- or 8-membered heterocyclyl)-C₁-C₆alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 7-membered heterocyclyl)-C₁-C₆alkyl-.


25 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 7-membered heterocyclyl)-C₁-C₆alkyl-, wherein the heterocyclyl has one or two N atoms.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 8-membered heterocyclyl)-C₁-C₆alkyl-.

30 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 8-membered heterocyclyl)-C₁-C₆alkyl-, wherein the heterocyclyl has one or two N atoms.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, which is



G is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G^1 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G^2 is CH or N;

G^3 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G^4 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G^5 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G^6 is CH or N;


G^7 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

R^s is an optional substituent; and


R^{s1} is an optional substituent,

provided that two O atoms are not adjacent to each other.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



5 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted spiro-heterocyclyl)-C₁-C₆alkyl-.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted spiro-heterocyclyl)-C₁-C₆alkyl-, wherein the optionally substituted spiro-heterocyclyl is selected from the group consisting of optionally substituted [4-4] spiro-heterocyclyl, optionally substituted [4-5] spiro-heterocyclyl, optionally substituted [4-6] spiro-heterocyclyl, optionally substituted [5-4] spiro-heterocyclyl, optionally substituted [5-5] spiro-heterocyclyl, optionally substituted [5-6] spiro-heterocyclyl, optionally substituted [6-4] spiro-heterocyclyl, optionally substituted [6-5] spiro-heterocyclyl and optionally substituted [6-6] spiro-heterocyclyl.

15 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted spiro-heterocyclyl)-C₁-C₆alkyl-, wherein the optionally substituted spiro-heterocyclyl is selected from the group consisting of optionally substituted [4-4] spiro-heterocyclyl, optionally substituted [4-5] spiro-heterocyclyl, optionally substituted [4-6] spiro-heterocyclyl, optionally substituted [5-4] spiro-heterocyclyl, optionally substituted [5-5] spiro-heterocyclyl, optionally substituted [5-6] spiro-heterocyclyl, optionally substituted [6-4] spiro-heterocyclyl, optionally substituted [6-5] spiro-heterocyclyl and optionally substituted [6-6] spiro-heterocyclyl, and wherein the optional substituent is a fused cycloalkyl, heterocyclyl, aryl or heteroaryl ring.


25 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R³⁸ is (optionally substituted spiro-heterocyclyl)-C₁-C₆alkyl-, wherein the spiro-heterocyclyl is optionally substituted with one or more substituents selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -

$S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl-OH, $-C_1-C_6$ alkyl- $C(O)-OH$, $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl

- 5 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted spiro-heterocyclyl)- C_1-C_6 alkyl-, wherein the optionally substituted



- 10 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted spiro-heterocyclyl)- C_1-C_6 alkyl-, wherein the optionally substituted



In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^s is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl- OH , Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}-cycloalkyl$, $-S(O)_{0-2}-heterocyclyl$, $-S(O)_{0-2}-aryl$, $-S(O)_{0-2}-heteroaryl$, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl- OH , $-C_1-C_6$ alkyl- $C(O)-OH$, $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{s1} is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl- OH , Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}-cycloalkyl$, $-S(O)_{0-2}-heterocyclyl$, $-S(O)_{0-2}-aryl$, $-S(O)_{0-2}-heteroaryl$, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl- OH , $-C_1-C_6$ alkyl- $C(O)-OH$, $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted bridged bicyclic ring system)- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted bridged bicyclic ring system)- C_1-C_6 alkyl-, wherein the bridged bicyclic ring system is selected from the group consisting of [1.1.0], [2.2.0], [2.2.1], [2.2.2], [3.2.0], [3.2.1], [3.2.2], [3.3.0], [3.3.1], [3.3.2], [4.2.0], [4.2.1], [4.3.0], [4.3.1], [4.3.2], [4.4.0], [4.4.1], [4.4.2] bridged bicyclic ring systems.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted bridged bicyclic ring system)- C_1-C_6 alkyl-, wherein the bridged bicyclic ring system is a bridged bicyclic amine.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (optionally substituted bridged bicyclic ring system)- C_1-C_6 alkyl- selected from the group



In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (substituted piperazine)- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein




wherein R^S is an optional substituent.

- 5 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N$ - C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N$ - C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 -
10 C_6 alkyl-, wherein the 5 to 10-membered heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N$ - C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 -




C_6 alkyl-, which is

- In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein
15 R^{38} is C_1 - C_6 alkyl- $S(O)_{0-2}$ - C_1 - C_6 alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is C_1 - C_6 alkyl- $S(O)_{0-2}$ - C_1 - C_6 alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, wherein the 5 to 10-membered heterocyclyl is a 6-membered heterocyclyl.

- In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein
20 R^{38} is C_1 - C_6 alkyl- $S(O)_{0-2}$ - C_1 - C_6 alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, which is




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$, wherein the 5 to 10-membered heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$, wherein the 5 to 10-membered heterocyclyl is a 6-membered heterocyclyl and each of R^{37} and R^{37a} are H.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$, which is



In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}S(O)_{0-2}\text{-aryl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}S(O)_{0-2}\text{-aryl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$, wherein the 5 to 10-membered heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}S(O)_{0-2}\text{-aryl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}-$,




which is

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}O-C_1-C_6\text{alkyl}-\text{piperazine}-C_1-C_6\text{alkyl}-$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein

R^{38} is $R^{37}O-C_1-C_6\text{alkyl}-\text{piperazine}-C_1-C_6\text{alkyl}-$, wherein D is $R^{38}-N$

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein

5 R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, wherein the 5 to 10-membered heterocycl is a six-membered heterocycl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein

10 R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, wherein D is




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, wherein the 5 to

10-membered heterocycl is a six-membered heterocycl and wherein D is .


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein

15 R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, which is




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$.

20 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein


R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, wherein D is .

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, wherein R^9 and R^{10} are independently H or $C_1-C_4\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, wherein R^9 and R^{10} are independently H

or $C_1-C_4\text{alkyl}$, and D is .

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein




5 R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-piperazine-}C_1-C_6\text{alkyl-}$, which is


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N}(R^{37})-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein
10 R^{38} is $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N}(R^{37})-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, wherein the 5 to 10-membered heterocycl is a six-membered heterocycl.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N}(R^{37})-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-$

$C_6\text{alkyl-}$, and D is .

15 In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N}(R^{37})-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-C_6\text{alkyl-}$, wherein the 5 to 10-membered heterocycl is a six-membered heterocycl, and D is




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein
20 R^{38} is $R^{37a}O-C(O)-C_1-C_6\text{alkyl-N}(R^{37})-C(O)-C_1-C_6\text{alkyl-(5 to 10-membered heterocycl)-}C_1-$

$C_6\text{alkyl-}$, which is .


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is $R^{11}-C_1-C_6\text{alkyl-C(O)-piperazine-}C_1-C_6\text{alkyl-}$.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein

25 R^{38} is $R^{11}-C_1-C_6\text{alkyl-C(O)-piperazine-}C_1-C_6\text{alkyl-}$ and D is .


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is R^{11} -C₁-C₆alkyl-C(O)-piperazine-C₁-C₆alkyl-, wherein R^{11} is -O-(amino acid).

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is R^{11} -C₁-C₆alkyl-C(O)-piperazine-C₁-C₆alkyl-, wherein R^{11} is -O-(amino acid) and D is



In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is C₀-C₆alkyl-(5 or 6-membered heterocyclyl)-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-.


In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is C₀-C₆alkyl-(5 or 6-membered heterocyclyl)-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-, wherein




In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-O-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-O-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein the 5-10-membered optionally substituted heterocycle is a 6-membered heterocycle, optionally substituted with C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-O-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein the oxo substituted 5 to 10-membered


heterocycle is a 5-membered heterocycle, for example  .

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-O-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein the 5-10-membered optionally substituted heterocycle is a 6-membered heterocycle, optionally substituted with C₁-C₆alkyl and the oxo

substituted 5 to 10-membered heterocycle is a 5-membered heterocycle, for example  .

In some embodiments of the first aspect, the compounds have the Formula (Ia), wherein R^{38} is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-O-(oxo substituted 5 to

10-membered heterocycle)-C₁-C₆alkyl-, selected from the group consisting of




In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R³⁸ is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R³⁸ is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein 5-10-membered optionally substituted heterocycle is a 6-membered heterocycle, optionally substituted with C₁-C₆alkyl.


In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R³⁸ is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein the oxo substituted 5 to 10-membered

heterocycle is a 5-membered heterocycle, for example




In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R³⁸ is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein 5-10-membered optionally substituted heterocycle is a 6-membered heterocycle, optionally substituted with C₁-C₆alkyl and the oxo

substituted 5 to 10-membered heterocycle is a 5-membered heterocycle, for example




In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R³⁸ is (5-10-membered optionally substituted heterocycle)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocycle)-C₁-C₆alkyl-, wherein 5-10-membered optionally substituted heterocycle is a 6-membered heterocycle, optionally substituted with C₁-C₆alkyl and the oxo


substituted 5 to 10-membered heterocycle is a 5-membered heterocycle, for example



selected from the group consisting of



and



In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is (5-10-membered optionally substituted heterocycle)- C_1 - C_6 alkyl-S(O)₀₋₂-(oxo substituted 5 to 10-membered heterocycle)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $(R^{23})(R^{24})P(O)-C_1-C_6$ alkyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $(R^{23})(R^{24})(O)P-C_1-C_6$ alkyl-N(R^{37})- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $(R^9)(R^{10})N-C(H)(R^{28})$ -.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6$ alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6$ alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, wherein the heterocyclyl is selected from the group consisting of tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidine, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, dioxanyl, oxathianyl, morpholinyl, dithianyl, piperazinyl, azathianyl, oxepanyl, theipanyl, azepanyl, dioxepanyl, oxatheipanyl, oxaazepanyl, dithiepanyl, thieazepanyl and diazepanyl.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6$ alkyl-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, wherein the heterocyclyl is selected from the group consisting of piperidinyl, morpholinyl and piperazinyl.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6$ alkyl-C(O)-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6$ alkyl-C(O)-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, wherein the heterocyclyl is selected from the group consisting of tetrahydrofuranyl,

tetrahydrothiophenyl, pyrrolidine, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, dioxanyl, oxathianyl, morpholinyl, dithianyl, piperazinyl, azathianyl, oxepanyl, theipanyl, azepanyl, dioxepanyl, oxatheipanyl, oxazepanyl, dithiepanyl, thiazepanyl and diazepanyl.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 5 R^{38} is $R^{29}O-C(O)-C(H)(C(O)-OR^{29a})-O-C_1-C_6alkyl-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6alkyl-$, wherein the heterocyclyl is selected from the group consisting of piperidinyl, morpholinyl and piperazinyl.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 10 R^{23} is selected from the group consisting of H, C_1-C_6alkyl , aryl, cycloalkyl, heteroaryl, 5 to 10-membered heterocyclyl, $-C_1-C_6alkyl-aryl$, $-C_1-C_6alkyl-heteroaryl$, $-C_1-C_6alkyl-cycloalkyl$ and $-C_1-C_6alkyl-(5 \text{ to } 10\text{-membered heterocyclyl})$.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 15 R^{23} is selected from the group consisting of -OH, $C_1-C_6alkoxy$, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl), -O- $C_1-C_6alkyl-aryl$, -O- $C_1-C_6alkyl-heteroaryl$, -O- $C_1-C_6alkyl-cycloalkyl$ and -O- $C_1-C_6alkyl-(5 \text{ to } 10\text{-membered heterocyclyl})$.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 20 R^{24} is selected from the group consisting of H, C_1-C_6alkyl , aryl, cycloalkyl, heteroaryl, 5 to 10-membered heterocyclyl, $-C_1-C_6alkyl-aryl$, $-C_1-C_6alkyl-heteroaryl$, $-C_1-C_6alkyl-cycloalkyl$ and $-C_1-C_6alkyl-(5 \text{ to } 10\text{-membered heterocyclyl})$.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 25 R^{24} is selected from the group consisting of -OH, $C_1-C_6alkoxy$, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl), -O- $C_1-C_6alkyl-aryl$, -O- $C_1-C_6alkyl-heteroaryl$, -O- $C_1-C_6alkyl-cycloalkyl$ and -O- $C_1-C_6alkyl-(5 \text{ to } 10\text{-membered heterocyclyl})$.

In some embodiments of the first aspect, the compounds have the Formula (a), wherein
 30 R^{28} is selected from the group consisting of $-CF_3$, $-CHF_2$, $-CH_2F$, CN, optionally substituted C_1-C_6alkyl and $C_3-C_6cycloalkyl$.

In some embodiments of the first aspect, the compounds have the Formula (a), wherein
 R^{28} is selected from the group consisting of $-CF_3$, $-CHF_2$, $-CH_2F$ and CN.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 35 R^{29} is H or C_1-C_6alkyl .

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
 R^{29a} is H or C_1-C_6alkyl .


In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{29} is a cation, for example a pharmaceutically acceptable cation, for example a cation selected from the group consisting of Li^+ , Na^+ , K^+ , $Mg^{2+}/2$ and $Ca^{2+}/2$.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
5 R^{29} is Na^+ or K^+ .


In some embodiments of the first aspect, the compounds have the Formula (1a), wherein R^{29a} is a cation, for example a pharmaceutically acceptable cation, for example a cation selected from the group consisting of Li^+ , Na^+ , K^+ , $Mg^{2+}/2$ and $Ca^{2+}/2$.

In some embodiments of the first aspect, the compounds have the Formula (1a), wherein
10 R^{29a} is Na^+ or K^+ .

In some embodiments of the first aspect, compounds of the present invention have the formulas Formula (II) and Formula (III):



(II)



(III)

including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

20 D is selected from the group consisting of pyridine, phenyl, imidazole, pyrazole, and tetrahydropyridine, wherein the pyridine, phenyl, imidazole, pyrazole and tetrahydropyridine are substituted with one R^{38} , or D is unsubstituted tetrahydropyridine; R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, (oxo substituted heterocyclyl)- C_1-C_2 alkyl- (wherein the oxo substituted heterocyclyl is further optionally
25 substituted with a substituent selected from the group consisting of $-N(R^9)(R^{10})$, C_1-C_6 alkyl, $-N(R^{37})(Ac)$, and $-OH$), $R^{37}O-(CH_2)_n-O-(CH_2)_n C(O)-N(R^{40})-CH_2-$, C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$, (heterocyclyl)- $C(O)-$ (wherein the heterocyclyl is optionally substituted with C_1-C_6 alkyl), C_1-C_6 alkyl- $S(O)_2-(CH_2)_2-N(A)-CH_2-$, C_0-C_6 alkyl-heterocyclyl- $(CH_2)_{1-3}-$, $HO-$

- heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₀-C₆alkyl-heterocyclyl-C(O)-, (C₁-C₆alkyl)-C(O)-heterocyclyl-CH₂-, R³⁷O-C₁-C₆alkyl-heterocyclyl-CH₂-, R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-(CH₂)₁₋₆-, C₀-C₆alkyl-heterocyclyl-C₁-C₆alkyl-N(R³⁹)-C(O)-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(A)-(CH₂)_{j1}-, R³⁷O-C(O)-C₀-C₆alkyl-heterocyclyl-CH₂-,
5 R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(R³⁹)-C(O)-, R³⁷-O-C(O)-C₁-C₆alkyl-heterocyclyl-C(O)-, HOOC-C₁-C₆alkyl-N(A)-CH₂-, (HOOC)(NR⁹R¹⁰)-C₁-C₆alkyl-N(A)-CH₂-, R³⁷-O-C(O)-heterocyclyl-C(O)-, C₀-C₆alkyl-heterocyclyl-C₀-C₆alkyl-heterocyclyl-C(O)-, R³⁷O-C(O)-C₁-C₆alkyl-C(O)-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, cycloalkyl-N(R³⁹)-C(O)-O-C₁-C₆alkyl-, R³⁷-O-C₁-C₆alkyl-O-C₁-C₆alkyl-C(O)-, C₁-C₆alkyl-SO₂-, (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, R³⁷O-C₁-C₆alkyl-heterocyclyl-CH₂-, (HO- substituted C₁-C₆alkyl-N(R³⁹)-C(O)-, NC-C₁-C₆alkyl-heterocyclyl-CH₂-, heterocyclyl-C₁-C₆alkyl-heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂-, C₁-C₆alkyl-S(O)₂-heterocyclyl-CH₂-, heteroaryl-C₁-C₆alkyl-heterocyclyl-CH₂-, R³⁷O-C₁-C₆alkyl-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl-, (di-fluoro substituted heterocyclyl)-C₁-C₆alkyl-, C₀-C₆alkyl-(5 or 6-membered heterocyclyl)-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-, H(O)C- and C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-, R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-C₁-C₆alkyl-;
20 wherein when D is imidazole, the imidazole is further optionally substituted with C₁-C₆alkyl;
R³⁷ is H, C₁-C₆alkyl;
R^{37a} is H, C₁-C₆alkyl;
A is H, Ac, -C(O)-CH₂-OMe, -C(O)-CH(NH₂)-C(CH₃)₃, -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(O)-H, -C(O)-C₁-C₆alkyl, -C₁-C₆alkyl-O-C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R³⁹)-cycloalkyl, -C(O)-N(R⁹)(R¹⁰), (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-, C₁-C₆alkyl and -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)-C(O)-OBn;
j is an integer ranging from 0 to 4, alternatively 0 to 2;
i is 2 or 3;
30 x is an integer ranging from 0 to 6, alternatively 2 or 3;
il is 2 or 3;
j1 is an integer ranging from 0 to 4, alternatively 1 or 2;
n is an integer ranging from 0 to 4;
n1 is an integer ranging from 0 to 4;
35 R³⁹ is H, C₁-C₆alkyl,

R^{40} is C_1 - C_6 alkyl- OR^{41} ;

R^{41} is H, C_1 - C_6 alkyl;

R^9 is H, C_1 - C_6 alkyl;

R^{10} is H, C_1 - C_6 alkyl;


5 R^{23} is selected from the group consisting of -OH, C_1 - C_6 alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl and -O-(5 to 10-membered heterocyclyl);

R^{24} is selected from the group consisting of -OH, C_1 - C_6 alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl);

R^2 is H or F;

10 R^{2a} is H, F, Cl;

G is selected from the group consisting of



R^{13} is H or C_1 - C_6 alkyl; and

15 each R^{20} is independently selected from the group consisting of H, halo, - $PO(C_1$ - C_6 alkyl) $_2$, - $S(O)_2$ - C_1 - C_6 alkyl) and - $C(O)$ - NH_2 .

In some embodiments of the first aspect, the compounds have the Formula (II).

In some embodiments of the first aspect, the compounds have the Formula (II), wherein

20 D is pyridine substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is selected from the group consisting of

25 $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0$ - C_6 alkyl-heterocyclyl- CH_2- , $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}O-C(O)-C_1$ - C_6 alkyl-heterocyclyl- $C(O)-$, C_0 - C_6 alkyl-heterocyclyl- C_0 - C_6 alkyl-heterocyclyl- $C(O)-$, $(R^9)(R^{10})N-C_1$ - C_6 alkyl- $C(O)$ -heterocyclyl- CH_2- , $(R^9)(R^{10})N-C(O)-C_1$ - C_6 alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_1$ - C_6 alkyl- $C(O)-O-C_1$ - C_6 alkyl-heterocyclyl- CH_2- , $NC-C_1$ - C_6 alkyl-

heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂- and N(R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is selected from the group consisting of

5 R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(A)-(CH₂)_{jl}-, R³⁷O-C(O)-C₀-C₆alkyl-heterocyclyl-CH₂-, R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(R³⁹)-C(O)-, R³⁷-O-C(O)-C₁-C₆alkyl-heterocyclyl-C(O)-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, NC-C₁-C₆alkyl-heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂- and N(R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

10

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄- or R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-(CH₂)_{il}-N(A)-(CH₂)_{jl}-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-.

15

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, alternatively R³⁷O-(CH₂)₂-N(A)-(CH₂)-, alternatively R³⁷O-(CH₂)₂-N(A)-(CH₂)₂-.

20 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-.

25 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₂-N(A)-(CH₂)-, and A is selected from the group consisting of -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰) and (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-.


30 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₂-N(A)-(CH₂)₂-, and A is -C(O)-N(R³⁹)-C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R³⁸, wherein R³⁸ is R³⁷O-(CH₂)₂-N(A)-(CH₂)-, and A is -C(O)-N(R³⁹)-C₁-C₆alkyl.

35

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is -C(O)-H.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (oxo substituted heterocyclyl)-C₁-C₂alkyl-; in some embodiments of the first aspect, the compounds have the Formula (II),



In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C₀-C₆alkyl-heterocyclyl-(CH₂)₁₋₃-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C₀-C₆alkyl-(7-membered heterocyclyl)-CH₂-. In some embodiments, the C₀-C₆alkyl-heterocyclyl-(CH₂)₁₋₃- is CH₃-(7-membered heterocyclyl)-CH₂-, for example C₀-C₆alkyl-(1,4-diazepanyl)-CH₂-, for example CH₃-(1,4-diazepanyl)-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}$ -, and A is -C(O)-N(R³⁹)-C₁-C₆alkyl,

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}-O-C(O)-C_1-C_6$ alkyl-heterocyclyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C₀-C₆alkyl-heterocyclyl-C₀-C₆alkyl-heterocyclyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$.

5 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-heterocyclyl-CH_2-$.

10 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $NC-C_1-C_6alkyl-heterocyclyl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $F_3C-C_1-C_6alkyl-heterocyclyl-CH_2-$.

15 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $N(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6alkyl-$.

20 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein the phenyl ring of group G is substituted with one R^{20} , which is $-PO(C_1-C_6alkyl)_2$, said R^{20} being ortho to the point of attachment of the nitrogen atom attached to the phenyl ring.

25 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , and wherein the phenyl ring of group G is substituted with one R^{20} , which is $-PO(C_1-C_6alkyl)_2$, said R^{20} being ortho to the point of attachment of the nitrogen atom attached to the phenyl ring.

30 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and wherein the phenyl ring of group G is substituted with one R^{20} , which is $-PO(C_1-C_6alkyl)_2$, said R^{20} being ortho to the point of attachment of the nitrogen atom attached to the phenyl ring.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- $C_1-C_6alkyl-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl-, wherein the optional substituent is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, C_1 - C_6 alkyl, $-C(O)-C_1$ - C_6 alkyl- OH , Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1$ - C_6 alkyl, $-S(O)_{0-2}$ -cycloalkyl, $-S(O)_{0-2}$ -heterocyclyl, $-S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1$ - C_6 alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1$ - C_6 alkyl- OH , $-C_1$ - C_6 alkyl- $C(O)-OH$ and $-C_1$ - C_6 alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1$ - C_6 alkyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (di-fluoro substituted heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C_0 - C_6 alkyl-(5 or 6-membered heterocyclyl)- C_1 - C_6 alkyl-piperazine- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C_1$ - C_6 alkyl- $C(O)$ -heterocyclyl- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl (for example, $-CH_3$).

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}$ - $N(A)-(CH_2)_{1-4}$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}$ - $N(A)-(CH_2)_{1-4}$ -, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-N(R^{39})$ -cycloalkyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl, wherein R^{38} is $R^{37}O-(CH_2)_2$ - $N(A)-(CH_2)$ -, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-N(R^{39})$ -cycloalkyl.


In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} and one C_1 - C_6 alkyl, wherein R^{38} is $R^{37}O-(CH_2)_2$ - $N(A)-(CH_2)$ -, and A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is C_0 - C_6 alkyl-heterocyclyl- $(CH_2)_{1-3}$ -, for example, piperazine- $(CH_2)_2$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is C_1 - C_6 alkyl-C(O)-O- C_1 - C_6 alkyl-C(O)-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is C_1 - C_6 alkyl-C(O)-O- C_1 - C_6 alkyl-C(O)-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl- wherein the heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein R^{38} is C_1 - C_6 alkyl-C(O)-O- C_1 - C_6 alkyl-C(O)-(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-,



In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is R^{37} O- C_1 - C_6 alkyl-C(O)-heterocyclyl- $(CH_2)_{1-6}$ -, for example, HO- C_1 - C_6 alkyl-C(O)-heterocyclyl- $(CH_2)_{1-2}$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is R^{37} O- C_1 - C_6 alkyl-C(O)-heterocyclyl- $(CH_2)_{1-6}$ -, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is R^{37} O- C_1 - C_6 alkyl-C(O)-heterocyclyl- $(CH_2)_{1-6}$ -, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl, R^{37} is H and the $(CH_2)_{1-6}$ is $-(CH_2)_{1-2}$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is phenyl substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is R^{37} O- $(CH_2)_{1-6}$ -N(A)- $(CH_2)_{1-4}$ -.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is R^{37} O- $(CH_2)_{1-6}$ -N(A)- $(CH_2)_{1-4}$ -, and A is -C(O)-N(R^{39})- C_1 - C_6 alkyl or -C(O)-N(R^{39})-cycloalkyl.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is phenyl substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1-C_6alkyl$ or $-C(O)-N(R^{39})-cycloalkyl$.

5 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is tetrahydropyridine substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$ or $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$.

10 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is tetrahydropyridine substituted with one R^{38} , wherein R^{38} is $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$.

15 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$ or $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

20 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein R^{38} is $cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$ or $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6alkyl$.

25 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$.

30 In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6alkyl$.

In some embodiments of the first aspect, the compounds have the Formula (II), wherein D is pyrazole substituted with one R^{38} , wherein the R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_2-$, and A is $-C(O)-N(R^{39})-C_1-C_6alkyl$.

In some embodiments of the first aspect, the compounds have the Formula (III).

In some embodiments of the first aspect, the compounds have the Formula (III), wherein D is pyridine, substituted with one R^{38} .

In some embodiments of the first aspect, the compounds have the Formula (III), wherein D is

5 pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, alternatively $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$.


In some embodiments of the first aspect, the compounds have the Formula (III), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is -C(O)-N(R^{39})-C₁-C₆alkyl.


10 In some embodiments of the first aspect, the compounds have the Formula (III), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$, and A is -C(O)-N(R^{39})-C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein D is further selected from the group heterocycle-C $\equiv$ C-, alternatively
15 morpholine-C $\equiv$ C-.


In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, (C₁-C₆alkyl-S(O)₂-(CH₂)₂-N(A)-CH₂-, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}-$
20 O-C(O)-C₁-C₆alkyl-heterocyclyl-C(O)-, HOOC-C₁-C₆alkyl-N(A)-CH₂-, (HOOC)(NR⁹R¹⁰)-C₁-C₆alkyl-N(A)-CH₂-, $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, cycloalkyl-N(R³⁹)-C(O)-O-C₁-C₆alkyl-, $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$, (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, NC-C₁-C₆alkyl-heterocyclyl-CH₂-, F₃C-C₁-C₆alkyl-heterocyclyl-CH₂- and
25 (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (oxo substituted heterocyclyl)-C₁-C₂alkyl-, wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of -N(R⁹)(R¹⁰), C₁-C₆alkyl, -N(R³⁷)(Ac), and -OH. Alternatively R^{38} is






In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R³⁸ is (oxo substituted heterocyclyl)-C₁-C₂alkyl-, wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of -N(R⁹)(R¹⁰), C₁-C₆alkyl, -N(R³⁷)(Ac), and -OH. Alternatively R³⁸ is



In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R³⁸ is (oxo substituted heterocyclyl)-C₁-C₂alkyl-, wherein the oxo substituted heterocyclyl is further substituted with a substituent selected from the group consisting of -N(R⁹)(R¹⁰), C₁-C₆alkyl, -N(R³⁷)(Ac), and -OH.


In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R³⁸ is C₁-C₆alkyl-heterocyclyl-(CH₂)₁₋₂-, alternatively C₁-C₆alkyl-piperazine-CH₂- or CH₃-piperazine-(CH₂)₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R³⁸ is (heterocyclyl)-C(O)-, wherein the heterocyclyl is optionally




substituted with C₁-C₆alkyl.. Alternatively R³⁸ is

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (heterocyclyl)-C(O)-, wherein the heterocyclyl is substituted with



In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C₀-C₆alkyl-heterocyclyl-(CH₂)₁₋₃-, alternatively heterocyclyl-



In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is HO-heterocyclyl-CH₂-, alternatively HO-pyrrolidine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (R⁹)(R¹⁰)N-heterocyclyl-CH₂-, alternatively NH₂-pyrrolidine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (R⁹)(R¹⁰)N-C₀-C₆alkyl-heterocyclyl-C(O)-, alternatively N(CH₃)₂-pyrrolidine-C(O)- or (CH(CH₃)₂)₂N-(CH₂)₂-piperazine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (C₁-C₆alkyl)-C(O)-heterocyclyl-CH₂-, alternatively CH₃-C(O)-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R³⁷O-C₁-C₆alkyl-heterocyclyl-CH₂-, for example, HO-C₁-C₆alkyl-heterocyclyl-CH₂-, alternatively HO-(CH₂)₂-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is HO-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, alternatively HO-(CH₂)-C(O)-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C₀-C₆alkyl-heterocyclyl-C₁-C₆alkyl-N(R³⁹)-C(O)-, alternatively morpholine-(CH₂)₂-NH-C(O)-, morpholine-(CH₂)₃-NH-C(O)- or CH₃-piperazine-(CH₂)₂-NH-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R^{37} -O-C(O)-heterocyclyl-C(O)-, alternatively EtO-C(O)-piperidine-C(O)-, BuO-C(O)-morpholine-C(O)-, HO-C(O)-piperidine-C(O)- or HO-C(O)-morpholine-C(O)-.

5 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C_0 - C_6 alkyl-heterocyclyl- C_0 - C_6 alkyl-heterocyclyl-C(O)-, alternatively C_0 - C_6 alkyl-heterocyclyl- C_1 - C_6 alkyl-heterocyclyl-C(O)-, morpholine-(CH_2)₂-piperazine-C(O)-, CH_3 -piperidine- CH_2 -piperazine-C(O)- or CH_3 -piperazine-piperidine-C(O)-.

10 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is CH_3 -piperazine-piperidine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C_1 - C_6 alkyl-SO₂-, alternatively Me-S(O)₂-.

15 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R^{37} O- C_1 - C_6 alkyl-heterocyclyl- CH_2 -, alternatively MeO-(CH_2)₂-piperazine- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (HO- substituted C_1 - C_6 alkyl-N(R^{39})-C(O)-, alternatively HO- CH_2 -[CH(OH)]₄- CH_2 -N(Me)-C(O)-.

20 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is heterocyclyl- C_1 - C_6 alkyl-heterocyclyl- CH_2 -, alternatively morpholine-(CH_2)₂-piperazine- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C_1 - C_6 alkyl-S(O)₂-heterocyclyl- CH_2 -, alternatively Me-S(O)₂-piperazine- CH_2 -.

25 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is heteroaryl- C_1 - C_6 alkyl-heterocyclyl- CH_2 -, imidazole-(CH_2)₂-piperazine- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R^{37} O- C_1 - C_6 alkyl-, alternatively HO-(CH_2)₄-.

30 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R^{37} O-(CH_2)₁₋₆-N(A)-(CH₂)₁₋₄-, alternatively R^{37} O-(CH₂)₂-N(A)-(CH₂)₁₋₂-, MeO-(CH₂)₂-N(A)-CH₂- or MeO-(CH₂)₂-N(A)-(CH₂)₂-.

35 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C_1 - C_6 alkyl-S(O)₂-(CH₂)₂-N(A)-CH₂-, alternatively CH_3 -S(O)₂-(CH₂)₂-N(A)-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-CH_2-$.

5 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$, alternatively $R^{37}O-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$, alternatively $HO-C(O)-(CH_2)_2-piperazine-CH_2-$, $EtO-C(O)-piperidine-CH_2-$, $EtO-C(O)-CH_2-piperidine-CH_2-$, $EtO-C(O)-CH_2-piperazine-CH_2-$, $HO-C(O)-piperidine-CH_2-$, $HO-C(O)-CH_2-piperidine-CH_2-$, $HO-C(O)-CH_2-piperazine-CH_2-$, $(CH_3)_3C-O-C(O)-piperazine-CH_2-$ or $HO-C(O)-pyrrolidine-CH_2-$.

10 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-C(O)-$.


In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$, alternatively $CH_3-CH_2-O-C(O)-(CH_2)_2-piperazine-C(O)-$ or $HO-C(O)-(CH_2)_2-piperazine-C(O)-$.

15 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $HOOC-C_1-C_6alkyl-N(A)-CH_2-$, alternatively $HOOC-(CH_2)_3-N(A)-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $(HOOC)(NR^9R^{10})-C_1-C_6alkyl-N(A)-CH_2-$, alternatively $(HOOC)(NH_2)CH-(CH_2)_4-N(A)-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$, alternatively $HO-C(O)-(CH_2)_2-C(O)-$.

25 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$, alternatively




In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$, alternatively $C_3cycloalkyl-NH-C(O)-O-(CH_2)_2-$.


30

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is R^{37} -O-C₁-C₆alkyl-O-C₁-C₆alkyl-C(O)-, alternatively MeO-(CH₂)₂-O-CH₂-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (R⁹)(R¹⁰)N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, alternatively



In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-,




alternatively

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is NC-C₁-C₆alkyl-heterocyclyl-CH₂-, alternatively NC-(CH₂)₂-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is F₃C-C₁-C₆alkyl-heterocyclyl-CH₂-, alternatively F₃C-CH₂-piperazine-CH₂-.


In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-heterocyclyl-



CH₂-, alternatively

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (optionally substituted 8- membered fused heterocyclyl)-C₁-



C₆alkyl, which is

, wherein

G is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

5 G¹ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G² is CH or N;

G³ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G⁴ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

G⁵ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

10 G⁶ is CH or N;


G⁷ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂;

R^s is an optional substituent; and

R^{s1} is an optional substituent,

provided that two O atoms are not adjacent to each other.


15 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-



C₆alkyl, selected from the group consisting of

In some embodiments of the first aspect, the compounds have the Formula (II) or

20 Formula (III), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-



wherein G is selected from the group consisting of CH₂, O, NH, S, SO and SO₂; G¹ is selected from the group consisting of CH₂, O, NH, S, SO and SO₂; and R^s is an optional substituent.

- 5 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^s is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH, -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

- 15 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{s1} is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH, -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

- 20 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R³⁸ is (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl-, wherein the optional substituent is selected from the group consisting of H, halo, -N(R⁹)(R¹⁰), nitro, -OH, oxo, C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, -S(O)₀₋₂-C₁-C₆alkyl, -S(O)₀₋₂-cycloalkyl, -S(O)₀₋₂-heterocyclyl, -S(O)₀₋₂-aryl, -S(O)₀₋₂-heteroaryl, -C(O)H, -C(O)-C₁-C₆alkyl, -C(O)-N(R⁹)(R¹⁰), -C₁-C₆alkyl-OH, -C₁-C₆alkyl-C(O)-OH and -C₁-C₆alkyl-C(O)-N(R⁹)(R¹⁰), wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (di-fluoro substituted heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is (di-fluoro substituted heterocyclyl)- C_1 - C_6 alkyl-, wherein the two
5 fluoro substituents are substituents on the same carbon atom.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is C_0 - C_6 alkyl-(5 or 6-membered heterocyclyl)- C_1 - C_6 alkyl-piperazine- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (II) or
10 Formula (III), wherein R^{38} is $R^{37}O$ - C_1 - C_6 alkyl-C(O)-heterocyclyl-(CH_2)₁₋₆-, for example, HO- C_1 - C_6 alkyl-C(O)-heterocyclyl-(CH_2)₁₋₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O$ - C_1 - C_6 alkyl-C(O)-heterocyclyl-(CH_2)₁₋₆-, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl.

15 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O$ - C_1 - C_6 alkyl-C(O)-heterocyclyl-(CH_2)₁₋₆-, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl, R^{37} is H and the -(CH_2)₁₋₆- is -(CH_2)₁₋₂-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{38} is $R^{37}O$ - C_1 - C_6 alkyl-C(O)-heterocyclyl- CH_2 -, for example, HO- C_1 -
20 C_6 alkyl-C(O)-heterocyclyl- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is selected from the group consisting of -C(O)- C_1 - C_6 alkyl-N(R^{39})-C(O)- C_1 - C_6 alkyl-N(R^9)(R^{10}), -C(O)-N(R^{39})- C_1 - C_6 alkyl, -C(=N R^{37})- C_1 - C_6 alkyl, -C(O)-(CH_2)_n-
25 S(O)₂- C_1 - C_6 alkyl, -C(O)-N(R^{39})-cycloalkyl and -C(O)-N(R^9)(R^{10}), (R^{23})(R^{24})P(O)O- C_1 - C_6 alkyl-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is H.

In some embodiments of the first aspect, the compounds have the Formula (II) or
30 Formula (III), wherein A is not H.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is Ac.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is -C(O)- CH_2 -OMe.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(\text{O})-\text{CH}(\text{NH}_2)-\text{C}(\text{CH}_3)_3$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(\text{O})-\text{H}$, $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(\text{O})-\text{CH}_3$, $-\text{C}(\text{O})-\text{CH}_2-$
5 CH_3 .

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-(\text{CH}_2)_2-\text{OMe}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{OH}$.

10 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^{39})-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^9)(\text{R}^{10})$, alternatively $-\text{C}(\text{O})-\text{CH}_2-\text{NH}-\text{C}(\text{O})-\text{CH}(\text{NH}_2)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{O})-\text{CH}_2-\text{NH}-\text{C}(\text{O})-\text{CH}_2-\text{NH}_2$ or $-\text{C}(\text{O})-\text{CH}[\text{CH}(\text{CH}_3)_2]-\text{NH}-\text{C}(\text{O})-\text{CH}_2-\text{NH}_2$.

In some embodiments of the first aspect, the compounds have the Formula (II) or
15 Formula (III), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(\text{O})-\text{NH}-\text{CH}_2-\text{CH}_3$, $-\text{C}(\text{O})-\text{NH}-\text{CH}_3$, $-\text{C}(\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$ or $-\text{C}(\text{O})-\text{N}(\text{CH}_3)_2$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(=\text{NR}^{37})-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(=\text{NH})\text{H}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or
20 Formula (III), wherein A is $-\text{C}(\text{O})-(\text{CH}_2)_n-\text{S}(\text{O})_2-\text{C}_1-\text{C}_6\text{alkyl}$, alternatively $-\text{C}(\text{O})-\text{CH}_2-\text{S}(\text{O})_2-\text{Me}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{cycloalkyl}$, alternatively $-\text{C}(\text{O})-\text{NH}-\text{cyclopentyl}$ or $-\text{C}(\text{O})-\text{NH}-\text{C}_3\text{cycloalkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or
25 Formula (III), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^9)(\text{R}^{10})$, alternatively $-\text{C}(\text{O})-\text{NH}_2$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is $(\text{R}^{23})(\text{R}^{24})\text{P}(\text{O})\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-$, alternatively $(\text{HO})_2\text{P}(\text{O})\text{O}-\text{CH}_2-\text{C}(\text{O})-$.

In some embodiments of the first aspect, the compounds have the Formula (II) or
30 Formula (III), wherein A is $\text{C}_1-\text{C}_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein A is not $\text{C}_1-\text{C}_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein R^{13} is H.

In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein each R^{20} is independently H or halo (for example, Br, Cl or F, alternatively F).

5 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein G includes a single R^{20} substituent.


In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein G includes a single R^{20} substituent selected from the group consisting of $-\text{PO}(\text{C}_1\text{-C}_6\text{alkyl})_2$ (for example, $-\text{PO}(\text{Me})_2$), $-\text{S}(\text{O})_2\text{-C}_1\text{-C}_6\text{alkyl}$ (for example, $-\text{S}(\text{O})_2\text{Me}$) and $-\text{C}(\text{O})\text{-NH}_2$.

10 In some embodiments of the first aspect, the compounds have the Formula (II) or Formula (III), wherein

R^{38} is selected from the group consisting of $R^{37}\text{O}-(\text{CH}_2)_{1-6}\text{-N}(\text{A})-(\text{CH}_2)_{1-4}\text{-}$, $(\text{C}_1\text{-C}_6\text{alkyl-S}(\text{O})_2-(\text{CH}_2)_2\text{-N}(\text{A})\text{-CH}_2\text{-}$, $R^{37}\text{O}-(\text{CH}_2)_j\text{-}[(\text{CH}_2)_i\text{O}]_x\text{-(CH}_2)_{i1}\text{-N}(\text{A})-(\text{CH}_2)_{j1}\text{-}$, $R^{37}\text{O-C}(\text{O})\text{-C}_0\text{-C}_6\text{alkyl-heterocyclyl-CH}_2\text{-}$, $R^{37}\text{O}-(\text{CH}_2)_j\text{-}[(\text{CH}_2)_i\text{O}]_x\text{-(CH}_2)_{i1}\text{-N}(\text{R}^{39})\text{-C}(\text{O})\text{-}$, $R^{37}\text{-O-C}(\text{O})\text{-C}_1\text{-C}_6\text{alkyl-heterocyclyl-C}(\text{O})\text{-}$, $\text{HOOC-C}_1\text{-C}_6\text{alkyl-N}(\text{A})\text{-CH}_2\text{-}$, $(\text{HOOC})(\text{NR}^9\text{R}^{10})\text{-C}_1\text{-C}_6\text{alkyl-N}(\text{A})\text{-CH}_2\text{-}$, $R^{37}\text{O-C}(\text{O})\text{-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-}$, $(\text{R}^9)(\text{R}^{10})\text{N-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-heterocyclyl-CH}_2\text{-}$, $\text{cycloalkyl-N}(\text{R}^{39})\text{-C}(\text{O})\text{-O-C}_1\text{-C}_6\text{alkyl-}$, $R^{37}\text{-O-C}_1\text{-C}_6\text{alkyl-O-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-}$, $(\text{R}^9)(\text{R}^{10})\text{N-C}(\text{O})\text{-C}_1\text{-C}_6\text{alkyl-heterocyclyl-CH}_2\text{-}$, $(\text{R}^9)(\text{R}^{10})\text{N-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-O-C}_1\text{-C}_6\text{alkyl-heterocyclyl-CH}_2\text{-}$, $\text{NC-C}_1\text{-C}_6\text{alkyl-heterocyclyl-CH}_2\text{-}$, $\text{F}_3\text{C-C}_1\text{-C}_6\text{alkyl-heterocyclyl-CH}_2\text{-}$ and $(\text{R}^9)(\text{R}^{10})\text{N-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-O-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-heterocyclyl-CH}_2\text{-}$; and

A is selected from the group consisting of $-\text{C}(\text{O})\text{-C}_1\text{-C}_6\text{alkyl-N}(\text{R}^{39})\text{-C}(\text{O})\text{-C}_1\text{-C}_6\text{alkyl-N}(\text{R}^9)(\text{R}^{10})$, $-\text{C}(\text{O})\text{-N}(\text{R}^{39})\text{-C}_1\text{-C}_6\text{alkyl}$, $-\text{C}(=\text{NR}^{37})\text{-C}_1\text{-C}_6\text{alkyl}$, $-\text{C}(\text{O})\text{-(CH}_2)_n\text{-S}(\text{O})_2\text{-C}_1\text{-C}_6\text{alkyl}$, $-\text{C}(\text{O})\text{-N}(\text{R}^{39})\text{-cycloalkyl}$, $-\text{C}(\text{O})\text{-N}(\text{R}^9)(\text{R}^{10})$ and $(\text{R}^{23})(\text{R}^{24})\text{P}(\text{O})\text{O-C}_1\text{-C}_6\text{alkyl-C}(\text{O})\text{-}$.

In some embodiments of the first aspect, the compounds have the Formula (IV):





including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of pyridine, phenyl, imidazole and heterocycle-C≡C-

5 (for example, morpholine-C≡C-), wherein said pyridine, phenyl and imidazole are each substituted with one R³⁸;

R³⁸ is selected from the group consisting of R³⁷O-(CH₂)₂-N(A)-CH₂- (for example, R³⁷O-

(CH₂)₂-N(A)-CH₂-), (oxo substituted heterocyclyl)-C₁-C₆alkyl- (for example ) ,

and (heterocyclyl)-C(O)- (for example, ) ,

10 wherein when D is imidazole, the imidazole is further optionally substituted with C₁-C₆alkyl (for example, -CH₃);

R³⁷ is H or C₁-C₆alkyl;

A is H or Ac;


R² is F;

15 R^{2a} is H; and

each R²⁰ is independently selected from the group consisting of H, -PO(C₁-C₆alkyl)₂ (for example, -PO(Me)₂), -S(O)₂-C₁-C₆alkyl) (for example, -S(O)₂Me) and -C(O)-NH₂.

In some embodiments of the first aspect, the compounds have the Formula (IV), wherein one R²⁰ is H and the other R²⁰ is -PO(C₁-C₆alkyl)₂, said -PO(C₁-C₆alkyl)₂, being ortho to the point of attachment of the nitrogen atom attached to the phenyl ring of group G.

In some embodiments of the first aspect, the compounds have the Formula (VI):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of pyridine, phenyl, imidazole, pyrazole and

5 tetrahydropyridine, each substituted with one R^{38} , or D is unsubstituted tetrahydropyridine;

R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$, $R^{37}O-(CH_2)_n-O-(CH_2)_{n1}C(O)-N(R^{40})-CH_2-$, C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$, (oxo substituted heterocyclyl)- C_1-C_6 alkyl- (wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of $-N(R^9)(R^{10})$, C_1-C_6 alkyl, $-N(R^{37})(Ac)$, $-OH$ and (heterocyclyl)- $C(O)-$, wherein the heterocyclyl is optionally substituted with C_1-C_6 alkyl), C_1-C_6 alkyl- $S(O)_2-(CH_2)_2-N(A)-CH_2-$, C_0-C_6 alkyl-heterocyclyl- $(CH_2)_{1-3}-$, HO -heterocyclyl- CH_2- , $(R^9)(R^{10})N$ -heterocyclyl- CH_2- , $(C_1-C_6$ alkyl)- $C(O)$ -heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- $(CH_2)_{1-6}-$, C_0-C_6 alkyl-heterocyclyl- C_1-C_6 alkyl- $N(R^{39})-C(O)-$, $R^{37}O-(CH_2)_j-[(CH_2)_{i1}O]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N$ -heterocyclyl- $C(O)-$, $R^{37}O-(CH_2)_j-[(CH_2)_{i1}O]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl-heterocyclyl- $C(O)-$, $HOOC-C_1-C_6$ alkyl- $N(A)-CH_2-$, $(HOOC)(NR^9R^{10})-C_1-C_6$ alkyl- $N(A)-CH_2-$, $R^{37}-O-C(O)$ -heterocyclyl- $C(O)-$, $(R^9)(R^{10})N-C_0-C_6$ alkyl-heterocyclyl- $C(O)-$, C_0-C_6 alkyl-heterocyclyl- C_0-C_6 alkyl-heterocyclyl- $C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl- $C(O)-$, $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2- , cycloalkyl- $N(R^{39})-C(O)-O-C_1-C_6$ alkyl-, $R^{37}-O-C_1-C_6$ alkyl- $O-C_1-C_6$ alkyl- $C(O)-$, C_1-C_6 alkyl- SO_2- , $(R^9)(R^{10})N-C(O)-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(HO$ - substituted C_1-C_6 alkyl)- $N(R^{39})-C(O)-$, $NC-C_1-C_6$ alkyl-heterocyclyl- CH_2- , heterocyclyl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $F_3C-C_1-C_6$ alkyl-heterocyclyl- CH_2- , C_1-C_6 alkyl- $S(O)_2$ -heterocyclyl- CH_2- , heteroaryl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-, $N(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2- , C_1-C_6 alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1-C_6 alkyl-, (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1-C_6 alkyl- and (di-fluoro substituted heterocyclyl)- C_1-C_6 alkyl-;

30 wherein when D is imidazole, the imidazole is further optionally substituted with C_1-C_6 alkyl;

R^{37} is H, C_1-C_6 alkyl;

R^{37a} is H, C_1-C_6 alkyl;

A is H, Ac, $-C(O)-CH_2-OMe$, $-C(O)-CH(NH_2)-C(CH_3)_3$, $-C(O)-(CH_2)_n-N(R^{39})-C(O)-C_1-$

C_6 alkyl- $N(R^9)(R^{10})-C(O)-N(R^{39})-C_1-C_6$ alkyl, $-C(O)-H$, $-C(O)-C_1-C_6$ alkyl, $-C_1-C_6$ alkyl- $O-$

35 C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl- OH , $-C(O)-C_1-C_6$ alkyl- $N(R^{39})-C(O)-C_1-C_6$ alkyl- $N(R^9)(R^{10})$, -

C(=NH)-H, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R³⁹)-cycloalkyl, -C(O)-N(R⁹)(R¹⁰), (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)- and C₁-C₆alkyl,

j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

5 x is an integer ranging from 0 to 6, alternatively 2 or 3;

i1 is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2;

n is an integer ranging from 0 to 4;

n1 is an integer ranging from 0 to 4;

10 R³⁹ is H or C₁-C₆alkyl;

R⁴⁰ is -C₁-C₆alkyl-OR⁴¹;

R⁴¹ is H or C₁-C₆alkyl;

R⁹ is H or C₁-C₆alkyl;

R¹⁰ is H or C₁-C₆alkyl;

15 R²³ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl and -O-(5 to 10-membered heterocyclyl);

R²⁴ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl);

R² is H or F; and

20 R^{2a} is H, F or Cl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R³⁸.

25 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is phenyl substituted with one R³⁸.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R³⁸, and further optionally substituted with C₁-C₆alkyl (for example -CH₃).

30 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyrazole substituted with one R³⁸.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is tetrahydropyridine substituted with one R³⁸, or D is unsubstituted tetrahydropyridine.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is selected from the group consisting of $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{ii}-N(R^{39})-C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl-heterocyclyl- $C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl- $C(O)-$, $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- CH_2- , cycloalkyl-
 5 $N(R^{39})-C(O)-O-C_1-C_6$ alkyl-, $R^{37}-O-C_1-C_6$ alkyl- $O-C_1-C_6$ alkyl- $C(O)-$, $(R^9)(R^{10})N-C(O)-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $NC-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $F_3C-C_1-C_6$ alkyl-heterocyclyl- CH_2- and $N(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI),
 10 wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$, for example, $MeO-(CH_2)_2-N(A)-CH_2-$ or $MeO-(CH_2)_2-N(A)-(CH_2)_2-$.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-(CH_2)_n-O-(CH_2)_{n1}C(O)-N(R^{40})-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (VI),
 15 wherein R^{38} is C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$, for example, C_1-C_6 alkyl-piperazine- CH_2- or CH_3 -piperazine- $(CH_2)_2-$.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$.
 20

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is C_1-C_6 alkyl-(7-membered heterocyclyl)- CH_2- . In some embodiments, the C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$ is CH_3 -(7-membered heterocyclyl)- CH_2- , for example C_1-C_6 alkyl-(1,4-diazepanyl)- CH_2- , for example CH_3 -(1,4-diazepanyl)- CH_2- .
 25

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1-C_6 alkyl-, wherein the optional substituent is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl- OH , Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}$ -cycloalkyl, $-S(O)_{0-2}$ -heterocyclyl, $-S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl- OH , $-C_1-C_6$ alkyl- $C(O)-OH$ and $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl,
 30


cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or -C₁-C₆alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R³⁸ wherein R³⁸ is (di-fluoro substituted heterocyclyl)-C₁-C₆alkyl-.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R³⁸ wherein R³⁸ is (di-fluoro substituted heterocyclyl)-C₁-C₆alkyl-, wherein the two fluoro substituents are substituents on the same carbon atom.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R³⁸ wherein R³⁸ is R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, for example, HO-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R³⁸ is (oxo substituted heterocyclyl)-C₁-C₆alkyl-, wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of -N(R⁹)(R¹⁰), C₁-C₆alkyl, -N(R³⁷)(Ac) and -OH. For example, R³⁸ is selected from




In some embodiments of the first aspect, the compounds have the Formula (VI),





In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (heterocyclyl)-C(O)-, wherein the heterocyclyl is optionally substituted with C_1 -



In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_1 - C_6 alkyl-S(O)₂-(CH₂)₂-N(A)-CH₂-, for example CH₃-S(O)₂-(CH₂)₂-N(A)-CH₂-.

10 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_0 - C_6 alkyl-heterocyclyl-(CH₂)₁₋₃-, for example heterocyclyl-(CH₂)-, piperazine-

CH₂-, morpholine-CH₂-, morpholine-(CH₂)₂-, CH₃-piperazine-(CH₂)₂-, morpholine-(CH₂)₃- or piperazine-(CH₂)₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is HO-heterocyclyl-CH₂-, for example HO-pyrrolidine-CH₂-.

15 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (R⁹)(R¹⁰)N-heterocyclyl-CH₂-, for example NH₂-pyrrolidine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (C₁-C₆alkyl)-C(O)-heterocyclyl-CH₂-, for example CH₃-C(O)-piperazine-CH₂-.

20 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is R³⁷O-C₁-C₆alkyl-heterocyclyl-CH₂-, for example, HO-C₁-C₆alkyl-heterocyclyl-CH₂-, for example HO-(CH₂)₂-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is HO-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, for example HO-(CH₂)-C(O)-piperazine-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_0 - C_6 alkyl-heterocyclyl- C_1 - C_6 alkyl- $N(R^{39})$ -C(O)-, for example, morpholine- $(CH_2)_2$ -NH-C(O)-, morpholine- $(CH_2)_3$ -NH-C(O)- or CH_3 -piperazine- $(CH_2)_2$ -NH-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI),
 5 wherein R^{38} is $R^{37}O$ -(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-, for example, CH_3 -O-[CH_2 - CH_2 -O]₃-(CH_2)₂-N(A)- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O$ -C(O)- C_0 - C_6 alkyl-heterocyclyl- CH_2 -, for example, $R^{37}O$ -C(O)- C_1 - C_6 alkyl-heterocyclyl- CH_2 -, HO-C(O)-(CH_2)₂-piperazine- CH_2 -, EtO-C(O)-piperidine- CH_2 -, EtO-C(O)-
 10 CH_2 -piperidine- CH_2 -, EtO-C(O)- CH_2 -piperazine- CH_2 -, HO-C(O)-piperidine- CH_2 -, HO-C(O)- CH_2 -piperidine- CH_2 -, HO-C(O)- CH_2 -piperazine- CH_2 -, (CH_3)₃C-O-C(O)-piperazine- CH_2 -, or HO-C(O)-pyrrolidine- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (R⁹)(R¹⁰)N-heterocyclyl-C(O)-, for example, $N(CH_3)_2$ -pyrrolidine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI),
 15 wherein R^{38} is $R^{37}O$ -(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-, for example, CH_3 -O-[CH_2 - CH_2 -O]₃-(CH_2)₂-N(A)-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O$ -C(O)- C_1 - C_6 alkyl-heterocyclyl-C(O)-, for example, CH_3 - CH_2 -O-C(O)-
 20 (CH_2)₂-piperazine-C(O)- or HO-C(O)-(CH_2)₂-piperazine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is HOOC- C_1 - C_6 alkyl-N(A)- CH_2 -, for example, HOOC-(CH_2)₃-N(A)- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (HOOC)(NR⁹R¹⁰)- C_1 - C_6 alkyl-N(A)- CH_2 -, for example, (HOOC)(NH₂)-CH-
 25 (CH_2)₄-N(A)- CH_2 -.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O$ -C(O)-heterocyclyl-C(O)-, for example, EtO-C(O)-piperidine-C(O)-, BuO-C(O)-morpholine-C(O)-, HO-C(O)-piperidine-C(O)- or HO-C(O)-morpholine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI),
 30 wherein R^{38} is (R⁹)(R¹⁰)N- C_0 - C_6 alkyl-heterocyclyl-C(O)-, for example, $N(CH_3)_2$ -pyrrolidine-C(O)-, ($CH(CH_3)_2$)₂N-(CH_2)₂-piperazine-C(O)-.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_0 - C_6 alkyl-heterocyclyl- C_0 - C_6 alkyl-heterocyclyl-C(O)-, for example, C_0 - C_6 alkyl-heterocyclyl- C_1 - C_6 alkyl-heterocyclyl-C(O)-, morpholine- $(CH_2)_2$ -piperazine-C(O)-,
 35 CH_3 -piperidine- CH_2 -piperazine-C(O)- or CH_3 -piperazine-piperidine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is R^{37} -O-C(O)-C₁-C₆alkyl-C(O)-, for example, HO-C(O)-(CH₂)₂-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (VI),



wherein R^{38} is $(R^9)(R^{10})$ N-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, for example,



5

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is cycloalkyl-N(R^{39})-C(O)-O-C₁-C₆alkyl-, for example, C₃cycloalkyl-NH-C(O)-O-(CH₂)₂.


In some embodiments of the first aspect, the compounds have the Formula (VI),

10 wherein R^{38} is R^{37} -O-C₁-C₆alkyl-O-C₁-C₆alkyl-C(O)-, for example, MeO-(CH₂)₂-O-CH₂-C(O)-.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C₁-C₆alkyl-SO₂-, for example, Me-S(O)₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI),

15 wherein R^{38} is $(R^9)(R^{10})$ N-C(O)-C₁-C₆alkyl-heterocyclyl-CH₂-, for example,



In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $(R^9)(R^{10})$ N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-heterocyclyl-CH₂-, for example,



In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , for example, $MeO-(CH_2)_2$ -piperazine- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (HO- substituted C_1-C_6 alkyl)- $N(R^{39})-C(O)-$, for example, $HO-CH_2-[CH(OH)]_4-CH_2-N(Me)-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $NC-C_1-C_6$ alkyl-heterocyclyl- CH_2- , for example, $NC-(CH_2)_2$ -piperazine- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is heterocyclyl- C_1-C_6 alkyl-heterocyclyl- CH_2- , for example, morpholine- $(CH_2)_2$ -piperazine- CH_2- .


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $F_3C-C_1-C_6$ alkyl-heterocyclyl- CH_2- , for example, F_3C-CH_2 -piperazine- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_1-C_6 alkyl- $S(O)_2$ -heterocyclyl- CH_2- , for example, $Me-S(O)_2$ -piperazine- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is heteroaryl- C_1-C_6 alkyl-heterocyclyl- CH_2- , for example, imidazole- $(CH_2)_2$ -piperazine- CH_2- .

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-C_1-C_6$ alkyl-, for example, $HO-(CH_2)_4-$.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $N(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2- , for




example,

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_1-C_6 alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_1-C_6 alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1-C_6 alkyl-.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl- wherein the heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein
 5 R^{38} is C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-,



In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein
 10 R^{38} is (optionally substituted 8-membered fused heterocyclyl)- C_1 - C_6 alkyl-, which is



G is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G¹ is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G² is CH or N;

15 G³ is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G⁴ is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G⁵ is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

G⁶ is CH or N;


G⁷ is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ;

20 R^s is an optional substituent; and


R^{s1} is an optional substituent,

provided that two O atoms are not adjacent to each other.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1 - C_6 alkyl, selected from



wherein G is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ; G^1 is selected from the group consisting of CH_2 , O, NH, S, SO and SO_2 ; and R^s is an optional substituent.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^s is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, -OH, oxo, C_1 - C_6 alkyl, $-C(O)-C_1-C_6$ alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}$ -cycloalkyl, $-S(O)_{0-2}$ -heterocyclyl, $-S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl-OH, $-C_1-C_6$ alkyl- $C(O)-OH$, $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{s1} is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, -OH, oxo, C_1 - C_6 alkyl, $-C(O)-C_1-C_6$ alkyl-OH, Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}$ -cycloalkyl, $-S(O)_{0-2}$ -heterocyclyl, $-S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl-OH, $-C_1-C_6$ alkyl- $C(O)-OH$, $-C_1-C_6$ alkyl- $C(O)-$

$N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1-C_6 alkyl-, wherein the
 5 optional substituent is selected from the group consisting of H, halo, $-N(R^9)(R^{10})$, nitro, $-OH$, oxo, C_1-C_6 alkyl, $-C(O)-C_1-C_6$ alkyl- OH , Ac, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-S(O)_{0-2}-C_1-C_6$ alkyl, $-S(O)_{0-2}$ -cycloalkyl, $-S(O)_{0-2}$ -heterocyclyl, $-S(O)_{0-2}$ -aryl, $-S(O)_{0-2}$ -heteroaryl, $-C(O)H$, $-C(O)-C_1-C_6$ alkyl, $-C(O)-N(R^9)(R^{10})$, $-C_1-C_6$ alkyl- OH , $-C_1-C_6$ alkyl- $C(O)-OH$ and $-C_1-C_6$ alkyl- $C(O)-N(R^9)(R^{10})$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl
 10 groups are themselves optionally substituted, for example with halo or $-C_1-C_6$ alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (di-fluoro substituted heterocyclyl)- C_1-C_6 alkyl-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is (di-fluoro substituted heterocyclyl)- C_1-C_6 alkyl-, wherein the two fluoro
 15 substituents are substituents on the same carbon atom.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2 -, for example, $HO-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein
 20 R^{38} is $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- $(CH_2)_{1-6}$ -, for example, $HO-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- $(CH_2)_{1-2}$ -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- $(CH_2)_{1-6}$ -, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl.

25 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein R^{38} is $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- $(CH_2)_{1-6}$ -, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl, R^{37} is H and the $-(CH_2)_{1-6}$ is $-(CH_2)_{1-2}$ -.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is
 30 selected from the group consisting of $-C(O)-(CH_2)_n-N(R^{39})-C(O)-C_1-C_6$ alkyl- $N(R^9)(R^{10})$ - $C(O)-N(R^{39})-C_1-C_6$ alkyl - $C(O)-C_1-C_6$ alkyl- $N(R^{39})-C(O)-C_1-C_6$ alkyl- $N(R^9)(R^{10})$ - $C(=NH)-H$, $-C(O)-(CH_2)_n-S(O)_2-C_1-C_6$ alkyl - $C(O)-N(R^{39})$ -cycloalkyl - $C(O)-N(R^9)(R^{10})$ and $(R^{23})(R^{24})P(O)O-C_1-C_6$ alkyl- $C(O)$ -.

In some embodiments of the first aspect, the compounds have the Formula (VI),
 35 wherein A is H.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is not H.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is Ac.

5 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-CH₂-OMe.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-CH(NH₂)-C(CH₃)₃.

10 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-(CH₂)_n-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), for example, -C(O)-CH₂-NH-C(O)-CH(NH₂)-CH(CH₃)₂.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-N(R³⁹)-C₁-C₆alkyl, for example, -C(O)-NH-CH₂-CH₃, -C(O)-NH-CH₃, -C(O)-NH-CH(CH₃)₂ or -C(O)-N(CH₃)₂.

15 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-H.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-C₁-C₆alkyl, for example, -C(O)-CH₃ or -C(O)-CH₂-CH₃.

20 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C₁-C₆alkyl-O-C₁-C₆alkyl, for example, -(CH₂)₂-OMe.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-C₁-C₆alkyl-OH.

25 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), for example, -C(O)-CH₂-NH-C(O)-CH₂-NH₂ or -C(O)-CH[CH(CH₃)₂]-NH-C(O)-CH₂-NH₂.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(=NH)-H.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, for example, -C(O)-CH₂-S₂-Me.

30 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-N(R³⁹)-cycloalkyl, for example, -C(O)-NH-cyclopentyl or -C(O)-NH-C₃cycloalkyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is -C(O)-N(R⁹)(R¹⁰), for example, -C(O)-NH₂.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is $(R^{23})(R^{24})P(O)O-C_1-C_6\text{alkyl}-C(O)-$, for example, $(HO)_2P(O)O-CH_2-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is $C_1-C_6\text{alkyl}$.


5 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein A is not $C_1-C_6\text{alkyl}$.

In some embodiments of the first aspect, the present invention is directed to compounds having the Formula (VI) wherein D is pyridine, substituted with R^{38} .

10 In some embodiments of the first aspect, the present invention is directed to compounds having the Formula (VI), wherein D is pyridine substituted with R^{38} , and R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$.

In some embodiments of the first aspect, the present invention is directed to compounds having the Formula (VI), wherein D is pyridine substituted with R^{38} , R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$ and A is selected from the group consisting of $-C(O)-(CH_2)_n-N(R^{39})-C(O)-C_1-C_6\text{alkyl}-N(R^9)(R^{10})$,.


In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is (oxo substituted heterocyclyl)- $C_1-C_2\text{alkyl}$ -; in some embodiments of the first aspect, the compounds have the Formula (VI),




In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}$ -.

25 In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R^{38} , wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6\text{alkyl}$ - wherein the heterocyclyl is a 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein
30 D is imidazole substituted with one R^{38} , wherein R^{38} is $C_1-C_6\text{alkyl}-C(O)-O-C_1-C_6\text{alkyl}-C(O)-(5$



to 10-membered heterocyclyl)-C₁-C₆alkyl-, which is




In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R³⁸, wherein R³⁸ is R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-, for example, HO-C₁-C₆alkyl-C(O)-heterocyclyl-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R³⁸, wherein R³⁸ is R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-(CH₂)₁₋₆-, for example, HO-C₁-C₆alkyl-C(O)-heterocyclyl-(CH₂)₁₋₂-.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R³⁸, wherein R³⁸ is R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-(CH₂)₁₋₆-, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl.

In some embodiments of the first aspect, the compounds have the Formula (VI), wherein D is imidazole substituted with one R³⁸, wherein R³⁸ is R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-(CH₂)₁₋₆-, wherein the heterocyclyl is a 5- or 6-membered heterocyclyl, R³⁷ is H and the -(CH₂)₁₋₆- is -(CH₂)₁₋₂-.

In some embodiments of the first aspect, the compounds have the Formula (VII)



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine or imidazole, wherein the pyridine and imidazole are substituted with one R³⁸;

R^{38} is selected from the group consisting of (oxo substituted heterocyclyl)- C_1 - C_6 alkyl-,
 (heterocyclyl)- $C(O)$ -, C_1 - C_6 alkyl, $R^{37}O-(CH_2)_2-N(A)-CH_2$ -, heterocyclyl- C_1 - C_6 alkyl- $N(R^{39})$ -
 $C(O)$ -, heterocyclyl- CH_2 -;

wherein when D is imidazole, the imidazole is further optionally substituted with C_1 - C_6 alkyl

5 (for example, $-CH_3$);

R^{37} is H or C_1 - C_6 alkyl;


A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-C_1$ - C_6 alkyl;


R^{39} is H or C_1 - C_6 alkyl;

R^2 is F; and


10 R^{2a} is H.

In some embodiments of the first aspect, the compounds have the Formula (VII),

wherein R^{38} is (oxo substituted heterocyclyl)- C_1 - C_6 alkyl-, for example,  or



15 In some embodiments of the first aspect, the compounds have the Formula (VII),

wherein R^{38} is (heterocyclyl)- $C(O)$ -, for example, .

In some embodiments of the first aspect, the compounds have the Formula (VII),
 wherein R^{38} is C_1 - C_6 alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VII),
 20 wherein R^{38} is not C_1 - C_6 alkyl.

In some embodiments of the first aspect, the compounds have the Formula (VII),
 wherein R^{38} is $R^{37}O-(CH_2)_2-N(A)-CH_2$ -, for example, $MeO-(CH_2)_2-N(A)-CH_2$ -.


In some embodiments of the first aspect, the compounds have the Formula (VII),
 wherein R^{38} is heterocyclyl- C_1 - C_6 alkyl- $N(R^{39})-C(O)$ -, for example morpholine- $(CH_2)_2-NH$ -
 25 $C(O)$ -.

In some embodiments of the first aspect, the compounds have the Formula (VII),
 wherein R^{38} is heterocyclyl- CH_2 -, for example, preferably morpholine- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (VII), wherein A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_1-\text{C}_6\text{alkyl}$, for example, $-\text{C}(\text{O})-\text{NH}-\text{CH}(\text{CH}_3)_2$ or $-\text{C}(\text{O})-\text{NH}-\text{CH}_2-\text{CH}_3$.

In some embodiments of the first aspect, the compounds have the Formula (VII),
5 wherein A is $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}$, for example, $-\text{C}(\text{O})-\text{CH}_3$.

In some embodiments of the first aspect, the compounds have the Formula (VIII)



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts,
10 prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;

R^{38} is $\text{R}^{37}\text{O}-(\text{CH}_2)_2-\text{N}(\text{A})-\text{CH}_2-$, for example, $\text{MeO}-(\text{CH}_2)_2-\text{N}(\text{A})-\text{CH}_2-$;

A is H or $-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}$, for example $-\text{C}(\text{O})-\text{CH}_3$;

15 R^{13} is H or $\text{C}_1-\text{C}_6\text{alkyl}$;

R^{37} is $\text{C}_1-\text{C}_6\text{alkyl}$;


R^2 is F;

R^{2a} is H; and

R^{20} is H or F.

20

In some embodiments of the first aspect, the compounds have the Formula (IX):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts,
25 prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;

R^{38} is $R^{37}O-(CH_2)_2-N(A)-CH_2-$, for example, $MeO-(CH_2)_2-N(A)-CH_2-$;


A is H or $-C(O)-C_1-C_6alkyl$;

R^{37} is H or C_1-C_6alkyl ; and

R^2 is F.

5

In some embodiments of the first aspect, the compounds have the Formula (X):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine, substituted with R^{38} ;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-heterocyclyl-CH_2-$, $F_3C-C_1-C_6alkyl-heterocyclyl-CH_2-$, $N(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$ and $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6alkyl-$;

R^{37} is H or C_1-C_6alkyl ;

A is selected from the group consisting of $-C(O)-C_1-C_6alkyl-N(R^{39})-C(O)-C_1-C_6alkyl-N(R^9)(R^{10})$, $-C(O)-N(R^{39})-C_1-C_6alkyl$, $-C(=NR^{37})-C_1-C_6alkyl$, $-C(O)-(CH_2)_n-S(O)_2-C_1-C_6alkyl$, $-C(O)-N(R^9)(R^{10})$ and $(R^{23})(R^{24})P(O)O-C_1-C_6alkyl-C(O)-$;

n is an integer ranging from 0 to 4;

R^{39} is H or C_1-C_6alkyl ;

R^9 is H or C_1-C_6alkyl ;

R^{10} is H or C_1-C_6alkyl ;

R^2 is F;

R^{2a} is H or F;

R^{23} is selected from the group consisting of -OH, C_1 - C_6 alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl and -O-(5 to 10-membered heterocyclyl);

R^{24} is selected from the group consisting of -OH, C_1 - C_6 alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl);


5 j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

x is an integer ranging from 0 to 6, alternatively 2 or 3;

il is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2; and



In some embodiments of the compounds of Formula (X), R^{38} further includes C_0 - C_6 alkyl-heterocyclyl- C_0 - C_6 alkyl-heterocyclyl-C(O)-, alternatively -C(O)-piperidine-piperazine- CH_3 .

In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}$ -, alternatively $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}$ -, MeO- $(CH_2)_2$ -
15 N(A)- CH_2 - or MeO- $(CH_2)_2-N(A)-(CH_2)_2$ -.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{il}-N(A)-(CH_2)_{j1}$ -, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-CH_2$ -.


In some embodiments of the first aspect, the compounds have the Formula (X), wherein
20 R^{38} is $R^{37}O-C(O)-C_0$ - C_6 alkyl-heterocyclyl- CH_2 -, alternatively $R^{37}O-C(O)-C_1$ - C_6 alkyl-heterocyclyl- CH_2 -, alternatively HO-C(O)- $(CH_2)_2$ -piperazine- CH_2 -, EtO-C(O)-piperidine- CH_2 -, EtO-C(O)- CH_2 -piperidine- CH_2 -, EtO-C(O)- CH_2 -piperazine- CH_2 -, HO-C(O)-piperidine- CH_2 -, HO-C(O)- CH_2 -piperidine- CH_2 - HO-C(O)- CH_2 -piperazine- CH_2 -, $(CH_3)_3C-O-C(O)$ -piperazine- CH_2 - or HO-C(O)-pyrrolidine- CH_2 -.

25 In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} is $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{il}-N(R^{39})-C(O)$ -, alternatively $CH_3-O-[CH_2-CH_2-O]_3-(CH_2)_2-N(A)-C(O)$ -.


In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} is $R^{37}-O-C(O)-C_1$ - C_6 alkyl-heterocyclyl-C(O)-, alternatively $CH_3-CH_2-O-C(O)-(CH_2)_2$ -
30 piperazine-C(O)- or HO-C(O)- $(CH_2)_2$ -piperazine-C(O)-.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} , wherein R^{38} is $(R^9)(R^{10})N-C_1$ - C_6 alkyl-C(O)-heterocyclyl- CH_2 -.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein




R^{38} is $(R^9)(R^{10})N-C(O)-C_1-C_6\text{alkyl-heterocyclyl-CH}_2-$, alternatively



5 In some embodiments of the first aspect, the compounds have the Formula (X), wherein

R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-C(O)-O-C}_1-C_6\text{alkyl-heterocyclyl-CH}_2-$, alternatively




In some embodiments of the first aspect, the compounds have the Formula (X), wherein


10 R^{38} is $F_3C-C_1-C_6\text{alkyl-heterocyclyl-CH}_2-$, alternatively $F_3C-CH_2\text{-piperazine-CH}_2-$.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein

R^{38} is $(R^9)(R^{10})N-C_1-C_6\text{alkyl-C(O)-O-C}_1-C_6\text{alkyl-C(O)-heterocyclyl-CH}_2-$, alternatively



In some embodiments of the first aspect, the compounds have the Formula (X), wherein R^{38} is C_1 - C_6 alkyl- $C(O)$ - O - C_1 - C_6 alkyl- $C(O)$ -(5 to 10-membered heterocyclyl)- C_1 - C_6 alkyl-, for



example

5 In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $-C(O)$ - C_1 - C_6 alkyl- $N(R^{39})$ - $C(O)$ - C_1 - C_6 alkyl- $N(R^9)(R^{10})$, alternatively $-C(O)$ - CH_2 -NH- $C(O)$ - $CH(NH_2)$ - $CH(CH_3)_2$, $-C(O)$ - CH_2 -NH- $C(O)$ - CH_2 -NH $_2$ or $-C(O)$ - $CH[CH(CH_3)_2]$ -NH- $C(O)$ - CH_2 -NH $_2$).

10 In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $-C(O)$ - $N(R^{39})$ - C_1 - C_6 alkyl, alternatively $-C(O)$ -NH- CH_2 - CH_3 , $-C(O)$ -NH- CH_3 , $-C(O)$ -NH- $CH(CH_3)_2$, $-C(O)$ -NH- $CH(CH_3)_2$ or $-C(O)$ -N(CH_3) $_2$.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $-C(=NR^{37})$ - C_1 - C_6 alkyl, alternatively $-C(=NH)H$.


15 In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $-C(O)$ -(CH_2) $_n$ - $S(O)_2$ - C_1 - C_6 alkyl, alternatively $-C(O)$ - CH_2 - $S(O)_2$ -Me.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $-C(O)$ - $N(R^9)(R^{10})$, alternatively $-C(O)$ -NH $_2$.

In some embodiments of the first aspect, the compounds have the Formula (X), wherein A is $(R^{23})(R^{24})P(O)O$ - C_1 - C_6 alkyl- $C(O)$ -, alternatively $(HO)_2P(O)O$ - CH_2 - $C(O)$ -.

20

In some embodiments of the first aspect, the compounds have the Formula (XI):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

wherein

5 D is imidazole substituted with one R^{38} and further substituted with C_1 - C_6 alkyl;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}$;


R^{37} is H or C_1 - C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl,

R^{39} is H or C_1 - C_6 alkyl;

10 R^2 is F;

R^{2a} is H; and




In some embodiments of the first aspect, the compounds have the Formula (XI), wherein

R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}$, $MeO-(CH_2)_2-N(A)-$

15 CH_2- and $MeO-(CH_2)_2-N(A)-(CH_2)_2-$.

In some embodiments of the first aspect, the compounds of have the Formula (XII):



20 wherein

including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is phenyl, substituted with R^{38} ;

25 R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}$;


R^{37} is H or C_1 - C_6 alkyl;

A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_1-\text{C}_6\text{alkyl}$, $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{cycloalkyl}$

R^{39} is H or $\text{C}_1-\text{C}_6\text{alkyl}$;

R^2 is F;


R^{2a} is H; and



In some embodiments of the first aspect, the compounds have the Formula (XII), wherein R^{38} is selected from the group consisting of $\text{R}^{37}\text{O}-(\text{CH}_2)_2-\text{N}(\text{A})-(\text{CH}_2)_{1-2}-$, $\text{MeO}-(\text{CH}_2)_2-\text{N}(\text{A})-\text{CH}_2-$ and $\text{MeO}-(\text{CH}_2)_2-\text{N}(\text{A})-(\text{CH}_2)_2-$.

10 In some embodiments of the first aspect, the compounds have the Formula (XII), wherein A is selected from the group consisting of $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_{3-6}\text{cycloalkyl}$, $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_3\text{cycloalkyl}$, $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_4\text{cycloalkyl}$, $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_5\text{cycloalkyl}$ and $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_6\text{cycloalkyl}$.

15 In some embodiments of the first aspect, the compounds have the formula (XIII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

20 D is imidazole substituted with one R^{38} and further substituted with $\text{C}_1-\text{C}_6\text{alkyl}$;

R^{38} is $\text{R}^{37}\text{O}-(\text{CH}_2)_{1-6}-\text{N}(\text{A})-(\text{CH}_2)_{1-4}-$;


R^{37} is H or $\text{C}_1-\text{C}_6\text{alkyl}$;

A is $-\text{C}(\text{O})-\text{N}(\text{R}^{39})-\text{C}_1-\text{C}_6\text{alkyl}$,

R^{39} is H or $\text{C}^1-\text{C}^6\text{alkyl}$;

25 R^2 is F;


R^{2a} is H; and



In some embodiments of the first aspect, the compounds have the Formula (XIII), wherein R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$, $MeO-(CH_2)_2-N(A)-CH_2-$ and $MeO-(CH_2)_2-N(A)-(CH_2)_2-$.

5

In some embodiments of the first aspect, the compounds have the Formula (XIV):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,


D is tetrahydropyridine substituted with R^{38} ;

R^{38} is $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$, $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$;

R^{37} is H or C_1-C_6alkyl ;

R^2 is F;

15 R^{2a} is H; and




In some embodiments of the first aspect, the compounds have the Formula (XIV), wherein R^{38} is $HO-C(O)-(CH_2)_2-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (XIV),

20 wherein R^{38} is $R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$, alternatively $MeO-(CH_2)_2-O-CH_2-C(O)-$.

In some embodiments of the first aspect, the compounds have the Formula (XV):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

5 D is pyrazole, substituted with R^{38} ;


R^{38} is cycloalkyl-N(R^{39})-C(O)-O-C₁-C₆alkyl-, R^{37} O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-;

A is -C(O)-N(R^{39})-C₁-C₆alkyl,

R^{39} is H or C₁-C₆alkyl;

R^2 is F;


10 R^{2a} is H; and



In some embodiments of the first aspect, the compounds have the Formula (XV), wherein R^{38} is cycloalkyl-N(R^{39})-C(O)-O-C₁-C₆alkyl-, alternatively C₃cycloalkyl-NH-C(O)-O-(CH₂)₂-.

15 In some embodiments of the first aspect, the compounds have the Formula (XV), wherein R^{38} is R^{37} O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-, for example, selected from the group consisting of R^{37} O-(CH₂)₂-N(A)-(CH₂)₁₋₂-, MeO-(CH₂)₂-N(A)-CH₂- and MeO-(CH₂)₂-N(A)-(CH₂)₂-.

In some embodiments of the first aspect, the compounds have the Formula (XVI):



D is pyridine substituted with one R³⁸;

A is selected from the group consisting of H, -C(O)-C₁-C₆alkyl, -C(O)-N(R³⁹)-C₁-C₆alkyl, and -C(O)-C₁-C₆alkyl-OH;

R³⁷ is H, C₁-C₆alkyl;

R³⁹ is H, C₁-C₆alkyl; and

10 R^2 is H.


In some embodiments of the first aspect, the compounds have the Formula (XVI), wherein R³⁸ is MeO-(CH₂)₂-N(A)-CH₂-.

In some embodiments of the first aspect, the compounds have the Formula (XVI), wherein A is -C(O)-C₁-C₆alkyl, for example, -C(O)-CH₃).

15 In some embodiments of the first aspect, the compounds have the Formula (XVI), wherein A is , -C(O)-N(R³⁹)-C₁-C₆alkyl, for example, -C(O)-NH-CH₂-CH₃.

In some embodiments of the first aspect, the compounds have the Formula (XVI), wherein A is -C(O)-C₁-C₆alkyl-OH, for example, -C(O)-CH₂-OH.

20 In some embodiments of the first aspect, the compounds have the Formula (XVII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine, substituted with R³⁸;


$$R^{38} \text{ is } R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-,$$

R³⁷ is H or C₁-C₆alkyl;

A is -C(O)-N(R³⁹)-C₁-C₆alkyl,


R^{39} is H or C_1 - C_6 alkyl;

R^2 is H; and



In some embodiments of the first aspect, the compounds have the Formula (XXVII),
 5 wherein R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}$ -, $MeO-(CH_2)_2-$,
 $N(A)-CH_2-$ and $MeO-(CH_2)_2-N(A)-(CH_2)_2-$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts,
 prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and
 enantiomers thereof, wherein,

D is pyridine or imidazole, each substituted with R^{38} , and wherein the imidazole is further

substituted with $-C_1$ - C_6 alkyl, for example $-CH_3$;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}$ - or $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2 -;


R^{37} is H or C_1 - C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl, $-C(O)-H$,

R^{39} is H or C_1 - C_6 alkyl;

R^2 is H or F;

R^{2a} is H or F; and




In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, alternatively $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$.

5 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$.


10 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-(CH_2)_2-N(A)-(CH_2)-$, A is -



15 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-H$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-H$.

20 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-(CH_2)_2-N(A)-(CH_2)-$, A is -




In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is imidazole substituted with one R^{38} and further substituted with one $-CH_3$, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, alternatively $R^{37}O-(CH_2)_2-N(A)-(CH_2)-$.

25 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is imidazole substituted with one R^{38} and further substituted with $-CH_3$, wherein R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$.

30 In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is imidazole substituted with one R^{38} and further substituted with $-CH_3$, wherein R^{38} is $HO-(CH_2)_2-N(A)-(CH_2)-$, and A is $-C(O)-N(R^{39})-C_1-C_6\text{alkyl}$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is imidazole substituted with one R^{38} and further substituted with $-CH_3$, wherein R^{38}




is $HO-(CH_2)_2-N(A)-(CH_2)_2-$, A is $-C(O)-N(R^{39})-C_1-C_6alkyl$ and G is


In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $R^{37}O-C_1-C_6alkyl-heterocycl-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-C_1-C_6alkyl-C(O)-heterocycl-CH_2-$, for example, $HO-CH_2-C(O)-piperazine-CH_2-$.

In some embodiments of the first aspect, the compounds have the Formula (XVIII), wherein D is pyridine substituted with one R^{38} , wherein R^{38} is $HO-C_1-C_6alkyl-C(O)-heterocycl-CH_2-$, for example, $HO-CH_2-C(O)-piperazine-CH_2-$, and G is



In some embodiments of the first aspect, the compounds have the Formula (XIX):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;


R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_2-$;

R^{37} is C_1-C_6alkyl ;

A is H or C₁-C₆alkyl,


R² is F;

R^{2a} is H; and




In some embodiments of the first aspect, the compounds have the Formula (XIX), wherein A is H.

In some embodiments of the first aspect, the compounds have the Formula (XIX), wherein R³⁷ is -CH₃.



In some embodiments of the first aspect, G is



In some embodiments of the first aspect, Ar is (R²)_q, wherein Ar is optionally substituted.

In some embodiments of the first aspect, D is pyridinyl, imidazolyl or triazolyl, each of which is substituted with one R³⁸.

In some embodiments of the first aspect, R³⁸ is selected from the group consisting of R³⁷O-C(O)-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, (R⁶)(R⁶)N-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-

C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl- and R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, wherein each of said alkyl and heterocyclyl is optionally substituted.

In some embodiments of the first aspect, D is pyridinyl substituted with one R³⁸.


5 In some embodiments of the first aspect, when R³⁸ is attached to D by a C₁-C₆ alkyl, the C₁-C₆ alkyl is -CH₂-.

In some embodiments of the first aspect, D is selected from the group consisting of C₁-C₆alkyl-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl -N(R⁶)-C(O)-, (R⁶)(R⁶)N-C(O)-O-heterocyclyl-C(O)-, heterocyclyl-C(O)-, PivO-heterocyclyl-C(O)-, C₁-C₆alkyl-O-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-N(R⁶)-heterocyclyl-C(O)-, (C₁-C₆alkyl)(Box)N-heterocyclyl-C(O)-, HO-heterocyclyl-C(O)-, HO-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-O-heterocyclyl-C(O)-, (R⁶)(R⁶)N-C₁-C₆alkyl -N(R⁶)-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C(O)- and (R⁶)(R⁶)N-heterocyclyl-C(O)-, wherein said each of said alkyl and heterocyclyl is optionally substituted.

In some embodiments of the first aspect, R⁶ is H.


15 In some embodiments of the first aspect, the compound is selected from the group consisting of:

20 In some embodiments of the first aspect, the compounds are selected from the group consisting of




including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof.


In one embodiment of the first aspect, the compound is



In one embodiment of the first aspect, the compound is



In one embodiment of the first aspect, the compound is



10

Compounds of above formulas may generally be prepared according to the following Schemes. Tautomers and solvates (e.g., hydrates) of the compounds of above formulas are also within the scope of the present invention. Methods of solvation are generally known in the art. Accordingly, the compounds of the present invention may be in the free, hydrate or salt form, and may be obtained by methods exemplified by the following schemes below.

The following examples and preparations describe the manner and process of making and using the invention and are illustrative rather than limiting. It should be understood that there may be other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.

20 Compounds according to the invention include but are not limited to those described in the examples below. Compounds were named using Chemdraw Ultra (versions 10.0, 10.0.4 or version 8.0.3), which are available through Cambridgesoft (www.Cambridgesoft.com, 100 Cambridge Park Drive, Cambridge, MA 02140, or were derived therefrom.

The data presented herein demonstrate the inhibitory effects of the kinase inhibitors of the invention. These data lead one to reasonably expect that the compounds of the invention are useful not only for inhibition of kinase activity, protein tyrosine kinase activity, or embodiments thereof, such as, VEGF receptor signaling, but also as therapeutic agents for the treatment of proliferative diseases, including cancer and tumor growth and ophthalmic diseases, disorders and conditions.


Synthetic Schemes and Experimental Procedures

The compounds of the invention can be prepared according to the reaction schemes or the examples illustrated below utilizing methods known to one of ordinary skill in the art. These schemes serve to exemplify some procedures that can be used to make the compounds of the invention. One skilled in the art will recognize that other general synthetic procedures may be used. The compounds of the invention can be prepared from starting components that are commercially available. Any kind of substitutions can be made to the starting components to obtain the compounds of the invention according to procedures that are well known to those skilled in the art.

All reagents and solvents were obtained from commercial sources and used as received. ¹H-NMR spectra were recorded on Mercury Plus Varian 400 MHz instrument in the solvents indicated. Low resolution mass-spectra (LRMS) were acquired on Agilent MSD instrument. Analytical HPLC was performed on Agilent 1100 instrument using Zorbax 3 μm, XDB-C8, 2.1 x 50 mm column; eluting with methanol/water containing 0.1% formic acid, with a gradient 5-95% methanol in 15 minutes. Automated column chromatography was performed on Biotage SP1 or Biotage SP4 instruments using Biotage® SNAP, SiliaSep™ or SiliaFlash® cartridges. Flash column chromatography was performed using silica gel (SiliaFlash F60, 40-63 μm, pore size 60 Å, SiliCycle®). Preparative column chromatography was performed on Gilson 215 instrument using Phenomenex Luna 15 μm, C18(2) 100A, 250 x 21 mm column eluting with a mixture methanol/water containing 0.05% of formic acid, with a gradient 0-95% methanol in up to 60 minutes.


Particular examples

Scheme 2



1

WO 2009/109035 A1




3: Example 2

Example 2

N-[3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)]-*N*-(1-methyl)-*N*-[3-(2-methoxyethyl)]urea

- 5 To a stirred solution of **1** (150 mg, 0.296 mmol) in THF (9 mL) at -78°C under nitrogen was added dropwise a solution of triphosgene (50 mg, 0.17 mmol) in THF (1 mL). The reaction mixture was allowed to warm to -25°C over 1 h, and a solution of methylamine in THF (0.6 mL, 2.0 M) was slowly added. The reaction mixture was allowed to warm-up to RT over 1.5 h and stirred at RT for 30 min. The reaction mixture was cooled down to -20°C and a solution of
- 10 triphosgene (120 mg, 0.40 mmol) in THF (2 mL) was slowly added. After 1 h of stirring between -20 and -10°C, a solution of methylamine in THF (1 mL, 2.0 M) was added. The reaction mixture was allowed to warm-up to RT over 1.5 h and stirred at RT overnight and then partitioned between AcOEt and water. The organic layer was collected and successively washed with 1N NaOH and brine, dried over anhydrous magnesium sulfate, filtered and concentrated.
- 15 The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV, then 10/90 over 5 CV), to afford the title compound **3** (35 mg, 0.06 mmol, 25% yield) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.74 (s, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.48 (d, *J* = 1.6 Hz, 1H), 8.31 (s, 1H), 8.23 (d, *J* = 8.2 Hz, 1H), 7.78-7.69 (m, 2H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.23-7.17 (m, 1H), 6.64 (dd, *J* = 5.4, 0.9 Hz, 1H), 6.62-6.58 (m, 1H), 6.38 (q, *J* =
- 20 4.4 Hz, 1H), 4.53 (s, 2H), 3.44-3.36 (m, 4H), 3.22 (s, 3H), 2.60 (d, *J* = 4.3 Hz, 3H), 2.58-2.52 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 565.2 (M+H).

Scheme 3

1

WO 2009/109035 A1

4: Example 3

Example 3


N-[3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)]-*N*-(1,1-dimethyl)-*N*-[3-(2-methoxyethyl)]urea

To a stirred suspension of **1** (200 mg, 0.394 mmol) in THF (25 mL) at -35°C under nitrogen was added dropwise a solution of triphosgene (222 mg, 0.75 mmol) in THF (5 mL).

5 The reaction mixture (suspension) was allowed to warm to -10°C over 1.5 h, and a solution of dimethylamine in MeOH (1.87 mL, 2.0 M) was slowly added. The reaction mixture was allowed to warm to RT over 1.5 h and DIPEA (300 µL, 1.72 mmol) was added. The reaction mixture was stirred at RT for 3.5 days then partitioned between AcOEt and a saturated aqueous solution of ammonium chloride. The organic layer was successively washed with a saturated
10 aqueous solution of ammonium chloride, a saturated aqueous solution of sodium bicarbonate, water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **4** (32 mg, 0.055 mmol, 14% yield) as an ivory solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.54 (d, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.32 (s, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 7.82 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H),
15 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 9.0 Hz, 1H), 6.64 (dd, *J* = 5.4, 0.9 Hz, 1H), 6.58 (bd, *J* = 2.5 Hz, 1H), 4.40 (s, 2H), 3.49 (t, *J* = 5.7 Hz, 2H), 3.25 (t, *J* = 5.7 Hz, 2H), 3.23 (s, 3H), 2.77 (s, 6H), 2.59-2.51 (m, 1H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (*m/z*): 579.6 (*M*+*H*).

20

Scheme 4




Example 4

25 *N*-[3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)]-*N*-[3-(2-methoxyethyl)]urea

To a stirred suspension of **1** (200 mg, 0.394 mmol) and DIPEA (200 µL, 1.12 mmol) in THF (28 mL) at -35°C under nitrogen was added dropwise a solution of triphosgene (133 mg, 0.45 mmol) in THF (2 mL). The reaction mixture was stirred from -35°C to -15°C over 30 min,
30 and a solution of ammonia in *i*-PrOH (1.87 mL, 2.0 M) was slowly added at -25°C. The reaction

mixture was allowed to warm-up to RT over 1.5 h and 28% ammonium hydroxide solution in water (3 mL) was added. The reaction mixture was then stirred at RT overnight, partitioned between AcOEt and water. The organic layer was successively washed with water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV, then 10/90 over 5 CV), to afford the title compound **5** (151 mg, 0.27 mmol, 73% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.49 (d, *J* = 1.6 Hz, 1H), 8.31 (s, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 7.79-7.69 (m, 2H), 7.38 (t, *J* = 9.0 Hz, 1H), 7.20 (dd, *J* = 8.9, 1.3 Hz, 1H), 6.64 (d, *J* = 5.3 Hz, 1H), 6.58 (bd, *J* = 2.5 Hz, 1H), 6.02 (s, 2H), 4.52 (s, 2H), 3.45-3.36 (m, 4H), 3.23 (s, 3H), 2.59-2.52 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 551.5 (M+H).

Scheme 6



Example 6


N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-*N*-(2-methoxyethyl)formimidamide

A suspension of **1** (150 mg, 0.296 mmol) and ethylformimidate hydrochloride (130 mg, 1.18 mmol) in MeCN/EtOH (10 mL/5 mL) was heated to reflux overnight. More ethylformimidate hydrochloride (130 mg, 1.18 mmol), MeCN (20 mL) and EtOH (10 mL) were added, and the reaction mixture was heated to reflux overnight then cooled to RT. Finally the reaction mixture was concentrated and partitioned between AcOEt and water. The aqueous layer was concentrated (the desired compound is water-soluble at pH around 4-5). The residue was purified by Gilson (Phenomenex, Luna, 15 μ, C18(2) 100A, 250 x 50.00 mm, 15 μm, 0.05% of formic acid in both MeOH/water : 20/80 to 95/5 over 60 min, flow = 30 mL/min), to afford the title compound **7** (30 mg, 0.056 mmol, 23% yield) as a yellow-mustard solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : mixture of isomers and/or rotamers, 9.62-9.48 (m, ~ 0.5H), 8.70-8.56 (m, ~ 0.5H), 8.53 (d, *J* = 5.5 Hz, 1H), 8.45-8.25 (m, 4H), 8.15-7.80 (m, ~ 2H), 7.75 (dd, *J* =

13.7, 2.3 Hz, 1H), 7.36 (t, $J = 9.1$ Hz, 1H), 7.36-7.30 (m, ~ 1 H), 7.24 (bd, $J = 10.2$ Hz, 1H), 6.67 (d, $J = 5.3$ Hz, 1H), 4H are masked by water's peak, 3.24 (s, 3H), 2.60-2.50 (m, 1H), 0.66-0.58 (m, 2H), 0.44-0.38 (m, 2H). MS (m/z): 535.6 ($M+H$).

5

Scheme 7




Example 7

10 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(((2-methoxyethyl)(2,2,2-trifluoroethyl)amino)-
methoxy)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea

A solution of **1** (150 mg, 0.296 mmol), DIPEA (0.3 mL, 1.72 mmol) and 2-iodo-1,1,1-trifluoroethane (2 mL, 20.29 mmol) in DMSO (4 mL) was stirred at 110°C overnight, then cooled to RT. The reaction mixture was partitioned between AcOEt and water. The organic layer was washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium bicarbonate, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified three times by Biotage (SNAP 12 g cartridge; MeOH/DCM: 00/100 to 10/90 over 20 CV, then 10/90 over 5 CV) and then by Gilson (Phenomenex, Luna 15 μ C18(2) 100A, 250 x 50.00 mm, 15 μ m, 0.05% formic acid in both MeOH/water: 60/40 to 95/5 over 60 min, flow = 30 mL/min), to afford the title compound **8** (2.6 mg, 0.004 mmol, 2% yield) as a colorless sticky film. ¹H NMR (400 MHz, MeCN-*d*₃) δ (ppm) : 8.55 (d, $J = 1.4$ Hz, 1H), 8.48 (d, $J = 5.5$ Hz, 1H), 8.06 (s, 1H), 8.02 (d, $J = 8.2$ Hz, 1H), 7.87 (dd, $J = 8.2, 2.2$ Hz, 1H), 7.72 (dd, $J = 13.6, 2.3$ Hz, 1H), 7.51 (bs, 1H), 7.26 (t, $J = 8.5$ Hz, 1H), 7.21 (dd, $J = 9.1, 2.3$ Hz, 1H), 6.62 (dd, $J = 5.4, 0.9$ Hz, 1H), 5.51 (bs, 1H), 3.93 (s, 2H), 3.48 (t, $J = 5.6$ Hz, 2H), 3.36 (q, $J = 9.8$ Hz, 2H), 3.27 (s, 3H), 2.85 (t, $J = 5.5$ Hz, 2H), 1.79-1.75 (m, 1H), 0.77-0.69 (m, 2H), 0.56-0.49 (m, 2H). MS (m/z): 590.6 ($M+H$).

Scheme 8



5


Example 8

1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-hydroxyethylamino)methyl)pyridin-2-yl)-thieno[3,2-
b]pyridin-7-yloxy)phenyl)urea


To a solution of **1** (400 mg, 0.788 mmol) in anhydrous DCM under nitrogen was slowly added BBr₃ in DCM (6.3 mL, 1.0 M) at -50°C. The reaction mixture was allowed to warm to
 10 RT over 5 h. The reaction mixture was then quenched by addition of methanol and concentrated. The residue was dissolved in a mixture of methanol/1N HCl/DMSO and purified twice by Gilson (Phenomenex, Luna, 15 μ, C18(2) 100A, 250 x 50.00 mm, 15 μm, 0.05% of formic acid in both MeOH/water : 20/80 to 95/5 over 60 min, flow = 30 mL/min), then
 15 MeOH/water : 20/80 to 70/30 over 60 min, flow = 30 mL/min), to afford the title compound **9** (53 mg, 0.107 mmol, 15% yield, formate salt) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.12 (s, 1H), 8.60 (d, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.32 (s, 1H), 8.30-8.21 (m, 2H), 7.92 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.74 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.37 (t, *J* = 9.1 Hz, 1H), 7.22 (dd, *J* = 9.1, 1.5 Hz, 1H), 6.94 (bd, *J* = 2.9 Hz, 1H), 6.64 (d, *J* = 5.5 Hz, 1H),
 20 3.83 (s, 2H), 3.50 (t, *J* = 5.7 Hz, 2H), 2.62 (t, *J* = 5.7 Hz, 2H), 2.59-2.51 (m, 1H), 0.67-0.60 (m, 2H), 0.45-0.39 (m, 2H), one NH and one OH are missing. MS (*m/z*): 494.6 (M+H).

Compound **10** (example 9) was prepared in one step by reacting *N*-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-*N*-(2-methoxyethyl)acetamide with BBr₃ reagent similarly to compound **9** (example 8, scheme 8).
 25

Table 1. Characterization of compound **10** (example 9)

Cpd	Ex.	Structure	Characterization
10	9	 <i>N</i>-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)-<i>N</i>-(2-hydroxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 9.22 (s, 1H), 8.56-8.46 (m, 2H), 8.36 and 8.32 (2s, 1H), 8.29 and 8.22 (2d, <i>J</i> = 8.0 Hz, 1H), 7.83-7.70 (m, 2H), 7.37 (t, <i>J</i> = 8.8 Hz, 1H), 7.22 (d, <i>J</i> = 9.2 Hz, 1H), 7.07-7.02 (m, 1H), 6.67-6.62 (m, 1H), 4.90 (s, 1H), 4.72 and 4.59 (2s, 2H), 3.59-3.45 (m, 2H), 3.38 (t, <i>J</i> = 5.6 Hz, 2H), 2.59-2.50 (m, 1H), 2.14 and 2.06 (2s, 3H), 0.67-0.61 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 536.6 (M+H).

Scheme 9



5

Example 10

2-cyclopropyl-*N*-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)-thieno[3,2-*b*]pyridin-7-yloxy)phenyl)acetamide

10 Step 1. *tert*-butyl (6-(7-(4-(2-cyclopropylacetamido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (12)


To a stirred solution of *tert*-butyl (6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (**11**, 500 mg, 0.95 mmol), cyclopropylacetic acid (115 mg, 1.149 mmol) and triethylamine (400 μL, 2.86 mmol) in DMF (10 mL) under nitrogen were added HOBT hydrate (161 mg, 1.05 mmol) and EDC hydrochloride (457 mg, 2.38 mmol) reagents, and the reaction mixture was stirred at RT overnight. More cyclopropylacetic acid (115 mg, 1.149 mmol) and EDC hydrochloride (500 mg, 2.61 mmol) were added, and the reaction mixture was stirred at RT overnight. The reaction mixture was then quenched by addition of water and extracted with AcOEt. The organic layer

was successively washed with water (x2), a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified twice by Biotage (SiliaFlash 40 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV and SiliaFlash 40 g; MeOH/DCM: 0/100 to 5/95 over 20 CV, then 5/95 to 10/90 over 10 CV), to afford the title compound **12** as pale yellow sticky solid. The material was used in the next step without any further purification. MS (m/z): 607.7 (M+H).

Step 2. 2-cyclopropyl-N-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)-thieno[3,2-b]pyridin-7-yloxy)phenyl)acetamide (**13**)

A solution of **12** (0.94 mmol) and TFA (10 mL) in DCM (50 mL) was stirred at RT for 3 h. The TFA was removed by co-evaporation with DCM and MeOH, the residue was diluted with water, and the pH was adjusted to 12-13 with 4N NaOH. The resultant suspension was sonicated for 10 min. The solid was collected by filtration, rinsed with water, and air-dried and purified by Biotage (SiliaSep 25 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 1/99 to 10/90 over 20 CV, then 10/90 to 20/80 over 10 CV) to provide a material that was triturated with methanol to afford the title compound **13** (245 mg, 0.48 mmol, 50% over 2 steps) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 10.20 (s, 1H), 8.57 (bd, *J* = 1.6 Hz, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.32 (s, 1H), 8.23 (d, *J* = 8.0 Hz, 1H), 7.94-7.86 (m, 2H), 7.47 (t, *J* = 8.7 Hz, 1H), 7.42 (dd, *J* = 9.1, 2.2 Hz, 1H), 6.67 (d, *J* = 5.3 Hz, 1H), 3.78 (s, 2H), 3.41 (t, *J* = 5.7 Hz, 2H), 3.24 (s, 3H), 2.65 (t, *J* = 5.7 Hz, 2H), 2.37-2.28 (m, 1H), 2.25 (d, *J* = 7.0 Hz, 2H), 1.14-1.02 (m, 1H), 0.57-0.43 (m, 2H), 0.28-0.15 (m, 2H). MS (m/z): 507.5 (M+H).

Scheme 10



Example 11

5 4,4,4-trifluoro-3-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-
b]pyridin-7-yloxy)phenylamino)-N-phenylbutanamide (19)

Step 1. N-(1-ethoxy-2,2,2-trifluoroethyl)-3-fluoro-4-(2-(5-((2-methoxyethylamino)-
methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)aniline (14)

10 A solution of **11** (2 g, 3.62 mmol), PTSA monohydrate (0.76 g, 3.98 mmol) and
 trifluoroacetaldehyde ethyl hemiacetal (2.38 mL, 18.11 mmol) in EtOH (50 mL) was heated to
 reflux overnight. More trifluoroacetaldehyde ethyl hemiacetal (1.2 mL, 9.13 mmol) was added
 and the reaction mixture was heated to reflux overnight. Once again, more trifluoroacetaldehyde
 ethyl hemiacetal (2 mL, 15.22 mmol) were added and the reaction mixture was heated to reflux
 15 overnight. Finally, another portion of trifluoroacetaldehyde ethyl hemiacetal (2 mL, 15.22

mmol) and PTSA monohydrate (0.76 g, 3.98 mmol) were added and the reaction mixture was heated to reflux for 5 days. The reaction mixture was concentrated and partitioned between AcOEt and water. The organic layer was successively washed with a saturated aqueous solution of sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 100 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **14** (1.519 g, 2.76 mmol, 76% yield) as a pale orange sticky solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.56 (d, *J* = 1.4 Hz, 1H), 8.50 (d, *J* = 5.5 Hz, 1H), 8.30 (s, 1H), 8.22 (d, *J* = 8.0 Hz, 1H), 7.89 (dd, *J* = 8.0, 2.2 Hz, 1H), 7.31 (t, *J* = 9.1 Hz, 1H), 7.11-7.02 (m, 2H), 6.87 (dd, *J* = 9.0, 1.8 Hz, 1H), 6.62 (dd, *J* = 5.3, 0.8 Hz, 1H), 5.73-5.64 (m, 1H), 3.78 (s, 2H), 3.77-3.59 (m, 2H), 3.41 (t, *J* = 5.7 Hz, 2H), 3.24 (s, 3H), 2.65 (t, *J* = 5.7 Hz, 2H), 1.15 (t, *J* = 7.0 Hz, 3H), one NH proton is missing. MS (m/z): 551.6 (M+H).

Step 2. *tert*-butyl (6-(7-(4-(1-ethoxy-2,2,2-trifluoroethylamino)-2-fluorophenoxy)-thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (**15**)

To a solution of **14** (1.354 g, 2.46 mmol) and DMAP (10 % mol) in DCM (45 mL) was added a solution of Boc₂O (0.751 g, 3.44 mmol) in DCM (5 mL). The reaction mixture was stirred at RT overnight. The reaction mixture was then concentrated and partitioned between AcOEt and water. The organic layer was successively washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (Snap 50g, HP-Sil; MeOH/DCM: 0/100 to 10/90 over 20 CV). The desired fractions were collected, concentrated and dried under high vacuum to afford the title compound **15** (1.484 g, 2.28 mmol, 93% yield) as a colorless sticky foam. MS (m/z): 651.7 (M+H).

Step 3. diethyl 2-(1-(4-(2-(5-((*tert*-butoxycarbonyl(2-methoxyethyl)amino)methyl)-pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenylamino)-2,2,2-trifluoroethyl)-malonate (**16**)

To a solution of **15** (1.484 g, 2.28 mmol) and diethyl malonate (0.415 mL, 2.74 mmol) in anhydrous THF (25 mL) under nitrogen was added NaH (274 mg, 6.84 mmol, 60% dispersion in mineral oil) and the reaction mixture was heated to reflux for 2h, then cooled to RT. The reaction mixture was then quenched with a saturated aqueous solution of ammonium chloride and extracted with AcOEt. The organic layer was washed with a saturated aqueous solution of ammonium chloride (x2) and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 50 g cartridge, MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **16** (1.794 g, 2.346 mmol, 103 % yield, crude) as a pale yellow sticky oil. MS (m/z): 765.6 (M+H).

Step 4. 2-(1-(4-(2-(5-((*tert*-butoxycarbonyl(2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenylamino)-2,2,2-trifluoroethyl)malonic acid (17)

A solution of **16** (1.794 g, 2.346 mmol) in a mixture of EtOH/1N NaOH (25 mL/11.7 mL) was stirred at RT overnight. The reaction mixture was then concentrated, diluted with water and the pH was adjusted to 3-4 by addition of 1N HCl. The resulting suspension was stirred for 30 min, and the solid was collected by filtration, rinsed with water, air-dried and dried under high vacuum to afford the title compound **17** (1.217 g; mixed with the acid **18**) as a pale yellow fluffy solid. MS (m/z): 665.5 and 709.5 (M+H).

Step 5. 3-(4-(2-(5-((*tert*-butoxycarbonyl(2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenylamino)-4,4,4-trifluorobutanoic acid (18)

A solution of **17** (1.21 g, mixture of **17** and **18**) in toluene (50 mL) was heated to reflux for 1h then cooled to RT. The reaction mixture was then concentrated, re-dissolved in MeOH, and concentrated again. The residue was triturated with a mixture of AcOEt/hexanes. The resulting suspension (gel) was collected by filtration, rinsed with hexanes, air-dried and dried under high vacuum to afford the title compound **18** (1.157 g, 1.74 mmol, quant. yield) as an off-white solid. MS (m/z): 665.6 (M+H).

Step 6. 4,4,4-trifluoro-3-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenylamino)-*N*-phenylbutanamided (19)

To a solution of **18** (200 mg, 0.30 mmol), aniline (42 mg, 0.45 mmol) and DIPEA (158 µL, 0.90 mmol) in DMF (4 mL) under nitrogen was added HATU reagent (229 mg, 0.60 mmol). The reaction mixture was stirred at RT overnight. The reaction mixture was then quenched by addition of a saturated aqueous solution of ammonium chloride, and extracted with AcOEt. The organic layer was successively washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium bicarbonate, water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **19** as a colorless sticky oil. MS (m/z): 740.8 (M+H).



A solution of this material (0.3 mmol) and TFA (5 mL) in DCM (25 mL) was stirred at RT for 3 hr. The reaction mixture was concentrated, diluted with a minimum of MeOH, and co-precipitated by addition of water. The pH was adjusted to 11-12 with 1N NaOH, and the suspension was stirred for 30 min. The solid was collected by filtration, rinsed with water, air-dried and dried under high vacuum to afford the title compound **19** (161 mg, 0.25 mmol, 84% yield over 2 steps) as an ivory solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 10.13 (s, 1H), 8.56 (d, *J* = 1.4 Hz, 1H), 8.48 (d, *J* = 5.3 Hz, 1H), 8.30 (s, 1H), 8.22 (d, *J* = 8.0 Hz, 1H), 7.89 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.57 (bd, *J* = 7.4 Hz, 2H), 7.34-7.27 (m, 2H), 7.24 (t, *J* = 9.1 Hz, 1H),

7.05 (bt, $J = 7.4$ Hz, 1H), 6.87 (dd, $J = 13.5, 2.7$ Hz, 1H), 6.69 (dd, $J = 8.6, 2.2$ Hz, 1H), 6.60 (d, $J = 9.4$ Hz, 1H), 6.55 (d, $J = 4.7$ Hz, 1H), 4.86-4.75 (m, 1H), 3.78 (s, 2H), 3.41 (t, $J = 5.7$ Hz, 2H), 3.24 (s, 3H), 2.92 (dd, $J = 15.3, 3.7$ Hz, 1H), 2.77 (dd, $J = 15.4, 9.5$ Hz, 1H), 2.65 (t, $J = 5.7$ Hz, 2H), 2.34-2.22 (m, 1H). MS (m/z): 640.5 ($M+H$).

5


Compounds **20-21** (examples **12-13**) were prepared in two steps from acid **18** and the corresponding amines similarly to compound **19** (example **11**, scheme 10).

Table 2. Characterization of compounds **20** and **21** (examples **12** and **13**)

Cpd	Ex.	Structure	Characterization
20	12	 4,4,4-trifluoro-3-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)phenylamino)-<i>N</i>-(4-fluorophenyl)butanamide	^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : 10.18 (s, 1H), 8.56 (d, $J = 1.8$ Hz, 1H), 8.48 (d, $J = 5.3$ Hz, 1H), 8.30 (s, 1H), 8.22 (d, $J = 8.2$ Hz, 1H), 7.89 (dd, $J = 8.2, 2.2$ Hz, 1H), 7.62-7.54 (m, 2H), 7.24 (t, $J = 9.2$ Hz, 1H), 7.19-7.11 (m, 2H), 6.87 (dd, $J = 13.5, 2.5$ Hz, 1H), 6.68 (dd, $J = 8.9, 2.1$ Hz, 1H), 6.58 (d, $J = 9.4$ Hz, 1H), 6.54 (d, $J = 5.3$ Hz, 1H), 4.86-4.74 (m, 1H), 3.78 (s, 2H), 3.41 (t, $J = 5.7$ Hz, 2H), 3.24 (s, 3H), 2.92 (dd, $J = 15.7, 3.7$ Hz, 1H), 2.75 (dd, $J = 15.7, 9.6$ Hz, 1H), 2.65 (t, $J = 5.7$ Hz, 2H), one NH is missing. MS (m/z): 658.5 ($M+1$).
21	13	 4,4,4-trifluoro-3-(3-fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)phenylamino)-<i>N</i>-methyl-<i>N</i>-phenylbutanamide	^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : 8.57 (d, $J = 1.4$ Hz, 1H), 8.50 (d, $J = 5.5$ Hz, 1H), 8.30 (s, 1H), 8.22 (d, $J = 8.0$ Hz, 1H), 7.89 (dd, $J = 8.1, 2.1$ Hz, 1H), 7.52 (bt, $J = 7.5$ Hz, 2H), 7.46-7.36 (m, 3H), 7.24 (t, $J = 9.2$ Hz, 1H), 6.81 (dd, $J = 13.5, 2.5$ Hz, 1H), 6.63 (dd, $J = 9.0, 1.8$ Hz, 1H), 6.59 (d, $J = 5.3$ Hz, 1H), 6.46 (bd, $J = 9.2$ Hz, 1H), 4.81-4.66 (m, 1H), 3.78 (s, 2H), 3.41 (t, $J = 5.7$ Hz, 2H), 3.24 (s, 3H), 3.19 (s, 3H), 2.65 (t, $J = 5.7$ Hz, 2H), 2.62-2.55 (m, 1H), 2.43 (bdd, $J = 16.0, 8.6$ Hz, 1H), one NH is missing. MS (m/z): 654.5 ($M+1$).

10

Scheme 11



5

Example 14

1-cyclopropyl-3-(2,3-difluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (25)

Step 1. *tert*-butyl (6-(7-(4-amino-2,3-difluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-

10 3-yl)methyl(2-methoxyethyl)carbamate (23)

To a stirred solution of 4-amino-2,3-difluorophenol (1.471 g, 10.14 mmol) in DMSO (11.5 mL) at RT under nitrogen was added potassium *tert*-butoxide (1.345 g, 11.98 mmol). After 30 min, *tert*-butyl (6-(7-chlorothieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (**22**, 4.0 g, 9.22 mmol) was added and the reaction mixture was heated at 100°C for 2.5 h, then cooled to RT. The reaction mixture was poured into water (90 mL) and stirred for 30 min. A saturated aqueous solution of sodium chloride was added and the mixture was stirred at RT for 3 days. The solid was collected by filtration, rinsed with water, air-dried and dried under high vacuum. The crude product was purified by Biotage (40+M cartridge; AcOEt/hexanes: 50/50 over 3 CV, 50/50 to 100% AcOEt over 6 CV, then 100% AcOEt over 8 CV), to provide a material that upon trituration with diethyl ether afforded title compound **23** (1.94 g, 3.58 mmol, 38% yield) as an off-white solid. MS (*m/z*): 543.3 (*M*+*H*).

Step 2. *tert*-butyl (6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (24)


To a stirred solution of aniline **23** (500 mg, 0.92 mmol) and DIPEA (0.8 mL, 4.61 mmol) in THF (18 mL) at -25°C under nitrogen was added dropwise a solution of triphosgene

(273 mg, 0.920 mmol) in THF (2 mL). The reaction mixture was stirred at -25°C and cyclopropylamine (0.32 mL, 4.61 mmol) was slowly added. The reaction mixture was allowed to warm to RT over 1.5 h and stirred at RT overnight. The reaction mixture was then partitioned between AcOEt and water. The organic layer was successively washed with a saturated aqueous solution of ammonium chloride, 1N NaOH and brine, dried over anhydrous magnesium sulfate, filtered and concentrated to afford the title compound **24** as an off-white solid. The crude material was used in the next step without any further purification. MS (m/z): 626.6 (M+H).

Step 3. 1-cyclopropyl-3-(2,3-difluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**25**)

A solution of intermediate **24** (0.92 mmol) and TFA (10 mL) in DCM (50 mL) was stirred at RT for 3 h. The reaction mixture was concentrated, diluted with a minimum of MeOH and water was added. The pH was adjusted to ca pH12 with 4N NaOH. The fine suspension was sonicated for 15 min, collected by filtration, rinsed with water and dried under high vacuum to afford the title compound **25** (578 mg, 0.9 mmol, 98% yield, TFA salt) as a pale ivory solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.78-8.61 (m, 1H), 8.57 (d, *J* = 1.6 Hz, 1H), 8.53 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.23 (d, *J* = 8.2 Hz, 1H), 8.02 (t, *J* = 7.8 Hz, 1H), 7.90 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.28 (td, *J* = 9.0, 2.1 Hz, 1H), 7.16-7.01 (m, 1H), 6.75 (d, *J* = 5.3 Hz, 1H), 3.78 (d, *J* = 6.1 Hz, 2H), 3.41 (t, *J* = 5.7 Hz, 2H), 3.24 (s, 3H), 2.65 (q, *J* = 6.0 Hz, 2H), 2.61-2.53 (m, 1H), 2.30-2.21 (m, 1H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 526.6 (M+H).

Scheme 12



Example 16

1-cyclopropyl-3-(5-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-*b*]-pyridin-7-yloxy)pyridin-2-yl)urea (29)

5 Step 1. *tert*-butyl (6-(7-(6-aminopyridin-3-yloxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (27)

A stirred suspension of **22** (1.0 g, 2.3 mmol), 2-amino-5-hydroxypyridine hydrochloride (405 mg, 2.77 mmol) and potassium *tert*-butoxide (817 mg, 6.91 mmol) in DMSO (20 mL) under nitrogen was heated to 95°C for 1 hr then cooled to RT. The reaction mixture was then
10 partitioned between water and AcOEt. The organic layer was successively washed with water, 0.1 N NaOH, a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified twice by Biotage (SNAP 50g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV and Silia Flash 80g; MeOH/DCM: 0/100 to 10/90 over 20 CV), to
15 afford the title compound **27** (634 mg, 1.249 mmol, 54% yield) as pale yellow sticky oil. MS (m/z): 508.6 (M+H).

Step 2. *tert*-butyl (6-(7-(6-(3-cyclopropylureido)pyridin-3-yloxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl(2-methoxyethyl)carbamate (28)


To a stirred solution of aniline **27** (634 mg, 1.249 mmol) and pyridine (303 µL, 3.746
20 mmol) in DMF (15 mL) at 0°C under nitrogen was added dropwise phenyl chloroformate (415 µL, 3.308 mmol). The reaction mixture was stirred at 0°C for 2 hrs and cyclopropylamine (433 µL, 6.250 mmol) was slowly added. The reaction mixture was allowed to warm-up to RT over 30 min and was heated at 55°C for 5 hr then cooled to RT. The reaction mixture was partitioned between AcOEt and a saturated aqueous solution of sodium bicarbonate. The organic layer was
25 successively washed with a saturated aqueous solution of sodium bicarbonate, 1N NaOH, a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SiliaFlash 40 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV). The desired fractions were collected, concentrated and dried under high vacuum to afford the title compound **28** (754 mg, 1.27 mmol,
30 quant. yield) as a pale yellow sticky oil. MS (m/z): 591.6 (M+H).

Step 3. 1-cyclopropyl-3-(5-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-*b*]-pyridin-7-yloxy)pyridin-2-yl)urea (29)

A solution of **28** (754 mg, 1.27 mmol) and TFA (5 mL) in DCM (25 mL) was stirred at RT for 5.5 hr. The TFA was removed by co-evaporation with DCM, dissolved in a minimum of
35 methanol, diluted with water, and the pH was adjusted to around 13 with 1N NaOH. The

resulting sticky suspension was extracted with DCM in the presence of traces of methanol. The combined organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified by Biotage (SiliaSep 40 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 1/99 to 10/90 over 20 CV) to produce a material that upon trituration with MeOH afforded the title compound **29** (360 mg, 0.734 mmol, 67% yield over 2 steps) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.23 (bs, 1H), 8.56 (d, *J* = 1.6 Hz, 1H), 8.51 (d, *J* = 5.5 Hz, 1H), 8.31 (s, 1H), 8.27-8.20 (m, 2H), 7.89 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.79-7.72 (m, 2H), 7.66 (bd, *J* = 9.0 Hz, 1H), 6.69 (d, *J* = 5.5 Hz, 1H), 3.78 (s, 2H), 3.41 (t, *J* = 5.9 Hz, 2H), 3.24 (s, 3H), 2.68-2.57 (m, 3H), 0.74-0.60 (m, 2H), 0.52-0.39 (m, 2H), one NH is missing. MS (*m/z*): 491.6 (M+H).

Scheme 13



15

Example 17

N-((6-(7-(6-(3-cyclopropylureido)pyridin-3-yloxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-*N*-(2-methoxyethyl)acetamide (**31**)

Step 1. 2-(((6-(7-(6-(3-cyclopropylureido)pyridin-3-yloxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl acetate (**30**)


To a stirred solution of compound **29** (108 mg, 0.22 mmol), acetoxyacetic acid (73 mg, 0.62 mmol) and triethylamine (114 μL, 0.82 mmol) in DMF (3 mL) under nitrogen were added EDC hydrochloride (118 mg, 0.62 mmol) and HOBT monohydrate (39 mg, 0.25 mmol) reagents, and the reaction mixture was stirred at RT overnight. The reaction was then quenched by addition of water and extracted with AcOEt. The organic phase was successively washed with water, a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of

ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The crude **30** was used in the next step without any further purification. MS (m/z): 591.7 (M+H).

Step 2. *N*-(((6-(7-(6-(3-cyclopropylureido)pyridin-3-yloxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-*N*-(2-methoxyethyl)acetamide (**31**)

To a stirred solution of **30** (from the previous step) in MeOH/THF (15/5 mL) was added 1N NaOH (2.6 mL). The reaction mixture was stirred at RT overnight, concentrated and diluted with water. The resultant suspension was shaken for 15 min. The solid was collected by filtration, rinsed with water and air-dried. The residue was purified by Biotage (SiliaSep 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV) to produce a material that upon trituration with methanol afforded the title compound **31** (79 mg, 0.144 mmol, 72% over 2 steps) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : mixture of rotamers, 9.23 (bs, 1H), 8.56-8.49 (m, 2H), 8.38-8.20 (m, 3H), 7.84-7.70 (m, 3H), 7.66 (bd, *J* = 9.0 Hz, 1H), 6.73-6.67 (m, 1H), 4.82-4.57 (m, 3H), 4.23 and 4.13 (2d, *J* = 6.0 Hz, 2H), 3.52-3.39 (m, 4H), 3.23-3.21 (2s, 3H), 2.65-2.57 (m, 1H), 0.74-0.60 (m, 2H), 0.53-0.37 (m, 2H). MS (m/z): 549.6 (M+H).

Scheme 14



WO 2009/109035 A1

33

Example 18

2-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl dihydrogen phosphate (**34**)

Step 1. di-*tert*-butyl 2-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]-pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl phosphate (33)





To a stirred suspension of compound **32** (200 mg, 0.35 mmol) and tetrazole (74 mg, 1.06 mmol) in DMF (3 mL) under argon was added (*t*-BuO)₂PNEt₂ (750 µL, 2.70 mmol) in three portions over 5 hr. The reaction mixture was stirred at RT for 2 days, cooled-down to -25°C and hydrogen peroxide (0.217 mL, 3.54 mmol, 50% in water) was slowly added. The reaction mixture was allowed to warm to RT over 1 h, and stirred at RT for 45 min. The reaction mixture was then cooled down again to -20°C and an aqueous solution of sodium metabisulfite (1.5 g in 10 mL of water) was slowly added. The reaction mixture was allowed to warm to RT over 1 h, and partitioned between water and AcOEt. The organic layer was successively washed with water, a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SiliaSep 25 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **33** as a sticky oil which was used in the next step without any further purification. MS (m/z): 646.5, 702.5, 758.7 (M+H).

Step 2. 2-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl dihydrogen phosphate (34)

To a stirred solution of **33** from the previous step in DCM (15 mL) was added a solution of 4M HCl in 1,4-dioxane (0.44 mL, 1.75 mmol). The reaction mixture (suspension) was stirred at RT for 1 h. The solid was collected by filtration, rinsed with DCM and dried under high vacuum. The residue was suspended in MeOH, concentrated and triturated with a minimum of methanol/water to afford the title compound **34** (136 mg, 0.21 mmol, 60% over 3 steps) as an off-white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : mixture of rotamers, 8.71 (s, 1H), 8.58-8.48 (m, 2H), 8.37 and 8.33 (2 s, 1H), 8.29 and 8.24 (2d, *J* = 8.2 Hz, 1H), 7.86-7.77 (m, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 9.0 Hz, 1H), 6.64 (d, *J* = 5.3 Hz, 1H), 6.57 (d, *J* = 2.5 Hz, 1H), 4.74-4.50 (m, 4H), 3.47 (bs, 4H), 3.24 and 3.21 (2s, 3H), 2.59-2.51 (m, 1H), 0.73-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 646.7 (M+H).

Compounds **35** - **38** (examples **19** - **22**) were prepared in one step by reacting the corresponding secondary amine precursors **25** (scheme 11), **179** (scheme 43), **29** (scheme 12) and **288** (scheme 64) with ethyl isocyanate.




Table 3. Characterization of compounds **35** - **38** (examples **19** - **22**)




Cpd	Ex.	Structure	Characterization
35	19	 <i>N</i>-[3-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)]-<i>N</i>-(1-ethyl)-<i>N</i>-(2-methoxyethyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.53 (d, <i>J</i> = 5.5 Hz, 1H), 8.51-8.46 (m, 2H), 8.33 (s, 1H), 8.25 (d, <i>J</i> = 8.2 Hz, 1H), 8.03 (bt, <i>J</i> = 7.8 Hz, 1H), 7.75 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.28 (td, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.88 (bd, <i>J</i> = 2.9 Hz, 1H), 6.75 (dd, <i>J</i> = 5.5, 0.6 Hz, 1H), 6.44 (t, <i>J</i> = 5.4 Hz, 1H), 4.53 (s, 2H), 3.44-3.35 (m, 4H), 3.23 (s, 3H), 3.12-3.04 (m, 2H), 2.61-2.53 (m, 1H), 1.02 (t, <i>J</i> = 7.1 Hz, 3H), 0.73-0.59 (m, 2H), 0.49-0.35 (m, 2H). MS (<i>m/z</i>): 597.6 (M+H).
36	20	 <i>N</i>-[3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)]-<i>N</i>-(1-ethyl)-<i>N</i>-[3-(2,5,8,11-tetraoxatridecan-13-yl)]urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.76 (s, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.49 (d, <i>J</i> = 2.0 Hz, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 1H), 7.79-7.69 (m, 2H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.61 (bd, <i>J</i> = 2.5 Hz, 1H), 6.44 (t, <i>J</i> = 5.4 Hz, 1H), 4.54 (s, 2H), 3.56-3.35 (m, 16H), 3.21 (s, 3H), 3.12-3.04 (m, 2H), 2.59-2.51 (m, 1H), 1.03 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (<i>m/z</i>): 711.7 (M+H).
37	21	 <i>N</i>-[3((6-(7-(6-(3-cyclopropylureido)-pyridin-3-yloxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)]-<i>N</i>-(1-ethyl)-<i>N</i>-[3-(2-methoxyethyl)]urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 9.23 (bs, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.48 (d, <i>J</i> = 1.8 Hz, 1H), 8.31 (s, 1H), 8.27-8.21 (m, 2H), 7.78-7.72 (m, 3H), 7.66 (bd, <i>J</i> = 9.0 Hz, 1H), 6.69 (d, <i>J</i> = 5.3 Hz, 1H), 6.44 (t, <i>J</i> = 5.4 Hz, 1H), 4.53 (s, 2H), 3.44-3.35 (m, 4H), 3.23 (s, 3H), 3.12-3.03 (m, 2H), 2.65-2.57 (m, 1H), 1.02 (t, <i>J</i> = 7.1 Hz, 3H), 0.74-0.60 (m, 2H), 0.51-0.38 (m, 2H). MS (<i>m/z</i>): 562.6 (M+H).
38	22	 <i>N</i>-[3-(2-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)ethyl)]-<i>N</i>-(1-ethyl)-<i>N</i>-[3-(2-methoxyethyl)]urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.75 (s, 1H), 8.51 (d, <i>J</i> = 5.5 Hz, 1H), 8.49 (bd, <i>J</i> = 1.6 Hz, 1H), 8.31 (s, 1H), 8.21 (d, <i>J</i> = 8.2 Hz, 1H), 7.81 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 9.2 Hz, 1H), 6.63 (bd, <i>J</i> = 5.4 Hz, 1H), 6.61 (bd, <i>J</i> = 2.7 Hz, 1H), 6.25 (t, <i>J</i> = 5.6 Hz, 1H), 3.45 (t, <i>J</i> = 7.4 Hz, 2H), 3.37 (t, <i>J</i> = 4.7 Hz, 2H), 3.31 (t, <i>J</i> = 4.9 Hz, 2H), 3.24 (s, 3H), 3.07-2.98 (m, 2H), 2.83 (t, <i>J</i> = 7.4 Hz, 2H), 2.59-2.51 (m, 1H), 0.97 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (<i>m/z</i>): 593.6 (M+H).

Compounds **39** - **44** (examples **23** - **28**) were prepared in one step by reacting the corresponding amine precursor **20** (table 2), **29** (scheme 12), **288** (scheme 64), **13** (scheme 9), **98** (scheme 25) and **108** (scheme 28), with acetic anhydride.

5



Table 4. Characterization of compounds **39-44** (examples **23-28**)

Cpd	Ex.	Structure	Characterization
39	23	 4,4,4-trifluoro-3-(3-fluoro-4-(2-(5-((N-(2-methoxyethyl)acetamido)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-phenylamino)-N-(4-fluorophenyl)butanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 10.29 (s, 1H), 8.55-8.46 (m, 2H), 8.34 and 8.31 (2s, 1H), 8.28 and 8.22 (2d, <i>J</i> = 8.2 Hz, 1H), 7.82-7.74 (m, 1H), 7.63-7.54 (m, 2H), 7.23 (t, <i>J</i> = 9.1 Hz, 1H), 7.19-7.10 (m, 2H), 6.87 (dd, <i>J</i> = 13.5, 2.5 Hz, 1H), 6.73-6.61 (m, 2H), 6.57-6.51 (m, 1H), 4.86-4.73 (m, 1H), 4.71 and 4.59 (2s, 2H), 3.54-3.40 (m, 4H), 3.24 and 3.21 (2s, 3H), 2.90 (dd, <i>J</i> = 15.4, 3.6 Hz, 1H), 2.76 (dd, <i>J</i> = 15.5, 9.7 Hz, 1H), 2.13 and 2.05 (2s, 3H). MS (m/z): 700.6 (M+H).
40	24	 N-((6-(7-(6-(3-cyclopropylureido)-pyridin-3-yloxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-methoxyethyl)-acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 9.24 (bs, 1H), 8.60-8.48 (m, 2H), 8.38-8.14 (m, 3H), 7.89-7.62 (m, 4H), 6.73-6.67 (m, 1H), 4.73-4.54 (m, 2H), 3.54-3.37 (m, 4H), 3.26-3.18 (m, 3H), 2.65-2.57 (m, 1H), 2.12 and 2.05 (2s, 3H), 0.74-0.60 (m, 2H), 0.52-0.39 (m, 2H). MS (m/z): 533.6 (M+H).
41	25	 N-(2-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl)-N-(2-methoxyethyl)-acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.75 (s, 1H), 8.58-8.47 (m, 2H), 8.33 and 8.31 (2s, 1H), 8.23 and 8.20 (2d, <i>J</i> = 8.1 Hz, 1H), 7.86 and 7.81 (2dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (bd, <i>J</i> = 10.2 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.61 (bd, <i>J</i> = 2.3 Hz, 1H), 3.57 (t, <i>J</i> = 7.4 Hz, 1H), 3.52 (t, <i>J</i> = 7.4 Hz, 1H), 3.47-3.40 (m, 4H), 3.26 and 3.25 (2s, 3H), 2.92 (t, <i>J</i> = 7.4 Hz, 1H), 2.84 (t, <i>J</i> = 7.3 Hz, 1H), 2.59-2.51 (m, 1H), 2.00 and 1.91 (2s, 3H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 564.6 (M+H).


Cpd	Ex.	Structure	Characterization
42	26	 2-cyclopropyl-N-(3-fluoro-4-(2-(5-((N-(2-methoxyethyl)-acetamido)methyl)pyridin-2-yl)thieno[3,2-b]-pyridin-7-yloxy)phenyl)-acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 10.20 (s, 1H), 8.55-8.48 (m, 2H), 8.37 and 8.33 (2s, 1H), 8.29 and 8.23 (2d, <i>J</i> = 8.1 Hz, 1H), 7.90 (dd, <i>J</i> = 13.2, 2.2 Hz, 1H), 7.82-7.75 (m, 1H), 7.47 (t, <i>J</i> = 8.8 Hz, 1H), 7.42 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.70-6.65 (m, 1H), 4.71 and 4.59 (2s, 2H), 3.54-3.40 (m, 4H), 3.24 and 3.21 (2s, 3H), 2.25 (d, <i>J</i> = 7.0 Hz, 2H), 2.13 and 2.05 (2s, 3H), 1.13-1.02 (m, 1H), 0.57-0.43 (m, 2H), 0.28-0.15 (m, 2H). MS (m/z): 549.6 (M+H).
43	27	 N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-(methylsulfonyl)ethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): mixture of rotamers, 8.80 (s, 1H), 8.58-8.50 (m, 2H), 8.39-8.33 (m, 1H), 8.32-8.23 (m, 1H), 7.86-7.77 (m, 1H), 7.76-7.70 (m, 1H), 7.38 (t, <i>J</i> = 8.8 Hz, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H), 6.68-6.63 (m, 2H), 4.72 and 4.60 (2s, 2H), 3.75-3.52 (m, 3H), 3.40-3.30 (m, 1H), 3.04 and 3.01 (2s, 3H), 2.59-2.50 (m, 1H), 2.19 and 2.09 (2s, 3H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 598.5 (M+H).
44	28	 (S)-N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-2-oxopyrrolidin-3-yl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.75 (s, 1H), 8.55 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.6 Hz, 1H), 8.36 (s, 1H), 8.30-8.25 (m, 2H), 7.84 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.2 Hz, 1H), 7.23-7.18 (m, 1H), 6.65 (d, <i>J</i> = 5.2 Hz, 1H), 6.60 (d, <i>J</i> = 2.4 Hz, 1H), 4.62-4.35 (m, 3H), 3.30-3.23 (m, 2H), 2.59-2.52 (m, 1H), 2.34-2.24 (m, 1H), 1.86 (s, 3H), 1.84-1.74 (m, 1H), 0.68-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (m/z): 575.5 (M+H).

Compounds 45 - 46 (examples 29 - 30) were prepared in two steps from the corresponding secondary amine precursor 179 (scheme 43) and 288 (scheme 64), and acetoxyacetic acid similarly to compound 31 (example 17, scheme 13).

Table 5. Characterization of compounds 45 - 46 (examples 29 - 30)

Cpd	Ex.	Structure	Characterization
45	29	 <i>N</i>-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2-<i>b</i>]-pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-<i>N</i>-(2,5,8,11-tetraoxatridecan-13-yl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.73 (s, 1H), 8.57-8.49 (m, 2H), 8.38-8.20 (m, 2H), 7.85-7.76 (m, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 9.5 Hz, 1H), 6.67-6.62 (m, 1H), 6.59 (d, <i>J</i> = 2.5 Hz, 1H), 4.81-4.57 (m, 3H), 4.24 and 4.15 (2d, <i>J</i> = 5.7 Hz, 2H), 3.58-3.37 (m, 16H), 3.22-3.19 (m, 3H), 2.59-2.51 (m, 1H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (<i>m/z</i>): 698.6 (M+H).
46	30	 <i>N</i>-(2-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)ethyl)-2-hydroxy-<i>N</i>-(2-methoxyethyl)-acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.71 (s, 1H), 8.58-8.48 (m, 2H), 8.33 and 8.31 (2s, 1H), 8.22 (t, <i>J</i> = 8.5 Hz, 1H), 7.87 and 7.82 (2dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.3 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 9.0 Hz, 1H), 6.64 (d, <i>J</i> = 5.3 Hz, 1H), 6.58 (bd, <i>J</i> = 2.3 Hz, 1H), 4.49 and 4.43 (2t, <i>J</i> = 5.5 Hz, 1H), 4.10 and 4.02 (2d, <i>J</i> = 5.5 Hz, 2H), 3.62-3.40 (m, 5H), one CH ₂ is masked by water's peak, 3.26 and 3.25 (2s, 3H), 2.96-2.83 (m, 2H), 2.59-2.51 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (<i>m/z</i>): 580.6 (M+H).

Scheme 15



Examples 31 and 32

tert-butyl 4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]-pyridin-2-yl)pyridin-3-yl)methyl)piperazine-1-carboxylate (48) and
1-cyclopropyl-3-(3-fluoro-4-(2-(5-(piperazin-1-ylmethyl)pyridin-2-yl)thieno[3,2-*b*]-pyridin-7-yloxy)phenyl)urea (49)

Step 1. tert-butyl 4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]-pyridin-2-yl)pyridin-3-yl)methyl)piperazine-1-carboxylate (48)

A suspension of 1-cyclopropyl-3-(3-fluoro-4-(2-(5-formylpyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (**47**, 3 g, 5.90 mmol, acetate salt), 1-boc-piperazine (1.65 g, 8.85 mmol) and acetic acid (675 μ L, 11.80 mmol) in NMP (50 mL) at RT under nitrogen was sonicated for 3 h in order to obtain a solution, then NaBH(OAc)₃ (3.95 g, 17.70 mmol) was added. The reaction mixture was stirred at RT for 3 days then quenched by addition of water. The pH was adjusted to 12-13 with 4N NaOH and the suspension was stirred and sonicated for 1h. The solid was collected by filtration, rinsed with water and air-dried. The residue was purified twice by Biotage (SNAP 50g KP-Sil cartridge; MeOH/DCM: 1/99 to 10/90 over 20 CV). The desired fractions were collected, concentrated, and co-precipitated with AcOEt with traces of methanol/hexanes to afford the title compound **48** (1.511 g, 2.44 mmol, 41% yield) as a white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.71 (s, 1H), 8.56 (bd, *J* = 2.0 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.25 (d, *J* = 8.2 Hz, 1H), 7.87 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bdd, *J* = 8.8, 1.2 Hz, 1H), 6.65 (d, *J* = 5.3 Hz, 1H), 6.57 (bd, *J* = 2.5 Hz, 1H), 3.57 (s, 2H), 4H are hidden by water's peak, 2.59-2.51 (m, 1H), 2.42-2.27 (m, 4H), 1.39 (s, 9H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 619.4 (M+H).




Step 2. 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(piperazin-1-ylmethyl)pyridin-2-yl)thieno[3,2-*b*]-pyridin-7-yloxy)phenyl)urea (49)




A solution of **48** (1.456 g, 2.35 mmol) and TFA (15 mL) in DCM (50 mL) was stirred at RT for 5 hr. The TFA was removed by co-evaporation with DCM, the residue was diluted with water, and the pH was adjusted to ~12-13 with 1N NaOH. The resultant suspension was sonicated for 15 min. The solid was collected by filtration, rinsed with water and dried under high vacuum to afford the title compound **49** (1.227 g, traces of TFA) as an off-white fluffy solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.76 (bs, 1H), 8.54 (d, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.32 (s, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 7.85 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.3 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 10.2 Hz, 1H), 6.64 (d, *J* = 5.5 Hz,





1H), 6.62 (bs, 1H), 3.58-3.48 (m, 2H), 2.73-2.64 (m, 4H), 2.59-2.52 (m, 1H), 2.38-2.25 (m, 4H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H), one NH is missing. MS (m/z): 519.6 (M+H).




Compounds **50** - **60** (examples **33** - **43**) were prepared in one step by reductive amination of compound **47** with an appropriate amine similarly to compound **48** (example **31**, scheme 15).




Table 6. Characterization of compounds **50** - **60** (examples **33** - **43**)




Cpd	Ex.	Structure	Characterization
50	33	 1-(4-(2-(5-(((bis(2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]-pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, MeOH- <i>d</i> ₄) δ (ppm): 8.65 (d, <i>J</i> = 1.6 Hz, 1H), 8.49 (d, <i>J</i> = 5.5 Hz, 1H), 8.14-8.08 (m, 2H), 8.00 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.69 (dd, <i>J</i> = 13.1, 2.5 Hz, 1H), 7.52 (t, <i>J</i> = 8.8 Hz, 1H), 7.25-7.20 (m, 1H), 6.66 (dd, <i>J</i> = 5.7, 1.0 Hz, 1H), 4.04-3.97 (br s, 2H), 3.61 (t, <i>J</i> = 5.5 Hz, 4H), 3.38 (s, 6H), 2.98-2.90 (m, 4H), 2.67-2.60 (m, 1H), 0.83-0.77 (m, 2H), 0.59-0.54 (m, 2H). MS (m/z): 566.6 (M+H).
50-A	33-A	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(((2-hydroxyethyl)(methyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79 (s, 1H), 8.56 (s, 1H), 8.51 (d, <i>J</i> = 5.48 Hz, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.021 Hz, 1H), 7.88 (m, 1H), 7.73 (m, 1H), 7.37 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (s, 1H), 6.63 (m, 2H), 4.45 (t, <i>J</i> = 5.48 Hz, 1H), 3.59 (sm, 2H), 3.52 (q, <i>J</i> = 6.065 Hz, 2H), 2.55 (m, 1H), 2.45 (t, <i>J</i> = 6.26 Hz, 2H), 2.19 (s, 3H), 0.644 (m, 2H), 0.429 (m, 2H). MS (m/z) 508.503 (M+H).
51	34	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]-pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, MeOH- <i>d</i> ₄) δ (ppm): 8.60 (d, <i>J</i> = 1.8 Hz, 1H), 8.49 (d, <i>J</i> = 5.3 Hz, 1H), 8.14-8.08 (m, 2H), 7.93 (dd, <i>J</i> = 8.0, 2.2 Hz, 1H), 7.70 (dd, <i>J</i> = 13.1, 2.9 Hz, 1H), 7.33 (t, <i>J</i> = 8.8 Hz, 1H), 7.25-7.20 (m, 1H), 6.66 (dd, <i>J</i> = 5.7, 1.0 Hz, 1H), 3.67 (s, 2H), 2.85-2.37 (m, 9H), 2.32 (s, 3H), 0.83-0.77 (m, 2H), 0.59-0.54 (m, 2H). MS (m/z): 533.6 (M+H).

Cpd	Ex.	Structure	Characterization
52	35	 (S)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-hydroxypyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.77-8.69 (m, 1H), 8.56 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.86 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.3 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (bd, <i>J</i> = 8.9 Hz, 1H), 6.64 (dd, <i>J</i> = 5.4, 0.7 Hz, 1H), 6.62-6.54 (m, 1H), 4.72 (d, <i>J</i> = 4.7 Hz, 1H), 4.25-4.16 (m, 1H), 3.67 (d, <i>J</i> = 13.5 Hz, 1H), 3.61 (d, <i>J</i> = 13.5 Hz, 1H), 2.69 (dd, <i>J</i> = 9.6, 6.3 Hz, 1H), 2.61 (q, <i>J</i> = 7.6 Hz, 1H), 2.58-2.51 (m, 1H), 2.47-2.39 (m, 1H), 2.34 (dd, <i>J</i> = 9.6, 3.5 Hz, 1H), 2.01 (hex, <i>J</i> = 6.5 Hz, 1H), 1.60-1.51 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 520.5 (M+H).
53	36	 (R)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-hydroxypyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.71 (s, 1H), 8.56 (d, <i>J</i> = 1.8 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.86 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 8.6 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.57 (bd, <i>J</i> = 2.3 Hz, 1H), 4.73 (bd, <i>J</i> = 4.5 Hz, 1H), 4.25-4.16 (m, 1H), 3.68 (d, <i>J</i> = 13.3 Hz, 1H), 3.62 (d, <i>J</i> = 12.9 Hz, 1H), 2.75-2.52 (m, 3H), 2.48-2.30 (m, 2H), 2.00 (hex, <i>J</i> = 7.0 Hz, 1H), 1.61-1.51 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 520.5 (M+H).
54	37	 (S)-1-cyclopropyl-3-(4-(2-(5-((3-(dimethylamino)pyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.70 (s, 1H), 8.59 (d, <i>J</i> = 1.8Hz, 1H), 8.55 (d, <i>J</i> = 5.5Hz, 1H), 8.36 (s, 1H), 8.27 (d, <i>J</i> = 8.0Hz, 1H), 7.89 (dd, <i>J</i> = 8.0, 1.9Hz, 1H), 7.42 (t, <i>J</i> = 9.0Hz, 1H), 7.25-7.23 (m, 1H), 6.68 (d, <i>J</i> = 5.3Hz, 1H), 6.62(d, <i>J</i> = 2.6Hz, 1H), 3.71(d, <i>J</i> = 3.5Hz, 1H), 3.62 (d, <i>J</i> = 3.5Hz, 1H), 2.75-2.70 (m, 2H), 2.66-2.57 (m, 2H), 2.52-2.47 (m, 1H), 2.35-2.33 (m, 1H), 2.13-2.11 (m, 6H), 1.92-1.87 (m, 1H), 1.67-1.62 (m, 1H), 0.71-0.67 (m, 2H), 0.48-0.45 (m, 2H). MS (m/z): 547.6 (M+H).


Cpd	Ex.	Structure	Characterization
54-A	37-A	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-morpholinoethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.83(s, 1H), 8.58-8.55(m, 2H), 8.36(s, 1H), 8.28(d, 1H, J=8.2Hz), 8.19(s, 1H), 7.89(dd, 1H, J1=1.9Hz, J2=8.2Hz), 7.77(dd, 1H, J1=2.3Hz, J2=13.5Hz), 7.41(t, 1H, J=9.0Hz), 7.25-7.22(m, 1H), 6.69-6.67(m, 1H), 3.59-3.57(m, 6H), 2.62-2.57(m, 1H), 2.54-2.42(m, 16H), 0.71-0.66(m, 2H), 0.48-0.44(m, 2H). MS (m/z): 632.7 (M+H)
54-B	37-B	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-methyl-1,4-diazepan-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.79 (s, 1H), 8.56 (bd, J = 1.4 Hz, 1H), 8.52 (d, J = 5.5 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.87 (dd, J = 8.2, 2.2 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.21 (dd, J = 8.9, 1.5 Hz, 1H), 6.68-6.61 (m, 2H), 3.68 (s, 2H), 2.70-2.61 (m, 4H), 2.59-2.50 (m, 5H), 2.24 (s, 3H), 1.77-1.67 (m, 2H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 547.6 (M+H)
54-C	37-C	 1-cyclopropyl-3-(4-(2-(5-((4-(dimethylamino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.25 (s, 1H), 8.58-8.54 (m, 2H), 8.36(s, 1H), 8.32 (s, 1H), 8.27 (d, 1H, J=8.0Hz), 7.89 (dd, 1H, J1=6.1Hz, J2=1.9Hz), 7.78 (dd, 1H, J1=2.5Hz, J2=13.7Hz), 7.40 (t, 1H, J=9.0Hz), 7.27-7.24 (m, 1H), 7.07 (d, 1H, J=1.9Hz), 6.69 (d, 1H, J=5.5Hz), 3.57 (s, 2H), 2.90-2.87 (m, 2H), 2.60-2.58 (m, 1H), 2.26 (s, 6H), 2.22-2.20 (m, 1H), 2.03-1.98 (m, 2H), 1.79-1.76 (m, 2H), 1.49-1.44 (m, 2H), 0.69-0.65 (m, 2H), 0.48-0.44 (m, 2H) (formate salt). MS (m/z): 561.7 (M+H)
54-D	37-D	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-((1-methylpiperidin-4-yl)methyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, CD ₃ OD) δ (ppm): 8.56-8.54 (m, 1H), 8.45 (d, 1H, J=5.5Hz), 8.08-8.06 (m, 2H), 7.89 (dd, 1H, J1=2.2Hz, J2=8.3Hz), 7.66 (dd, 1H, J1=2.3Hz, J2=12.9Hz), 7.29 (m, 1H, J=8.8Hz), 7.20-7.18 (m, 1H), 6.63 (dd, 1H, J1=1.0Hz, J2=5.5Hz), 3.61 (s, 2H), 2.86-2.83 (m, 2H), 2.62-2.54 (m, 8H), 2.24 (s, 3h), 2.21-2.20 (D, 2H, J=7.0Hz), 1.99 (t, 2H, J=10.4Hz), 1.77-1.74 (m, 2H), 1.60-1.48 (m, 1H), 1.27-1.15 (m, 2H), 0.78-0.73 (m, 2H), 0.54-0.53 (m, 2H). MS (m/z): 630.6 (M+H)

Cpd	Ex.	Structure	Characterization
54-E	37-E	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H), 8.54 (bd, J = 1.6 Hz, 1H), 8.52 (d, J = 5.5 Hz, 1H), 8.32 (s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 7.85 (dd, J = 8.1, 2.1 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.20 (bd, J = 10.2 Hz, 1H), 6.64 (d, J = 5.3 Hz, 1H), 6.57 (bd, J = 2.3 Hz, 1H), 3.53 (s, 2H), 2.65-2.51 (m, 2H), 2.49-2.32 (m, 8H), 0.95 (d, J = 6.7 Hz, 6H), 0.71-0.58 (m, 2H), 0.50-0.38 (m, 2H). MS (m/z): 561.5 (M+H).
54-F	37-F	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H), 8.57 (bd, J = 1.4 Hz, 1H), 8.52 (d, J = 5.5 Hz, 1H), 8.34 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.88 (dd, J = 8.1, 2.2 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.20 (bd, J = 9.2 Hz, 1H), 6.65 (d, J = 5.3 Hz, 1H), 6.59 (bd, J = 2.5 Hz, 1H), 3.62 (s, 2H), 3.16-3.10 (m, 4H), 2.88 (s, 3H), 2.57-2.52 (m, 1H), 4H are hidden by waters peak, 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 567.2 (M+H).
54-G	37-G	 1-(4-(2-(5-((4-(2-(1H-imidazol-1-yl)ethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H), 8.54 (bd, J = 1.4 Hz, 1H), 8.52 (d, J = 5.5 Hz, 1H), 8.32 (s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 7.85 (dd, J = 8.1, 2.1 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.61 (bs, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.20 (dd, J = 8.9, 1.3 Hz, 1H), 7.17 (bs, 1H), 6.85 (bs, 1H), 6.64 (dd, J = 5.4, 0.7 Hz, 1H), 6.58 (bd, J = 2.5 Hz, 1H), 4.05 (t, J = 6.4 Hz, 2H), 3.54 (s, 2H), 2.60 (t, J = 6.5 Hz, 2H), 2.58-2.54 (m, 1H), 2.50-2.30 (m, 8H), 0.72-0.58 (m, 2H), 0.49-0.37 (m, 2H). MS (m/z): 613.5 (M+H).

Cpd	Ex.	Structure	Characterization
55	38	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.3 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.3 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 9.0 Hz, 1H), 6.64 (dd, <i>J</i> = 5.4, 0.7 Hz, 1H), 6.57 (bd, <i>J</i> = 2.5 Hz, 1H), 4.48-4.30 (m, 1H), 3.54 (s, 2H), 3.48 (q, <i>J</i> = 6.0 Hz, 2H), 2.59-2.51 (m, 1H), 2.48-2.30 (m, 8H), one CH ₂ is hidden, 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 563.6 (M+H).
56	39	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.3 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (bd, <i>J</i> = 9.0 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.57 (bd, <i>J</i> = 2.5 Hz, 1H), 3.54 (s, 2H), 3.41 (t, <i>J</i> = 5.9 Hz, 2H), 3.22 (s, 3H), 2.59-2.51 (m, 1H), 2.49-2.30 (m, 10H), 0.72-0.58 (m, 2H), 0.50-0.37 (m, 2H). MS (m/z): 577.6 (M+H).
57	40	 1-(4-(2-(5-((4-(2-cyanoethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (dd, <i>J</i> = 9.0, 1.4 Hz, 1H), 6.64 (dd, <i>J</i> = 5.5, 0.8 Hz, 1H), 6.58 (bd, <i>J</i> = 2.5 Hz, 1H), 3.56 (s, 2H), 2.66 (bt, <i>J</i> = 6.5 Hz, 2H), 2.59-2.35 (m, 11H), 0.72-0.58 (m, 2H), 0.50-0.37 (m, 2H). MS (m/z): 572.7 (M+H).

Cpd	Ex.	Structure	Characterization
58	41	 ethyl 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidine-4-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.71 (s, 1H), 8.54 (d, <i>J</i> = 1.4 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.86 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 9.0 Hz, 1H), 6.65 (d, <i>J</i> = 5.5 Hz, 1H), 6.58 (bd, <i>J</i> = 2.7 Hz, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 3.54 (s, 2H), 2.82-2.72 (m, 2H), 2.59-2.51 (m, 1H), 2.35-2.25 (m, 2H), 2.10-2.00 (m, 2H), 1.84-1.76 (m, 2H), 1.64-1.51 (m, 2H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.49-0.37 (m, 2H). MS (<i>m/z</i>): 590.6 (M+H).
59	42	 ethyl 2-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)acetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.71 (s, 1H), 8.53 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.3 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.84 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (bd, <i>J</i> = 8.8 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.58 (bd, <i>J</i> = 2.5 Hz, 1H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 3.52 (s, 2H), 2.84-2.75 (m, 2H), 2.59-2.51 (m, 1H), 2.22 (d, <i>J</i> = 6.7 Hz, 2H), 1.97 (bt, <i>J</i> = 10.8 Hz, 2H), 1.73-1.56 (m, 3H), 1.28-1.17 (m, 2H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (<i>m/z</i>): 604.6 (M+H).
60	43	 ethyl 2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)acetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (d, <i>J</i> = 1.4 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.5 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 10.3 Hz, 1H), 6.64 (d, <i>J</i> = 5.3 Hz, 1H), 6.58 (bd, <i>J</i> = 2.3 Hz, 1H), 4.07 (q, <i>J</i> = 7.1 Hz, 2H), 3.55 (s, 2H), 3.19 (s, 2H), 2.59-2.51 (m, 1H), 2.47-2.35 (m, 4H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.49-0.37 (m, 2H), 4H are hidden by solvents. MS (<i>m/z</i>): 605.6 (M+H).

Scheme 16



Example 44

2-(4-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)acetic acid (**61**)

5

10



15

To a stirred solution of ester **60** (85 mg, 0.14 mmol) in a mixture of MeOH/THF (5/5 mL) was added 1N NaOH (2 mL). The reaction mixture was stirred at RT for 3 h, concentrated, diluted with a minimum of water, quenched with 1N HCl to neutral pH, and concentrated. The residue was purified by Biotage (SNAP 10 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 5/95 to 30/70 over 20 CV then 100% MeOH over 10 CV), to afford the title compound **44** (72 mg, 0.118 mmol, 84% yield) as an ivory solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.95 (s, 1H), 8.55 (bd, *J* = 1.8 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.25 (d, *J* = 8.0 Hz, 1H), 7.86 (dd, *J* = 8.1, 2.0 Hz, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.40-7.00 (m, 1H), 7.20 (bd, *J* = 9.0 Hz, 1H), 6.72 (bd, *J* = 2.7 Hz, 1H), 6.64 (d, *J* = 5.3 Hz, 1H), 3.57 (s, 2H), 2.69 (bs, 4H), 2.59-2.51 (m, 1H), 2.48 (bs, 2H, partially hidden), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H), 4H are hidden by water's peak, presence of 1 eq. of methanol. MS (*m/z*): 577.6 (M+H).


20

Compounds **62** - **63** (examples **45** – **46**) were prepared in one step by hydrolysis of the esters **58** and **59** with sodium hydroxide, similarly to compound **61** (example 44, scheme 16) with a final purification by preparative HPLC.

Table 7. Characterization of compounds **62** and **63** (examples **45** and **46**)

Cpd	Ex.	Structure	Characterization
62	45	 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidine-4-carboxylic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 12.12 (bs, 1H), 8.71 (s, 1H), 8.54 (bd, <i>J</i> = 1.4 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.86 (bd, <i>J</i> = 8.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 8.8 Hz, 1H), 6.65 (d, <i>J</i> = 5.5 Hz, 1H), 6.57 (bd, <i>J</i> = 2.5 Hz, 1H), 3.54 (s, 2H), 2.84-2.70 (m, 2H), 2.59-2.51 (m, 1H), 2.27-2.16 (m, 1H), 2.11-1.98 (m, 2H), 1.85-1.74 (m, 2H), 1.64-1.49 (m, 2H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 562.5 (M+H).
63	46	 2-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)acetic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.89 (s, 1H), 8.54 (bd, <i>J</i> = 1.4 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 1H), 8.19 (bs, 2H, formate salt), 7.85 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.21 (bd, <i>J</i> = 9.0 Hz, 1H), 6.73 (bd, <i>J</i> = 2.5 Hz, 1H), 6.64 (d, <i>J</i> = 5.3 Hz, 1H), 3.53 (s, 2H), 2.80 (bd, <i>J</i> = 11.2 Hz, 2H), 2.59-2.51 (m, 1H), 2.14 (bd, <i>J</i> = 6.5 Hz, 2H), 1.98 (bt, <i>J</i> = 10.9 Hz, 2H), 1.64 (bd, <i>J</i> = 10.0 Hz, 3H), 1.28-1.13 (m, 2H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H), one OH carboxylic acid is missing, bis-formate salt. MS (m/z): 576.5 (M+H).

Scheme 17



Example 47

1-(4-(2-(5-((4-acetylpiperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (66)

5

Step 1. 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(hydroxymethyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (64)

To a suspension of **47** (5.60 g, 12.49 mmol) in a mixture of DCM (200 mL)/MeOH (20 mL) in a 1 L round-bottomed flask was added sodium triacetoxyborohydride (5.29 g, 24.97 mmol). The reaction mixture was stirred at RT for 5 h. More sodium triacetoxyborohydride (5.29 g, 24.97 mmol) was added and the mixture was stirred at RT for 16 h. Then NaBH₄ (2 g, 52.9 mmol) was added to the reaction mixture that was stirred at RT for 24 h. Finally, more NaBH₄ (2 g, 52.9 mmol) was added and the reaction mixture was heated to reflux for 5 h, then cooled to RT, concentrated, quenched with 10% HCl (100 mL), and neutralized slowly with a saturated aqueous solution of NaHCO₃ (200 mL) to give a grey precipitate. The suspension was shaken for 15 min and the solid was collected by filtration, rinsed with water (2x 25 mL) and dried under high vacuum to afford the title compound **64** (5.34 g, 11.85 mmol, 94% yield) as a light grey solid. MS (m/z): 451.5 (M+H). The material was used in the next step with no additional purification.

Step 2. 1-(4-(2-(5-(chloromethyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (65)

Into a 500 mL round-bottom flask containing **64** (5.34 g, 11.85 mmol) was added slowly SOCl₂ (30 mL, 411 mmol). The yellow solution was stirred at RT for 2 h and cooled to 0°C. The reaction mixture was quenched by addition of ice (150 g) and water (100 mL), and the yellow suspension was shaken at RT for 1 h. The solid was collected by filtration, rinsed with water and dried under high vacuum. The crude product was triturated with AcOEt to afford the title compound **65** (5.55 g, purity ~ 40% by HPLC, contaminated with the des-cyclopropyl side-product) as a yellow solid. MS (m/z): 469.1 (M+H). The material was used in the next step with no additional purification.



Step 3. 1-(4-(2-(5-((4-acetylpiperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (66)


A stirred solution of **65** (1 g, 2.13 mmol, 40%, from the previous step), 1-acetyl-piperazine (328 mg, 2.56 mmol) and DIPEA (1.12 mL, 6.40 mmol) in DMSO (20 mL) was heated at 70°C overnight, then rt. The reaction mixture was quenched by addition of water and 1N NaOH. The resultant suspension was collected by filtration, rinsed with water and air-dried.

The crude product was purified twice by Biotage (SNAP 50 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV then 10/90 to 15/85 over 10CV; SiliaFlash 120 g cartridge, 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV then 10/90 to 20/80 over 10 CV) to produce a material that upon trituration with MeOH
 5 afforded the title compound **66** (79 mg, 0.14 mmol, 6% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.71 (s, 1H), 8.57 (d, *J* = 1.8 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.34 (s, 1H), 8.25 (d, *J* = 8.0 Hz, 1H), 7.88 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H), 7.38 (t, *J* = 9.0 Hz, 1H), 7.20 (bd, *J* = 9.0 Hz, 1H), 6.65 (d, *J* = 5.5 Hz, 1H), 6.57 (bd, *J* = 2.3 Hz, 1H), 3.59 (s, 2H), 3.48-3.40 (m, 4H), 2.59-2.51 (m, 1H), 2.44-2.31 (m, 4H), 1.98 (s,
 10 3H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 561.5 (M+H).


Compounds **67** - **69** (examples **48** - **50**) were prepared in one step by reacting the appropriate amines with the chloride **65**, similarly to compound **66** (example **47**, scheme 17).

Table 8. Characterization of compounds **67** - **69** (examples **48** - **50**)

Cpd	Ex.	Structure	Characterization
67	48	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-oxopiperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2- <i>b</i>]-pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.77 (s, 1H), 8.58 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.34 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.90 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.79 (bs, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.65 (dd, <i>J</i> = 5.5, 0.8 Hz, 1H), 6.62 (bd, <i>J</i> = 2.5 Hz, 1H), 3.63 (s, 2H), 3.20-3.12 (m, 2H), 2.98 (s, 2H), 2.62-2.51 (m, 3H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (<i>m/z</i>): 533.6 (M+H).
68	49	 ethyl 3-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2- <i>b</i>]-pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)propanoate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.3 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.64 (dd, <i>J</i> = 5.5, 0.8 Hz, 1H), 6.58 (bd, <i>J</i> = 2.5 Hz, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 3.53 (s, 2H), 2.58-2.30 (m, 13H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H), 0.72-0.58 (m, 2H), 0.49-0.37 (m, 2H). MS (<i>m/z</i>): 619.7 (M+H).

Cpd	Ex.	Structure	Characterization
69	50	 (1 <i>S</i> ,4 <i>S</i>)- <i>tert</i> -butyl 5-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2- <i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate	MS (<i>m/z</i>): 631.7 (<i>M</i> + <i>H</i>).

Scheme 18



5

Example 51

3-(4-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)propanoic acid (70)


To a stirred solution of **68** (100 mg, 0.16 mmol) in a mixture of MeOH/THF (5/5 ml) was added 1N NaOH (2.42 ml). The reaction mixture was heated at 60°C for 40 min, then rt. The reaction mixture was concentrated, diluted with water, neutralized with 1N HCl until formation of a precipitate-gel (pH around 4-5) and sonicated for 1 h. The solid was collected by filtration, rinsed with water, and air-dried. The crude solid was triturated and sonicated in a minimum of methanol. The solid was collected by filtration, rinsed with methanol and dried under high vacuum to afford the desired product (66 mg, 0.11 mmol, 69% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : one OH carboxylic acid is missing, 8.72 (s, 1H), 8.54 (bd, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.85 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H), 7.38 (t, *J* = 9.0 Hz, 1H), 7.20 (dd, *J* = 9.0, 1.2 Hz, 1H), 6.64 (dd, *J* = 5.5, 0.8 Hz, 1H), 6.58 (bd, *J* = 2.5 Hz, 1H), 3.58 (s, 2H), 2.65-2.30 (m, 13H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 591.5 (*M*+*H*).

magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 10 g column; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV, 10/90 to 20/80 over 10 CV then 20/80 over 5 CV), to afford the title compound **72** (35 mg, 0.066 mmol, 69% yield, traces of TFA) as a white sticky solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.55 (d, *J* = 1.8 Hz, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.35 (s, 1H), 8.26 (d, *J* = 8.0 Hz, 1H), 7.83 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (dd, *J* = 8.9, 1.5 Hz, 1H), 6.65 (dd, *J* = 5.3, 0.6 Hz, 1H), 6.58 (bd, *J* = 2.7 Hz, 1H), 4.59 (s, 2H), 3.37 (s, 2H), 3.28 (t, *J* = 5.5 Hz, 2H), 2.95 (t, *J* = 5.4 Hz, 2H), 2.59-2.51 (m, 1H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H), one NH is missing. MS (*m/z*): 533.4 (M+H).

10


Compound **73** (example **53**) was prepared in one step by Boc-deprotection of compound **69** (example **50**), similarly to compound **72** (example **52**, scheme 19).

Table 9. Characterization of compound **73** (example **53**)

Cpd	Ex.	Structure	Characterization
73	53	 1-(4-(2-(5-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylmethyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 9.01 (s, 1H), 8.56 (d, <i>J</i> = 1.6 Hz, 1H), 8.51 (d, <i>J</i> = 5.6 Hz, 1H), 8.31 (s, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.74 (dd, <i>J</i> = 14.0, 2.8 Hz, 1H), 7.37 (t, <i>J</i> = 8.8 Hz, 1H), 7.21 (d, <i>J</i> = 10 Hz, 1H), 6.84 (s, 1H), 6.64 (d, <i>J</i> = 5.6 Hz, 1H), 4.10 (s, 0.5H, NH), 3.38 (s, 1H), 3.17 (s, 1H), 3.03 (d, <i>J</i> = 10.0 Hz, 1H), 2.76 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 2.70-2.64 (m, 1H), 2.58-2.51 (m, 1H), 2.35 (d, <i>J</i> = 8.8 Hz, 1H), 1.69 (d, <i>J</i> = 8.8 Hz, 1H), 1.42 (d, <i>J</i> = 8.8 Hz, 1H), 0.67-0.61 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 531.5 (M+H).

15

Scheme 20



Example 55

5 (S)-1-(4-(2-(5-((4-(2-amino-3-methylbutanoyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-
b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (76)

Step 1. (S)-tert-butyl 1-(4-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-
b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate (75)

10 To a stirred solution of compound **49** (150 mg, 0.289 mmol, scheme 15), Boc-L-valine (94 mg, 0.43 mmol) and triethylamine (120 μ L, 0.87 mmol) in DMF (5 mL) under nitrogen were added HOBT monohydrate (49 mg, 0.32 mmol) and EDC hydrochloride (139 mg, 0.72 mmol) reagents, and the reaction mixture was stirred at RT overnight. The reaction mixture was then partitioned between AcOEt and a saturated aqueous solution of sodium bicarbonate. The

15 organic layer was successively washed with a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by Biotage (Snap 25g; MeOH/DCM: 1/99 to 10/90 over 20 CV), to afford the title compound **75** (171 mg, 0.238 mmol, 82% yield) as a colorless sticky film. MS (m/z): 718.4 (M+H).


20 Step 2. (S)-1-(4-(2-(5-((4-(2-amino-3-methylbutanoyl)piperazin-1-yl)methyl)pyridin-2-
yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (76)

A solution of **75** (171 mg, 0.238 mmol) and TFA (2 mL) in DCM (10 mL) was stirred at RT for 2 h. The TFA was removed by co-evaporation with DCM, diluted with a minimum of


water, and the pH was adjusted to around 10 with a saturated aqueous solution of sodium bicarbonate and a few drops of 1N NaOH at the end. The resultant suspension was sonicated for 15 min. The solid was collected by filtration, rinsed with water and dried under high vacuum. The crude product was purified by Biotage (SiliaFlash 12 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 5/95 to 15/85 over 20 CV, then 15/85 to 20/80 over 10 CV), to afford the title compound **76** (110 mg, 0.178 mmol, 74% yield) as a white sticky solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.75 (s, 1H), 8.57 (d, *J* = 1.6 Hz, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.34 (s, 1H), 8.25 (d, *J* = 8.2 Hz, 1H), 7.88 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H), 7.38 (t, *J* = 9.0 Hz, 1H), 7.21 (bd, *J* = 8.8 Hz, 1H), 6.65 (d, *J* = 5.3 Hz, 1H), 6.61 (bd, *J* = 2.5 Hz, 1H), 3.59 (s, 2H), 3.54-3.42 (m, 5H), 2.59-2.51 (m, 1H), 2.48-2.28 (m, 4H), 2.20-1.80 (m, 2H), 1.74-1.62 (m, 1H), 0.87 (d, *J* = 6.8 Hz, 3H), 0.78 (d, *J* = 6.7 Hz, 3H), 0.73-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (*m/z*): 519.6 and 618.7 (M+H).

Compound **77** (example **56**) was prepared in two steps starting from the piperazine **49**, similarly to compound **76** (example **55**, scheme 20).

Table 10. Characterization of compound **77** (example **56**).

Cpd	Ex.	Structure	Characterization
77	56	 1-(4-(2-(5-((4-(2-aminoacetyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.81 (s, 1H), 8.58 (d, <i>J</i> = 1.8 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.35 (s, 1H), 8.26 (d, <i>J</i> = 8.2 Hz, 1H), 7.88 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.74 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.66-7.42 (m, 2H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (bd, <i>J</i> = 10.2 Hz, 1H), 6.69-6.62 (m, 2H), 3.81 (s, 2H), 3.62 (s, 2H), 3.56-3.48 (m, 2H), 3.42-3.35 (m, 2H), 2.59-2.52 (m, 1H), 2.48-2.35 (m, 4H), 0.72-0.58 (m, 2H), 0.49-0.37 (m, 2H). MS (<i>m/z</i>): 519.5 and 576.5 (M+H). (TFA salt)

Scheme 21



Example 57

5 (S)-2-(4-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)ethyl 2-amino-3-methylbutanoate (79)


10 Step 1. (S)-2-(4-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)ethyl 2-(*tert*-butoxycarbonylamino)-3-methylbutanoate (78)

To a stirred solution of the compound **55** (example **38**, table 6) (100 mg, 0.178 mmol), Boc-L-Val-OH (58 mg, 0.27 mmol) and DMAP (4.4 mg, 0.036 mmol) in DMF (4 mL) under nitrogen was added DCC reagent (73 mg, 0.35 mmol), and the reaction mixture was stirred at RT overnight. More Boc-L-Val-OH (60 mg, 0.28 mmol), DCC (95 mg, 0.46 mmol) and DMF (2 mL) were added, respectively. The reaction mixture was stirred at RT overnight. Once again, more Boc-L-Val-OH (60 mg, 0.28 mmol), DCC (95 mg, 0.46 mmol) and DMF (1 mL) were added. The reaction mixture was stirred at RT overnight then partitioned between AcOEt and a saturated aqueous solution of sodium bicarbonate. The organic layer was successively washed with a saturated aqueous solution of sodium bicarbonate, water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 1/99 to 10/90 over 20 CV), to afford the title compound **77** (115 mg, 0.15 mmol, 85% yield) as white sticky solid. MS (*m/z*): 762.4 (*M*+*H*).

Step 2. (S)-2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)ethyl 2-amino-3-methylbutanoate (**79**)

A solution of **78** (115 mg, 0.15 mmol) and TFA (2 mL) in DCM (10 mL) was stirred at RT for 3 h. The TFA was removed by co-evaporation with DCM, diluted with a minimum of water, and the pH was adjusted to around 9 with a saturated aqueous solution of sodium bicarbonate (and few drops of 1N NaOH at the end). The aqueous solution was extracted with DCM containing traces of methanol. The organic extract was dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by Biotage (SNAP 10 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 5/95 to 20/80 over 20 CV), to afford the title compound **79** (36 mg, 0.05 mmol, 36% yield) as a white sticky solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.54 (d, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.3 Hz, 1H), 8.32 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.85 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.73 (dd, *J* = 13.4, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 10.4 Hz, 1H), 6.64 (d, *J* = 5.3 Hz, 1H), 6.58 (bd, *J* = 2.2 Hz, 1H), 4.26-4.18 (m, 1H), 4.11-4.03 (m, 1H), 3.54 (s, 2H), 3.10 (d, *J* = 5.3 Hz, 1H), 2.59-2.30 (m, 11H), 1.88-1.78 (m, 1H), 0.87 (d, *J* = 6.8 Hz, 3H), 0.83 (d, *J* = 6.7 Hz, 3H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H), NH₂ is missing. MS (*m/z*): 662.7 (M+H).

Scheme 22



20



Example 59

3-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-*N*-methylpropanamide (**81**)

A stirred suspension of compound **49** (100 mg, 0.19 mmol, scheme 15) and *N*-methylacrylamide (1.5 mL) in acetonitrile (20 mL) was heated to 110°C overnight in a sealed flask. The reaction mixture was cooled to RT, concentrated, and the residue was purified twice by Biotage (SNAP 25 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 5/95 to 15/85 over 20 CV and SiliaFlash 12 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 5/95 to 15/85 over 20 CV, then 15/85 over 5 CV), to afford the title compound **81** (50 mg, 0.08 mmol, 43% yield) as a white sticky solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.85 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.85-7.77 (m, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 8.9 Hz, 1H), 6.64 (bd, *J* = 5.4 Hz, 1H), 6.57 (bd, *J* = 2.5 Hz, 1H), 3.54 (s, 2H), 2.59-2.51 (m, 6H), 2.47-2.11 (m, 10H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS 604.4 (m/z): (M+H).

Compounds **82-83** (examples **60-61**) were prepared in one step by reacting compound **49** (example **32**) with an appropriate Michael acceptor similarly to compound **81** (example **59**, scheme 22).

Table 12. Characterization of compounds **82-83** (examples **60-61**)

Cpd	Ex.	Structure	Characterization
82	60	 3-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2- <i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)propanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.55 (s, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.25 (d, <i>J</i> = 8.2 Hz, 1H), 7.86 (bd, <i>J</i> = 8.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.5 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 2H), 7.20 (bd, <i>J</i> = 8.8 Hz, 1H), 6.77 (bs, 1H), 6.65 (d, <i>J</i> = 5.3 Hz, 1H), 6.58 (bd, <i>J</i> = 2.5 Hz, 1H), 3.56 (bs, 2H), 2.59-2.51 (m, 1H), 2.50-2.15 (m, 8H), two CH ₂ are hidden by solvent's peak, 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (m/z): 590.5 (M+H).
83	61	 3-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2- <i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)- <i>N,N</i> -dimethyl-propanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (bd, <i>J</i> = 8.8 Hz, 1H), 6.64 (d, <i>J</i> = 5.5 Hz, 1H), 6.57 (bd, <i>J</i> = 2.5 Hz, 1H), 3.55 (s, 2H), 2.95 (s, 3H), 2.79 (s, 3H), 2.59-2.51 (m, 1H), 2.50-2.20 (m, 8H), two CH ₂ are hidden by solvent's peak, 0.72-0.59 (m, 2H), 0.49-0.37 (m, 2H). MS (m/z): 618.7 (M+H).

Example 62.


1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2,2,2-trifluoroethyl)piperazin-1-yl)methyl)-pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (84)

5

A solution of **49** (200 mg, 0.39 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (134 mg, 0.58 mmol) and DIPEA (0.2 mL, 1.16 mmol) and in THF (15 mL) was stirred and heated at 85°C for 4 h in a sealed flask, then at RT (scheme 22). The reaction mixture was concentrated, diluted with a minimum of methanol in water. The pH was adjusted to 10-11 with a saturated aqueous solution of sodium bicarbonate and a few drops of 1N NaOH at the end. The suspension was shaken for 15 min and the solid was collected by filtration, rinsed with water and dried under high vacuum. The crude product was purified by Biotage (SiliaFlash 25 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 1/99 to 10/90 over 20 CV), to afford the title compound **84** (26 mg, 0.043 mmol, 11% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.54 (bd, *J* = 1.4 Hz, 1H), 8.52 (d, *J* = 5.5 Hz, 1H), 8.33 (s, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 7.85 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H), 7.38 (t, *J* = 9.0 Hz, 1H), 7.20 (dd, *J* = 9.0, 1.4 Hz, 1H), 6.64 (dd, *J* = 5.5, 0.8 Hz, 1H), 6.58 (bd, *J* = 2.5 Hz, 1H), 3.55 (s, 2H), 3.15 (q, *J* = 10.2 Hz, 2H), 2.69-2.51 (m, 5H), 2.48-2.35 (m, 4H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS 601.6 (*m/z*): (M+H).

20

Scheme 23



Example 63


N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-2-methoxy-*N*-(2-methoxyethyl)acetamide (85)

5 To a solution of **1** (107 mg, 0.211 mmol, scheme 1) and methoxy acetyl chloride (38.5 μ l, 0.422 mmol) in THF (4.2 mL) under nitrogen was added DIPEA (110 μ l, 0.632 mmol) and the mixture was stirred at RT overnight. Methanol was added and the reaction mixture was concentrated. The residue was purified by Biotage (SNAP 50 g cartridge; MeOH/DCM: 0/100 to 20/80 over 20 CV), to afford the desired product (39 mg, 0.067 mmol, 31% yield) as an off-
 10 white solid. ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : mixture of rotamers, 8.71 (s, 1H), 8.54-8.49 (m, 2H), 8.36 and 8.33 (2s, 1H), 8.29 and 8.24 (2d, J = 8.4 Hz, 1H), 7.82-7.69 (m, 2H), 7.38 (t, J = 8.8 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.67-6.62 (m, 1H), 6.59-6.55 (m, 1H), 4.66 and 4.61 (2s, 2H), 4.24 and 4.14 (2s, 2H), 3.50-3.18 (m, 10H), 2.60-2.50 (m, 1H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (m/z): 580.6 (M+H).

15

Compound **86** (example 64) was prepared in one step by reacting **1** with the corresponding carbonyl chloride reagent similarly to compound **85** (example 63, scheme 23).

Table 12a. Characterization of compound **86** (example 64)

Cpd	Ex.	Structure	Characterization
86	64	 <i>N</i>-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)-<i>N</i>-(2-methoxyethyl)propionamide	^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : mixture of rotamers, 8.71 (s, 1H), 8.54-8.48 (m, 2H), 8.35 and 8.32 (2s, 1H), 8.28 and 8.23 (2d, J = 8.0 Hz, 1H), 7.80-7.70 (m, 2H), 7.38 (t, J = 8.8 Hz, 1H), 7.20 (d, J = 8.8 Hz, 1H), 6.67-6.62 (m, 1H), 6.57 (d, J = 2.0 Hz, 1H), 6.61-6.54 (m, 1H), 4.72 and 4.60 (2s, 2H), 3.54-3.40 (m, 4H), 3.23 and 3.21 (2s, 3H), 2.59-2.51 (m, 1H), 2.50-2.30 (m, 2H), 1.04-0.95 (m, 3H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 564.6 (M+H).

20

Example 65

(S)-2-amino-*N*-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-*N*-(2-methoxyethyl)-3,3-dimethylbutanamide (88)

Step 1. (S)-tert-butyl 1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate (87)




To a stirred solution of **1** (100 mg, 0.197 mmol, scheme 1) and Boc-L-TLE-OH (51 mg, 0.22 mmol) under nitrogen in DMF (10 mL) at RT, were added DIPEA (0.120 mL, 0.69 mmol) followed by HATU (225 mg, 0.59 mmol). The reaction mixture was stirred overnight at rt. Ethyl acetate was added, washed with water, saturated ammonium chloride and saturated sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by Biotage (Snap 25g; MeOH/DCM: 0/100 to 20/80 over 20 CV), to afford the title compound **87** that used directly for the next step. Yield assumed quantitative.



Step 2. (S)-2-amino-N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-methoxyethyl)-3,3-dimethylbutanamide (88)

To a solution of **87** (142 mg, 0.197 mmol) in DCM (10 mL) was added TFA (3 mL, 38.9 mmol) and water (0.2 mL). The reaction mixture was stirred overnight at RT, concentrated, diluted with ethyl acetate, and successively washed with a saturated aqueous solution of sodium bicarbonate, 1N NaOH and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by Biotage (SNAP 50 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 40/60 over 20 CV), to afford the title compound **88** (39 mg, 0.064 mmol, 32% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : mixture of rotamers, 8.75 (s, 1H), 8.59-8.50 (m, 2H), 8.37 and 8.32 (2s, 1H), 8.28 and 8.24 (2d, *J* = 8.0 Hz, 1H), 7.85 and 7.80 (2dd, *J* = 8.0 and 2.0 Hz, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.2 Hz, 1H), 7.20 (d, *J* = 8.8 Hz, 1H), 6.66-6.57 (m, 2H), 5.18-4.40 (m, 2H), 3.88-2.95 (m, 8H), 2.59-2.51 (m, 1H), 0.93 and 0.91 (2s, 9H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H), primary amine is missing. MS (*m/z*): 621.7 (M+H).


Compounds **89-91** (examples **66-68**) were prepared in one step by coupling **1** with the appropriate carboxylic acid similarly to compound **88** (example **65**, scheme 23). Compounds **92** (example **69**) and **92-A** (example **69-A**) were prepared in two steps starting from 2-amino-*N*-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridine-2-yl)pyridine-3-yl)methyl)-*N*-(2-methoxyethyl)acetamide, similarly to compound **88** (example **65**, scheme 23).

Table 13. Compounds **89-92** (examples **66-69**)

Cpd	Ex.	Structure	Characterization
89	66	 (<i>S</i>)-<i>N</i>-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-<i>N</i>-(2-methoxyethyl)propanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): mixture of rotamers, 8.76 (s, 1H), 8.56-8.48 (m, 2H), 8.36 and 8.33 (2s, 1H), 8.28 and 8.24 (2d, <i>J</i> = 8.8 Hz, 1H), 7.84-7.70 (m, 2H), 7.38 (t, <i>J</i> = 8.8 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 6.67--6.60 (m, 2H), 5.26-4.40 (m, 4H), 3.78-3.30 (m, 4H), 3.22 and 3.20 (2s, 3H), 2.60-2.50 (m, 1H), 1.25-1.19 (m, 3H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 580.6 (M+H).
90	67	 <i>N</i>-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)-<i>N</i>-(2-methoxyethyl)-2-(methylsulfonyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.14 (s, 1H), 8.57-8.48 (m, 2H), 8.40-8.23 (m, 2H), 7.86-7.70 (m, 2H), 7.37 (t, <i>J</i> = 9.2 Hz, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (s, 1H), 6.67-6.62 (m, 1H), 4.85-4.53 (m, 4H), 3.65-3.40 (m, 4H), 3.26 (s, 3H), 3.16 (s, 3H), 2.58-2.50 (m, 1H), 0.67-0.61 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 628.5 (M+H).
91	68	 (<i>S</i>)-benzyl 2-(1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-3-methyl-1-oxobutan-2-ylamino)-2-oxoethylcarbamate	MS (<i>m/z</i>): 798.4 (M+H).

Cpd	Ex.	Structure	Characterization
92	69	 (S)-2-amino-N-(2-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl)-3-methylbutanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): mixture of rotamers, 8.73 (s, 1H), 8.58-8.50 (m, 2H), 8.38-8.12 (m, 3H), 7.88-7.70 (m, 3H), 7.38 (t, <i>J</i> = 9.2 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 6.67-6.62 (m, 1H), 6.58 (d, <i>J</i> = 1.2 Hz, 1H), 4.74 and 4.63 (2s, 2H), 4.21-3.97 (m, 2H), 3.57-3.30 (m, 4H), 3.24 and 3.21 (2s, 3H), 3.09-3.01 (m, 1H), 2.59-2.50 (m, 1H), 2.02-1.90 (m, 1H), 0.90 (d, <i>J</i> = 6.8 Hz, 3H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H), 0.68-0.61 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 664.4 (M+H).
92-A	69-A	 2-(2-aminoacetamido)-N-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): mixture of rotamers, 8.75 (s, 1H), 8.58-8.48 (m, 2H), 8.38-8.11 (m, 3H), 7.87-7.69 (m, 2H), 7.38 (t, <i>J</i> = 8.8 Hz, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 6.67-6.58 (m, 2H), 4.74 and 4.63 (2s, 2H), 4.16 and 4.02 (2d, <i>J</i> = 4.4 Hz, 2H), 3.56-3.10 (m, 9H), 2.59-2.50 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 622.6 (M+H)

Scheme 24




Example 70

5 (S)-2-(2-aminoacetamido)-N-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)-thieno[3,2-
b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-methoxyethyl)-3-methylbutanamide (93)

To a solution of **91** (270 mg, 0.338 mmol, table 13) in MeOH (20 mL) was added palladium black (180 mg, 1.692 mmol) and the solution was degassed by bubbling nitrogen for 10 min. The mixture was placed under hydrogen (balloon), stirred overnight under hydrogen,
 10 then under nitrogen and pyridine by bubbling nitrogen into the solution. The reaction mixture was filtered through a celite pad, rinsed with methanol, and concentrated. The residue was

purified by Gilson (Phenomenex, Luna, 15 μ , C18(2) 100A, 250 x 50.00 mm, 15 μ m, 0.05% of formic acid in both MeOH/water : 20/80 to 95/5 over 60 min, flow = 30 mL/min), then (Phenomenex, Luna, 15 μ , C18(2) 100A, 250 x 50.00 mm, 15 μ m, 0.05% of formic acid in both MeOH/water (30 mL/min): 20/80 to 95/05 over 60 min), to afford the title compound **93** (24 mg, 0.037 mmol, 10% yield, hydrated formate salt) as a beige solid. ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : mixture of rotamers, 9.10-8.97 (m, 1H), 8.60-8.47 (m, 2H), 8.38-8.05 (m, 4H), 7.88-7.70 (m, 2H), 7.37 (d, J = 9.2 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 6.92-6.81 (m, 1H), 6.67-6.62 (m, 1H), 5.06-4.50 (m, 3H), 3.90-2.80 (m, 9H), 2.59-2.50 (m, 1H), 2.29-2.19 (m, 2H), 2.10-1.95 (m, 1H), 0.94-0.78 (m, 6H), 0.67-0.61 (m, 2H), 0.45-0.39 (m, 2H). MS (m/z): 664.8 (M+H).

Scheme 26



Example 72

1-(3-fluoro-4-(2-(5-((2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)-3-(3-(methylsulfonyl)phenyl)urea (105)

Step 1. (6-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methanol (101)

To a stirred suspension of **94** (3 g, 7.59 mmol) in DCM (50 mL) at RT under nitrogen was added NaBH(OAc)₃ (3.39 g, 15.99 mmol) in one portion. The reaction mixture was stirred at RT overnight, and quenched by addition of 10% HCl and suspended in a mixture of water and DCM. The solid was collected by filtration, rinsed with water, DCM and dried under high vacuum to afford the title compound **101** (2.26 g, 5.69 mmol, 75% yield) as a yellow-mustard solid which was used in the next step without further purification. MS (m/z): 398.1 (M+H).

Step 2. 2-(5-(chloromethyl)pyridin-2-yl)-7-(2-fluoro-4-nitrophenoxy)thieno[3,2-*b*]-pyridine (**102**)

A solution of **101** (2.23 g, 5.61 mmol) in thionyl chloride (8.14 mL) under nitrogen was stirred at RT overnight. The reaction mixture was cooled down to 0°C, and ice was added. The resultant suspension was stirred for 1 h, the solid was collected by filtration, rinsed with water and dried under high vacuum to afford the title compound **102** (2.06 g, 4.96 mmol, 88% yield) as a yellow fluffy solid which was used in the next step without any further purification. MS (m/z): 416.4 and 418.4 (M+H).

Step 3. 1-((6-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-pyrrolidin-2-one (**103**)

A mixture of **102** (500 mg, 1.202 mmol), ethyl 4-aminobutanoate (403 mg, 2.405 mmol) and DIPEA (0.630 mL, 3.61 mmol) under nitrogen in acetonitrile (12 mL) was heated to reflux for 3 days, then cooled to RT. The reaction mixture was then concentrated. The crude product was purified by Biotage (25M column; MeOH/DCM: 0/100 to 20/80 over 20 CV). The desired fractions were collected, concentrated and dried under high vacuum to afford the title compound **103** (270 mg, 0.58 mmol, 48% yield). MS (m/z): 465.5 (M+H).


Step 4. 1-((6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)pyrrolidin-2-one (**104**)

A suspension of **103** (270 mg, 0.581 mmol), iron (649 mg, 11.63 mmol), and ammonium chloride (187 mg, 3.49 mmol) in MeOH (10 mL) and water (1 mL), was heated to reflux for 3 h, then cooled to RT. The mixture was then filtered through celite and the cake was rinsed with methanol. The mother liquor was concentrated, and partitioned between a saturated aqueous solution of NaHCO₃ and ethyl acetate. The aqueous phase was extracted 3 times with DCM. The combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, re-dissolved in ethyl acetate, washed with 1N NaOH, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by Biotage (SNAP 50 g cartridge; MeOH/DCM: 0/100 to 20/80 over 20 CV), to afford the title compound **104** (220 mg, 0.50 mmol, 87% yield) as beige solid. MS (m/z): 435.5 (M+H).

Step 5. 1-(3-fluoro-4-(2-(5-((2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)-3-(3-(methylsulfonyl)phenyl)urea (**105**)

To a solution of **104** (50 mg, 0.115 mmol) in THF (2.3 mL) under nitrogen at -78°C was added DIPEA (201 µl, 1.151 mmol) followed by 4-nitrophenyl chloroformate (116 mg, 0.575 mmol). The reaction mixture was kept at -78°C over 1 hour. 3-(Methylsulfonyl)aniline hydrochloride (143 mg, 0.690 mmol) was added at -78°C and the reaction mixture was allowed to warm to room temperature slowly. The reaction mixture was then quenched by addition of methanol, concentrated, dissolved in ethyl acetate, and successively washed with NH₄Cl and NaHCO₃, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 20/80 over 20 CV), to afford the title compound **105** (14.8 mg, 0.023 mmol, 20% yield) as beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.28 (s, 1H), 9.21 (s, 1H), 8.54 (d, *J* = 5.6 Hz, 1H), 8.53 (d, *J* = 2.4 Hz, 1H), 8.36 (s, 1H), 8.27 (d, *J* = 8.4 Hz, 1H), 8.18 (t, *J* = 2.0 Hz, 1H), 7.82-7.74 (m, 2H), 7.70 (dt, *J* = 8.0, 1.6 Hz, 1H), 7.59 (t, *J* = 8.0 Hz, 1H), 7.55 (dt, *J* = 8.0, 1.6 Hz, 1H), 7.47 (t, *J* = 8.8 Hz, 1H), 7.31 (d, *J* = 8.8 Hz, 1H), 6.69 (d, *J* = 5.2 Hz, 1H), 4.46 (s, 2H), 3.40-3.28 (m, 2H, hidden under water peak), 3.21 (s, 3H), 2.31 (t, *J* = 8.0 Hz, 2H), 1.95 (quint, *J* = 7.6 Hz, 2H). MS (*m/z*): 632.5 (M+H).

Scheme 27




Example 73

3-(3-(3-fluoro-4-(2-(5-((2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)ureido)benzamide (**106**)

To a solution of **104** (83 mg, 0.191 mmol, scheme 26) in THF (19 mL) at -10°C was added DIPEA (334 µl, 1.910 mmol) and triphosgene (56.7 mg, 0.191 mmol). The reaction mixture was stirred for 90 min at -10°C then 3-aminobenzamide (104 mg, 0.764 mmol) was added. The reaction mixture was allowed to warm to RT, stirred for 3 h, quenched with MeOH, and concentrated. The residue was suspended in 2 mL of MeOH and a saturated aqueous

solution of ammonium chloride was added, stirred for 30 min, collected by filtration, and dried. The crude product was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 30/70 over 20 CV) to produce a material that was further purified by Gilson (Phenomenex, Luna, 15 μ , C18(2) 100A, 250 x 50.00 mm, 15 μ m, 0.05% of formic acid in both MeOH/water (30 mL/min): 30/70 to 95/5 over 60 min), to afford the title compound **106** (8.7 mg, 0.015 mmol, 7% yield, formate salt) as an yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ (ppm): 11.34 (s, 1H), 11.06 (s, 1H), 8.55-8.50 (m, 2H), 8.41 (s, 4H), 8.35 (s, 1H), 8.26 (d, $J = 8.0$ Hz, 1H), 8.05 (t, $J = 2.0$ Hz, 1H), 7.90-7.77 (m, 3H), 7.71-7.67 (m, 1H), 7.44-7.38 (m, 3H), 7.34-7.27 (m, 2H), 6.68 (dd, $J = 5.2, 0.8$ Hz, 1H), 4.46 (s, 2H), 3.31 (t, $J = 7.2$ Hz, 2H), 2.31 (t, $J = 8.0$ Hz, 2H), 1.95 (quint, $J = 8.0$ Hz, 2H). MS (m/z): 597.5 ($M+H$).

Scheme 28



Example 74

(S)-1-(4-(2-(5-((3-amino-2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (108)

Step1. (S)-tert-butyl 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)methyl)-2-oxopyrrolidin-3-ylcarbamate (107)

To a suspension of **47** (230 mg, 0.51 mmol, scheme 15) in DCM (5.1 mL) were added (S)-4-amino-2-(tert-butoxycarbonylamino)butanoic acid (224 mg, 1.03 mmol) and acetic acid (59 μ L, 1.03 mmol). After stirring for 20 min at room temperature, NaBH(OAc)₃ (326 mg, 1.54 mmol) was added. The reaction mixture was stirred for 16 h, quenched by addition of 1N NaOH, and concentrated. The solid was collected by filtration and purified by Biotage (SNAP

50g cartridge; MeOH/DCM: 0/100 to 20/80 over 20 CV), to afford the title compound **107** (120 mg, 0.19 mmol, 37% yield). MS (m/z): 633.7 (M+H).




Step 2. (S)-1-(4-(2-(5-((3-amino-2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea

5 To a solution of **107** (120 mg, 0.19 mmol) in DCM (20 mL) was added water (0.5 mL) and TFA (4 mL, 51.9 mmol). The reaction mixture was stirred at RT for 6 h, concentrated, diluted with ethyl acetate, and washed with 1N NaOH. The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic layers (a lot of
10 unsoluble material stayed on the walls of the separatory funnel which was dissolved in MeOH and combined with the organic layers) were concentrated. A 1N NaOH solution was added; the suspension was stirred for 30 min and the solid was collected by filtration. The crude product was purified by Biotage (SNAP 50 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 40/60 over 20 CV), to afford the title compound **108** (77 mg, 0.14 mmol, 76% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.77 (s, 1H), 8.55-8.51 (m, 2H),
15 8.36 (s, 1H), 8.27 (d, *J* = 8.0 Hz, 1H), 7.81 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.73 (dd, *J* = 13.6, 2.4 Hz, 1H), 7.38 (t, *J* = 9.2 Hz, 1H), 7.20 (d, *J* = 8.8 Hz, 1H), 6.65 (d, *J* = 5.6 Hz, 1H), 6.60 (d, *J* = 2.4 Hz, 1H), 4.52(d, *J* = 15.2 Hz, 1H), 4.45 (d, *J* = 15.2 Hz, 1H), 4.15-3.65 (m, 2H), 3.58 (t, *J* = 8.8 Hz, 1H), 3.30-3.14 (m, 2H), 2.59-2.52 (m, 1H), 2.34-2.23 (m, 1H), 1.77-1.65 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.37 (m, 2H). MS (m/z): 533.6 (M+H).


20

Compounds **109-111** (examples **75-77**) were prepared in two steps by reductive amination of **47** with the appropriately substituted γ-amino-acids similarly to compound **108** (example **74**, scheme 28).

Table 14. Characterization of compounds **109-111** (examples **75-77**)

Cpd	Ex	Structure	Characterization
109	75	 (<i>R</i>)-1-(4-(2-(5-((3-amino-2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.98 (s, 1H), 8.55 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (d, <i>J</i> = 5.2 Hz, 1H), 8.37 (s, 1H), 8.28 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.2 Hz, 1H), 7.19 (dd, <i>J</i> = 9.2, 1.2 Hz, 1H), 7.14-6.76 (bs, 2H), 6.71 (d, <i>J</i> = 2.8 Hz, 1H), 6.66 (d, <i>J</i> = 5.2 Hz, 1H), 4.58 (d, <i>J</i> = 16.0 Hz, 1H), 4.46 (d, <i>J</i> = 16.0 Hz, 1H), 3.89 (t, <i>J</i> = 9.2 Hz, 1H), 3.4-3.20 (m, hidden under water peak, 2H), 2.59-2.51 (m, 1H), 2.40-2.30 (m, 1H), 1.92-1.80 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.39 (m, 2H). MS (<i>m/z</i>): 533.6 (M+H).
110	76	 (<i>S</i>)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-hydroxy-2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 9.70 (s, 1H), 8.54-8.50 (m, 2H), 8.43 (s, 1H), 8.35 (s, 1H), 8.27 (d, <i>J</i> = 8.0 Hz, 1H), 7.81-7.72 (m, 2H), 7.48 (s, 1H), 7.35 (t, <i>J</i> = 9.2 Hz, 1H), 7.24 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 6.65 (d, <i>J</i> = 5.2 Hz, 1H), 4.46 (s, 2H), 4.19 (t, <i>J</i> = 8.0 Hz, 1H), 3.30-3.14 (m, 2H), 2.58-2.52 (m, 1H), 2.33-2.24 (m, 1H), 1.79-1.68 (m, 1H), 0.65-0.59 (m, 2H), 0.44-0.38 (m, 2H). MS (<i>m/z</i>): 534.5 (M+H).
111	77	 (±)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-hydroxy-2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-<i>b</i>]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.54-8.51 (m, 2H), 8.35 (s, 1H), 8.27 (d, <i>J</i> = 8.0 Hz, 1H), 7.79 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 8.8 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 1H), 6.65 (d, <i>J</i> = 5.2 Hz, 1H), 6.58 (d, <i>J</i> = 2.8 Hz, 1H), 5.20 (d, <i>J</i> = 4.0 Hz, 1H), 4.54 (d, <i>J</i> = 15.6 Hz, 1H), 4.42 (d, <i>J</i> = 15.6 Hz, 1H), 4.33-4.27 (m, 1H), 3.54 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 3.10 (dd, <i>J</i> = 10.4, 1.6 Hz, 1H), 2.64 (dd, <i>J</i> = 16.8, 6.4 Hz, 1H), 2.59-2.52 (m, 1H), 2.13 (dd, <i>J</i> = 16.8, 2.0 Hz, 1H), 0.68-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (<i>m/z</i>): 534.6 (M+H).

Scheme 29



5

Example 78:

1-cyclopropyl-3-(3-fluoro-4-(2-(4-((2-methoxyethylamino)methyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**113**)

10 Step 1: tert-butyl 4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl(2-methoxyethyl)carbamate (**112**)

To a solution of **111-A** (760 mg, 1.451 mmol) in THF (15 mL) was added TEA (0.607 mL, 4.35 mmol) and triphosgene (431 mg, 1.451 mmol) in THF (5 mL) and the mixture was stirred at RT for an hour. Cyclopropylamine (166 mg, 2.90 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction mixture was concentrated then partitioned between DCM and saturated NaHCO₃ solution. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. Purification of the residue by column chromatography (EtOAc) afforded the compound **112** (560 mg, 64% yield) as a white solid. MS (m/z) = 607.2 (M+H).

Step 2: 1-cyclopropyl-3-(3-fluoro-4-(2-(4-((2-methoxyethylamino)methyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (113)

To a solution of **112** (560 mg, 0.923 mmol) in DCM (10 mL) was added 4.0M HCl in dioxane (0.923 mL, 3.69 mmol) and the reaction mixture was stirred at RT for 2 hours. The mixture was diluted with saturated NaHCO₃ solution and the layers were separated. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant solid was triturated with Et₂O to afford title compound **113** (350 mg, 75% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (s, 1H), 8.48 (d, *J* = 5.48 Hz, 1H), 8.00 (s, 1H), 7.82 (d, *J* = 8.41 Hz, 1H), 7.70 (m, 1H), 7.44 (d, *J* = 8.22 Hz, 1H), 7.36 (t, *J* = 9.19 Hz, 1H), 7.19 (m, 1H), 6.56 (m, 2H), 3.75 (s, 2H), 3.39 (t, *J* = 5.67 Hz, 2H), 3.22 (s, 3H), 2.64 (t, *J* = 5.67 Hz, 2H), 2.53 (m, 1H), 0.63 (m, 2H), 0.41 (m, 2H). MS (*m/z*) = 507.5 (M+H).

Example 79

N-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-N-(2-methoxyethyl)acetamide (114)

To a suspension of **113** (100 mg, 0.197 mmol) in pyridine (3 mL) was added Ac₂O (30.2 mg, 0.296 mmol) and the reaction mixture was stirred for an hour. The mixture was concentrated then re-dissolved in EtOAc and washed with saturated CuSO₄ solution then water. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant solid was triturated with Et₂O to afford title compound **114** (97 mg, 90% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.68 (s, 1H), 8.48 (m, 1H), 8.03 (s, 1H, rotamer), 7.83 (m, 2H, rotamer), 7.70 (m, 1H), 7.36 (m, 3H), 7.18 (m, 1H), 6.56 (m, 2H), 4.57 (s, 2H, rotamer), 3.43 (s, 3H), 3.29 (s, 2H), 3.20 (s, 2H, rotamer), 2.49 (m, 1H), 2.06 (s, 3H, rotamer), 0.63 (m, 2H), 0.41 (m, 2H). MS (*m/z*) = 549.57 (M+H).

Example 80

N-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-2-(2-methoxyethoxy)-N-(2-methoxyethyl)acetamide (115)

To a suspension of **113** (120 mg, 0.237 mmol) in THF (3 mL) was added 2-(2-methoxyethoxy)acetyl chloride (54.2 mg, 0.355 mmol) and TEA (71.9 mg, 0.711 mmol) and the reaction mixture was stirred overnight at RT. The reaction mixture was diluted with EtOAc then washed with saturated ammonium chloride solution. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant solid was triturated with Et₂O

to give title compound **115** (113 mg, 77% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.72 (s, 1H), 8.50 (d, *J* = 5.48, 1H), 8.05 (s, 1H, rotamer), 7.90 (m, 2H, rotamer), 7.75 (m, 1H), 7.20 (m, 3H), 7.19 (m, 1H), 6.59 (m, 2H), 4.61 (s, 1H, rotamer), 4.31 (s, 2H, rotamer), 3.61 (m, 2H), 3.49 (m, 6H), 3.23 (m, 7H), 2.55 (m, 1H), 0.64 (m, 2H), 0.43 (m, 2H).

5 MS (m/z) = 623.66 (M+H).

Example 80-A




N-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-2-hydroxy-N-(2-methoxyethyl)acetamide (**115-A**)

10


To a solution of **113** (168 mg, 0.332 mmol) in DMF (8 mL) at RT was added DIPEA (0.203 mL, 1.161 mmol), followed by HATU reagent (378 mg, 0.995 mmol). The reaction mixture was stirred overnight at RT. Ethyl acetate was added, the reaction mixture was washed with water, saturated ammonium chloride solution and saturated sodium bicarbonate solution,
15 dried over anhydrous sodium sulfate and concentrated. The residue was purified via Biotage (0-50% MeOH/EtOAc; SNAP 50 g cartridge) to give an off-white solid which upon trituration with ether/acetone afforded title compound **115-A** (20mg, 11% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): contains 2 rotamers: 8.74 (s, 1H), 8.54 (d, 1H, *J*=5.5Hz), 8.10, 8.07 (2s, 1H), 7.94, 7.89 (2d, 2H, *J*=8.2 Hz), 7.78 (dd, 1H, *J*₁=2.4 Hz, *J*₂=13.5 Hz), 7.44-7.38
20 (m, 3H), 7.25-7.22 (m, 1H), 6.63-6.61 (m, 2H), 4.73-4.61 (m, 3H), 4.28, 4.14 (2d, 2H, *J*=5.5 Hz), 3.51-3.40(m, 4H), 3.27 (s, 3H), 2.60-2.56 (m, 1H), 0.71-0.67 (m,2H), 0.48-0.44 (m, 2H). MS: 565.5(MH+).

Compounds **116-117** (examples **81-82**) were prepared by reacting the corresponding
25 NH-precursors described in WO 2009/109035 A1 with Ac₂O, similarly to compound **114** (example **79**, scheme 29).

Table 15. Characterization of compounds **116** to **117-A** (examples **81** to **82-A**).

Cpd	Ex	Structure	Characterization
116	81	 N-((6-(7-(3-chloro-4-(3-cyclopropylureido)phenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.5 (m, 2H), 8.30-8.20 (m, 3H), 7.97 (s, 1H), 7.76 (m, 1H), 7.25 - 7.20 (m, 2H), 6.67 (m, 1H), 4.69 (s, 1H), 4.56 (s, 2H), 3.45 (m, 3H), 3.28 (s, 3H), 3.18 (s, 1H), 2.5 (m, 1H), 2.1 (s, 3H), 0.65 (m, 2H), 0.41 (m, 2H). MS (m/z) = 566.617 (M ⁺).
117	82	 N-((2-(7-(4-(3-(2,4-difluorophenyl)ureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.37 (s, 1H), 8.62 (s, 1H), 8.51 (d, <i>J</i> = 5.48 Hz, 1H), 8.03 (m, 1H), 7.89 (s, 1H), 7.73 (m, 1H), 7.43 (t, <i>J</i> = 8.99 Hz, 1H), 7.32 (m, 1H), 7.21 (m, 1H), 7.035 (m, 2H), 6.67 (d, <i>J</i> = 5.48 Hz, 1H), 4.65 (s, 2H), 3.81 (s, 3H), 3.40 (s, 2H), 3.23 (s, 2H), 2.086 (s, 3H). MS (m/z) = 652.56 (M+H).
117-A	82-A	 N-((2-(7-(2-fluoro-4-(3-isopropylureido)phenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.25(s, 1H), 8.58(s, 1H), 8.55(d, 1H, <i>J</i> =5.5Hz), 7.94(s,1H), 7.76(dd, 1H, <i>J</i> ₁ =2.6Hz, <i>J</i> ₂ =13.7Hz), 7.39(t, 1H, <i>J</i> =9.0Hz), 7.21-7.19(m, 1H), 7.08(s, 1H), 6.70-6.68(m, 2H), 4.70(s, 2H), 3.87(s, 3H), 3.81-3.79(m, 1H), 3.46(s, 3H), 3.42(t, 2H), 3.32(t,2H), 3.29(s, 3H), 2.14(s, 3H), 1.15(s, 3H), 1.13(s, 3H). MS: 555(MH ⁺)

Scheme 30



Example 83

5 1-(2,4-difluorophenyl)-3-(3-fluoro-4-(2-(3-morpholinoprop-1-ynyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (119)

To a solution of **118** (150 mg, 0.391 mmol) in DCM (7 mL) was added the 2,4-difluorophenyl isocyanate (121 mg, 0.782 mmol) and the reaction mixture was stirred at RT overnight. The resultant solid was collected by filtration, dissolved in DCM and purified by column chromatography (EtOAc to 10% MeOH in EtOAc) to afford title compound **119** (71 mg, 34% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.36 (s, 1H), 8.61 (s, 1H), 8.54 (d, *J* = 5.28, 1H), 8.03 (m, 1H), 7.78 (s, 1H), 7.73 (m, 1H), 7.43 (t, *J* = 8.99 Hz, 1H), 7.34 (m, 1H), 7.23 (m, 1H), 7.05 (m, 1H), 6.71 (d, *J* = 5.48 Hz, 1H), 3.63 (s, 2H), 3.59 (m, 4H), 2.52 (m, 4H). MS (*m/z*) = 539.62 (M+H)

10


15

Example 84

1-(3-fluoro-4-(2-(3-morpholinoprop-1-ynyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-phenylurea
(**120**)

To a solution of **118** (150 mg, 0.391 mmol) in DCM (7 mL) was added phenyl isocyanate (93 mg, 0.782 mmol) and the reaction mixture was stirred at RT overnight. The resultant solid was collected by filtration and then purified by column chromatography (EtOAc +1% NH₄OH to 10% MeOH in EtOAc +1% NH₄OH) to produce title compound **120** (37 mg, 19% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.06 (s, 1H), 8.81 (s, 1H), 8.54 (d, *J* = 5.48 Hz, 1H), 7.79 (s, 1H), 7.73 (m, 1H), 7.44 (m, 3H), 7.27 (m, 3H), 6.98 (t, *J* = 7.24 Hz, 1H), 6.70 (d, *J* = 5.48 Hz, 1H), 3.63 (s, 2H), 3.60 (m, 4H), 2.48 (m, 4H). MS (*m/z*) = 503.62 (M+H).

Scheme 31



Example 85

1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-oxomorpholino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**123**)

Step 1: 4-((6-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)morpholin-3-one (**121**)

To a solution of **102** (350 mg, 0.842 mmol, scheme 26) in THF (10 mL) was added a solution of the anion [made from morpholin-3-one (340 mg, 4 eq., 3.37 mmol) and NaH (81 mg, 4 eq., 3.37 mmol)] in THF (5 mL)) and the mixture was heated to reflux for 8 hours. The

mixture was quenched with saturated NH_4Cl solution and extracted with DCM. The organic phase was collected, dried over anhydrous Na_2SO_4 , filtered and concentrated. The resultant solid was triturated with acetone to give title compound **121** (135 mg, 33% yield) which was used in the next step with no additional purification. MS (m/z) = 481.2 ($M+H$)


5 Step 2: 4-((6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)morpholin-3-one (**122**)

To a suspension of **121** (135 mg, 0.281) in MeOH (10 mL) was added Zinc powder (184 mg, 2.81 mmol) and NH_4Cl (60.1 mg, 1.124 mmol) in water (1 mL) and the reaction mixture was stirred at reflux for 5 hours then stirred at RT for 2 days. The mixture was filtered,
10 concentrated, dissolved in DCM and MeOH and the resultant solution was then washed with water. The organic phase was collected, dried over anhydrous Na_2SO_4 , filtered and concentrated. The resultant solid **122** (65 mg, 51% yield) was used directly in the next step with no additional purification. MS (m/z) = 451.49 ($M+H$)

15 Step 3: 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-oxomorpholino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**123**)

To a solution of **122** (65 mg, 0.144 mmol) in THF (7 mL) was added TEA (0.06 mL, 0.433 mmol) and triphosgene (42.8 mg, 0.144 mmol) in THF (2 mL) and the mixture was stirred at RT for an hour. Cyclopropylamine (16.48 mg, 0.289 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction mixture was diluted with DCM and
20 washed with saturated NH_4Cl solution. The organic phase was collected, dried over anhydrous Na_2SO_4 , filtered and concentrated. The resultant solid was triturated with acetone to afford title compound **123** (18 mg, 23% yield) as an olive colored solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 8.69 (s, 1H), 8.55 (s, 1H), 8.51 (d, $J = 5.48$ Hz, 1H), 8.34 (s, 1H), 8.25 (d, $J = 8.22$ Hz, 1H), 7.82 (m, 1H), 7.71 (m, 1H), 7.36 (t, $J = 8.99$ Hz, 1H), 7.19 (m, 1H), 6.63 (d, $J = 5.48$ Hz, 1H), 6.55 (s, 1H), 4.60 (s, 2H), 4.12 (s, 2H), 3.83 (m, 2H), 3.36 (m, 2H), 2.49 (m, 1H), 0.64 (m, 2H), 0.42 (m, 2H). MS (m/z) = 534.51 ($M+H$)
25

Scheme 32



Example 86:

5 1-(2,4-difluorophenyl)-3-(3-fluoro-4-(2-(4-(pyrrolidine-1-carbonyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (127)

Step 1: (4-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)phenyl)(pyrrolidin-1-yl)methanone (125)

10 To a solution of **124** (1.685 g, 4.57 mmol) in DME (30 mL) was added 4-(pyrrolidine-1-carbonyl)phenylboronic acid (1 g, 4.57 mmol), Pd(PPh₃)Cl₂ (0.32 g, 0.457 mmol), CsF (2.080 g, 13.70 mmol), Na₂CO₃ (1.452 g, 13.70 mmol) in water (5 mL) and the reaction mixture was degassed with N₂ for 5 min before heating to reflux for 4 hours. The reaction was cooled to RT and diluted with EtOAc and water. The layers were separated and the organic phase was

15 collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant black solid was triturated with Et₂O to afford title compound **125** (1.5 g, 71% yield) as a dark brown solid which was used in the next step with no additional purification. MS (m/z) = 464.48 (M+H)

Step 2: (4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)phenyl)(pyrrolidin-1-yl)methanone (126)

20 To a suspension of **125** (1.5 g, 3.24 mmol) in MeOH (60 mL) was added Zinc powder (1.693 g, 25.9 mmol) and NH₄Cl (0.346 g, 6.47 mmol) and the reaction mixture was heated to

reflux for 5 hours. The mixture was cooled to RT and filtered. The filtrate was concentrated and the residue was dissolved in DCM and washed with water. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to give title compound **126** (1.3 g, 93% yield) as a brown oil which became a puffy solid after removal of residual solvent in high vacuum. MS (m/z) = 434.50 (M+H)

Step 3: 1-(2,4-difluorophenyl)-3-(3-fluoro-4-(2-(4-(pyrrolidine-1-carbonyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**127**)

To a solution of **126** (125 mg, 0.288 mmol) in DCM (6 mL) was added the 2,4-difluorophenyl isocyanate (134 mg, 0.865 mmol) and the reaction mixture was stirred at RT overnight. The reaction mixture was then concentrated and the resultant solid was triturated with acetone and collected by filtration to give title compound **127** (100 mg, 59% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.37 (s, 1H), 8.61 (s, 1H), 8.51 (d, *J* = 5.48 Hz, 1H), 8.14 (s, 1H), 8.04 (m, 1H), 7.94 (m, 2H), 7.76 (m, 1H), 7.64 (m, 2H), 7.45 (t, *J* = 8.99 Hz, 1H), 7.35 (m, 1H), 7.22 (m, 1H), 7.06 (m, 1H), 6.63 (d, *J* = 5.48 Hz, 1H), 3.48-3.37 (m, 4H), 1.85 (m, 4H). MS (m/z) = 589.546 (M+H)

Example 87

1-(3-fluoro-4-(2-(4-(pyrrolidine-1-carbonyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (**128**)

To a solution of **126** (150 mg, 0.346 mmol) in DCM (7 mL) was added isopropyl isocyanate (265 mg, 3.11 mmol) and the reaction mixture was heated to reflux for 8 hours. The mixture was cooled to RT and concentrated. Purification by column chromatography (EtOAc) afforded the title compound **128** which was further triturated with Et₂O (90 mg, 50% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (s, 1H), 8.50 (d, *J* = 5.28 Hz, 1H), 8.49 (s, 1H), 7.93 (d, *J* = 8.41 Hz, 2H), 7.70 (m, 1H), 7.63 (d, *J* = 8.41 Hz, 2H), 7.35 (t, *J* = 9.19 Hz, 1H), 7.11 (m, 1H), 6.60 (d, *J* = 5.48 Hz, 1H), 6.15 (d, *J* = 7.63 Hz, 1H), 3.74 (m, 1H), 3.59-3.40 (m, 4H), 1.88-1.79 (m, 4H), 1.09 (d, *J* = 6.46 Hz, 6H). MS (m/z) = 519.65 (M+H)

Example 88

1-cyclopropyl-3-(3-fluoro-4-(2-(4-(pyrrolidine-1-carbonyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**129**)

To a solution of **126** (150 mg, 0.346 mmol) in DCM (7 mL) was added TEA (105 mg, 1.038 mmol) and triphosgene (103 mg, 0.346 mmol) and the reaction mixture was stirred for 30

minutes. Cyclopropylamine (39.5 mg, 0.692 mmol) was added and the mixture was stirred at RT overnight. The mixture was concentrated and re-dissolved in EtOAc then washed with saturated NH₄Cl solution. The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated. Purification by column chromatography (10% MeOH in EtOAc) afforded title compound **129** (40 mg, 22% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.71 (s, 1H), 8.51 (m, 1H), 8.13 (s, 1H), 7.93 (d, *J* = 7.82 Hz, 2H), 7.73 (m, 1H), 7.63 (d, *J* = 7.82 Hz, 2H), 7.37 (t, *J* = 8.61 Hz, 1H), 7.18 (m, 1H), 6.61 (m, 1H), 6.56 (s, 1H), 3.47-3.42 (m, 4H), 1.86-1.81 (m, 4H), 2.53 (m, 1H), 0.64 (m, 2H), 0.411 (m, 2H). MS (*m/z*) = 517.533 (M+H)

10


Example 89

1-(3-fluoro-4-(2-(4-(pyrrolidine-1-carbonyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-(3-(methylsulfonyl)phenyl)urea (**130**)

To a solution of **126** (150 mg, 0.346 mmol) in THF (6 mL) was added TEA (175 mg, 1.730 mmol) and triphosgene (103 mg, 0.346 mmol) in THF (1 mL) and the mixture was stirred for 30 minutes. 3-(Methylsulfonyl)benzenaminium chloride (144 mg, 0.692 mmol) was added and the mixture was stirred at RT overnight. The mixture was then concentrated and the resultant solid was triturated with acetone, DCM and MeOH, followed by recrystallization from hot DMF. An additional trituration with acetone afforded **130** (25 mg, 11% yield) as a grey powder. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.32 (s, 1H), 9.24 (s, 1H), 8.52 (d, *J* = 5.48 Hz, 1H), 8.16 (s, 1H), 8.13 (s, 1H), 7.94 (d, *J* = 8.41 Hz, 2H), 7.75 (m, 1H), 7.66 - 7.62 (m, 3H), 7.56 - 7.53 (m, 2H), 7.45 (m, 1H), 7.31 (m, 1H), 6.64 (d, *J* = 5.48 Hz, 1H), 3.48 - 3.37 (m, 4H), 3.19 (s, 3H), 1.86 - 1.81 (m, 4H). MS (*m/z*) = 631.437 (M+H).

20

Scheme 33



Example 90

5 1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-((2-oxopyrrolidin-1-yl)methyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (137)

Step 1: tert-butyl 4-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methylamino)butanoate (132)

10 To a suspension of aldehyde **131** (200 mg, 0.502 mmol) in DCM (10 mL) was added *tert*-butyl 5-amino-2-oxopentanoate (282 mg, 1.506 mmol) and AcOH (0.029 mL, 1 eq., 0.502 mmol) and the reaction mixture was stirred for 30 minutes. NaB(OAc)₃H (266 g, 1.255 mmol) was added and the reaction mixture was stirred for an additional 24 hours. The reaction mixture was then diluted with excess DCM and washed with water. The organic phase was collected,
 15 dried over anhydrous Na₂SO₄, filtered and concentrated to afford the title compound **132** as an oil (272 mg, 100% yield, crude) that was used in the next step with no additional purification. MS (m/z) = 541.59 (M+H).

Step 2: 4-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methylamino)butanoic acid (133)

To a solution of **132** (272 mg, 0.502 mmol) in DCM (10 mL) was added HCl (4 M in Et₂O) (0.502 mg, 2.009 mmol) and the reaction mixture was stirred at RT for 4 hours. The reaction mixture was then concentrated to afford title compound **133** as a yellow solid (244 mg, 100% yield, crude) that was used in the next step with no additional purification. MS (m/z) = 486.1 (M+H).

Step 3: methyl 4-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methylamino)butanoate (**134**)

A solution of **133** (242 mg, 0.498 mmol) in dry MeOH (10 mL) was heated in the presence of PTSA (95 mg, 0.498 mmol) for an hour. The reaction mixture was cooled to RT then neutralized with solid sodium bicarbonate. The mixture was then concentrated and partitioned between water and DCM. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford the title compound **134** (249 mg, 100% yield, crude) that was used directly in the next step with no additional purification. MS (m/z) = 500.1 (M+H).

Step 4: 1-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)pyrrolidin-2-one (**135**)

A solution of **134** (249 mg, 0.498 mmol) in toluene (9 mL) and DME (1 mL) was heated to reflux for 24 hours. The mixture was cooled to RT and concentrated. Purification of the residue by column chromatography (10% MeOH in EtOAc) afforded title compound **135** (125 mg, 54% yield) as a yellow solid. MS (m/z) 467.41 (M+H).

Step 5: 1-((2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)pyrrolidin-2-one (**136**)


To a solution of **135** (125 mg, 0.267 mmol) in MeOH (10 mL) was added zinc powder (140 mg, 2.14 mmol) and ammonium chloride (42.9 mg, 0.80 mmol) in water (1 mL) and the reaction mixture was heated to reflux for 4 hours. The mixture was cooled to RT, filtered and concentrated. The residue was partitioned between water and DCM/MeOH and the organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford title compound **136** (77 mg, 66% yield) that was used crude in the next step with no additional purification. MS (m/z) = 438.50 (M+H).

Step 6: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-((2-oxopyrrolidin-1-yl)methyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**137**)

To a solution of **136** (77 mg, 0.176 mmol) in THF (10 mL) was added TEA (0.074 mL, 0.528 mmol) and triphosgene (52.2 mg, 1.451 mmol) in THF (5 mL) and the mixture was stirred at RT for an hour. Cyclopropylamine (10.5 mg, 0.176 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction mixture was then concentrated and partitioned between with DCM and saturated NaHCO₃ solution. The organic phase was collected, dried

over anhydrous Na_2SO_4 , filtered and concentrated. Purification of the residue by column chromatography (10% MeOH in EtOAc) afforded title compound **137** (47 mg, 51% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6) δ (ppm): 8.69 (s, 1H), 8.50 (d, $J = 5.48$ Hz, 1H), 7.89 (s, 1H), 7.70 (m, 1H), 7.35 (t, $J = 8.99$ Hz, 1H), 7.17 (m, 1H), 7.05 (s, 1H), 6.65 (d, $J = 5.48$ Hz, 1H), 6.55 (m, 1H), 4.46 (s, 2H), 3.82 (s, 3H), 3.22 (t, $J = 6.84$ Hz, 2H), 2.52 (m, 1H), 2.27 (t, $J = 7.82$ Hz, 2H), 1.90 (m, 2H), 0.63 (m, 2H), 0.40 (m, 2H). MS (m/z) = 521.638 ($\text{M}+\text{H}$)

Scheme 34



Example 91

1-cyclopropyl-3-(4-(2-(5-((2,5-dioxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea (140)

Step 1: 1-((6-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)pyrrolidine-2,5-dione (138)

To a solution of **102** (200 mg, 0.481 mmol, scheme 26) in DMF (5 mL) was added Cs_2CO_3 (313 mg, 0.962 mmol) and succinimide (95 mg, 0.962 mmol) and the reaction mixture was stirred at RT for 4 hours. The reaction mixture was poured into water and extracted with EtOAc. The organic phase was collected, dried over anhydrous Na_2SO_4 , filtered and concentrated to afford title compound **138** (100 mg, 43% yield) that was triturated with Et_2O and used with no additional purification. MS (m/z) = 479.50 ($\text{M}+\text{H}$)


Step 2: 1-((6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)pyrrolidine-2,5-dione (139)

To a suspension of **138** (100 mg, 0.209 mmol) in MeOH (10 mL) was added zinc (109 mg, 1.672 mmol) and NH₄Cl (44.7 mg, 0.836 mmol) in water (1 mL) and the reaction mixture was heated to reflux for 48 hrs, cooled to RT and concentrated. The crude product was dissolved in MeOH/DCM and washed with water. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford title compound **139** (80 mg, 85% yield) that was used without additional purification. MS (m/z) = 448.47 (M+H).

Step 3: 1-cyclopropyl-3-(4-(2-(5-((2,5-dioxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea (**140**)

To a solution of **139** (101 mg, 0.225 mmol) in THF (6 mL) at -35°C was added TEA (0.094 mL, 1.126 mmol) and triphosgene (80 mg, 0.270 mmol) in THF (1 mL) and the mixture was warmed to -10°C over an hr. Cyclopropylamine (64.3 mg, 1.126 mmol) was added and the reaction mixture was stirred at RT for 1.5 hrs. The reaction mixture was diluted with EtOAc then washed with saturated NH₄Cl solution. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. Purification by column chromatography (10% MeOH in EtOAc) afforded title compound **140** (20 mg, 17% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (s, 1H), 8.53 (s, 1H), 8.50 (d, *J* = 5.48 Hz, 1H), 8.32 (s, 1H), 8.22 (d, *J* = 8.021, 1H), 7.81 (m, 1H), 7.70 (m, 1H), 7.36 (t, *J* = 9.19 Hz, 1H), 7.18 (m, 1H), 6.62 (d, *J* = 4.89 Hz, 1H), 6.55 (s, 1H), 4.62 (s, 2H), 2.68 (s, 4H), 2.53 (m, 1H), 0.63 (m, 2H), 0.41 (m, 2H). M (m/z) = 532.543 (M+H)

Scheme 35



Example 92

5 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-methyl-2-oxoimidazolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (141)

To a solution of 1-methylimidazolidin-2-one (192 mg, 1.919 mmol) in DMF (10 mL) was added NaH (79 mg, 6.2 eq., 0.1.983 mmol) and the mixture was stirred for 15 mins. A solution of **65** (150 mg, 0.320 mmol, scheme 17) in DMF (5 mL) was added and the reaction mixture was stirred at RT for 3 hours. The mixture was then poured into water and extracted well with EtOAc. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. Purification by column chromatography (10% MeOH in EtOAc) afforded title compound **141** (17 mg, 10% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.71 (s, 1H), 8.54 (s, 1H), 8.51 (d, *J* = 5.48 Hz, 1H), 8.33 (s, 1H), 8.26 (d, *J* = 8.02 Hz, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.38 (t, *J* = 8.99 Hz, 1H), 7.20 (m, 1H), 6.65 (m, 1H), 6.56 (s, 1H), 4.35 (s, 2H), 7.33 (m, 4H, partially obscured by H₂O peak), 2.69 (s, 3H), 2.55 (m, 1H), 0.65 (m, 2H), 0.43 (m, 2H). MS (*m/z*) = 533.49 (M+H).

Example 93

1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2,2-dioxo-2-thiapyrrolidin-1-ylmethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (142)


5 To a solution of 1,3-propanesultam (155 mg, 1.280 mmol) in DMF (10 mL) was added NaH (53.7 mg, 4.2 eq., 1.343 mmol) and the mixture was stirred for 15 mins. A solution of **65** (150 mg, 0.320 mmol, scheme 17) in DMF (5 mL) was added and the reaction mixture was stirred at RT for 3 hours. The mixture was poured into water and extracted with EtOAc. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated.
10 Purification by column chromatography (10% MeOH in EtOAc) afforded title compound **142** (17 mg, 9% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.83 (s, 1H), 8.58-8.55 (m, 2H), 8.36(s, 1H), 8.28 (d, 1H, J=8.2Hz), 8.19 (s, 1H), 7.89 (dd, 1H, J1=1.9Hz, J2=8.2Hz), 7.77 (dd, 1H, J1=2.3Hz, J2=13.5Hz), 7.41 (t, 1H, J=9.0Hz), 7.25-7.22 (m, 1H), 6.69-6.67 (m, 1H), 3.59-3.57 (m, 6H), 2.62-2.57 (m, 1H), 2.54-2.42 (m, 16H), 0.71-0.66 (m, 15 2H), 0.48-0.44 (m, 2H). MS (m/z) = 554.518 (M+H).

Example 94



1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-oxoimidazolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (143)

20 To a solution of imidazolidin-2-one (165 mg, 6 eq., 1.919 mmol) in DMF (10 mL) was added NaH (79 mg, 0.1.983 mmol) and the mixture was stirred for 15 min. A solution of **65** (150 mg, 0.320 mmol, scheme 17) in DMF (5 mL) was added and the reaction mixture was stirred at RT for 3 hours. The mixture was poured into water and extracted with EtOAc. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (20% MeOH in DCM) to afford title compound **143** as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.74 (s, 1H), 8.58 (m, 1H), 8.56 (d, 1H, J = 5.3Hz), 8.38(s, 1H), 8.31(d, 1H, J = 8.0Hz), 7.85(dd, 1H, J = 2.1Hz and 8.2 Hz), 7.77(dd, 1H, J = 2.5 and 13.7Hz), 7.42(t, 1H, J 9.2Hz), 7.25 - 7.23(m, 1H), 6.69 (d, 25 1H, J = 5.3Hz), 6.60 (m, 1H), 6.57 (s, 1H), 4.36 (s, 2H), 3.34-3.30 (m, 4H), 2.60-2.58(m, 1H), 0.70-0.67(m, 2H), 0.48-0.46 (m, 2H). MS (m/z) = 519.5 (M+H).
30

Scheme 37



WO 2009/026717 A1



Example 96

5 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (154)

Step 1: 2-(1-((1,3-dioxolan-2-yl)methyl)-1H-pyrazol-4-yl)-7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridine (145)

10 To a suspension **144** (3.57 g, 8.57 mmol) in DME (50 mL) and water (5 mL) was added 1-((1,3-dioxolan-2-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2 g, 7.14 mmol), CsF (3.25 g, 21.42 mmol), NaHCO₃ (1.799 g, 36 mmol) and Pd(PPh₃)₄ (0.825 g, 0.714 mmol), and the reaction mixture was heated to reflux overnight. The mixture was cooled to RT, diluted with EtOAc and washed with water. The organic phase was collected, dried over

15 anhydrous Na₂SO₄, filtered and concentrated. The resultant solid was triturated with Et₂O to afford title compound **145** (3 g, 95% yield) as a beige solid. MS (m/z) = 443.51 (M+H).

Step 2: 2-(4-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)acetaldehyde (146)

To a solution of **145** (900 mg, 2.034 mmol) in THF (20 mL) was added 3M HCl (30 mL) and the reaction mixture was heated to reflux for 24 hours. The mixture was cooled to RT, and concentrated. The residual aqueous solution was treated with solid sodium bicarbonate and then extracted with DCM. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The crude aldehyde **146** (810 mg, 100% yield) was used in the next step with no additional purification. MS (m/z) = 399.3 (M+H)

Step 3: 7-(2-fluoro-4-nitrophenoxy)-2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridine (152)

To a solution of **146** (450 mg, 1.13 mmol, Scheme 36) in NMP (10 mL) was added AcOH (0.129 mL, 2.259 mmol) and 1-methylpiperazine (113 mg, 2.259 mmol) and the reaction mixture was stirred at RT for an hour. Sodium triacetoxyborohydride (718 mg, 6.10 mmol) was added and the mixture was stirred at RT overnight. The mixture was diluted with saturated NaHCO₃ solution then solid NaHCO₃ was added to neutralize the acid. The mixture was extracted with DCM and the extract was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (eluent 10% MeOH to 50% MeOH in EtOAc) to afford title compound **152** (250 mg, 27% yield) as a brown oil. MS (m/z) = 483.53 (M+H).

Step 4: 3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)aniline (153)

To a solution of **152** (150 mg, 0.311 mmol) in MeOH (20 mL) was added ammonium chloride (33.3 mg, 0.622 mmol) in water (5 mL) and zinc powder (81 mg, 3.01 mmol) and the reaction mixture was heated to reflux for 3 hours. The mixture was cooled to RT then filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in DCM and washed with water. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford title compound **153** (132 mg, 92% yield) that was used directly in the next step with no additional purification. MS (m/z) = 453.2 (M+H).


Step 5: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (154)

To a stirred solution of **153** (203 mg, 0.449 mmol) and pyridine (0.109 mL, 1.346 mmol) in DMF (10 mL) at 0°C under nitrogen was added phenyl chloroformate (1.76 mg, 1.121 mmol) and the reaction mixture was stirred at 0°C for 2 hrs. Cyclopropylamine (128 mg, 2.243 mmol) was added and the reaction mixture was heated at 55°C for 5 hrs. The reaction mixture was partitioned between EtOAc and saturated sodium bicarbonate solution, then washed with a

saturated ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (eluent EtOAc to 30% MeOH in EtOAc) to afford title compound **154** (30 mg, 12% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.43 (s, *J* = 5.48 Hz, 1H), 8.33 (s, 1H), 7.99 (s, 1H), 7.74 (m, 1H), 7.67 (s, 1H), 7.60 (bs, 1H), 7.32 (t, *J* = 8.99 Hz, 1H), 7.22 (m, 1H), 6.63 (d, *J* = 5.48 Hz, 1H), 4.25 (t, *J* = 6.46 Hz, 2H), 2.73 (t, *J* = 6.46 Hz, 2H), 2.55 (m, 1H), 2.45 (m, 4H), 2.28 (m, 4H), 2.12 (s, 3H), 0.61 (m, 2H), 0.40 (m, 4H). MS (*m/z*) = 536.54 (M+H).


Example 97

10 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (155)



Title compound **155** was obtained similarly to compound **154** (example 96, Scheme 37) using morpholine in the reductive amination step instead of 1-methylpiperazine. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.67 (s, 1H), 8.41 (m, 1H), 8.33 (s, 1H), 7.98 (s, 1H), 7.70 (d, *J* = 13.69, 1H), 7.67 (s, 1H), 7.34 (t, *J* = 8.80 Hz, 1H), 7.17 (d, *J* = 8.61 Hz, 1H), 6.54 (bs, 1H), 6.51 (d, *J* = 5.48 Hz, 1H), 4.26 (m, 2H), 3.53 (t, *J* = 4.11 Hz, 4H), 2.72 (t, *J* = 6.45 Hz, 2H), 2.52 (m, 1H), 2.41 (BS, 4H), 0.63 (m, 2H), 0.40 (m, 2H). MS (*m/z*) = 523.57.

Scheme 38



Example 98

25 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)ethyl cyclopropylcarbamate (157)


Step 1: 2-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)ethanol (156)

To a solution of **146** (3 g, 7.53 mmol) in DCM (100 mL) and MeOH (100 mL) was added NaBH₄ (0.57 g, 15.06 mmol) and the reaction mixture was stirred at 0°C for 20 min. The mixture was quenched with saturated NH₄Cl solution then extracted with DCM. The extract was collected, dried over anhydrous Na₂SO₄, filtered, concentrated and the residue was purified by flash column chromatography (eluent 10% MeOH in EtOAc) to afford title compound **156** (1 g, 36% yield) as white solid. MS (m/z) = 371.40 (M+H).


Step 2: 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)ethyl cyclopropylcarbamate (157)

To a stirred solution of **156** (900 mg, 2.430 mmol) and pyridine (0.59 mL, 7.29 mmol) in DMF (10 mL) at 0°C under nitrogen was added phenyl chloroformate (951 mg, 6.07 mmol) and the reaction mixture was stirred at 0°C for 2 hrs. Cyclopropylamine (694 mg, 12.15 mmol) was added and the reaction mixture was heated at 55°C for 5 hrs. The reaction mixture was then partitioned between EtOAc and saturated sodium bicarbonate solution. The organic phase was collected then washed a saturated ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (eluent EtOAc to 30% MeOH in EtOAc) to afford title compound **157** (300 mg, 23% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (s, 1H), 8.43 (d, *J* = 5.47 Hz, 1H), 8.33 (s, 1H), 8.03 (s, 1H), 7.72(m, 1H), 7.70 (m, 1H), 7.41 (m, 1H), 7.35 (t, *J* = 9.19 Hz, 1H), 7.19 (m, 1H), 6.54 (m, 2H), 4.34 (m, 4H), 2.53 (m, 1H), 2.49 (m, 1H), 0.65 (m, 2H), 0.54 (m, 2H), 0.43 (m, 2H), 0.36 (m, 2H). MS (m/z) = 537.58 (M+H).

Scheme 39



WO 2009/109035 A1



Example 99

5 1-((2-(7-(2-fluoro-4-cyclopropylaminocarbonylaminophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-cyclopropyl-1-(2-methoxyethyl)urea (**161**)

Step 1: 3-cyclopropyl-1-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-1-(2-methoxyethyl)urea (**159**)

10 To a solution of **158** (150 mg, 0.294 mmol) in THF (5 mL) was added TEA (0.123 mL, 0.881 mmol) and triphosgene (43.6 mg, 0.147 mmol) in THF (1 mL) and the mixture was stirred at RT for an hour. Cyclopropylamine (84 mg, 1.469 mmol) was added and the reaction mixture was stirred at RT for 2 hrs. The reaction mixture was concentrated then partitioned between DCM and saturated NaHCO₃ solution. The organic phase was collected, dried over
15 anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography (eluent 0% MeOH in EtOAc) to afford title compound **159** (40 mg, 25% yield) as an oil. MS (m/z) = 541.54 (M+H)

Step 2: 1-((2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-cyclopropyl-1-(2-methoxyethyl)urea (**160**)

20 To a solution of **159** (300 mg, 0.555 mmol) in MeOH (10 mL) was added zinc powder (145 mg, 2.22 mmol) and ammonium chloride (59.4 mg, 1.11 mmol) and the reaction mixture was heated to reflux for 3 hours. The mixture was cooled to RT and filtered. The solvent was evaporated and the residue was extracted with DCM. The extract was dried over anhydrous

Na₂SO₄, filtered and concentrated. The crude title compound **160** (283 mg, 100% yield) was used in the next step with no additional purification. MS (m/z) = 511.2 (M+H).


Step 3: 1-((2-(7-(2-fluoro-4-cyclopropylaminocarbonylaminophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-cyclopropyl-1-(2-methoxyethyl)urea

5 **(161)**

To a stirred solution of **160** (283 mg, 0.554 mmol) and pyridine (0.134 mL, 1.663 mmol) in DMF (10 mL) at 0°C under nitrogen was added phenyl chloroformate (158 mg, 1.386 mmol) and the reaction mixture was stirred at 0°C for 2 hrs. Cyclopropylamine (0.195 mL, 2.77 mmol) was added and the reaction mixture was heated at 55°C for 5 hrs. The reaction mixture was partitioned between EtOAc and saturated sodium bicarbonate solution, then washed a saturated ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by flash column chromatography (eluent EtOAc to 20% MeOH in EtOAc) to afford title compound **161** (100 mg, 30% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.70 (s, 1H), 8.50 (d, *J* = 5.48 Hz, 1H), 7.89 (s, 1H), 7.70 (m, 1H), 7.35 (t, *J* = 9.19 Hz, 1H), 7.19 (m, 1H), 6.93 (s, 1H), 6.64 (d, *J* = 5.48 Hz, 1H), 6.56 (s, 1H), 6.51 (m, 1H), 4.54 (s, 2H), 3.82 (s, 3H), 3.27 (m, 2H), 3.25 (m, 2H), 3.19 (s, 3H), 2.54 (m, 2H), 0.63 (m, 2H), 0.55 (m, 2H), 0.41 (m, 2H), 0.37 (m, 2H). MS (m/z) = 594.61 (M+H).

Example 99-A

20 1-((2-(7-(4-isopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-ethyl-1-(2-methoxyethyl)urea (**161-A**)




161-A: Example 99-A

Title compound **161-A** (example 99-A) was obtained similarly to compound **161** (example 99, scheme 39) starting from the compound **158** and using ethylisocyanate in the first step and isopropylisocyanate in the third step. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.73(s, 1H), 8.55(d, 1H, *J* = 5.5Hz), 7.93(s, 1H), 7.73(dd, 1H, *J*₁=2.5Hz, *J*₂=13.5Hz), 7.40(t, 1H, *J*=9.0Hz), 7.17-7.15(m, 1H), 6.99(s, 1H), 6.69(d, 1H, *J*=5.3Hz), 6.46(t, 1H, *J*=5.5Hz), 6.18(d, 1H, *J*=7.8Hz), 4.61(s, 2H), 3.88(s, 3H), 3.86-3.78(m, 1H), 3.40-3.38(m, 2H), 3.35-3.34(m, 2H), 3.26(s, 3H), 3.16-3.08(m, 2H), 1.15(s, 3H), 1.13(s, 3H), 1.05(t, 3H, *J*=7.2Hz). MS: 584.6 (MH+).

Example 99-B

1-((2-(7-(4-cyclopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-ethyl-1-(2-methoxyethyl)urea (**161-B**)


**161-B: Example 99-B**

5

Title compound **161-B** (example **99-B**) was obtained similarly to compound **161** (example **99**, scheme 39) starting from the compound **158** and using ethylisocyanate in the first step. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.75 (s, 1H), 8.55 (d, 1H, J=5.4Hz), 7.93 (s, 1H), 7.75 (dd, 1H, J₁=2.3Hz, J₂=13.5Hz), 7.41 (t, 1H, J=9.0Hz), 7.24-7.39 (m, 1H), 6.99 (s, 1H), 6.70 (d, 1H, J=5.3Hz), 6.60 (m, 1H), 6.46 (t, 1H, J=5.7Hz), 4.61 (s, 2H), 3.88 (s, 3H), 3.54-3.51 (m, 2H), 3.38-3.33 (m, 2H), 3.26 (s, 3H), 3.13-3.09 (m, 2H), 2.70-2.56 (m, 1H), 1.06 (t, 3H, J=7.2Hz), 0.71-0.67 (m, 2H), 0.48-0.44 (m, 2H). MS: 582.6 (MH⁺).

10

Scheme 40



Example 100

5 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (166)

Step 1: 1-(2-(4-bromo-1H-pyrazol-1-yl)ethyl)pyrrolidin-2-one (162)

To a solution of 3-bromopyrazole (5 g, 34 mmol), 1-(2-hydroxyethyl)pyrrolidin-2-one (5.75 g, 51 mmol), PPh₃ (13.38 g, 51 mmol) in THF (100 mL) was added DEAD (8.89 g, 51 mmol) and the reaction mixture was stirred at RT overnight. The mixture was concentrated, co-evaporated with Et₂O then dissolved in Et₂O and cooled in a fridge for 3 hrs whereupon Ph₃P=O precipitated out. The mixture was then filtered and concentrated to afford title compound **162** (8.78 g, 100% yield) which was used in the next step with no additional purification. MS (m/z) = 259.12/261.12 (M+H).

Step 2: 1-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)pyrrolidin-2-one (163)

To a solution of **162** (8.78 g, 34 mmol) in toluene (150 mL) was added bis(pinacolato)diboron (12.96 g, 51 mmol), KOAc (8.35 g, 85 mmol) and Pd(PPh₃)₄ (1.96 g, 1.701 mmol) and the reaction mixture was heated to reflux for 4 hours. The mixture was concentrated and the residue was purified by flash column chromatography (eluent EtOAc to 25% MeOH/EtOAc) to afford title compound **163** (6.3 g, 60% yield) as a yellow oil. MS (m/z) = 306.4 (M+H).

Step 3: 1-(2-(4-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)pyrrolidin-2-one (**164**)

To a solution of iodide **144** (2.1 g, 5.05 mmol, scheme 36) in DME (60 mL), at RT, was added boronate **163** (2.31 g, 7.57 mmol), NaHCO₃ (1.272 g, 15.14 mmol) in H₂O (5 mL), CsF (2.3 g, 15.14 mmol) and Pd (PPh₃)₄ (0.583 g, 0.505 mmol), and the reaction mixture was degassed with N₂ for 10 minutes before being heated to reflux for 4 hrs. The reaction mixture was cooled to RT, and partitioned between EtOAc and H₂O. The organic phase was separated and washed with additional H₂O then dried over anhydrous sodium sulfate and filtered. The solvent was removed under reduced pressure and the crude product was triturated with diethyl ether to afford title compound **164** (2 g, 85% yield) as a brown solid. MS (m/z) = 468.48 (M+H).

Step 4: 1-(2-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)pyrrolidin-2-one (**165**)


To a suspension of **164** (0.5 g, 1.07 mmol) in MeOH (20 mL) was added Zinc (0.28 g, 4.28 mmol) and ammonium chloride (0.114 g, 2.139 mmol) and the reaction mixture was heated to reflux for 3 hours. The mixture was cooled to RT and filtered. The filtrate was concentrated and the resultant oil was partitioned between water and DCM. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant solid was triturated with Et₂O to give title compound **165** (0.468 mg, 100% yield, crude) as a black solid. MS (m/z) = 438.4 (M+H).

Step 5: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**166**)

To a stirred solution of **165** (400 mg, 0.914 mmol) and pyridine (0.222 mL, 2.74 mmol) in DMF (10 mL) at 0°C under nitrogen was added phenyl chloroformate (0.287 mg, 2.286 mmol) and the reaction mixture was stirred at 0°C for 2 hrs. Cyclopropylamine (0.322 mL, 4.57 mmol) was added and the reaction mixture was heated at 55°C for 5 hrs. The reaction mixture was partitioned between EtOAc and saturated sodium bicarbonate solution, then washed with saturated ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (eluent EtOAc to 20%

MeOH in EtOAc) to afford title compound **166** (250 mg, 53% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (s, 1H), 8.44 (d, *J* = 5.48 Hz, 1H), 8.35 (s, 1H), 8.035 (s, 1H), 7.74 (m, 1H), 7.70 (s, 1H), 7.35 (t, *J* = 8.99 Hz, 1H), 7.19 (d, *J* = 8.99 Hz, 1H), 6.55 (m, 2H), 4.28 (t, *J* = 5.87 Hz, 2H), 3.59 (t, *J* = 5.86 Hz, 2H), 3.17 (t, *J* = 6.84 Hz, 2H), 2.55 (m, 1H), 2.15 (t, *J* = 7.83 Hz, 2H), 1.86 (m, 2H), 0.64 (m, 2H), 0.42 (m, 2H). MS (*m/z*) = 521.38 (M+H)

Scheme 41

**Example 101**

4-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methylamino)butanoic acid (**168**)

Aldehyde **167** (0.075 g, 0.16 mmol, scheme 67), O-tert-butyl-4-aminobutyric acid (0.077 g, 0.48 mmol) and acetic acid (0.03 mL, 0.5 mmol) were dissolved in 2:1 mixture dichloromethane/NMP (75 mL) to give a colorless solution. This was stirred for 20 min at RT, then sodium triacetoxyborohydride (0.136 g, 0.64 mmol) was added and the mixture was stirred at RT for 3 h. The reaction mixture was then partitioned between ethyl acetate and water, producing a white precipitate isolated by suction filtration. The isolated solid was dissolved in 1:1 mixture methanol/dichloromethane then concentrated. The residue was purified by flash column chromatography (eluent 5-15 % methanol/chloroform) to yield a colorless solid. The

material was suspended in acetic acid (15 mL), and HCl in dioxane (4M, 1.05 mL) was added, forming a gummy precipitate. This mixture was stirred for 3 h then the supernatant was decanted. The residue was triturated with ethyl acetate, then purified by silica gel chromatography (eluent 60/35/5 % chloroform/methanol/NH₄OH) to give title compound **168** (29 mg, 31 % yield) as a colorless solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.60 (d, J=1.8, 1H); 8.54 (d, J=5.5, 1H); 8.53 (s, 1H); 8.36 (s, 1H); 8.27 (d, J=8.0, 1H); 8.07-8.01 (m, 1H); 7.94 (dd, J=8.0, 2.0, 1H); 7.31-7.25 (m, 1H); 6.96 (d, J=2.9, 1H); 6.76 (d, J=5.3, 1H); 3.85 (s, 2H); 2.62 (t, J=6.6, 2H); 2.56 (m, 1H); 2.29 (t, J=7.2, 2H); 1.69 (quint, J=6.9, 2H); 0.69-0.63 (m, 2H); 0.44-0.40 (m, 2H). LRMS (M+H): 554.6

Example 102

1-cyclopropyl-3-(2,3-difluoro-4-(2-(5-((2-oxopyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (169)

To a solution of aldehyde **167** (200 mg, 0.429 mmol) in DMF (10 mL) were added 4-aminobutyric acid (133 mg, 1.286 mmol) and acetic acid (0.049 mL, 0.858 mmol). After stirring for 20 min at RT, sodium triacetoxyborohydride (454 mg, 2.144 mmol) was added. Stirring was continued for an additional 18 h. Water was added to form a precipitate that was collected by filtration, rinsed with water and purified via Biotage [linear gradient 0-20%, (methanol+2%NH₄OH)/dichloromethane; SiliaFlash 25 g cartridge] followed by a trituration with methanol. Title compound **169** was obtained as an off-white solid (131.8 mg, 57.4 % yield). ¹H NMR (400 MHz, MeOH-*d*₄) δ (ppm) : 8.54 (d, *J* = 5.2 Hz, 1H), 8.53 (d, *J* = 2.0 Hz, 1H), 8.47 (s, 1H), 8.37 (s, 1H), 8.27 (d, *J* = 8.4 Hz, 1H), 8.04 (t, *J* = 9.2 Hz, 1H), 7.80 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.29 (td, *J* = 8.8, 2.0 Hz, 1H), 6.87 (d, *J* = 2.8 Hz, 1H), 6.77 (d, *J* = 5.2 Hz, 1H), 4.46 (s, 2H), 3.39-3.27 (m, 2H), 2.60-2.53 (m, 1H), 2.31 (t, *J* = 8.0 Hz, 2H), 1.96 (q, *J* = 7.6 Hz, 2H), 0.69-0.63 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 536.6 (M+H).

Example 103



2-amino-6-(((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methylamino)hexanoic acid (170)


Aldehyde **167** (0.110 g, 0.236 mmol), N-Boc-lysine (0.105 g, 0.424 mmol) and acetic acid (0.05 mL, 0.9 mmol) were dissolved in a 2:1 mixture dichloromethane/NMP (75 mL) to give a colorless solution. This was stirred for 20 min at RT, then sodium triacetoxyborohydride (0.150 g, 0.71 mmol) was added and the mixture was stirred at RT for 5 h. The reaction mixture

was partitioned between dichloromethane and water, producing a white precipitate that was isolated by suction filtration, dissolved in a 1:1 mixture of methanol/dichloromethane then concentrated and purified by flash column chromatography (eluent 70/25/5 % chloroform/methanol/NH₄OH) to provide a colorless solid. This material was suspended in acetic acid (20 mL), and HCl in dioxane (4M, 0.6 mL) was added, forming a gummy precipitate. This mixture was stirred for 3 h then the supernatant was decanted. The residue was triturated with ethyl acetate and dried *in vacuo* yielding the title compound **170** (100 mg, 60% yield) as a colorless solid, presumably as a tri-hydrochloride salt. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 9.53 (br s, 2H); 8.81 (d, J=1.8, 1H); 8.62 (d, J=5.7, 1H); 8.60 (s, 1H); 8.46 (s, 1H); 8.41 (d, J=8.2, 1H); 8.38-8.25 (br s, 3H); 8.22 (dd, J=8.4, 2.0, 1H); 8.05-8.01 (m, 1H); 7.33-7.27 (m, 1H); 7.03 (d, J=2.4, 1H); 6.88 (d, J=5.5, 1H); 4.25-4.20 (br s, 2H); 3.90-3.85 (m, 1H); 2.98-2.90 (m, 2H); 2.58-2.52 (m, 1H); 1.85-1.78 (m, 2H); 1.78-1.70 (m, 2H); 1.55-1.45 (m, 1H); 1.45-1.35 (m, 1H); 0.68-0.63 (m, 2H); 0.44-0.40 (m, 2H). LRMS (M+H): 597.5


Compounds **171-172** (examples **104-105**) were prepared in one step by reductive amination of aldehyde **167** similarly to compound **48** (example **31**, Scheme 15). Compound **173** (example **106**) was synthesized similarly to the compound **168** (example **101**, Scheme 41) starting from the aldehyde **47** (Scheme 15)

Table 16. Characterization of compounds **171-173** (examples **104-106**)

Cpd	Ex	Structure	Characterization
171	104	 1-(4-(2-(5-(5,8,11,14-tetraoxa-2-azapentadecyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-2,3-difluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, MeOH- <i>d</i> ₄) δ (ppm) : 8.61 (d, <i>J</i> = 1.2 Hz, 1H), 8.54 (d, <i>J</i> = 5.6 Hz, 1H), 8.50 (bs, 1H), 8.35 (s, 1H), 8.27 (d, <i>J</i> = 8.4 Hz, 1H), 8.03 (t, <i>J</i> = 8.0 Hz, 1H), 7.95 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.28 (td, <i>J</i> = 8.4, 2.0 Hz, 1H), 6.91 (d, <i>J</i> = 2.4 Hz, 1H), 6.76 (d, <i>J</i> = 5.6 Hz, 1H), 3.90 (s, 2H), 3.57-3.46 (m, 12H), 3.42-3.36 (m, 2H), 3.21 (s, 3H), 2.77 (t, <i>J</i> = 5.2 Hz, 2H), 2.61-2.53 (m, 1H), 0.69-0.63 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 658.4 (M+H).
172	105	 3-(4-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)propanoic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.59 (d, <i>J</i> =1.6, 1H); 8.49 (d, <i>J</i> =5.5, 1H); 8.10 (d, <i>J</i> =8.2, 1H); 8.09 (s, 1H); 7.95-7.90 (m, 2H); 7.21-7.15 (m, 1H); 6.71 (d, <i>J</i> =4.9, 1H); 3.73 (s, 2H); 3.30-3.20 (m, 6H); 2.85-2.70 (br s, 4H); 2.65-2.55 (m, 3H); 0.79-0.74 (m, 2H); 0.55-0.50 (m, 2H). LRMS (M+H): 609.6

Cpd	Ex	Structure	Characterization
173	106	 (S)-1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)pyrrolidine-2-carboxylic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.09 (s, 1H); 8.60 (d, J=1.6, 1H); 8.51 (d, J=5.5, 1H); 8.33 (s, 1H); 8.26 (s, 1H); 8.25 (d, J=7.6, 1H); 7.93 (dd, J=8.2, 2.1, 1H); 7.74 (dd, J=13.7, 2.5, 1H); 7.37 (t, J=9.0, 1H); 7.22-7.19 (m, 1H); 6.93 (d, J=2.4, 1H); 6.63 (d, J=5.3, 1H); 4.05 (d, J=13.5, 1H); 3.75 (d, J=13.7, 1H); 3.34-3.30 (m, 1H); 3.05-3.00 (m, 1H); 2.55-2.50 (m, 2H); 2.15-2.09 (m, 1H); 1.89-1.80 (m, 1H); 1.80-1.71 (m, 2H); 0.66-0.61 (m, 2H); 0.44-0.40 (m, 2H). LRMS (M+H): 548.5

Scheme 42



5

Example 107

1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-morpholinoethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (178)

Step 1. 4-(2-(6-bromopyridin-3-yl)ethyl)morpholine (175)

- 10 Aldehyde **174** (0.76 g, 3.8 mmol), morpholine (3.3 g, 38 mmol) and acetic acid (0.44 mL, 7.6 mmol) were dissolved in dichloromethane (100 mL) to give a colorless solution, which was stirred for 20 min. Sodium triacetoxyborohydride (2.42 g, 11.4 mmol) was added and the mixture was stirred at RT for 18 h. The reaction mixture was quenched with 1M HCl (50 mL), the layers were separated, and the organic phase was washed with a further 1M HCl (50 mL).
- 15 The combined acidic aqueous phase was basified with 3M NaOH, and extracted with dichloromethane. The organic phase was washed with saturated sodium bicarbonate solution and brine, dried over anhydrous MgSO₄, filtered and concentrated. The residue was purified by

flash column chromatography (eluent 10 % methanol/chloroform) to give title compound **175** (1.04 g, 100 % yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.23 (d, J=1.5, 1H); 7.41-7.39 (m, 2H); 3.73-3.70 (m, 4H); 2.75 (t, J=7.0, 2H); 2.56 (t, 6.8, 2H); 2.51-2.47 (m, 4H). LRMS (M+H): 271.1, 273.1.

5 Step 2: 4-(2-(6-(7-chlorothieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl)morpholine (176)

To 7-chlorothienopyridine (0.81 g, 4.8 mmol) in THF (100 mL) at – 78 °C was added n-butyllithium (2.5 M in hexanes, 2.1 mL, 5.1 mmol), dropwise. The mixture was allowed to warm to 0 °C then zinc chloride (1.0 M in diethyl ether, 4.8 mL, 4.8 mmol) was added. The mixture was stirred and warmed to room temperature. Bromide **175** (1.0 g, 3.7 mmol) and
10 tetrakis(triphenylphosphine)palladium (0.85 g, 0.74 mmol) in THF (75 mL) were added dropwise, and the resultant mixture was heated to reflux for 2 h. It was then cooled and ammonium chloride (2.0 mL) was added, and the mixture was concentrated. The residue was partitioned between water and ethyl acetate, resulting in a thick precipitate. This was isolated by suction filtration and triturated with ethyl acetate, to provide title compound **176** (1.35 g, 100 %
15 yield, crude) as a yellow solid. LRMS (M+H): 360.4

Step 3: 3-fluoro-4-(2-(5-(2-morpholinoethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)aniline (5)


To a solution of 4-amino-2-fluorophenol hydrochloride (0.792 g, 4.84 mmol) in DMSO (50 mL) was added potassium *tert*-butoxide (1.05 g, 9.31 mmol), and the dark mixture was
20 stirred for 30 min. Then compound **176** (1.34 g, 3.72 mmol) in DMSO (25 mL) was added, and the resultant mixture was heated to 140 °C for 1 h. The reaction mixture was poured into water, which was then extracted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous MgSO₄, filtered and concentrated. Flash column chromatography of the residue (eluent 10% methanol/chloroform) afforded title compound **177** (0.15 g, 9 %
25 yield). LRMS (M+H): 451.5

Step 4: 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-morpholinoethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (178)

To a solution of **177** (0.15 g, 0.33 mmol) and pyridine (0.06 mL, 0.07 mmol) in DMF (75 mL) at 0°C was added phenyl chloroformate (0.05 mL, 0.4 mmol). The reaction mixture
30 was stirred at 0°C for 1 h then cyclopropylamine (0.07 mL, 1.0 mmol) was added. The mixture was warmed to room temperature and stirred for an additional 18 h. It was then poured into water, forming a precipitate which was isolated by suction filtration. The solid was rinsed with ether and dried. Silica gel chromatography (5-10 % MeOH/EtOAc) of the material followed by Gilson Reverse Phase HPLC (Luna C₁₈, 30-55% MeOH/water, 45 min) and lyophilization,

followed by partitioning of the residue between dichloromethane and 1M NaOH, washing the organic phase with brine, drying over anhydrous MgSO_4 , filtering and concentrating gave title compound **178** (47 mg, 27 % yield) as a colorless solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm) : 8.78 (s, 1H); 8.53 (d, $J=1.6$, 1H); 8.51 (d, $J=5.5$, 1H); 8.30 (s, 1H); 8.19 (d, $J=8.2$, 1H); 7.83 (dd, $J=8.2$, 2.2, 1H); 7.73 (dd, $J=13.7$, 2.4, 1H); 7.38 (t, $J=9.0$, 1H); 7.22-7.18 (m, 1H); 6.65-6.61 (m, 2H); 3.59-3.55 (m, 4H); 2.81 (t, $J=7.2$, 2H); 2.60-2.51 (m, 3H); 2.48-2.42 (m, 4H); 0.66-0.63 (m, 2H); 0.44-0.41 (m, 2H). LRMS ($\text{M}+\text{H}$): 534.3.


Scheme 43

**Example 108**

1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-methyl-5,8,11,14-tetraoxa-2-azapentadecyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**180**)

Amine **179** (0.15 g, 0.23 mmol), 40% aqueous formaldehyde (0.70 g, 23 mmol) and acetic acid (0.13 mL, 2.3 mmol) were dissolved in dichloromethane (25 mL) to give a colorless solution. Sodium triacetoxyborohydride (0.199 g, 0.938 mmol) was added and the mixture was stirred at RT for 10 min. The reaction mixture was then washed with H_2O , saturated NaHCO_3 , and brine, dried over anhydrous MgSO_4 , filtered and concentrated. Silica gel chromatography of the residue (15 % methanol/chloroform) resulted in partially purified product which was further purified by Gilson Reverse Phase HPLC (Luna C_{18} , 30-55% MeOH/water, 45 min) then lyophilized. The material was partitioned between 1M NaOH and dichloromethane, and the organic phase was collected and concentrated to yield title compound **180** (0.071 g, 46 % yield) as a colorless solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm) : 8.74 (s, 1H); 8.55 (d, $J=1.4$, 1H); 8.51 (d, $J=5.5$, 1H); 8.32 (s, 1H); 8.24 (d, $J=8.2$, 1H); 7.86 (dd, $J=8.2$, 2.2, 1H); 7.73 (dd, $J=13.5$, 2.5, 1H); 7.38 (t, $J=8.8$, 1H); 7.22-7.18 (m, 1H); 6.64 (d, $J=5.3$, 1H); 6.60 (d, $J=2.4$, 1H); 3.60 (s, 2H); 3.55 (t, $J=5.9$, 2H); 2.53-3.47 (m, 10H); 3.39 (t, $J=5.7$, 2H); 3.20 (s, 3H); 2.58-2.52 (m, 3H); 2.21 (s, 3H); 0.66-0.63 (m, 2H); 0.44-0.41 (m, 2H). LRMS ($\text{M}+\text{H}$): 654.7

Scheme 44

Example 109

5 1-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-
 yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea (183)

Step 1: tert-butyl 2-(6-(7-(2-fluoro-4-(3-(5-methylisoxazol-3-
 yl)ureido)phenoxy)thieno[3,2-b]pyridin-2-yl) pyridin-3-yl)ethyl(2-methoxyethyl)carbamate
 10 (182)

To a solution of compound **181** (0.25 g, 0.46 mmol, scheme 64) and DIPEA (0.20 mL, 1.2 mmol) in THF (60 mL) at 0°C was added triphosgene (0.055 g, 0.19 mmol) and the mixture was stirred for 10 min. Then 3-amino-5-methylisoxazole (0.091 g, 0.93 mmol) was added, the mixture was stirred for an additional 20 min, then warmed to room temperature and stirred for 2
 15 h. Excess triphosgene was quenched with 1 mL water then the mixture was concentrated. The residue was partitioned between water and ethyl acetate, and the organic phase was collected, washed with water, saturated aqueous sodium bicarbonate, and brine. It was then dried over anhydrous MgSO₄, filtered, concentrated and purified by flash column chromatography (eluent 3 % methanol/ethyl acetate) to give title compound **182** (0.17 g, 56 % yield).


20 Step 2: 1-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-
 b]pyridin-7-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea (183)

Compound **182** (0.17 g, 0.26 mmol) was suspended in dichloromethane (50 mL) and TFA (1 mL) was added. This solution was stirred for 1 h then the mixture was concentrated. The residue was partitioned between ethyl acetate and water, washed with 3M NaOH and brine,
 25 then dried over anhydrous MgSO₄, filtered and concentrated. The residue was triturated with diethyl ether and dried *in vacuo* to afford title compound **183** (0.125 g, 87 % yield). ¹H NMR

(400 MHz, DMSO-*d*₆) δ (ppm) : 9.74 (s, 1H); 9.33 (s, 1H); 8.52 (d, J=5.5, 1H); 8.51-8.50 (m, 1H); 8.29 (s, 1H); 8.18 (d, J=8.0, 1H); 7.81 (dd, J=8.2, 2.2, 1H); 7.74 (J=12.9, 2.5, 1H); 7.46 (t, J=9.0, 1H); 7.30-7.27(m, 1H); 6.66 (d, J=5.5, 1H); 6.55 (s, 1H); 3.37 (t, J=5.7, 2H); 3.22 (s, 1H); 2.82-2.75 (m, 4H); 2.68 (t, J=5.5, 2H); 2.37 (s, 3H). LRMS (M+H): 563.5.

5

Scheme 45



185: Example 110

Example 110

N-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (185)

10

Step 1: tert-butyl 2-(6-(7-(2-fluoro-4-(1-(4-fluorophenylcarbamoyl)cyclopropanecarboxamido)phenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl(2-methoxyethyl)carbamate, (184)

To a solution of compound **181** (0.25 g, 0.46 mmol, scheme 64), 1-(4-fluorophenylcarbamoyl) cyclopropanecarboxylic acid (0.21 g, 0.93 mmol), and DIPEA (0.32 mL, 1.9 mmol) in DMF (25 mL) was added HATU reagent (0.44 g, 1.2 mmol) and the resultant mixture was stirred at room temperature for 48 h. The mixture was partitioned between water and ethyl acetate, and the organic phase washed with water, saturated aqueous sodium bicarbonate, saturated aqueous ammonium chloride, and brine. It was then dried over anhydrous MgSO₄, filtered and concentrated. Silica gel chromatography (ethyl acetate) of the residue provided title compound **184** (0.23 g, 67 % yield).

15

20

Step 2: N-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (185)


Compound **184** (0.23 g, 0.31 mmol) was suspended in dichloromethane (50 mL) and TFA (1.1 mL) was added. The reaction mixture was stirred for 18 h then concentrated. The residue was partitioned between ethyl acetate and water, the organic phase was collected,

25

washed with 3M NaOH and brine, then dried over anhydrous MgSO_4 , filtered and concentrated.

The residue was triturated with diethyl ether and dried *in vacuo* to provide title compound **185** (0.16 g, 81% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 10.41 (s, 1H); 10.02 (s, 1H); 8.52 (d, $J=5.5$, 1H); 8.50-8.48 (m, 1H); 8.29 (s, 1H); 8.18 (d, $J=8.2$, 1H); 7.90 (dd, $J=13.1$, 2.2, 1H); 7.81 (dd, $J=8.2$, 2.2, 1H); 7.64-7.60 (m, 2H); 7.50-7.45 (m, 2H); 7.18-7.12 (m, 2H); 6.65 (d, $J=5.5$, 1H); 3.37 (t, $J=5.7$, 2H); 3.22 (s, 3H); 2.82-2.74 (m, 4H); 2.70-2.66 (m, 2H); 1.47 (s, 4H). LRMS ($\text{M}+\text{H}$): 644.6

Scheme 46



Example 111

N-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (**187**).

Step 1: tert-butyl 2-(6-(7-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-3-yl)ethyl(2-methoxyethyl)carbamate (**186**).


To a solution of compound **181** (0.24 g, 0.45 mmol, scheme 64) in 2-propanol (50 mL) was added a solution of 4-fluorophenylacetyl isothiocyanate (0.1M, 0.8 mmol) in acetonitrile (8 mL). The resultant mixture was heated to 70°C for 1 h, then cooled and concentrated. Silica gel chromatography of the residue (eluent 5 % methanol/chloroform) afforded the title compound **186** (0.19 g, 58% yield).

Step 2: N-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-(4-fluorophenyl)acetamide (**187**).

To a solution of **186** (0.19 g, 0.26 mmol) in acetic acid (10 mL) was added aqueous HCl (3M, 1.0 mL, 3.0 mmol). The mixture was stirred at room temperature for 3 h then partially concentrated. The residue was partitioned between ethyl acetate and water, the organic phase

was collected, washed with saturated aqueous sodium bicarbonate and brine. It was then dried over anhydrous MgSO_4 , filtered and concentrated. The residue was purified by flash column chromatography (eluent 15 % methanol/chloroform) to give title compound **187** (80 mg, 49 % yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 8.53(d, $J = 5.5$, 1H), 8.50(d, $J = 1.6$, 1H), 8.30(s, 1H), 8.18(d, $J = 7.8$, 1H), 8.04(dd, $J = 11.2$, 1.6, 1H), 7.89(dd, $J = 8.2$, 2.2, 1H), 7.54-7.50(m, 2H), 7.40-7.35(m, 2H), 7.22-7.15(m, 2H), 6.67(d, $J = 5.5$, 1H), 3.83(s, 2H), 3.40(s, 2H), 3.37(t, $J = 5.7$, 2H), 3.22(s, 3H), 2.82-2.75 (m, 4H), 2.69 (t, $J = 5.7$, 2H). LRMS ($\text{M}+\text{H}$): 634.4

Scheme 47



WO 2009/109035 A1




189: Example 112Example 112


1-((2-(7-(2-fluoro-4-cyclopropylaminocarbonylaminophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-isopropyl-1-(2-methoxyethyl)urea (**189**)

To a solution of **188** (85 mg, 0.166 mmol) in DCM (5 mL) was added isopropyl isocyanate (70.8 mg, 0.832 mmol) and the reaction mixture was stirred at RT overnight. The mixture was diluted with EtOAc then washed with water, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by column chromatography (eluent EtOAc to 20% MeOH in EtOAc) to afford title compound **189** (57 mg, 58% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 8.69 (s, 1H), 8.49 (d, $J = 5.48$ Hz, 1H), 7.89 (s, 1H), 7.70 (m, 1H), 7.35 (t, $J = 8.99$ Hz, 1H), 7.19 (m, 1H), 6.94 (s, 1H), 6.64 (d, $J = 5.28$ Hz, 1H), 6.55 (m, 1H), 6.10 (d, $J = 5.48$ Hz, 1H), 4.55 (s, 2H), 3.83 (s, 3H), 3.79 (m, 1H), 3.21 (s, 3H), 2.53 (m, 1H), 1.05 (d, $J = 6.45$ Hz, 6H), 0.63 (m, 2H), 0.40 (m, 2H). MS (m/z) = 596.43 ($\text{M}+\text{H}$).


Compounds **190**, **193-195** (examples **113**, **115-117**) were prepared similarly to compound **189** (example **112**, scheme 47) from precursors described in WO 2009/109035 A1 and compound **113** (example **78**, scheme 29).

Table 17. Characterization of compounds **190-195** (examples **113-117**)

Cpd	Ex	Structure	Characterization
190	113	 1-((6-(7-(4-cyclopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-3-isopropyl-1-(2-methoxyethyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.72 (s, 1H), 8.51 (d, <i>J</i> = 5.28 Hz, 1H), 8.48 (m, 1H), 8.301 (s, 1H), 8.23 (d, <i>J</i> = 11.55 Hz, 1H), 7.74 (m, 2H), 7.37 (t, <i>J</i> = 9.19 Hz, 1H), 7.20 (m, 1H), 6.64 (d, <i>J</i> = 5.47 Hz, 1H), 6.57 (m, 1H), 6.14 (d, <i>J</i> = 7.62 Hz, 1H), 4.52 (s, 2H), 3.81 (m, 1H), 3.44 (m, 1H), 3.20 (s, 3H), 1.06 (d, <i>J</i> = 6.46 Hz, 6H), 0.65 (m, 2H), 0.42 (m, 2H). MS (<i>m/z</i>) = 593.47 (M+H).
193	115	 1-(4-(7-(4-cyclopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-3-isopropyl-1-(2-methoxyethyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.74(s, 1H), 8.53(d, 1H, <i>J</i> =5.5Hz), 8.06(s, 1H), 7.90(d, 2H, <i>J</i> =8.4Hz), 7.77(dd, 1H, <i>J</i> ₁ =2.5Hz, <i>J</i> ₂ =13.7Hz), 7.41(t, 1H, <i>J</i> =9.0Hz), 7.37(d, 2H, <i>J</i> =8.4Hz), 7.24-7.22(m, 1H), 6.63-6.60(m, 2H), 6.13(d, 1H, <i>J</i> =7.4Hz), 4.65(s, 2H), 3.86-3.81(m, 1H), 3.44(t, 2H, <i>J</i> =5.7Hz), 3.36(t, 2H, <i>J</i> =4.3Hz), 3.28(s, 3H), 2.61-2.56(m, 1H), 1.11(s, 3H), 1.10(s, 3H), 0.71-0.68(m, 2H), 0.48-0.44(m, 2H). MS: 592.6(MH+).
194	116	 1-(4-(7-(4-cyclopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-3-cyclopentyl-1-(2-methoxyethyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.75 (s, 1), 8.53(d, 1H, <i>J</i> =5.5Hz), 8.06(s, 1H), 7.90(d, 1H, <i>J</i> =8.5Hz), 7.77(dd, 1H, <i>J</i> ₁ =2.3Hz, <i>J</i> ₂ =13.5Hz), 7.41(t, 1H, <i>J</i> =9.0Hz), 7.37(d, 2H, <i>J</i> =8.4Hz), 7.25-7.22(m, 1H), 6.36-6.61(m, 2H), 6.18(d, 1H, <i>J</i> =7.0Hz), 4.56(s, 2H), 4.02-3.96(m, 1H), 3.45-3.43(t, 2H, <i>J</i> =5.9Hz), 3.66(t, 2H, <i>J</i> =5.9Hz), 3.23(s, 3H), 2.61-2.56(m, 1H), 1.84-1.78(m, 2H), 1.66-1.62(m, 2H), 1.54-1.49(m, 2H), 1.46-1.40(m, 2H), 0.89-0.66(m, 2H), 0.48-0.44(m, 2H). MS: 618.5(MH+).

Cpd	Ex	Structure	Characterization
195	117	 1-(4-(7-(4-cyclopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-3-ethyl-1-(2-methoxyethyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.73(s, 1H), 8.52(d, 1H, J=5.5Hz), 8.06(s, 1H), 7.90(d, 2H, J=8.4Hz), 7.76(dd, 1H, J ₁ =2.3Hz, J ₂ =13.5Hz), 7.42(t, 1H, J=9.0Hz), 7.36(d, 2H, J=8.4Hz), 7.25-7.22(m, 1H), 6.63-6.60(m, 2H), 6.45(t, 1H, J=5.5Hz), 4.56(s, 2H), 3.46-3.43(m, 2H), 3.36-3.4(m, 2H), 3.27(s, 3H), 3.14-3.10(m, 2H), 2.60-2.58(m, 1H), 1.06(t, 3H, J=7.0Hz), 0.70-0.67(m, 2H), 0.49-0.47(m, 2H). MS: 578.5(MH ⁺).

Scheme 48

Example 118

5 1-(3-fluoro-4-(2-(5-((2-oxo-1,3-oxazinan-3-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (201)

Step1: 3-((6-bromopyridin-3-yl)methylamino)propan-1-ol (196)

To a solution of 6-bromonicotinaldehyde (1.25 g, 6.72 mmol) in DCM (25 mL) was
 10 added 3-aminopropan-1-ol (1.514 g, 20.16 mmol) and acetic acid (0.385 mL, 6.72 mmol), and

the reaction mixture was stirred for 10min. Sodium triacetoxyborohydride (3.56 g, 16.80 mmol) was added and the reaction mixture was stirred at RT overnight. The reaction mixture was then diluted with EtOAc and extracted with water. The organic phase was discarded. The aqueous phase was concentrated and the resultant solid was stirred with a mixture of DCM and acetone then filtered. The filtrate was collected, dried over Na₂SO₄, and concentrated to give a yellowish material, which upon trituration with Et₂O afforded title compound **196** (0.9g, 55% yield) as an off-white solid. MS: 246 (MH⁺).

Step 2: 3-((6-bromopyridin-3-yl)methyl)-1,3-oxazinan-2-one (**197**)

To a solution of **196** (0.9 g, 3.67 mmol) in DCM (30 mL) was added CDI (0.595 g, 3.67 mmol), and the reaction mixture was stirred at RT over weekend. The mixture was then concentrated and the residue was purified by flash column chromatography (eluent EtOAc) to afford the title compound **197** (373 mg, 38 % yield) as colorless oil. MS: 271(HM⁺).

Step 3: 3-((6-(7-chlorothieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-1,3-oxazinan-2-one (**199**)

To a solution of **197** (373 mg, 1.376 mmol) in toluene (10 mL) was added the 7-chloro-2-(tributylstannyl)thieno[3,2-b]pyridine **198** (631 mg, 1.376 mmol) and Pd(PPh₃)₄ (159 mg, 0.138 mmol). The reaction mixture was heated to reflux for 24 hours. The reaction mixture was then cooled to RT and concentrated. The residue was triturated with Et₂O to afford the title compound **199** (363mg, 73% yield) as beige solid. MS: 360(MH⁺).

Step 4: 3-((6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-1,3-oxazinan-2-one (**200**)

To a solution of 4-amino-2-fluorophenol (70.7 mg, 0.556 mmol) in DMSO (5 mL) was added sodium *tert*-butoxide (53.4 mg, 0.556 mmol) and the reaction mixture was stirred for 30 min. Chloride **199** (100 mg, 0.278 mmol) was added and the reaction mixture was heated at 100°C overnight. The mixture was then cooled to RT and poured into water (20 mL) and the precipitated product was collected by filtration and purified by Biotage (MeOH/EtOAc 0-50%, SNAP 25g cartridge) to give title compound **200** (147 mg, 33 % yield) as a beige solid. MS: 451(MH⁺).


Step 5: 1-(3-fluoro-4-(2-(5-((2-oxo-1,3-oxazinan-3-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (**201**)

A reaction mixture consisting of amine **200** (100mg, 0.222 mmol) and 2-isocyanatopropane (434mg, 5.10mmol) in DCM (3mL) was heated to 80°C in a sealed flask overnight. The mixture was then cooled to RT and purified by Biotage (SiliaFlash 12 g cartridge, 0-12% MeOH/CHCl₃) to afford after the separation title compound **201** (35 mg, 29.4 % yield) as beige solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.67 (s, 1H), 8.55 (d, 1H,

J=1.8Hz), 8.50 (d, 1H, J=5.3Hz), 8.33 (s, 1H), 8.25 (d, 1H, J=8.2Hz), 7.84 (dd, 1H, J₁=2.2Hz, J₂=8.2Hz), 7.69 (dd, J₁=2.5Hz, J₂=13.7Hz), 7.35 (t, 1H, J=9.0Hz), 7.12-7.10 (m, 1H), 6.62 (d, 1H, J=5.1Hz), 6.14 (d, 1H, J=7.4Hz), 4.50 (s, 2H), 4.21 (t, 2H, J=5.1Hz), 3.77-3.72 (m, 1H), 3.30-3.28 (m, 2H), 1.97-1.92 (m, 2H), 1.10 (s, 3H), 1.08 (s, 3H). MS: 536.4 (MH)⁺

5

Scheme 49

Example 119

10 1-(3-fluoro-4-(2-(4-((2-oxopyrrolidin-1-yl)methyl)phenyl)thieno[3,2-b]pyridin-7-
yloxy)phenyl)-3-isopropylurea (205)

Step 1: 1-(4-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)pyrrolidin-
2-one (203)

A mixture of compound **202** (1 g, 2.411 mmol), ethyl 4-aminobutanoate hydrochloride
 15 (0.808 g, 4.82 mmol) and DIPEA (1.263 mL, 7.23 mmol) in acetonitrile (12 mL) was heated to
 reflux for 2 days. The reaction mixture was cooled to room temperature and concentrated. The
 residue was dissolved in ethyl acetate and washed with saturated ammonium chloride solution.
 The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was
 purified using Biotage (MeOH/EtOAc, 0-20%, SNAP 50 g cartridge) to give the title compound
 20 **203** (580 mg, 52 % yield) as beige solid. MS: 464(MH⁺).

Step 2: 1-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)pyrrolidin-
2-one (204)


The reaction mixture consisting of the nitro compound **203** (580 mg, 1.25 mmol), iron
 powder (594 mg, 10.64 mmol), and ammonium chloride (57.6 mg, 1.076 mmol) in EtOH/water
 25 mixture (16 mL/8 mL) was stirred for 2 hr at 80°C. The reaction mixture was filtered while hot.

The filtrate was concentrated to give title compound **204** (542 mg, 100 % yield) as a brown solid. MS: 434(MH)+.

Step 3: 1-(3-fluoro-4-(2-(4-((2-oxopyrrolidin-1-yl)methyl)phenyl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (**205**)

5 Title compound **205** was obtained starting from the compound **204** and following a procedure similar to the one used in the synthesis of compound **201** (example 118, scheme 48).
¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 1H: 8.66 (s, 1H), 8.48 (d, 1H, J=5.5Hz), 8.02 (s, 1H), 7.86-7.84 (m, 2H), 7.70 (dd, 1H, J1=2.3Hz, J2=13.5Hz), 7.37-7.32 (m, 3H), 7.13-7.10 (m, 1H), 6.58 (dd, 1H, J1=0.8Hz, J2=5.3Hz), 6.13 (d, 1H, J=7.4Hz), 4.41 (s, 2H), 3.78-3.74 (m, 1H),
 10 3.27 (t, 2H, J=7.3Hz), 2.29 (t, 2H, J=8.2Hz), 1.94-1.91 (m, 2H), 1.10 (s, 3H), 1.08 (s, 3H). MS: 519.5(MH+).

Scheme 50



15 Example 120

2-(((2-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl acetate (**208**)

20 Step 1: 2-(((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl acetate (**206**)

To a solution of **158** (423 mg, 0.925 mmol, scheme 39) in DMF (18 mL) was added 2-acetoxyacetic acid (164 mg, 1.387 mmol), DIPEA (0.565 mL, 3.24 mmol) and HATU reagent (1055 mg, 2.77 mmol). The reaction mixture was stirred at room temperature for 1hr followed by addition of NaHCO₃ saturated solution (200 mL) and EtOAc (300mL). A white precipitate
 25 was formed which was collected by filtration and discarded. The organic layer of the filtrate

was collected, dried over anhydrous sodium sulfate and concentrated to give a yellowish solid, which was triturated with ether to give title compound **206** (570 mg, 111 % yield, crude) that was used in the next step with no additional purification. MS: 558 (MH)+.


Step 2: 2-(((2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl acetate (**207**)

The reaction mixture consisting of **206** (300 mg, 0.538 mmol), ammonium chloride (24.75 mg, 0.463 mmol) and iron powder (255 mg, 4.57 mmol) in ethanol (6 mL)/water (3.0 mL) was heated to reflux for 1h. The reaction mixture was filtered while hot and concentrated. The residue was purified by Biotage (MeOH/DCM, 0-20%, SNAP 25 g cartridge) to give the title compound **207** (133 mg, 0.252 mmol, 47 % yield) as a white solid. MS: 528(MH)+.

Step 3: 2-(((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)(2-methoxyethyl)amino)-2-oxoethyl acetate (**208**)

To a solution of **207** (130 mg, 0.246 mmol) in THF (20 mL) at 0°C was added DIPEA (0.172 mL, 0.986 mmol) and triphosgene (43.9 mg, 0.148 mmol). The reaction mixture was stirred for 1hr at 0°C before cyclopylamine (70.3 mg, 1.232 mmol) was added. The reaction mixture was allowed to warm up to room temperature and stirred for 1hr before concentration. The residue was purified by Biotage (MeO/DCM, 0-20%, SNAP 25 g cartridge) to give the title compound **208** (104 mg, 0.170 mmol, 69 % yield) as a white solid. MS: 611 (MH)+.

Scheme 51



Example 121

N-(((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide (**212**)

Step 1: N-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide (210)

To a solution of **158** (100 mg, 0.219 mmol, scheme 51) in pyridine (6 mL) at 0°C was added acetic anhydride (0.022 mL, 0.230 mmol) and the reaction mixture was stirred at room temperature for 2 hr. The reaction mixture was partitioned between EtOAc and CuSO₄ (1M) solution, the organic layer was collected, washed with 1N HCl and then water, dried over anhydrous sodium sulfate and concentrated. The residue was purified by Biotage (MeOH/DCM, 0-15%, SNAP 25 g cartridge) to give title compound **210** (80 mg, 0.160 mmol, 73 % yield) as a white solid. MS: 500(MH)+.


Step 2: N-((2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide (211)

Title compound **211** was obtained starting from the compound **210** and following a procedure similar to the one used in the synthesis of compound **207** (scheme 50). MS: 470 (MH)+.

Step 3: N-((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-N-(2-methoxyethyl)acetamide (212)

Title compound **212** was obtained starting from the compound **211** and following a procedure similar to the one used in the synthesis of compound **208** (scheme 50). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.75 (s, 1H), 8.55 (d, 1H, J=5.3Hz), 7.95 and 7.93 (s, 1H), 7.76 (dd, 1H, J1=2.3Hz, J2=13.5Hz), 7.41 (t, 1H, J=9.0Hz), 7.24-7.21 (m, 1H), 7.08 and 6.92 (s, 1H), 6.70 (d, 1H, J=5.5Hz), 6.60 (m, 1H), 4.74 and 4.70 (s, 2H), 3.88 and 3.86 (s, 3H), 3.45 (m, 2H), 3.36 (m, 1H), 3.28 (s, 3H), 3.24 (m, 1H), 2.60-2.57 (m, 1H), 2.14 and 2.12 (s, 3H), 0.71-0.66 (m, 2H), 0.48-0.44 (m, 2H). MS: 553 (MH)+.

Scheme 52



Example 122

5 2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(2-morpholinoethyl)-1H-imidazole-5-carboxamide (217)

Step 1: 2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazole-5-carboxylic acid (214).

10 To a suspension of ester **213** (1.5 g, 3.50 mmol) in THF (10 mL) was added a solution of LiOH (0.419 g, 17.51 mmol) in water (10.00 mL) and the reaction mixture was stirred overnight. The THF was evaporated under reduced pressure, water was added and the solution was acidified with 1N HCl to pH1 to form a precipitate that was collected by filtration and dried to give title compound **214** (1.4 g, 3.38 mmol, 96 % yield) as a white solid. MS 415(MH)+.

15 Step 2: 2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(2-morpholinoethyl)-1H-imidazole-5-carboxamide (215)

To a solution of acid **214** (180 mg, 0.434 mmol) in DMF (8 mL) was added 2-morpholinoethanamine (0.114 mL, 0.869 mmol), DIPEA (0.266 mL, 1.520 mmol) and HATU reagent (1.303 mmol). The reaction mixture was stirred at RT for 4 hr. NaHCO₃ saturated solution (5mL) and EtOAc (5mL) were added to form a precipitate that was collected by filtration. The organic layer of the filtrate was separated, dried over anhydrous sodium sulfate, concentrated and the residue was combined with the collected precipitate to give title compound **215** (180 mg, 0.342 mmol, 79% yield) as a white solid. MS: 527.5(MH)+.

25 Step 3: 2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(2-morpholinoethyl)-1H-imidazole-5-carboxamide (216)

The reaction mixture of the nitro compound **215** (180 mg, 0.342mmol), iron powder (162 mmol), and ammonium chloride (15.7 mg, 0.294 mmol) in EtOH/water mixture (10mL/5mL) was heated to reflux for 1hr. The reaction mixture was filtered while hot. The filtrate was concentrated to give title compound **216** (130 mg, 0.262 mmol, 77 % yield) as a white solid. MS: 497.5(MH)+.

Step 4: 2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(2-morpholinoethyl)-1H-imidazole-5-carboxamide (217)


To a suspension of aniline **216** (130 mg, 0.262 mmol) in THF (10 mL) at 0°C was added DIPEA (0.137 mL, 0.785 mmol) and triphosgene (38.8 mg, 0.131 mmol). The reaction mixture was stirred at 0°C for 1hr before cyclopropylamine (0.054 mL, 0.785 mmol) was added and the mixture was stirred for 10 min at 0°C. The reaction mixture was slowly warmed to room temperature and stirred over weekend then partitioned between NaHCO₃ saturated solution and EtOAc. The organic layer (suspension) was concentrated, the residue was dry-loaded onto a column (Biotage, MeOH/DCM, 0- 25%, SNAP 10 g cartridge), purified twice then triturated with ether and acetone to give title compound **217** (30.4 mg, 0.052 mmol, 20% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.75(s, 1H), 8.59(d, 1H, J=5.5Hz), 8.48(m, 1H), 8.07(s, 1H), 7.78-7.74(m, 1H), 7.71(s, 1H), 7.42(t, 1H, J=9.0Hz), 7.25-7.22(m, 1H), 6.74(d, 1H, J=5.5Hz), 6.61-6.60(m, 1H), 4.22(s, 3H), 3.62(t, 4H, J=4.5Hz), inside 3.38-3.33(m, 2H), 2.60-2.57(m, 1H), 2.52-2.46(m, 6H), 0.71-0.67(m, 2H), 0.48-0.46(m, 2H). MS: 580.6 (MH)+

Example 123

2-(7-(2-fluoro-4-(3-isopropylureido)phenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(2-morpholinoethyl)-1H-imidazole-5-carboxamide (218)

Title compound **218** was obtained starting from the compound **216** and following a procedure similar to the one used in the synthesis of compound **201** (scheme 48). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.73(s, 1H), 8.59(d, 1H, J=5.3Hz), 8.48(t, 1H, J=5.5Hz), 8.07(s, 1H), 7.76-7.71(m, 2H), 7.41(t, 1H, J=9.0Hz), 7.17(d, 1H, J=8.2Hz), 6.73(d, 1H, J=5.1Hz), 6.19(d, 1H, J=7.7Hz), 4.21(s, 3H), 3.83-3.78(m, 1H), 3.61(m, 4H), inside 3.39(m, 2H), 2.51-2.46(m, 6H), 1.15(s, 3H), 1.14(s, 3H). MS: 582.6 (MH)+

Scheme 53



5

Example 124

1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-(pyrrolidine-1-carbonyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (222)

10 Step 1: 2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazole-5-carbonyl chloride (219)

To a pre-cooled solution of acid **214** (1.25 g, 3.02 mmol, scheme 52) in THF (12.07 mL) was added DMF (0.023 mL, 0.302 mmol) and oxalyl chloride (0.660 mL, 7.54 mmol) and the resultant solution was stirred at 0°C for 30min. The solvent was evaporated, the residue was triturated with ether and dried under high vacuum to give title compound **219** (1.306 g, 3.02 mmol, 100 % yield) as a beige solid. MS: 429.2 (MH⁺, COOMe), 433.1 (COCl, MH⁺).

Step 2: (2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)(pyrrolidin-1-yl)methanone (220)

A suspension of the acyl chloride **219** (700 mg, 1.617 mmol) and pyrrolidine (0.3 mL, 3.63 mmol) in DCM (50 mL) was stirred at room temperature overnight. The reaction mixture was concentrated. The residue was triturated with ether to give title compound **220** (756 mg, 1.617 mmol, 100 % yield) as beige solid. MS: 468.3(MH⁺).

Step 3: (2-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)(pyrrolidin-1-yl)methanone (221)

Title compound **221** was obtained starting from the compound **220** and following a procedure similar to the one used in the synthesis of compound **207** (scheme 50). MS: 438.4 (MH⁺).

Step 4: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-(pyrrolidine-1-carbonyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (222)

Title compound **222** was obtained starting from the compound **221** and following a procedure similar to the one used in the synthesis of compound **208** (scheme 50). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.76 (s, 1H), 8.59 (d, 1H, J=5.3Hz), 8.06 (s, 1H), 7.76 (dd, 1H, J₁=2.1Hz, J₂=13.5Hz), 7.59 (s, 1H), 7.42 (t, 1H, J=9.0Hz), 7.24-7.22 (m, 1H), 6.74 (d, 1H, J=5.5Hz), 6.60 (s, 1H), 4.07 (s, 3H), 3.72-3.69 (m, 4H), 2.60-2.58 (m, 1H), 1.93-1.90 (m, 4H), 0.70-0.67 (m, 2H), 0.47-0.45 (m, 2H). MS: 521.5 (MH)⁺


Example 125

1-(3-fluoro-4-(2-(1-methyl-5-(pyrrolidine-1-carbonyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (223)

Title compound **223** was obtained starting from the compound **221** and following a procedure similar to the one used in the synthesis of compound **201** (scheme 48). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.74 (s, 1H), 8.58 (d, 1H, J=5.5Hz), 8.06 (s, 1H), 7.73 (dd, 1H, J₁=2.1Hz, J₂=13.5Hz), 7.5 (s, 1H), 7.41 (t, 1H, J=9.0Hz), 7.18-7.16 (m, 2H), 6.74 (d, 1H, J=5.4Hz), 6.19 (d, 1H, J=7.6Hz), 4.07 (s, 3H), 3.83-3.78 (m, 1H), 3.70-3.68 (m, 4H), 1.91 (m, 4H), 1.15 (s, 3H), 1.13 (s, 3H). MS: 523.2 (MH)⁺

Example 126


2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-N-(3-morpholinopropyl)-1H-imidazole-5-carboxamide (224)



224: Example 126

Title compound **224** was obtained in three steps starting from the acyl chloride **219**, similarly to compound **222** (example **123**, scheme 53). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.75(s, 1H), 8.59 (d, 1H, J=5.3Hz), 8.53 (m, 1H), 8.07(s, 1H), 7.76 (dd, 1H, J₁=2.3Hz, J₂=13.5Hz), 7.71 (s, 1H), 7.42 (t, 1H, J=9.0Hz), 7.25-7.23 (m, 1H), 6.74 (d, 1H, J=5.3Hz), 6.62-6.61 (m, 1H), 4.22 (s, 3H), 3.62-3.60 (m, 4H), 3.31-3.28 (m, 2H), 2.59-2.58 (m, 1H), 2.38-2.34 (m, 6H), 1.73-1.70 (m, 2H), 0.70-0.68 (m, 2H), 0.48-0.46 (m, 2H). MS: 594.6(MH)⁺

Scheme 54

Example 127

1-cyclopropyl-3-(3-fluoro-4-(2-(5-(pyrrolidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (226)

Step 1: 6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinic acid (225)


To a suspension of aldehyde **47** (200 mg, 0.446 mmol, scheme 15) in DMF (10 mL) was added Oxone® (330 mg, 0.535 mmol) at RT and the reaction mixture was stirred at 50°C for 16 hours. The reaction mixture was cooled to 0°C, treated with 1N aqueous HCl (20 mL) and stirred at RT for an additional hour. The resultant precipitate was collected by filtration, washed with water (30 mL) and dried. The crude product was triturated with MeOH to afford title compound **225** (165 mg, 80% yield) as a beige solid. NMR (400 MHz, CD₃OD) δ (ppm): 9.66 (bs, 1H), 8.98 (dd, J = 1.9, 0.9 Hz, 1H), 8.51 (d, J = 5.5 Hz, 1H), 8.31 (s, 1H), 8.22 (dd, J = 8.1, 1.9 Hz, 1H), 8.17 (dd, J = 8.1, 0.9 Hz, 1H), 7.77 (dd, J = 13.7, 2.5 Hz, 1H), 7.45 (bs, 1H), 7.37 (t, J = 9.1 Hz, 1H), 7.26 (dd, J = 8.9, 1.5 Hz, 1H), 6.62 (d, J = 5.3, 0.8 Hz, 1H), 2.60-2.52 (m, 1H), 0.69-0.56 (m, 2H), 0.50-0.37 (m, 2H). [Carboxylic OH is not seen]. MS: 465.3 (MH)⁺.




Step 2. 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(pyrrolidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (226)




To a solution of acid **225** (70 mg, 0.151 mmol), DIPEA (0.105 mL, 0.603 mmol) and pyrrolidine (0.025 mL, 0.301 mmol) in DMF (4 mL) was added HATU reagent (143 mg, 0.377 mmol). The mixture was stirred for 16 h at RT then partitioned between ethyl acetate and water. The organic phase was collected, washed with water, 1M NaOH, and brine, dried over anhydrous MgSO₄, filtered and concentrated. The residue was purified by Biotage (MeOH/DCM, 0-15%, SNAP 10 g cartridge), then using chromatotron (eluent MeOH/DCM, 5-10%) followed by trituration with a mixture Et₂O/MeOH/Acetone to give title compound **226** (15 mg, 0.029 mmol, 19% yield) ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : OH from carboxylic acid is missing, 9.66 (bs, 1H), 8.98 (dd, *J* = 1.9, 0.9 Hz, 1H), 8.51 (d, *J* = 5.5 Hz, 1H), 8.31 (s, 1H), 8.22 (dd, *J* = 8.1, 1.9 Hz, 1H), 8.17 (dd, *J* = 8.1, 0.9 Hz, 1H), 7.77 (dd, *J* = 13.7, 2.5 Hz, 1H), 7.45 (bs, 1H), 7.37 (t, *J* = 9.1 Hz, 1H), 7.26 (dd, *J* = 8.9, 1.5 Hz, 1H), 6.62 (d, *J* = 5.3, 0.8 Hz, 1H), 2.60-2.52 (m, 1H), 0.69-0.56 (m, 2H), 0.50-0.37 (m, 2H). MS (*m/z*): 465.3 (M+H)





Compounds **227-233** and **235-238** (examples **128-134** and **136-139**) were prepared in one step starting from the acid **225** similarly to compound **226** (example **127**, scheme 54). Compounds **239-241** (examples **140-142**) were obtained by alkaline hydrolysis of compounds **236-238**, respectfully similarly to compound **61** (example **44**, scheme 16).




Table 18. Characterization of compounds **227-241** (examples **128-142**)

Cpd	Ex	Structure	Characterization
227	128	 (R)-1-cyclopropyl-3-(4-(2-(5-(3-(dimethylamino)pyrrolidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.82 (dd, 1H, <i>J</i> ₁ =1.5Hz, <i>J</i> ₂ =5.3Hz), 8.74(s, 1H), 8.59(dd, 1H, <i>J</i> =5.4Hz), 8.50(s, 1H), 8.39(d, 1H, <i>J</i> =8.1Hz), 8.16-8.12(m, 1H), 7.77(dd, 1H, <i>J</i> ₁ =2.3Hz, <i>J</i> ₂ =13.5Hz), 7.42(t, 1H, <i>J</i> =9.1Hz), 7.25-7.23(m, 1H), 6.72(d, 1H, <i>J</i> =5.5Hz), 6.61(d, 1H, <i>J</i> =2.5Hz), 3.82-3.77(m, 0.5Hz), 3.69-3.59(m, 2H), 3.56-3.46(m, 0.5H), 3.32-3.25(m, 1H), 2.84-2.70(m, 1H), 2.60-2.54(m, 1H), 2.36(s, 3H), 2.16(s, 3H), 2.19-2.07(m, 1H), 0.71-0.68(m, 2H), 0.49-0.45(m, 2H). MS: 561.6(MH) ⁺


Cpd	Ex	Structure	Characterization
228	129	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-methylpiperazine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.75(s, 1H), 8.71-8.70(m, 1H), 8.58(d, 1H, J=5.5Hz), 8.49(s, 1H), 8.40(dd, 1H, J1=0.8Hz, J2=8.2Hz), 8.03(dd, 1H, J1=2.2Hz, J2=8.2Hz), 7.77(dd, 1H, J1=2.6Hz, J2=13.7Hz), 7.42(t, 1H, J=9.0Hz), 7.25-7.23(m, 1H), 6.71(d, 1H, J=5.3Hz), 6.61(m, 1H), 3.69(s, br, 2H), 3.45-3.42(m, 2H), 2.61-2.58(m, 1H), 2.42-2.35(m, 4H), 2.24(s, 3H), 0.71-0.61(m, 2H), 0.48-0.45(m, 2H). MS: 547 (MH) ⁺
229	130	 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-(2,5,8,11-tetraoxatridecan-13-yl)nicotinamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.08 (dd, 1H, J=2.1Hz), 8.86 (t, 1H, J=5.7Hz), 8.74 (s, 1H), 8.58 (d, 1H, J=5.2Hz), 8.51 (s, 1H), 8.44 (d, 1H, J=8.2Hz), 8.37 (dd, 1H, J1=2.2Hz, J2=8.8Hz), 7.77 (dd, 1H, J1=2.6Hz, J2=13.7Hz), 7.42 (t, J=9.0Hz), 7.25-7.23 (m, 1H), 6.71 (d, 1H, J=5.3Hz), 6.61-6.60 (m, 1H), 3.62-3.54 (m, 6H), 3.54-3.49 (m, 8H), 3.44-3.42 (m, 2H), 3.25 (s, 3H), 2.60-2.58 (m, 1H), 0.70-0.68 (m, 2H), 0.47-0.46 (m, 2H). MS: 654.3(MH) ⁺
230	131	 1-cyclopropyl-3-(4-(2-(5-(4-(2-(diisopropylamino)ethyl)piperazine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80(s, 1H), 8.71(dd, 1H, J1=0.8Hz, J2=2.2Hz), 8.58(d, 1H, J=5.5Hz), 8.49(s, 1H), 8.39(dd, 1H, J1=0.8Hz, J2=8.2Hz), 8.02(dd, 1H, J1=2.1Hz, J2=8.2Hz), 7.77(dd, 1H, J1=2.6Hz, J2=13.7Hz), 7.42(t, 1H, J=9.0Hz), 7.60-7.23(m, 1H), 6.72(d, 1H, J=4.7Hz), 6.65-6.64(m, 1H), 3.67(s, br, 1H), 3.43-3.41(m, 2H), 3.00-2.97(m, 2H), 2.60-2.57(m, 1H), 2.57-2.54(m, 2H), 2.49-2.45(m, 2H), 2.37-2.33(m, 2H), 1.00-0.98 (m, 12H), 0.71-0.68 (m, 2H), 0.49-0.47 (m, 2H). MS: 660.7 (MH) ⁺

Cpd	Ex	Structure	Characterization
231	132	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(2-morpholinoethyl)piperazine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.82(s, 1H), 8.71(dd, 1H, J ₁ =0.8Hz, J ₂ =2.2Hz), 8.58(d, 1H, J=5.5Hz), 8.49(s, 1H), 8.40(dd, 1H, J ₁ =0.8Hz, J ₂ =8.2Hz), 8.02(dd, 1H, J ₁ =2.1Hz, J ₂ =8.2Hz), 7.77(dd, 1H, J ₁ =2.4Hz, J ₂ =13.5Hz), 7.42(t, 1H, J=9.0Hz), 7.26-7.23(m, 1H), 6.72(d, 1H, J=5.3Hz), 6.68(s, br, 1H), 3.67(d, br, 2H), 3.58(t, 5H, J=4.5Hz), 3.44-3.39(m, 3H), 2.60-2.56(m, 1H), 2.53-2.41(m, 10H), 0.71-0.67(m, 2H), 0.49-0.45(m, 2H). MS: 646.6(MH) ⁺
232	133	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-((1-methylpiperidin-4-yl)methyl)piperazine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.76(s, 1H), 8.71(m, 1H), 8.58(d, 1H, J=5.3Hz), 8.49(s, 1H), 8.39(d, 1H, J=8.0Hz), 8.02(dd, 1H, J ₁ =2.1Hz, J ₂ =8.2Hz), 7.77(dd, 1H, J ₁ =2.4Hz, J ₂ =13.5Hz), 7.42(t, 1H, J=9.0Hz), 7.25-7.23(m, 1H), 6.71(d, 1H, J=5.2Hz), 6.63-6.62(m, 1H), 3.68(s, br, 2H), 3.44-3.39(m, 1H), 2.76-2.74(m, 2H), 2.61-2.57(m, 1H), 2.44-2.37(m, 4H), 2.19-2.15(m, 5H), 1.83(t, 2H, J=10.6Hz), 1.70-1.67(m, 2H), 1.49-1.44(m, 1H), 1.17-1.10(m, 3H), 0.71-0.67(m, 2H), 0.48-0.45(m, 2H). MS: 644.7 (MH) ⁺
233	134	 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-(2-(4-methylpiperazin-1-yl)ethyl)nicotinamide formate salt	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.07(dd, 1H, J=1.6Hz), 8.94(s, 1H), 8.73(t, 1H, J=5.4Hz), 8.58(d, 1H, J=5.5Hz), 8.51(s, 1H), 8.43(d, 1H, J=8.4Hz), 8.35(dd, 1H, J ₁ =2.1Hz, J ₂ =8.4Hz), 8.22(s, 1H), 7.78(dd, 1H, J ₁ =2.4Hz, J ₂ =13.7Hz), 7.42(t, 1H, J=9.0Hz), 7.25(d, 1H, J=8.8Hz), 6.75(d, 1H, J=2.4Hz), 6.71(d, 1H, J=5.3Hz), 3.48-3.43(m, 2H), 2.62-2.59(m, 1H), 2.81-2.53(m, 10H), 2.29(s, 3H), 0.71-0.66(m, 2H), 0.48-0.44(m, 2H). MS: 590.6 (MH) ⁺

Cpd	Ex	Structure	Characterization
235	136	 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-(2-morpholinoethyl)nicotinamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.07-9.06 (m, 1H), 8.75-8.74 (m, 2H), 8.59 (dd, 1H, J=5.4Hz), 8.51 (s, 1H), 8.44 (dd, 1H, J=8.2Hz), 8.35 (dd, 1H, J ₁ =2.2Hz, J ₂ =8.4Hz), 7.77 (dd, 1H, J ₁ =2.4Hz, J ₂ =13.7Hz), 7.42 (t, 1H, J=9.1Hz), 7.25-7.23 (m, 1H), 6.71 (d, 1H, J=5.3Hz), 6.62 (m, 1H), 3.62 (m, 4H), 3.49-3.45 (m, 2H), 2.61-2.53 (m, 1H), 2.47 (m, 4H), 0.71-0.67 (m, 2H), 0.47-0.45 (m, 2H). MS: 577.5 (MH) ⁺
236	137	 ethyl 3-(4-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperazin-1-yl)propanoate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.73 (m, 2H), 8.58 (d, 1H, J=5.4Hz), 8.49 (s, 1H), 8.40 (d, 1H, J=8.2Hz), 8.03 (dd, 1H, J ₁ =2.0Hz, J ₂ =8.2Hz), 7.77 (dd, 1H, J ₁ =2.5Hz, J ₂ =13.5Hz), 7.42 (t, 1H, J=9.0Hz), 7.25-7.23 (m, 1H), 6.72 (d, 1H, J=5.3Hz), 6.61-6.60 (m, 1H), 4.10 (q, 2H), 3.66 (m, br, 2H), 3.42-3.39 (m, 2H), 2.67-2.63 (m, 3H), 2.61-2.57 (m, 2H), 2.51-2.49 (m, 3H), 2.43 (m, br, 2H), 1.22 (t, 3H), 0.71-0.68 (m, 2H), 0.48-0.46 (m, 2H). MS: 633.6 (MH) ⁺
237	138	 ethyl 1-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperidine-3-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.74(s, 1H), 8.71(s, 1H), 8.58(d, 1H, J=5.5Hz), 8.49(s, 1H), 8.40(d, 1H, J=8.2Hz), 8.03(s, br, 1H), 7.77(dd, 1H, J ₁ =2.4Hz, J ₂ =13.5Hz), 7.43(t, 1H, J=9.0Hz), 7.25-7.23(m, 1H), 6.72(d, 1H, J=5.4Hz), 6.61-6.60(m, 1H), 4.50-4.48(m, 0.5Hz), 4.19-4.00(m, 2H), 3.98-3.94(m, 0.5Hz), 3.68-3.66(m, 0.5Hz), 3.50-3.48(m, 0.5Hz), 3.22-3.16(m, 1H), 2.72-2.68(m, 1H), 2.62-2.57(m, 1H), 2.06-2.00(m, 1H), 1.72-1.64(m, 2H), 1.64-1.56(m, 1H), 1.27-1.23(m, 1.5H), 1.20-1.11(m, 1.5H), 0.71-0.67(m, 2H), 0.48-0.45(m, 2H). MS: 604.5 (MH) ⁺
238	139	 butyl 4-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)morpholine-2-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79(s, 1H), 8.74(s, 1H), 8.59(d, 1H, J=5.3Hz), 8.51(s, 1H), 8.43(d, 1H, J=8.2Hz), 8.08-8.04(m, 1H), 7.77(dd, 1H, J ₁ =2.4Hz, J ₂ =13.7Hz), 7.42(t, 1H, J=9.0Hz), 7.26-7.23(m, 1H), 6.72(d, 1H, J=5.3Hz), 6.65-6.64(m, 1H), 4.42-4.35(m, 1.5Hz), 4.22-4.00(m, 2H), 3.96-3.82(m, 1.5H), 3.78-3.44(m, 4H), 2.62-2.56(m, 1H), 1.69-1.44(m, 2H), 1.44-1.18(m, 2H), 0.98-0.78(m, 2H), 0.71-0.64(m, 2H), 0.48-0.44(m, 2H). MS: 634.5(MH) ⁺

Cpd	Ex	Structure	Characterization
239	140	 3-(4-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperazin-1-yl)propanoic acid tetraacetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): one OH carboxylic acid is missing, 9.14 (bs, 1H), 8.67 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 8.54 (d, <i>J</i> = 5.5 Hz, 1H), 8.45 (s, 1H), 8.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.99 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.74 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.22 (bd, <i>J</i> = 8.8 Hz, 1H), 6.97 (bs, 1H), 6.68 (bd, <i>J</i> = 5.5 Hz, 1H), 3.74-3.55 (m, 2H), 2H are hidden by water's peak, 2.66-2.30 (m, 9H), 0.70-0.57 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 605.4 (M+H).
240	141	 1-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperidine-3-carboxylic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.28-9.07(m, 1H), 8.71(s, 1H), 8.60-8.54(m, 1H), 8.48(s, 1H), 8.39(d, 1H, <i>J</i> =8.4Hz), 8.06-8.00(m, 1H), 7.77(d, 1H, <i>J</i> =5.4Hz), 7.40(t, 1H, <i>J</i> =9.0Hz), 7.26-7.20(m, 1H), 7.05-6.85(m, 1H), 6.69(s, 1H), 4.59-4.51(m, 0.4H), 4.08-3.99(m, 0.6Hz), 3.70-3.62(m, 1H), 3.58-3.51(m, 1H), 3.08-2.98(m, 1H), 2.61-2.57(m, 1H), 2.10-1.97(m, 1H), 1.78-1.64(m, 2H), 1.64-1.52(m, 1H), 1.39-1.27(m, 1H), 0.68-0.67(m, 2H), 0.48-0.44(m, 2H). MS: 576.4 (MH)+
241	142	 4-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)morpholine-2-carboxylic acid	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.10-8.98(m, 1H), 8.76(s, 1H), 8.60-8.52(m, 1H), 8.49(s, 1H), 8.41(d, 1H, <i>J</i> =8.2Hz), 8.10-8.03(m, 1H), 7.77(d, 1H, <i>J</i> =5.4Hz), 7.40(t, 1H, <i>J</i> =9.0Hz), 7.26-7.20(m, 1H), 7.05-6.82(m, 1H), 6.69(s, 1H), 4.55-4.40(m, 0.7H), 4.20-4.12(m, 1.3Hz), 4.00-3.84(m, 2H), 3.70-3.60(m, 2H), 3.60-3.50(m, 1H), 2.61-2.57(m, 1H), 0.68-0.67(m, 2H), 0.48-0.44(m, 2H). MS: 578.1 (MH)+

Scheme 55

Example 143

5 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-methyl-N-((2R,3S,4S,5S)-2,3,4,5,6-pentahydroxyhexyl)nicotinamide (244)

Step 1: (2R,3S,4S,5S)-2,3,4,5,6-pentakis(tert-butyldimethylsilyloxy)-N-methylhexan-1-amine (242)

10 To a solution of N-methyl-D-glucamine (0.5 g, 2.56 mmol) in acetonitrile (25.6 mL) at 0°C was added TBDMSCl (1.930 g, 12.81 mmol) and DBU (1.930 mL, 12.81 mmol). The reaction mixture was stirred for 20 min at 0°C before it was warmed up to room temperature then stirred overnight. MS showed a mixture of tri- and tetra-TBDMS protected compounds. The reaction mixture was concentrated and the residue was partitioned between EtOAc/H₂O, the
 15 organic phase was collected, washed with water, 1N HCl solution and brine, dried and concentrated to give title compound **242** (1.53 g, 2.346 mmol, 92 % yield) as a yellowish syrup that was used as is. MS: 538.6, 652.7.

Step 2: 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-methyl-N-((2R,3S,4S,5S)-2,3,4,5,6-pentakis(tert-butyldimethylsilyloxy)hexyl)nicotinamide (243)


20 To a solution of acid **225** (220 mg, 0.474 mmol, scheme 54), amine **242** (309 mg, 0.474 mmol) and DIPEA (0.331 mL, 1.895 mmol) in DMF (5mL) was added HATU reagent (270 mg, 0.710 mmol). The mixture was stirred overnight at room temperature then partitioned between

ethyl acetate and water. The organic layer was collected, washed with water, 1M NaOH, and brine, dried over anhydrous MgSO_4 , filtered and concentrated. The residue was purified by Biotage (MeOH/DCM, 0-15%, SNAP 10g cartridge) to afford title compound **243** (250 mg, 0.254 mmol, 54 % yield) as a white solid. MS: 985.4 (MH⁺).

Step 3: 6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-N-methyl-N-((2R,3S,4S,5S)-2,3,4,5,6-pentahydroxyhexyl)nicotinamide (244)

To a solution of **243** (250 mg, 0.228 mmol) in THF (5 mL) was added TBAF (1.0M in THF) (0.273 mL, 0.273 mmol) and the reaction mixture was stirred for 2 hr at RT before concentration. The residue was purified by Biotage, (MeOH/DCM, 20-50%, SNAP 25 g cartridge) and Gilson (Phenomenex, Luna, 15 μ , C18(2) 100A, 250 x 50.00 mm, 15 μ m, 0.05% of formic acid in both MeOH/H₂O, 40-90%, flow = 30 mL/min), to afford title compound **244** (10 mg, 0.016 mmol, 7 % yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.72 (d, 1H, J=3.9Hz), 8.47 (s, br, 1H), 8.19-8.13 (m, 2H), 8.13-8.00 (m, 1H), 7.65 (dd, 1H, J1=2.5Hz, J2=13.1Hz), 7.29 (t, 1H, J=8.8Hz), 7.20-7.17 (m, 1H), 6.64 (d, 1H, J=5.3Hz), 4.20-4.18 (m, 0.45H), 4.07-4.04 (m, 0.55H), 3.83-3.53 (m, 7H), 3.17 (s, 3H), 2.62-2.57 (m, 1H), 0.78-0.73 (m, 2H), 0.54-0.50 (m, 2H). MS: 642.6(MH⁺).

Scheme 56



Example 144

1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-methoxyethylamino)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (247)


Step 1. tert-butyl 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridine-2-yl)-1*H*-pyrazol-1-yl)ethyl(2-methoxyethyl)carbamate (**246**)

To a stirred solution of tert-butyl 2-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-1*H*-pyrazol-1-yl)ethyl(2-methoxyethyl)carbamate (**245**, 1.22 g, 2.312 mmol) and pyridine (374 μ L, 4.62 mmol) in DMF (30 mL) at 0°C was added phenyl chloroformate (348 μ L, 2.77 mmol) and the reaction mixture was stirred for 30 min. Cyclopropylamine (407 μ L, 5.78 mmol) was added at 0°C and the reaction mixture was heated at 60°C for an additional 30 min. After cooling to RT, the reaction mixture was quenched by addition of water and a saturated solution of ammonium chloride, and extracted with AcOEt. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV). The desired fractions were collected and concentrated to afford the title compound **246** (722 mg, 0.18 mmol, 61% yield) as a yellow solid. MS (*m/z*): 611.63 (M+H).

Step 2. 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-methoxyethylamino)ethyl)-1*H*-pyrazol-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (**247**)

To a solution of **246** (722 mg, 0.18 mmol) in DCM (30 mL) was added TFA (7 mL) and the reaction mixture was stirred for 45 min. The reaction mixture was concentrated, diluted with water and 4M NaOH to pH 11 and extracted with AcOEt. The extract was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 50 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 15/85 over 20 CV), to produce a material that upon trituration with AcOEt. afforded the title compound **247** (3.15 mg, 0.617 mmol, 52% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.71 (s, 1H), 8.44 (d, *J* = 5.6 Hz, 1H), 8.33 (s, 1H), 8.01 (d, *J* = 0.8 Hz, 1H), 7.72 (d, *J* = 2.4 and 13.6 Hz, 1H), 7.68 (s, 1H), 7.35 (t, *J* = 9.2 Hz, 1H), 7.22-7.16 (m, 1H), 6.57 (d, *J* = 2.4 Hz, 1H), 6.53 (d, *J* = 5.6 Hz, 1H), 4.21 (t, *J* = 6.0 Hz, 2H), 3.36 (t, *J* = 5.6 Hz, 2H), 2.98 (s, 3H), 2.97 (t, *J* = 6.0 Hz, 2H), 2.68 (t, *J* = 5.6 Hz, 2H), 2.59-2.50 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (*m/z*): 511.54 (M+H).

Scheme 57



Example 145

5 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-methoxyethylamino)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (253)

Step 1. 2-(4-iodo-1H-imidazol-1-yl)-N-(2-methoxyethyl)ethanamine (248)

To a stirred solution of 4-iodoimidazole (8.8 g, 45.4 mmol) in THF (200 mL) at 0°C under nitrogen was added portion-wise NaH 60% (1.99 g, 49.9 mmol). After 15 min, 1-bromo-2-chloroethane (4.53 mL, 54.4 mmol) was added at 0°C . The reaction mixture was heated at 60°C for 20h. After cooling to RT, the reaction mixture was diluted with water and extracted with AcOEt. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 340 g cartridge; MeOH/AcOEt: 0/100 to 5/95 over 20 CV), to afford crude 1-(2-chloroethyl)-4-iodo-1H-imidazole not shown in the scheme 57 (7 g, 27.26 mmol, 60% yield) as colorless oil. MS (m/z): 256.83 (M+H).

To a stirred solution of crude 1-(2-chloroethyl)-4-iodo-1H-imidazole (7 g, 27.26 mmol) in DMSO (20 mL) was added 2-methoxyethylamine (7.75 mL, 89 mmol). The reaction mixture was heated at 60°C for 20h. After cooling to RT, the reaction mixture was diluted with water and extracted with AcOEt. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 340 g cartridge; MeOH/AcOEt: 0/100 to 13/87 over 20 CV), to afford the title compound **248** (2.64 g, 8.94 mmol, 60% yield) as colorless oil. MS (m/z): 296.12 (M+H).

Step 2. tert-butyl 2-(4-iodo-1H-imidazol-1-yl)ethyl(2-methoxyethyl)carbamate (**249**)

To a stirred solution of **248** (2.64 g, 8.94 mmol) in DCM (30 mL) was added di-tert-butyl dicarbonate (2.75 g, 12.60 mmol). The reaction mixture was stirred at RT for 18 h and concentrated. The residue was purified by Biotage (SNAP 100 g cartridge; AcOEt/Hexane: 20/80 to 100/0 over 20 CV), to afford the title compound **249** (2.16 g, 5.47 mmol, 56% yield) as light yellow oil. MS (m/z): 396.07 (M+H).

Step 3. tert-butyl 2-(4-(7-chlorothieno[3,2-*b*]pyridin-2-yl)-1H-imidazol-1-yl)ethyl(2-methoxyethyl)carbamate (**250**)

To a stirred solution of 7-chlorothieno[3,2-*b*]pyridine (1.39 g, 8.20 mmol) in THF (30 mL) at -15°C was added n-BuLi (3.28 mL, 8.20 mmol). After 30 min, ZnCl₂ (1.12 g, 8.20 mmol) was added at -15°C and the reaction mixture was allowed to warm to RT over 45 min. A solution of palladium tetrakis(triphenylphosphine) (0.126 g, 0.11 mmol) and iodide **249** (2.16 g, 5.47 mmol) in THF (10 mL) was added and the mixture was heated to reflux for 45 min then concentrated. The reaction mixture was diluted with water and ammonium hydroxide and extracted with DCM. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 340 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **250** (2.37 g, 5.43 mmol, 99% yield) as light brown solid. MS (m/z): 437.45 (M+H).

Step 4. tert-butyl 2-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-1H-imidazol-1-yl)ethyl(2-methoxyethyl)carbamate (**251**)

To a stirred solution of 4-amino-2-fluorophenol hydrochloride (1.96 g, 11.96 mmol) in NMP (15 mL) was added t-BuOK (2.93 g, 26.1 mmol). After 30 min, chloride **250** (4.75 g, 10.87 mmol) was added and the reaction mixture was heated at 100°C for 2h.

In a separate flask a solution of 4-amino-2-fluorophenol HCl (1.96 g, 11.96 mmol) in NMP (15 mL) was treated with t-BuOK (2.93 g, 26.1 mmol) and the resultant phenolate solution was added to the original reaction mixture at 100°C. After 30 min, the reaction was quenched by addition of water and the mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue

was purified by Biotage (SNAP 80 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **251** (1.2 g, 2.27 mmol, 21% yield) as light brown solid. MS (m/z): 528.64 (M+H).

Step 5. tert-butyl 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-

5 b]pyridin-2-yl)-1*H*-imidazol-1-yl)ethyl(2-methoxyethyl)carbamate (**252**)




To a stirred solution of amine **251** (1.2 g, 2.27 mmol) and pyridine (368 μ L, 4.55 mmol) in DMF (11 mL) at 0°C was added phenyl chloroformate (342 μ L, 2.73 mmol) and the reaction mixture was stirred for 30 min. Cyclopropylamine (401 μ L, 5.69 mmol) was added at 0°C and the reaction mixture was heated at 60°C for 45 min. After cooling to RT, the reaction mixture
10 was diluted with water and a saturated solution of ammonium chloride and extracted with AcOEt. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **252** (1 g, 1.63 mmol, 72% yield) as a beige solid. MS (m/z): 611.70 (M+H).


15 Step 6. 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-methoxyethylamino)ethyl)-1*H*-imidazol-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (**253**)

To a solution of **252** (1 g, 1.63 mmol) in DCM (50 mL) was added TFA (15 mL) and the reaction mixture was stirred for 1.5 h then concentrated, diluted with water and 4M NaOH to pH 11 and extracted with DCM/MeOH. The extract was washed with water, brine, dried over
20 anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **253** (800 mg, 1.56 mmol, 96% yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.69(s, 1H), 8.42(d, *J* = 5.6 Hz, 1H), 7.91(d, *J* = 1.2 Hz, 1H), 7.75(d, *J* = 0.8 Hz, 1H), 7.72(dd, *J* = 2.4 and 13.6 Hz, 1H), 7.66(s, 1H), 7.36(t, *J* = 8.8 Hz, 1H), 7.21-7.16(m, 1H), 6.57(d, *J* = 2.85 Hz, 1H), 6.54(d, *J* = 5.6 Hz, 1H), 4.06(t, *J* = 6.4 Hz, 2H), 3.36(t, *J* = 5.6 Hz, 2H), 3.22(s, 3H), 2.89(t, *J* = 6.4 Hz, 2H), 2.67 (t, *J* = 5.6 Hz, 2H), 2.58-2.53 (m, 1H), 0.68-0.61 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 511.56 (M+H).

Compound **254** (example 146) was synthesized starting from compound **247** (scheme
30 56) and following a procedure similar to that described above for the synthesis of compound **114** (example 79, scheme 29). Compound **254-A** (example 146-A) was synthesized starting from compound **253** (scheme 57) and following a procedure similar to the described above for the synthesis of compound **114** (example 79, scheme 29).. Compounds **255** - **256** (examples 147 – 148) were prepared in one step by reacting the corresponding secondary amine precursors
35 **247** (scheme 56) and **253** (scheme 57) with ethyl isocyanate.


Table 19. Characterization of compounds **254** - **256** (examples **146** -**148**)




Cpd	Ex.	Structure	Characterization
254	146	 N-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridine-2-yl)-1H-pyrazol-1-yl)ethyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm) : mixture of rotamers, 8.69 (s, 1H), 8.44 (dd, J = 2.0 and 5.6 Hz, 1H), 8.34 and 8.31 (s, 1H), 8.09 and 8.04 (s, 1H), 7.72 (dd, J = 2.0 and 13.6 Hz, 1H), 7.70 (s, 1H), 7.35 (t, J = 9.2 Hz, 1H), 7.22-7.16 (m, 1H), 6.57 (d, J = 2.8 Hz, 1H), 6.54 (t, J = 4.8 Hz, 1H), 4.36 and 4.26 (t, J = 5.6 Hz, 2H), 3.75 and 3.67 (t, J = 5.6 Hz, 2H), 3.43-3.20 (m, 4H), 3.25 and 3.22 (s, 3H), 2.59-2.50 (m, 1H), 2.01 and 1.72 (s, 3H), 0.68-0.62 (m, 2H), 0.45-0.41 (m, 2H). MS (m/z): 553.3 (M+H).
254-A	146-A	 N-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridine-2-yl)-1H-imidazol-1-yl)ethyl)-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): mixture of rotamers, 8.79 (s, 1H), 8.46-8.41 (m, 1H), 7.92 (dd, J = 8.5, 1.1 Hz, 1H), 7.79-7.65 (m, 3H), 7.35 (t, J = 9.1 Hz, 1H), 7.19 (bd, J = 9.0 Hz, 1H), 6.68-6.61 (m, 1H), 6.58-6.53 (m, 1H), 4.24 and 4.14 (2t, J = 6.2 Hz, 2H), 3.69 and 3.62 (2t, J = 6.3 Hz, 2H), 3.41 (bs, 2H), one CH ₂ is masked by water, 3.25 and 3.24 (2s, 3H), 2.59-2.51 (m, 1H), 2.03 and 1.74 (2s, 3H), 0.71-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 553.6 (M+H).
255	147	 N-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridine-2-yl)-1H-pyrazol-1-yl)ethyl)-N-(1-ethyl)-N-[3-(2-methoxyethyl)]urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm) : 8.74 (s, 1H), 8.44 (d, J = 5.4 Hz, 1H), 8.29 (s, 1H), 8.05 (s, 1H), 7.76-7.68 (m, 1H), 7.69 (s, 1H), 7.35 (t, J = 8.8 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.61 (bs, 1H), 6.54 (d, J = 5.6 Hz, 1H), 6.21 (t, J = 4.8 Hz, 1H), 4.24 (t, J = 6.0 Hz, 2H), 3.36 (t, J = 6.0 Hz, 2H), 3.28 (t, J = 5.6 Hz, 2H), 3.21 (s, 3H), 3.02 (quint, J = 6.4 Hz, 2H), 2.59-2.50 (m, 1H), 0.98 (t, J = 7.2 Hz, 2H), 0.69-0.61 (m, 2H), 0.46-0.39 (m, 2H). MS (m/z): 582.6 (M+H).

Cpd	Ex.	Structure	Characterization
256	148	 <i>N</i>-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)-1<i>H</i>-imidazol-1-yl)ethyl)-<i>N</i>-(1-ethyl)-<i>N</i>-[3-(2-methoxyethyl)]urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.74 (s, 1H), 8.43 (d, <i>J</i> = 5.6 Hz, 1H), 7.88 (d, <i>J</i> = 1.2 Hz, 1H), 7.72 (dd, <i>J</i> = 2.0 and 13.6 Hz, 1H), 7.71 (s, 1H), 7.66 (s, 1H), 7.35 (t, <i>J</i> = 8.8 Hz, 1H), 7.22-7.18 (m, 1H), 6.61 (d, <i>J</i> = 2.4 Hz, 1H), 6.55 (d, <i>J</i> = 5.6 Hz, 1H), 6.29 (t, <i>J</i> = 5.2 Hz, 1H), 4.12 (t, <i>J</i> = 6.4 Hz, 2H), 3.57 (t, <i>J</i> = 6.8 Hz, 2H), 3.31 (t, <i>J</i> = 4.8 Hz, 2H), 3.23 (t, <i>J</i> = 4.8 Hz, 2H), 3.22 (s, 3H), 3.06-2.99 (m, 2H), 2.60-2.51 (m, 1H), 0.98 (t, <i>J</i> = 7.2 Hz, 3H), 0.70-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 582.4 (M+H).


Compounds **257** - **259** (examples **149** - **151**) were prepared in two steps from the corresponding secondary amine precursors **247** (scheme 56), **253** (scheme 57) and **171** (Table 16); and acetoxyacetic acid similarly to compound **31** (example 17, scheme 13). Compound **259-A** (example **151-A**) was prepared from the amine precursor **25** (scheme 11) by following the procedure shown above for the synthesis of compound **115-A** (example 80-A, scheme 29).

Table 20. Characterization of compounds **257** -**259** (examples **149** - **151**)

Cpd	Ex	Structure	Characterization
257	149	 <i>N</i>-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-<i>b</i>]pyridin-2-yl)-1<i>H</i>-pyrazol-1-yl)ethyl)-2-hydroxy-<i>N</i>-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.74 (s, 1H), 8.44 (dd, <i>J</i> = 1.6 and 5.6 Hz, 1H), 8.33 and 8.31 (s, 1H), 8.09 and 8.04 (s, 1H), 7.72 (dd, <i>J</i> = 2.0 and 13.6 Hz, 1H), 7.70 (s, 1H), 7.35 (t, <i>J</i> = 9.2 Hz, 1H), 7.22-7.16 (m, 1H), 6.60 (d, <i>J</i> = 2.0 Hz, 1H), 6.54 (t, <i>J</i> = 5.2 Hz, 1H), 4.51 and 4.46 (t, <i>J</i> = 5.6 Hz, 1H), 4.36 and 4.30 (t, <i>J</i> = 6.0 Hz, 2H), 4.11 and 3.80 (d, <i>J</i> = 5.6 Hz, 2H), 3.72 and 3.69 (t, <i>J</i> = 6.0 Hz, 2H), 3.48-3.13 (m, 4H), 3.25 and 3.21 (s, 3H), 2.59-2.50 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (<i>m/z</i>): 569.2 (M+H).

Cpd	Ex	Structure	Characterization
258	150	 N-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-imidazol-1-yl)ethyl)-2-hydroxy-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.80 (s, 1H), 8.43 (dd, <i>J</i> = 2.0 and 5.6 Hz, 1H), 7.92 (dd, <i>J</i> = 1.2 and 8.8 Hz, 1H), 7.78-7.65 (m, 3H), 7.35 (t, <i>J</i> = 9.2 Hz, 1H), 7.22-7.17 (m, 1H), 6.65 (d, <i>J</i> = 2.4 Hz, 1H), 6.55 (dd, <i>J</i> = 1.6 and 5.2 Hz, 1H), 4.55-4.51 (m, 1H), 4.24 and 4.18 (2t, <i>J</i> = 6.0 Hz, 2H), 4.13 and 3.84 (2d, <i>J</i> = 5.6 Hz, 2H), 3.67 and 3.62 (2t, <i>J</i> = 6.0 Hz, 2H), 3.46-3.23 (m, 4H), 3.26 and 3.22 (2s, 3H), 2.58-2.52 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 569.5 (M+H).
259	151	 N-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-N-(2,5,8,11-tetraoxatridecan-13-yl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.80 (s, 1H), 8.56-8.50 (m, 2H), 8.38 and 8.35 (s, 1H), 8.29 and 8.24 (d, <i>J</i> = 8.4 Hz, 1H), 8.02 (t, <i>J</i> = 8.4 Hz, 1H), 7.82 and 7.79 (dd, <i>J</i> = 3.2 and 8.0 Hz, 1H), 7.31-7.25 (m, 1H), 6.98 (d, <i>J</i> = 3.2 Hz, 1H), 6.76-6.75 (d, <i>J</i> = 5.6 Hz, 1H), 4.79 and 4.60 (t, <i>J</i> = 5.6 Hz, 1H), 4.66 and 4.65 (s, 2H), 4.25 and 4.15 (d, <i>J</i> = 5.2 Hz, 2H), 3.58-3.37 (m, 17H), 3.21 and 3.20 (s, 3H), 2.60-2.54 (m, 1H), 0.68-0.63 (m, 2H), 0.44-0.40 (m, 2H). MS (m/z): 716.2 (M+H).
259-A	151-A	 N-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)-2-hydroxy-N-(2-methoxyethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : mixture of rotamers, 8.57-8.51 (m, 2H), 8.48 (bs, 1H), 8.38 and 8.35 (2s, 1H), 8.30 and 8.25 (2d, <i>J</i> = 8.0 Hz, 1H), 8.03 (bt, <i>J</i> = 7.7 Hz, 1H), 7.84-7.76 (m, 1H), 7.29 (td, <i>J</i> = 8.9, 1.8 Hz, 1H), 6.88 (bd, <i>J</i> = 2.9 Hz, 1H), 6.79-6.74 (m, 1H), 4.82-4.60 (m, 3H), 4.23 and 4.13 (2d, <i>J</i> = 5.8 Hz, 2H), 3.51-3.39 (m, 4H), 3.23 and 3.21 (2s, 3H), 2.61-2.52 (m, 1H), 0.73-0.59 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 584.4 (M+H).

Scheme 58



Example 153

- 5 1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (266)

Step 1. 1-(2,2-diethoxyethyl)-4-iodo-1H-imidazole (260)

To a stirred solution of 4-iodoimidazole (10 g, 51.6 mmol) and bromoacetaldehyde diethyl acetal (9.31 mL) in DMSO (30 mL) was added K_2CO_3 (10.69 g, 77 mmol). The reaction mixture was heated at 110°C for 16h. After cooling to RT, the reaction mixture was diluted with water and extracted with AcOEt. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; AcOEt/Hex: 0/100 to 50/50 over 20 CV). The desired fractions were collected and concentrated to afford title compound 260 (11.29 g, 36.4 mmol, 71% yield) as yellow oil. MS (m/z): 310.97 (M+H).

Step 2. 7-chloro-2-(1-(2,2-diethoxyethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridine (261)

To a stirred solution of 7-chlorothieno[3,2-*b*]pyridine (9.26 g, 54.6 mmol) in THF (88 mL) at -15°C was added *n*-BuLi (21.84 mL, 54.6 mmol). After 30 min, a solution of ZnCl₂ 0.5M in THF (109 mL, 54.6 mmol) was added at -15°C and the reaction mixture was warmed to RT over 45 min. A solution of palladium tetrakis(triphenylphosphine) (0.841 g, 0.73 mmol) and iodide **260** (11.29 g, 36.4 mmol) in THF (33 mL) was added and the mixture was heated to reflux for 3h then concentrated. The residue was diluted with water and ammonium hydroxide and extracted with DCM. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; AcOEt/Hex: 0/100 to 100/0 over 20 CV) to produce a material that upon trituration with MTBE afforded the title compound **261** (1.2 g, 3.41 mmol, 9% yield) as light-brown solid. MS (m/z): 437.45 (M+H).

Step 3. 4-(2-(1-(2,2-diethoxyethyl)-1*H*-imidazol-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluoroaniline (**262**)

To a stirred solution of 4-amino-2-fluorophenol hydrochloride (1.39 g, 8.53 mmol) in DMSO (20 mL) was added *t*-BuOK (1.99 g, 17.76 mmol). After 30 min, chloride **261** (2.5 g, 7.11 mmol) was added and the reaction mixture was heated at 100°C for 1h.

In a separate flask a solution of 4-amino-2-fluorophenol hydrochloride (1.39 g, 8.53 mmol) in DMSO (20 mL) was treated with *t*-BuOK (1.99 g, 17.76 mmol) and the resultant phenolate solution was added to the original reaction mixture at 100°C. After 30 min, the mixture was poured into water (300 mL) to form a precipitate that was collected by filtration and dried under high vacuum to afford the title compound **262** (2.86 g, 6.46 mmol, 91% yield) as light brown solid. MS (m/z): 443.44 (M+H).

Step 4. 1-cyclopropyl-3-(4-(2-(1-(2,2-diethoxyethyl)-1*H*-imidazol-4-yl)thieno[3,2-*b*]pyridine-7-yloxy)-3-fluorophenyl)urea (**263**)

To a stirred solution of amine **262** (2.86 g, 6.46 mmol) and pyridine (1.04 mL, 12.93 mmol) in DMF (50 mL) at 0°C was added phenyl chloroformate (973 µl, 7.76 mmol). After 30 min, cyclopropylamine (1.14 mL, 16.16 mmol) was added at 0°C and the reaction mixture was heated at 60°C for 45 min. More cyclopropylamine (1 mL, 14.18 mmol) was added and the reaction mixture was heated at 60°C for an additional 10 min. After cooling to RT, the reaction mixture was quenched by addition of water to form a precipitate. The solid was collected by filtration, washed with water and dried under vacuum for 2h. The residue was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV). The desired fractions were collected, concentrated, triturated with MTBE and dried under high vacuum to afford the title compound **263** (2.95 g, 5.61 mmol, 87% yield) as a pink solid. MS (m/z): 526.60 (M+H).

Step 5. 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-oxoethyl)-1*H*-imidazol-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (264)

To a solution of acetal **263** (2.95 g, 5.61 mmol) in AcOH/H₂O (20/20 mL) was added concentrated HCl (2 mL) and the reaction mixture was heated at 90°C for 1 h. The reaction mixture was concentrated, diluted with water and 4M NaOH to pH 10 to form a precipitate that was collected by filtration, washed with water and dried under vacuum. The material was then purified by Biotage (SNAP 100 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 15/85, over 20 CV) to afford the title compound **264** (1.2 g, 2.66 mmol, 47% yield) as a brown solid. MS (m/z): 484.51 (M+H).


Step 6. 1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1*H*-imidazol-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (266)

To a solution of **264** (300 mg, 0.66 mmol), N-methylpiperazine (74 µl, 0.66 mmol) and AcOH (76 µl, 1.33 mmol) in NMP (10 mL) was added sodium triacetoxyborohydride (422 mg, 1.99 mmol) and the reaction mixture was stirred for 2.5 days at RT. The reaction mixture was quenched with saturated sodium bicarbonate solution and extracted with DCM. The organic extract was successively washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 40 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 15/85 over 20 CV) and by Gilson (Phenomenex, Luna 15µ, C18(2) 100A, 250 x 50.0 mm, 15µm; 0.05% of formic acid in both MeOH/water : 20/80 to 95/5 over 60 min, flow; 30 mL/min) to afford the title compound **266** (180 mg, 0.33 mmol, 51 % yield, di-formate salt) as a white solid.


¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.42 (bs, 1H), 8.41 (d, *J* = 5.6 Hz, 1H), 8.29 (bs, 2H), 7.90 (d, *J* = 0.8 Hz, 1H), 7.76 (d, *J* = 1.2 Hz, 1H), 7.73 (dd, *J* = 2.4 and 13.6 Hz, 1H), 7.65 (s, 1H), 7.33 (t, *J* = 8.8 Hz, 1H), 7.23 (bs, 1H), 7.23-7.19 (m, 1H), 6.54 (d, *J* = 5.6 Hz, 1H), 4.13 (t, *J* = 6.0 Hz, 2H), 2.66 (t, *J* = 6.4 Hz, 2H), 2.57-2.52 (m, 1H), 2.50-2.25 (m, 8H), 2.19 (s, 3H), 0.65-0.60 (m, 2H), 0.44-0.39 (m, 2H). MS (m/z): 536.3 (M+1).

Compound **267** was prepared from the aldehyde **264** similarly to compound **169** (example **102**, scheme 41).

Table 21. Characterization of compound **267** (example **154**)

Cpd	Ex.	Structure	Characterization
267	154	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 9.36 (s, 1H), 8.42 (d, <i>J</i> = 5.6 Hz, 1H), 8.38 (bs, 1H), 7.91 (d, <i>J</i> = 0.8 Hz, 1H), 7.75 (d, <i>J</i> = 0.8 Hz, 1H), 7.73 (dd, <i>J</i> = 2.4 and 13.6 Hz, 1H), 7.67 (s, 1H), 7.33 (t, <i>J</i> = 9.2 Hz, 1H), 7.24-7.19 (m, 1H), 7.16 (bs, 1H), 6.55 (d, <i>J</i> = 5.6 Hz, 1H), 4.17 (t, <i>J</i> = 5.6 Hz, 2H), 3.59-3.52 (m, 2H), 3.24 (t, <i>J</i> = 7.2 Hz, 2H), 2.57-2.52 (m, 1H), 2.17 (t, <i>J</i> = 8.0 Hz, 2H), 1.89 (quin, <i>J</i> = 7.6 Hz, 2H), 0.65-0.60 (m, 2H), 0.44-0.40 (m, 2H). MS (<i>m/z</i>): 521.5 (M+1).

Scheme 59



5

Example **155**

1-Cyclopropyl-3-(3-fluoro-4-(2-(1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**271-A**)

Step 1: 3-Fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)aniline (**268**)

To a solution of 4-amino-2-fluorophenol (1.83 g, 14.38 mmol) in DMSO (30 mL) was added potassium *tert*-butoxide (1.61 g, 14.38 mmol). After 15 min, 7-chloro-2-iodothieno[3,2-b]pyridine (2.5 g, 8.46 mmol, Ragan J. A. *et al*, Organic Process Research and Development,

10

2003, 7, 676-683) was added and the reaction mixture was heated at 100°C for 60 min. The mixture was cooled down to RT then poured into water (250 mL) at 40-45°C and stirred for 30 min. The precipitate was collected by filtration, washed with water, dried and purified by flash column chromatography on silica gel (eluent 60% EtOAc in Hexane) to afford title compound **268** (1.06 g, 32% yield) as a brown solid. ¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.41 (d, J = 5.4 Hz, 1H), 7.75 (s, 1H), 7.03 (t, J = 9.0 Hz, 1H), 6.57-6.45 (m, 3H), 3.83 (s, 2H).

Step 2: 1-Cyclopropyl-3-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)urea (269)

To a solution of amine **268** (1.7 g, 3.98 mmol) in DMF (7 mL) was added pyridine (0.55 mL, 6.77 mmol) at RT and the resultant solution was stirred for 10 min under Ar atmosphere. Phenyl chloroformate (0.75 mL, 5.97 mmol) was added at 0°C and the mixture was stirred at RT for 40 min. Cyclopropylamine (1.1 mL, 15.9 mmol) was added to the mixture, and the reaction mixture was warmed to 50°C and stirred for 2 hours. The mixture was then cooled to RT then poured into water (150 mL) and stirred for 30 min. The precipitate was collected by filtration, washed with water and dried. The crude product was triturated with EtOAc to afford title compound **269** (1.75 g, 86% yield) as a pale-violet solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.70 (br, 1H), 8.45 (d, J = 5.4 Hz, 1H), 7.91 (s, 1H), 7.72 (dd, J = 13.5, 2.4 Hz, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.23 (m, 1H), 6.62 (d, J = 5.4 Hz, 1H), 6.56 (br, 1H), 2.60-2.40 (m, 1H), 0.70-0.60 (m, 2H), 0.48-0.35 (m, 2H).

Step 3: tert-Butyl 4-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (270)

Iodide **269** (2 g, 4.26 mmol), 1-N-Boc-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine (1.85 g, 5.96 mmol), NaHCO₃ (1.1 g, 12.8 mmol) and tetrakis(triphenylphosphine)palladium (0.49 g, 0.43 mmol) were suspended in a mixture of DME/water (80 mL/16 mL). The mixture was degassed with an Ar flow, heated at 80°C and stirred for 16 hours. The mixture was then cooled and filtered through a pad of Celite and washed with EtOAc. The filtrate was diluted with water and extracted with EtOAc. The extract was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated. The residue was purified by flash chromatography on silica gel (eluent 3% MeOH in DCM) to afford title compound **270** (1.7 g, 78% yield) as a white solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.73 (s, 1H), 8.45 (d, J = 5.4 Hz, 1H), 7.72 (dd, J = 13.5, 2.4 Hz, 1H), 7.55 (s, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.24-7.16 (m, 1H), 6.60 (br, 1H), 6.57 (d, J = 5.4 Hz, 1H), 6.40 (br, 1H), 4.15-4.00 (m, 2H), 3.63-3.54 (m, 2H), 2.70-2.40 (m, 3H), 1.44 (s, 9H), 0.70-0.60 (m, 2H), 0.48-0.35 (m, 2H).


Step 4: 1-Cyclopropyl-3-(3-fluoro-4-(2-(1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea di-hydrochloride salt (**271**)

To a suspension of **270** (996 mg, 1.90 mmol) in EtOAc (20 mL) was added 1N HCl-EtOAc (11.4 mL, 11.4 mmol). The reaction mixture was stirred for 18 hours, the precipitate was collected by filtration, washed with EtOAc (30 mL) and dried to afford title compound **271** (962 mg, 100% yield) as a pale yellow solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 9.22 (br, 2H), 9.03 (s, 1H), 8.58 (d, J = 6.0 Hz, 1H), 7.74 (dd, J = 13.5, 2.7 Hz, 1H), 7.70 (s, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.25-7.15 (m, 1H), 6.77 (d, J = 6.0 Hz, 1H), 6.72 (s, 1H), 6.47 (s, 1H), 4.80-4.30 (br, 1H), 3.85-3.75 (m, 2H), 3.42-3.31 (m, 2H), 2.90-2.80 (m, 2H), 2.60-2.40 (m, 1H), 0.70-0.60 (m, 2H), 0.48-0.35 (m, 2H).

Step 5: 1-Cyclopropyl-3-(3-fluoro-4-(2-(1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**271-A**)

To a stirred solution of the dihydrochloride **271** (150 mg, 0.302 mmol) in EtOAc (50 mL) was added a saturated solution of NaHCO₃ (50 mL). The reaction mixture was stirred for 1h to give a suspension. The solid was collected by filtration, rinsed with water, dried under vacuum and purified by Biotage (SNAP 25 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 15/85 over 20 CV) to produce a material that upon trituration with AcOEt afforded the title compound **271-A** (45 mg, 0.106 mmol, 35% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ(ppm): 8.75 (s, 1H), 8.43 (d, J = 5.6 Hz, 1H), 7.71 (dd, J = 2.0 and 13.6 Hz, 1H), 7.47 (s, 1H), 7.34 (t, J = 9.2 Hz, 1H), 7.23-7.16 (m, 1H), 6.62 (s, 1H), 6.55 (d, J = 5.6 Hz, 1H), 6.43 (s, 1H), 3.40 (bs, 2H), 2.93 (t, J = 5.6 Hz, 2H), 2.59-2.50 (m, 1H), 2.46 (bs, 2H), 0.66-0.62 (m, 2H), 0.44-0.40 (m, 2H). MS (m/z): 425.42 (M+H)

Scheme 60

**273: Example 156**

Example 156

4-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-5,6-dihydropyridin-1(2*H*)-yl)-4-oxobutanoic acid (273)

5 Step 1. Methyl 4-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-5,6-dihydropyridin-1(2*H*)-yl)-4-oxobutanoate (272)


To a stirred suspension of **271** (150 mg, 0.302 mmol) and DIPEA (123 μ L, 0.707 mmol) in DMF (10 mL) was added methyl succinyl chloride (65 μ L, 0.53 mmol). The reaction mixture was stirred at RT for 2.5 days. Water was added and the reaction mixture was extracted with
10 DCM. The organic layer was successively washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **272** (120 mg, 0.223 mmol, 63% yield) as an off-white solid. MS (m/z): 539.5 (M+H).

Step 2. 4-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-5,6-dihydropyridin-1(2*H*)-yl)-4-oxobutanoic acid (273)


To a stirred suspension of **272** (120 mg, 0.223 mmol) in THF/MeOH (5/5 mL) was added NaOH 1M (3 mL, 3.00 mmol). The reaction mixture was stirred at RT for 16h and concentrated. The residue was then diluted with water and extracted with DCM/MeOH. The organic layer was successively washed with brine, dried over anhydrous sodium sulfate, filtered
20 and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 15/85 over 20 CV) to afford a material that upon trituration with AcOEt afforded the title compound **273** (10 mg, 0.019 mmol, 9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.90-8.79 (bs, 1H), 8.35 (d, *J* = 5.6 Hz, 1H), 7.64-7.56 (m, 1H), 7.32-7.29 (m, 1H), 7.27-6.96 (m, 4H), 6.68-6.60 (m, 1H), 6.48-6.40 (m, 1H), 5.14-5.01 (m, 1H), 3.94-3.88
25 (m, 1H), 3.68-3.48 (m, 2H), 2.63-2.56 (m, 2H), 2.50-2.30 (m, 3H), 2.20-2.08 (m, 1H), 1.92-1.79 (m, 1H), 0.57-0.52 (m, 2H), 0.34-0.30 (m, 2H). MS (m/z): 525.39 (M+H).

Compound **274** (example 157) was prepared in one step from compound **271** and 2-(2-methoxyethoxy)acetyl chloride similarly to compound **272** (scheme 60).

Table 22. Characterization of compound **274** (example **157**)

Cpd	Ex.	Structure	Characterization
274	157	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(2-methoxyethoxy)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.83 (s, 1H), 8.45 (d, <i>J</i> = 5.6 Hz, 1H), 7.72 (dd, <i>J</i> = 2.0 and 13.6 Hz, 1H), 7.55 (d, <i>J</i> = 6.8 Hz, 1H), 7.34 (t, <i>J</i> = 9.2 Hz, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 1H), 6.69 (s, 1H), 6.57 (d, <i>J</i> = 5.6 Hz, 1H), 6.46-6.36 (m, 1H), 4.27-4.12 (m, 4H), 3.73-3.62 (m, 2H), 3.61-3.56 (m, 2H), 3.52-3.47 (m, 2H), 3.25 (s, 3H), 2.73-2.65 (m, 1H), 2.65-2.50 (m, 2H), 0.67-0.62 (m, 2H), 0.44-0.40 (m, 2H). MS (<i>m/z</i>): 541.5 (<i>M</i> +1).

Scheme 61

Example **158**

1-cyclopropyl-3-(3-fluoro-4-(2-(1-(methanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**275**)

10 To a stirred suspension of compound **271** (150 mg, 0.302 mmol) and K₂CO₃ (180 mg, 1.302 mmol) in DMF (10 mL) was added 2,5,8,11-tetraoxatridecan-13-yl methanesulfonate (112 mg, 0.39 mmol, *K. Fukase, et.al. SynLett., 2005, 2342-2346*). The reaction mixture was stirred at RT for 2.5 days, diluted with water and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue

15 was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 15/85 over 20 CV) to produce a material that upon trituration with Et₂O/hexane afforded an unexpected compound


275 (35 mg, 0.07 mmol, 21% yield) as yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.71 (s, 1H), 8.45 (d, *J* = 5.6 Hz, 1H), 7.71 (dd, *J* = 2.8 and 13.6 Hz, 1H), 7.57 (s, 1H), 7.35 (t, *J* = 8.8 Hz, 1H), 7.22-7.16 (m, 1H), 6.02-5.95 (m, 2H), 6.44 (t, *J* = 3.2 Hz, 1H), 3.95-3.90 (m, 2H), 3.42 (t, *J* = 6.4 Hz, 2H), 2.96 (s, 3H), 2.58-2.50 (m, 1H), 0.68-0.62 (m, 2H), 0.44-0.41 (m, 2H). MS (*m/z*): 503.3 (M+H).

Example 159

1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-morpholinopropyl)-1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (276)

To a stirred solution of compound **271** (150 mg, 0.302 mmol) and DIPEA (227 μl, 1.302 mmol) in DMF (10 mL) was added 4-(3-chloropropyl)morpholine (53.3 mg, 0.325 mmol). The reaction mixture was stirred at 50°C for 2h. More 4-(3-chloropropyl)morpholine (212 mg, 1.3 mmol) was added in 4h and the reaction mixture was heated at 50°C for an additional 19h. The reaction mixture was then diluted with water and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge; MeOH/DCM: 0/100 to 15/85 over 20 CV) to produce a material that upon trituration with AcOEt afforded title compound **276** (40 mg, 0.07 mmol, 22% yield) as beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.77 (s, 1H), 8.44 (d, *J* = 5.2 Hz, 1H), 7.71 (dd, *J* = 2.4 and 13.6 Hz, 1H), 7.48 (s, 1H), 7.34 (t, *J* = 9.2 Hz, 1H), 7.22-7.18 (m, 1H), 6.60 (d, *J* = 2.4 Hz, 1H), 6.55 (d, *J* = 5.2 Hz, 1H), 6.37 (s, 1H), 3.56 (q, *J* = 4.8 Hz, 4H), 3.12 (bs, 2H), 2.70-2.62 (m, 2H), 2.62-2.58 (m, 2H), 2.58-2.50 (m, 1H), 2.43 (t, *J* = 7.2 Hz, 2H), 2.40-2.32 (m, 2H), 2.30 (t, *J* = 7.2 Hz, 2H), 1.64 (quint, *J* = 6.8 Hz, 2H), 0.66-0.62 (m, 2H), 0.44-0.41 (m, 2H). MS (*m/z*): 552.4. (M+H).

Scheme 62




Example 160

1-cyclopropyl-3-(3-fluoro-4-(2-(1-(4-hydroxybutyl)-1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (277)

To a stirred suspension of compound **271-A** (80 mg, 0.188 mmol) and AcOH (12 μ l, 0.207 mmol) in DCM (10 mL) was added 2,5,8,11-tetraoxatridecan-13-al (78 mg, 0.377 mmol, *L. Gorini, et.al. SynLett., 2006, 948-950*). After 30 min, sodium triacetoxyborohydride (120 mg, 0.565 mmol) was added and the reaction mixture was stirred at RT for 1h. DMF (1 mL) and THF (2 mL) were added to the suspension that was stirred at RT for and additional 18h. The reaction mixture was diluted with water and concentrated. The residue was purified by Biotage (SNAP 25 g cartridge; MeOH/DCM: 0/100 to 15/85 over 20 CV) to afford a material that upon trituration with MTBE afforded an unexpected compound **277** (30 mg, 0.06 mmol, 32% yield) as beige solid. ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) : 8.78 (s, 1H), 8.44 (d, $J = 5.2$ Hz, 1H), 7.71 (dd, $J = 2.4$ and 13.6 Hz, 1H), 7.47 (s, 1H), 7.33 (t, $J = 9.2$ Hz, 1H), 7.22-7.15 (m, 1H), 6.63 (d, $J = 2.0$ Hz, 1H), 6.55 (d, $J = 5.2$ Hz, 1H), 6.37 (s, 1H), 3.40 (t, $J = 6.4$ Hz, 1H), 3.14-3.09 (m, 2H), 2.68-2.50 (m, 5H), 2.40 (t, $J = 6.4$ Hz, 2H), 1.56-1.41 (m, 4H), 0.68-0.61 (m, 2H), 0.44-0.40 (m, 2H). MS (m/z): 497.2 (M+H).

15

Scheme 63



Example 161

1-cyclopropyl-3-(3-fluoro-4-(2-(6-((2-oxopyrrolidin-1-yl)methyl)pyridin-3-yl)thieno[3,2-
b]pyridin-7-yloxy)phenyl)urea (283)

5 Step 1. 5-bromo-2-(1,3-dioxan-2-yl)pyridine (278)

To solution of 5-bromo-2-formylpyridine (10 g, 53.8 mmol), 1,3-propanediol (3.89 mL, 53.8 mmol) in toluene (30 mL) was added CSA (1.249 g, 5.38 mmol). The reaction mixture was heated to reflux for 4h with a Dean-Stark trap. The reaction mixture was quenched by addition of saturated solution of sodium bicarbonate and extracted with EtOAc. The organic layer was
10 washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford compound **278** (13.37 g, 54.8 mmol, 101% yield, crude) as a brown solid that was used in the next step with no additional purification.. MS (m/z): 244.06-246.06 (M+H).

Step 2. 2-(6-(1,3-dioxan-2-yl)pyridin-3-yl)-7-chlorothieno[3,2-*b*]pyridine (279)

To a stirred solution of 7-chlorothieno[3,2-*b*]pyridine (12.08 g, 71.2 mmol) in THF (138
15 mL) at -15°C was added n-BuLi (30.7 mL, 77.0 mmol). After 30 min, a solution of ZnCl₂ 0.5 M in THF (142 mL, 71.2 mmol) was added at -15°C and the reaction mixture was allowed to warm to RT over 45 min. A solution of palladium tetrakis(triphenylphosphine) (1.266 g, 1.096 mmol) and bromide **278** (13.37 g, 54.8 mmol) in THF (18.5 mL) was added and the mixture was heated to reflux for 2h then concentrated. The residue was diluted with water and ammonium
20 hydroxide and extracted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was triturated with MTBE to afford the title compound **279** (10.70 g, 32.2 mmol, 59% yield) as light brown solid. MS (m/z): 333.33 (M+H).

25 Step 3. 4-(2-(6-(1,3-dioxan-2-yl)pyridin-3-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluoroaniline (280)

To a stirred solution of 4-amino-2-fluorophenol hydrochloride (5.79 g, 35.4 mmol) in DMSO (40 mL) was added t-BuOK (8.66 g, 77.0 mmol). After 30 min, chloride **279** (10.70 g, 32.2 mmol) was added and the reaction mixture was heated at 100°C for 1.5h. More solution of 4-amino-2-fluorophenol HCl (860 mg, 7.70 mmol) and t-BuOK (0.86 g, 7.70 mmol) in DMSO (4
30 mL) was added to the reaction mixture that was heated at 100°C for an additional 15 min. The reaction mixture was then poured into water (300 mL) to form a precipitate that was collected by filtration, dried under vacuum and triturated with MTBE to afford the title compound **280** (12.39 g, 29.3 mmol, 91% yield) as a beige solid. MS (m/z): 424.39 (M+H).

35 Step 4. 1-(4-(2-(6-(1,3-dioxan-2-yl)pyridin-3-yl)thieno[3,2-*b*]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (281)

To a stirred solution of compound **280** (6.32 g, 14.92 mmol) and pyridine (2.41 mL, 17.91 mmol) in DMF (70 mL) at 0°C was added phenyl chloroformate (2.25 mL, 17.91 mmol). After 30 min cyclopropylamine (2.63 mL, 37.3 mmol) was added at RT and the reaction mixture was heated at 60°C for 45 min. After cooling to RT the reaction mixture was diluted with water to form a precipitate that was collected by filtration, dried and purified by Biotage (SNAP 100 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 10/90 over 20 CV), to produce a material that upon trituration with EtOAc afforded the title compound **281** (2.71 g, 5.35 mmol, 36% yield) as a beige solid. MS (m/z): 507.2 (M+H).


Step 5. 1-cyclopropyl-3-(3-fluoro-4-(2-(6-formylpyridin-3-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (**282**)

A solution of **281** (2.71 mg, 5.35 mmol) in a mixture AcOH/water (32 mL/8 mL) was heated at 90°C for 29 h. After cooling to RT the reaction mixture was diluted with water to form a precipitate that was collected by filtration and dried under vacuum to afford the title compound **282** (2.25 g, 5.02 mmol, 94% yield) as a brown solid. MS (m/z): 449.2 (M+H).

Step 6. 1-cyclopropyl-3-(3-fluoro-4-(2-(6-((2-oxopyrrolidin-1-yl)methyl)pyridin-3-yl)thieno[3,2-*b*]pyridin-7-yloxy)phenyl)urea (**283**)

To a stirred solution of aldehyde **282** (0.5 g, 1.115 mmol) and AcOH (128 µl, 2.23 mmol) in DMF (10 mL) was added 4-aminobutyric acid (345 mg, 3.34 mmol). After 40 min, sodium triacetoxyborohydride (945 mg, 4.46 mmol) was added and the reaction was stirred at RT for 22 h. The reaction mixture was then diluted with water to form a precipitate that was collected by filtration, dried under vacuum and purified by Biotage (SNAP 50 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 15/85 over 20 CV) and by Gilson (Phenomenex, Luna 15µ, C18(2) 100A, 250x50.0 mm, 15µm; 0.05% of formic acid in both MeOH/water : 30/80 to 95/5 over 60 min, flow; 30 mL/min), to afford the title compound **283** (20 mg, 0.04 mmol, 3% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.28 (s, 1H), 9.06 (d, *J* = 2.4 Hz, 1H), 8.53 (d, *J* = 5.6 Hz, 1H), 8.42 (bs, 1H), 8.26 (dd, *J* = 2.4 and 8.0 Hz, 1H), 8.25 (s, 1H), 7.74 (dd, *J* = 2.0 and 13.6 Hz, 1H), 7.41-7.34 (m, 2H), 7.24-7.20 (m, 1H), 7.08 (bs, 1H), 6.62 (d, *J* = 5.6 Hz, 1H), 4.53(s, 2H), 2.58-2.51 (m, 1H), 2.32 (t, *J* = 8.0 Hz, 2H), 1.98 (quin, *J* = 7.2 Hz, 2H), 0.65-0.60 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 518.5 (M+H).

Scheme 64



Example 162

5 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno
[3,2-*b*]pyridin-7-yloxy)phenyl)urea (288)

Step 1. 2-(6-bromopyridin-3-yl)-N-(2-methoxyethyl)ethanamine (284)

To solution of aldehyde **174** (6.93 g, 34.6 mmol, scheme 42), 2-methoxyethylamine
 10 (9.04 mL, 104 mmol) and AcOH (2.08 mL, 36.4 mmol) in DCM (77 mL) at 0°C was added
 sodium triacetoxyborohydride (18.36 g, 87 mmol). The reaction mixture was stirred at RT for
 18h. The reaction was quenched by addition of HCl 10%, and the mixture was extracted with
 HCl 10%. The acidic aqueous extract was basified at 0°C with 4M aqueous NaOH solution (pH
 10) and further extracted with DCM. The organic layer was successively washed with water,
 15 brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford title compound
284 (6.79 g, 26.2 mmol, 76% yield, crude) as an yellow oil that was used in the next step with
 no additional purification. ¹H. MS (m/z): 258.9-260.9 (M+H).

Step 2. tert-butyl 2-(6-bromopyridin-3-yl)ethyl(2-methoxyethyl)carbamate (285)

To a solution of crude **284** (6.79 g, 26.2 mmol) in DCM (52 mL) was added di-tert-butyl dicarbonate (9.13 mL, 93.3 mmol). The reaction mixture was stirred at RT for 18 h then concentrated. The residue was purified by Biotage (SNAP 100 g cartridge; AcOEt/Hex: 0/100 to 30/70 over 20 CV). The desired fractions were collected and concentrated to afford the title compound **285** (5.53 g, 15.39 mmol, 59% yield) as light yellow oil. MS (m/z): 359.1-361.1 (M+H).

Step 3. tert-butyl 2-(6-(7-chlorothieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)ethyl(2-methoxyethyl)carbamate (**286**)

To a stirred solution of 7-chlorothieno[3,2-*b*]pyridine (4.26 g, 25.09 mmol) in THF (64 mL) at -15°C was added n-BuLi (10.77 mL, 25.09 mmol). After 30 min, ZincCl₂ (3.42 g, 25.09 mmol) was added at -15°C and the reaction mixture was allowed to warm to RT over 45 min. A solution of palladium tetrakis(triphenylphosphine) (0.387 g, 0.335 mmol) and bromide **285** (6.01 g, 16.73 mmol) in THF (20 mL) was added and the mixture was heated to reflux for 1h and concentrated. The reaction was quenched by addition of water and ammonium hydroxide and the mixture was extracted with DCM. The extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 340 g cartridge; AcOEt/Hex: 50/50 to 100/0 over 20 CV), to afford title compound **286** (3.74 g, 8.35 mmol, 50% yield) as yellow oil. MS (m/z): 448.48 (M+H).

Step 4. tert-butyl 2-(6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)ethyl(2-methoxyethyl)carbamate (**181**, scheme 44)

To a stirred solution of 4-amino-2-fluorophenol HCl (2.01 g, 12.32 mmol) in NMP (13 mL) was added t-BuOK (3.0 g, 26.7 mmol). After 30 min, chloride **286** (4.6 g, 10.27 mmol) was added and the reaction mixture was heated at 100°C for 1.5 h. The reaction mixture was poured into water (100 mL) to form a precipitate that was collected by filtration, dried and triturated with MTBE, to afford the title compound **181** (2.98 g, 5.53 mmol, 54% yield) as a beige solid. MS (m/z): 538.8 (M+H).

Step 5. tert-butyl 2-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)pyridin-3-yl)ethyl(2-methoxyethyl)carbamate (**287**)


To a stirred solution of compound **181** (1.0 g, 1.58 mmol) and pyridine (450 mL, 5.56 mmol) in DMF (25 mL) at 0°C was added phenyl chloroformate (582 µl, 4.64 mmol). After 2 h cyclopropylamine (643 µl, 9.28 mmol) was added at RT and the reaction mixture was heated at 60°C for 5h. After cooling to RT the reaction was quenched by addition of water and the mixture extracted with AcOEt. The extract was successively washed with water, NaOH 1N, saturated solution of ammonium chloride, brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 80 g cartridge;

MeOH/DCM: 1/99 to 10/90 over 20 CV), to afford the title compound **287** (840 mg, 1.35 mmol, 86% yield) as a pink solid. MS (m/z): 622.5 (M+H).

Step 6. 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-(2-methoxyethylamino)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**288**)

5 To a solution of **287** (840 mg, 1.35 mmol) in DCM (25 mL) was added TFA (10 mL) and the reaction mixture was stirred for 18 h. The reaction mixture was concentrated, diluted with water and 4N NaOH to pH 13 to form a precipitate which was collected by filtration, washed with water, and dried and purified twice by Biotage (SNAP 50g; MeOH/DCM: 1/99 to 15/85 over 20 CV) to produce a material that upon trituration with MeOH afforded the title compound **288** (338 mg, 0.65 mmol, 48% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.72 (s, 1H), 8.54-8.49 (m, 2H), 8.30 (s, 1H), 8.19 (d, *J* = 8.2 Hz, 1H), 7.81 (dd, *J* = 8.0, 2.2 Hz, 1H), 7.73 (dd, *J* = 13.5, 2.5 Hz, 1H), 7.38 (t, *J* = 9.1 Hz, 1H), 7.20 (bd, *J* = 8.6 Hz, 1H), 6.63 (d, *J* = 5.5 Hz, 1H), 6.58 (bd, *J* = 2.5 Hz, 1H), 3.37 (t, *J* = 5.7 Hz, 2H), 3.23 (s, 3H), 2.84-2.73 (m, 4H), 2.68 (t, *J* = 5.7 Hz, 2H), 2.59-2.51 (m, 1H), 2.00-1.50 (m, 1H), 0.72-15 0.58 (m, 2H), 0.50-0.36 (m, 2H).). MS (m/z): 522.6 (M+H).

Scheme 65



20

Example 163

1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-(2-oxopyrrolidin-1-yl)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**295**)

Step 1. 2-(6-bromopyridin-3-yl)ethanol (**289**)

To a solution of aldehyde **174** (1.4 g, 7.0 mmol, schemes 42 and 64) in methanol (100 mL) was added sodium borohydride (0.27 g, 7.0 mmol) and the mixture was stirred at room temperature for 30 min. Water (1 mL) was added, and the mixture was concentrated. The residue was then partitioned between ethyl acetate and water. The organic phase was dried (anhydrous MgSO_4), filtered and concentrated. Silica gel chromatography (10 % methanol/ethyl acetate) of the residue gave title compound **289** (1.0 g, 71 % yield) as a colorless solid. MS (M+H): 202.1, 204.1

Step 2. 2-bromo-5-(2-bromoethyl)pyridine (**290**)

Alcohol **289** (1.75 g, 8.66 mmol) was treated with phosphorous tribromide (5.0 mL, 53 mmol) and the mixture was heated for 5 min, until the solid had melted and re-solidified. The mixture was cooled, treated with ice and partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was collected, washed with saturated aqueous sodium bicarbonate and brine, dried (anhydrous MgSO_4), filtered and concentrated. Silica gel chromatography of the residue (eluent DCM) provided title compound **290** (2.0 g, 7.6 mmol, 87 % yield) as a colorless solid. MS (M+H): 266.0

Step 3. 1-(2-(6-bromopyridin-3-yl)ethyl)pyrrolidin-2-one (**291**)

To a mixture of dibromide **290** (1.7 g, 6.4 mmol) in 2-pyrrolidone (10 mL, 130 mmol) at room temperature was added sodium hydride, 40% dispersion in mineral oil (1.16 g, 19.3 mmol). This reaction mixture was then heated to 100°C for 2 h, then cooled to RT and partitioned between water and ethyl acetate. The organic phase was collected, washed with water, saturated aqueous ammonium chloride, and brine. It was then dried (anhydrous MgSO_4), filtered and concentrated. Silica gel chromatography (10 % methanol/ethyl acetate) gave title compound **291** (1.3 g, 75 % yield) as a colorless solid. ^1H NMR (400 MHz, CDCl_3) δ (ppm): 8.17-8.16 (m, 1H); 7.42-7.37 (m, 2H); 3.49 (t, $J=7.4$, 2H); 3.28 (t, $J=6.9$, 2H); 2.79 (t, $J=7.2$, 2H); 2.30 (t, $J=7.8$, 2H); 1.95 (quintet, 7.6, 2H). MS (M+H): 269.1, 271.1

Step 4. 1-(2-(6-(7-chlorothieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl)pyrrolidin-2-one (**292**)

To 7-chlorothienopyridine (0.95 g, 5.6 mmol) in THF (75 mL) at -78°C was added *n*-butyllithium (2.5 M in hexanes, 2.4 mL, 6.0 mmol), dropwise. The solution was stirred for 30 min then warmed to 0°C and zinc chloride (1.0 M in ether, 6.5 mL, 6.5 mmol) was added. The reaction mixture was stirred for 20 min, then bromide **291** (1.25 g, 4.64 mmol) and tetrakis(triphenylphosphine) palladium (0.54 g, 0.46 mmol) in THF (15 mL) were added. The

mixture then was heated to reflux for 3 h and cooled to RT. The excess base was quenched with 1 mL saturated aqueous ammonium chloride, and the mixture was concentrated. The residue was partitioned between water and diethyl ether, producing a yellow precipitate, which was isolated by suction filtration, triturated with ethyl acetate and dried *in vacuo* to give title compound **292** (1.2 g, 72 %). MS (M+H): 358.3

Step 5: 1-(2-(6-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl)pyrrolidin-2-one (**293**)

To chlorothienopyridine **292** (1.2 g, 3.4 mmol) in diphenyl ether (20 mL) was added 2-fluoro-4-nitrophenol (1.58 g, 10.1 mmol) and potassium carbonate (2.32 g, 16.8 mmol) and the resultant mixture was heated to 200°C for 10 h. Extra 2-fluoro-4-nitrophenol (1.58 g, 10.1 mmol) and potassium carbonate (2.32 g, 16.8 mmol) were added and the mixture was heated at 200°C for a further 6 h. The mixture was cooled to RT, partitioned between ethyl acetate and 1M aqueous NaOH then filtered through celite. The organic phase was collected, washed with water and brine, dried (anhydrous MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography (10 % methanol/ethyl acetate) to afford title compound **293** (0.76 g, 47 % yield), contaminated with ~10 % starting material **292**, as a yellow solid. MS (M+H): 479.5

Step 6: 1-(2-(6-(7-(4-amino-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)ethyl)pyrrolidin-2-one (**294**)


To impure **293** (0.76 g, 1.6 mmol) in EtOH (75 mL) was added zinc dust (1.04 g, 15.9 mmol), iron filings (0.89 g, 16 mmol) and saturated aqueous ammonium chloride solution (2 mL). The resultant mixture was heated to reflux for 18 h, then cooled, filtered through celite, concentrated and re-dissolved in dichloromethane. The solution was washed with water, 1 M NaOH, and brine, dried (anhydrous MgSO₄), filtered, concentrated and the residue was purified by silica gel chromatography (15 % MeOH/chloroform) to afford title compound **294** (0.33 g, 46 % yield). MS (M+H): 449.2

Step 7: 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(2-(2-oxopyrrolidin-1-yl)ethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**295**)

To a solution of **294** (0.33 g, 0.74 mmol) and pyridine (0.13 mL, 1.6 mmol) in DMF (15 mL) at 0°C was added phenyl chloroformate (0.12 mL, 0.96 mmol). The reaction mixture was stirred for 15 min then cyclopropylamine (2.0 mL, 28 mmol) was added. The mixture was warmed to RT, stirred for an additional 18 h and partitioned between water and ethyl acetate. The organic phase was collected, washed with water, 1M NaOH, and brine, dried (anhydrous MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography (20 % methanol/ethyl acetate) to afford title compound **295** (0.21 g, 54 %). ¹H NMR (400 MHz,

DMSO-*d*₆) δ (ppm): 8.71 (s, 1H); 8.52-8.50 (m, 2H); 8.31 (s, 1H); 8.20 (d, *J*=8.2, 1H); 7.82 (dd, *J*=8.2, 2.2, 1H); 7.73 (dd, *J*=13.5, 2.5, 1H); 7.38 (t, *J*=9.0, 1H); 7.22-7.18 (m, 1H); 6.64 (d, *J*=5.5, 1H); 6.59 (d, *J*=2.5, 1H); 3.48 (t, *J*=7.0, 2H); 3.35 (t?, obscured by water peak), 2.85 (t, *J*=6.8, 2H); 2.58-2.52 (m, 1H); 2.16 (t, *J*=7.8, 2H); 1.89 (quintet, *J*=7.4, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS: (calc.) 531.17 (found) 532.4 (MH)⁺

Scheme 66



10

Example 164

1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-(morpholinomethyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (298)

15 Step 1: 4-((2-(7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)morpholine (296)

To a suspension of aldehyde **131** (0.8 g, 2.008 mmol, scheme 33) and morpholine (0.437 mL, 5.02 mmol) in dichloromethane (40.2 mL) was added acetic acid (0.230 mL, 4.02 mmol) and the reaction mixture was stirred for 1 h. Sodium triacetoxyborohydride (1.277 g, 6.02 mmol) was added and the mixture was stirred for an additional 4 h. The reaction mixture was extracted with 1M HCl and the organic phase was discarded. The aqueous phase was neutralized with 3M NaOH and extracted with dichloromethane. The DCM extract was washed with brine, dried (anhydrous Na₂SO₄), and evaporated to afford title compound **296** (907 mg, 1.932 mmol, 96%

yield, crude). The material was used in the next step with no additional purification. MS: 470(MH)+.

Step 2: 3-fluoro-4-(2-(1-methyl-5-(morpholinomethyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)aniline (297)

A mixture of nitro compound **296** (907 mg, 1.932 mmol), iron powder (917 mg, 16.42 mmol) and ammonium chloride (89 mg, 1.661 mmol) in a solvent system ethanol (24.0 mL) and water (12.0 mL) was heated to 90°C for 1hr. The reaction mixture was filtered while hot and concentrated. The residue was purified by Biotage (MeOH.DCM, 0-20%, SNAP 25 g cartridge) to give title compound **297** (700 mg, 1.593 mmol, 82 % yield) as a white solid. MS: 440(MH+).

Step 3: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-methyl-5-(morpholinomethyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (298)


To a solution of aniline **297** (200 mg, 0.455 mmol) in THF (20 mL) at 0°C was added DIPEA (0.318 mL, 1.820 mmol) and triphosgene (81 mg, 0.273 mmol). The mixture was stirred at 0°C for 1hr before cyclopropylamine (0.160 mL, 2.275 mmol) was added, and was allowed to warm to RT over 1 hr. The mixture was concentrated and purified by Biotage (MeOH/DCM, 0-22%, SNAP 25 g cartridge) to afford title compound **298** (54 mg, 0.103 mmol, 22.7 % yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.69 (s, 1H), 8.50 (d, 1H, J=5.5Hz), 7.89(s, 1H), 7.70 (dd, 1H, J1=2.3Hz, J2=13.9Hz), 7.35 (t, 1H, J=9.0Hz), 7.18-7.16 (m, 1H), 6.96 (s, 1H), 6.65 (d, 1H, J=5.5Hz), 6.55-6.54 (m, 1H), 3.91 (s, 3H), 3.55 (t, 4H, J=3.4Hz), 3.51 (s, 2H), 2.54-2.51 (m, 1H), 2.37 (m, 4H), 0.65-0.61 (m, 2H), 0.42-0.38 (m, 2H). MS: 523.6 (MH)+

Example 165

1-(3-fluoro-4-(2-(1-methyl-5-(morpholinomethyl)-1H-imidazol-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)-3-isopropylurea (299)

Title compound **299** was obtained starting from the compound **297** and following a procedure similar to the one used in the synthesis of compound **201** (scheme 48). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.73(s, 1H), 8.55(d, 1H, J=5.4Hz), 7.94(s, 1H), 7.73(dd, 1H, J1=2.4Hz, J2=13.5Hz), 7.40(t, 1H, J=9.0Hz), 7.17-7.15(m, 1H), 7.02(s, 1H), 6.69(d, 1H, J=5.5Hz), 6.19(d, 1H, 7.6Hz), 3.97(s, 3H), 3.83-3.78(m, 1H), 3.62-3.60(t, 4H, J=4.1Hz), 3.57(s, 2H), 2.43(m, 4H), 1.15(s, 3H), 1.14(s, 3H). 525.5 (MH)+

Scheme 67



1-Cyclopropyl-3-(2,3-difluoro-4-(2-(5-formylpyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (167, scheme 41)

Step 1: 2-bromo-5-(1,3-dioxolan-2-yl)pyridine (300)

To a solution of 6-bromonicotinaldehyde (10.1 g, 51.6 mmol) in toluene (400 mL) was added ethylene glycol (11.4 mL, 206 mmol) and p-toluenesulfonic acid (0.98 g, 5.16 mmol), and the reaction mixture was heated to reflux with azeotropic removal of the water using a Dean-Stark trap, for 2.5 h. The mixture was cooled down and washed with saturated NaHCO₃ solution and brine. The organic phase was dried over anhydrous MgSO₄ and concentrated to afford title compound **300** (11.7 g, 98% yield) as a brown solid, which was used in the next step without further purification. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.46 (d, J = 2.7 Hz, 1H), 7.65 (dd, J = 8.1, 2.7 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 5.83 (s, 1H), 4.20-4.00 (m, 4H).

Step 2: 2-(5-(1,3-Dioxolan-2-yl)pyridin-2-yl)-7-chlorothieno[3,2-b]pyridine (301)

To a solution of 7-chlorothieno[3,2-b]pyridine (14 g, 82.4 mmol) in THF (137 mL) was added, at -78°C, a solution of n-BuLi (34.4 mL, 89.3 mmol, 2.6 M in hexanes) and the reaction mixture was stirred for 10 min. A solution of ZnCl₂ (89 mL, 89.3 mmol, 1.0 M in Et₂O) was added and the mixture was stirred at RT for 10 min. Pd(PPh₃)₄ (3.18 g, 2.75 mmol) was added along with a solution of **300** (15.8 g, 68.7 mmol) in THF (50 mL) and the reaction mixture was heated to reflux under an atmosphere of N₂ gas for 1 hour. The reaction mixture was then cooled to RT, and partitioned between saturated ammonium hydroxide solution and EtOAc. The

organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. The resultant material was triturated with EtOAc to afford the title compound **301** (21.4 g, 98% yield) as a beige solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.71 (d, J = 2.1 Hz, 1H), 8.67 (d, J = 5.1 Hz, 1H), 8.49 (s, 1H), 8.36 (d, J = 8.1 Hz, 1H), 8.01 (dd, J = 8.1, 2.1 Hz, 1H), 7.61 (d, J = 5.1 Hz, 1H), 5.91 (s, 1H), 4.16-3.96 (m, 4H).

Step 3: 4-(2-(5-(1,3-Dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-2,3-difluoroaniline (**302**)

To a solution of 4-amino-2,3-difluorophenol (1.59 g, 7.49 mmol) in DMSO (10 mL) was added potassium *tert*-butoxide (1.1 g, 8.98 mmol), and the reaction mixture was stirred for 2 hours. Chloride **301** (1.6 g, 4.99 mmol) was added and the reaction mixture was heated at 100°C for 2 hours. The mixture was cooled down then poured into water (150 mL) at 40-45°C and stirred for 30 min. The precipitate was collected by filtration, washed with water and dried overnight. The crude product was triturated with EtOAc/Hexane (2/1, 100 mL) for 1h, to afford title compound **302** (1.7 g, 79% yield) as a pale violet solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.70 (d, J = 2.1 Hz, 1H), 8.53 (d, J = 5.4 Hz, 1H), 8.39 (s, 1H), 8.31 (d, J = 8.1 Hz, 1H), 7.98 (dd, J = 8.1, 2.1 Hz, 1H), 7.10-7.00 (m, 1H), 6.71 (d, J = 5.1 Hz, 1H), 6.72-6.61 (m, 1H), 5.90 (s, 1H), 5.64 (s, 2H), 4.16-3.96 (m, 4H).

Step 4: 1-(4-(2-(5-(1,3-Dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-2,3-difluorophenyl)-3-cyclopropylurea (**303**)


To a solution of **302** (1.7 g, 3.98 mmol) in DMF (7 mL) was added pyridine (0.55 mL, 6.77 mmol) at RT and the resultant reaction mixture was stirred for 10 min under Ar atmosphere. Phenyl chloroformate (0.75 mL, 5.97 mmol) was added at 0°C and the mixture was stirred at RT for an additional 40 min. Cyclopropylamine (1.1 mL, 15.9 mmol) was added to the mixture, and the reaction mixture was warmed to 50°C and stirred for 2 hours. The mixture was then cooled, poured into water (150 mL) and stirred for 30 min. The precipitate was collected by filtration, washed with water and dried overnight. The crude product was triturated with EtOAc for 1h and collected by filtration to afford title compound **303** (1.75 g, 86% yield) as a pale violet solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 8.71 (d, J = 2.1 Hz, 1H), 8.55 (d, J = 5.4 Hz, 1H), 8.46 (s, 1H), 8.42 (s, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.10-7.95 (m, 1H), 7.99 (dd, J = 8.1, 2.1 Hz, 1H), 7.40-7.22 (m, 1H), 6.87 (br, 1H), 6.78 (d, J = 5.1 Hz, 1H), 5.90 (s, 1H), 4.16-3.96 (m, 4H), 2.64-2.50 (m, 1H), 0.75-0.60 (m, 2H), 0.50-0.35 (m, 2H).

Step 5: 1-Cyclopropyl-3-(2,3-difluoro-4-(2-(5-formylpyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**167**, scheme 41)

To a suspension of **303** (1.75 g, 3.43 mmol) in THF (56 mL) was added aqueous 5N HCl solution (14 mL, 70 mmol) at 0°C and the reaction mixture was stirred at RT. After 2 hours, the

mixture was concentrated, basified with aqueous 5N NaOH solution and stirred at RT for 1 hour. The precipitate was collected by filtration and dried to afford title compound **167** (1.55 g, 97% yield) as a beige solid. ¹H NMR (300 MHz, DMSO-d₆) δ (ppm): 10.14 (s, 1H), 9.14 (d, J = 2.1 Hz, 1H), 8.59 (d, J = 5.4 Hz, 1H), 8.59 (s, 1H), 8.54 (d, J = 8.1 Hz, 1H), 8.49 (s, 1H), 8.10-8.00 (m, 1H), 7.35-7.25 (m, 1H), 6.89 (br, 1H), 6.82 (d, J = 5.1 Hz, 1H), 2.64-2.50 (m, 1H), 0.75-0.60 (m, 2H), 0.50-0.35 (m, 2H)

Scheme 68



Example 166

1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(piperazin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**308**)

Step 1. tert-butyl 4-(2-(4-iodo-1H-imidazol-1-yl)ethyl)piperazine-1-carboxylate (**304**)

To a stirred solution of 4-iodoimidazole (25 g, 129 mmol) and 1-bromo-2-chloroethane (12.87 ml, 155 mmol) in DMSO (250 ml) under nitrogen was added K_2CO_3 (26.7 g, 193 mmol).

The reaction mixture was heated at 80°C for 30 min. More 1-bromo-2-chloroethane (1.28 ml, 15.5 mmol) was added and the reaction mixture was heated at 80°C for an additional 30 min. Finally, 1-Boc-piperazine (28.8 g, 155 mmol) was added and the reaction mixture heated at 80°C for 1h, cooled to RT and partitioned between water and AcOEt. The organic layer was collected, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 340 g cartridge; Hexane/AcOEt: 40/60 to 0/100 over 15 CV) followed by another purification under different conditions (SNAP 100 g cartridge; MeOH/DCM: 0/100 to 5/95 over 15 CV), to afford title compound **304** (4 g, 9.85 mmol, 8% yield) as white solid. MS (m/z): 407.18 (M+H).

Step 2. tert-butyl 4-(2-(4-(7-chlorothieno[3,2-*b*]pyridin-2-yl)-1*H*-imidazol-1-yl)ethyl)piperazine-1-carboxylate (**305**)

To a stirred solution of 7-chlorothieno[3,2-*b*]pyridine (2.95 g, 17.39 mmol) in THF (60 ml) at -15°C was added n-BuLi (2.5M, 6.96 ml, 17.39 mmol). After 30 min, a solution of ZnCl₂ in Et₂O (1M, 17.39 mL, 17.39 mmol) was added at -15°C and the reaction mixture was warmed to RT over 45 min. A solution of palladium tetrakis(triphenylphosphine) (0.268 g, 0.232 mmol) and **304** (4.71 g, 11.59 mmol) in THF (18 ml) was added and the mixture was heated to reflux for 1h then concentrated. The residue was diluted with water and ammonium hydroxide and extracted with DCM. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was triturated with a mixture of MTBE/Hexane, to afford the title compound **305** (3.75 g, 8.37 mmol, 72% yield) as a beige solid. MS (m/z): 448.46 (M+H).

Step 3. tert-butyl 4-(2-(4-(7-(4-amino-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-1*H*-imidazol-1-yl)ethyl)piperazine-1-carboxylate (**306**)

To a stirred solution of 4-amino-2-fluorophenol x HCl (1.64 g, 10.05 mmol) in NMP (30 mL) was added t-BuOK (2.25 g, 20.1 mmol). After 30 min, compound **305** (3.75 g, 8.37 mmol) was added and the reaction mixture was heated at 100°C for 1h. A solution of 4-amino-2-fluorophenol HCl (1.64 g, 10.05 mmol) in NMP (30 mL) in a separate flask was treated with t-BuOK (2.25 g, 20.1 mmol) and the resultant phenolate solution was added to the reaction mixture at 100°C. After 30 min, the reaction was quenched by addition of water and the precipitate was collected by filtration, dried and triturated with MTBE to afford the title compound **306** (2.10 g, 3.90 mmol, 47% yield) as a beige solid. MS (m/z): 539.39 (M+H).

Step 4. tert-butyl 4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-*b*]pyridin-2-yl)-1*H*-imidazol-1-yl)ethyl)piperazine-1-carboxylate (**307**)

To a stirred solution of **306** (2.10 g, 3.90 mmol) and pyridine (631 µl, 4.68 mmol) in DMF (20 ml) at 0°C was added phenyl chloroformate (587 µl, 4.68 mmol). After 45 min





cyclopropylamine (687 μ l, 9.75 mmol) was added at 0°C and the reaction mixture was heated at 60°C for 30 min. After cooling to RT the reaction mixture was quenched by addition of water and extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Biotage (SNAP 100 g cartridge; MeOH/DCM: 0/100 to 10/90 over 20 CV), to afford the title compound **307** (1.4 g, 2.25 mmol, 58% yield) as a beige solid. MS (m/z): 622.33 (M+H).



Step 5. 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(piperazin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**308**)

To a solution of **307** (1.4 g, 2.25 mmol) in DCM (30 ml) was added TFA (2 mL) and the reaction mixture was stirred for 1 h. More TFA (3 mL) was added and the reaction mixture was stirred for an additional 3 h then concentrated, diluted with water and 1M NaOH to pH 11. The solid was collected by filtration, rinsed with water and dried. The residue was purified by Biotage (SNAP 80 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 0/100 to 35/65 over 30 CV), to afford the title compound **308** (870 mg, 1.67 mmol, 74% yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.75 (s, 1H), 8.42 (d, *J* = 5.6 Hz, 1H), 7.91 (s, 1H), 7.76 (s, 1H), 7.72 (dd, *J* = 2.4 and 13.6 Hz, 1H), 7.65 (s, 1H), 7.35 (t, *J* = 8.8 Hz, 1H), 7.19 (d, *J* = 8.8 Hz, 1H), 6.60 (bs, 1H), 6.54 (d, *J* = 5.6 Hz, 1H), 4.12 (t, *J* = 6.0 Hz, 2H), 2.68 (t, *J* = 4.8 Hz, 4H), 2.62 (t, *J* = 6.0 Hz, 2H), 2.59-2.50 (m, 1H), 2.41-2.30 (m, 4H), 0.69-0.60 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 522.6 (M+H).


Compounds **309** (example 167) and **310** (example 168) were prepared by reacting compounds **307** (scheme 68) and compound **49** (scheme 15) with acetoxycetic acid, similarly to compound **30** (scheme 13). Compound **311** (example 169) was synthesized by following the procedures described above for the synthesis of compound **49** (scheme 15). Compounds **312** (example 170) and **313** (example 171) were obtained similarly to compound **31** (scheme 13). Compound **314** (example 172) was synthesized by following the procedures described above for the synthesis of compound **75** (scheme 20).

Table 23. Characterization of compounds **309-314** (examples 167-172)

Cpd	Ex.	Structure	Characterization
309	167	 2-(4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-imidazol-1-yl)ethyl)piperazin-1-yl)-2-oxoethyl acetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.89 (s, 1H), 8.42 (d, <i>J</i> = 5.6 Hz, 1H), 7.93 (d, <i>J</i> = 0.8 Hz, 1H), 7.79 (d, <i>J</i> = 0.8 Hz, 1H), 7.72 (dd, <i>J</i> = 2.4 and 13.6 Hz, 1H), 7.67 (s, 1H), 7.35 (t, <i>J</i> = 9.2 Hz, 1H), 7.22-7.16 (m, 1H), 6.58-6.54 (m, 1H), 6.54 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (s, 2H), 4.15 (t, <i>J</i> = 6.0 Hz, 2H), 3.39-3.31 (m, 4H), 2.70 (t, <i>J</i> = 6.0 Hz, 2H), 2.58-2.51 (m, 1H), 2.48-2.40 (m, 4H), 2.06 (s, 3H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (m/z): 622.7 (M+1).
310	168	 2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-2-oxoethyl acetate	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.73 (br, 1H), 8.58 (s, 1H), 8.52 (d, <i>J</i> = 5.4 Hz, 1H), 8.34 (s, 1H), 8.26 (d, <i>J</i> = 8.1 Hz, 1H), 7.88 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.73 (dd, <i>J</i> = 13.8, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.23-7.19 (m, 1H), 6.65 (d, <i>J</i> = 5.4 Hz, 1H), 6.59 (d, <i>J</i> = 2.1 Hz, 1H), 4.76 (s, 2H), 3.61 (s, 2H), 3.48-3.36 (m, 4H), 2.57-2.53 (m, 1H), 2.44-2.37 (m, 4H), 2.07 (s, 3H), 0.67-0.62 (m, 2H), 0.46-0.41 (m, 2H). MS (m/z): 619.7 (MH) ⁺
311	169	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.78 (bs, 1H), 8.54 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 7.6 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.0 Hz, 1H), 7.20 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 6.64-6.60 (m, 2H), 3.58 (s, 2H), 2.81-2.71 (m, 2H), 2.60-2.50 (m, 7H), 2.31-2.23 (m, 2H), 0.72-0.58 (m, 2H), 0.50-0.37 (m, 2H), one NH is missing. MS (m/z): 545.5 (M+1).
312	170	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-(2-hydroxyacetyl)piperazin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm) : 8.72 (s, 1H), 8.42 (d, <i>J</i> = 5.6 Hz, 1H), 7.93 (d, <i>J</i> = 1.2 Hz, 1H), 7.79 (d, <i>J</i> = 0.8 Hz, 1H), 7.72 (dd, <i>J</i> = 2.4 and 13.6 Hz, 1H), 7.66 (s, 1H), 7.35 (t, <i>J</i> = 9.2 Hz, 1H), 7.21-7.16 (m, 1H), 6.60-6.56 (m, 1H), 6.54 (d, <i>J</i> = 5.6 Hz, 1H), 4.55 (t, <i>J</i> = 5.6 Hz, 2H), 4.14 (t, <i>J</i> = 6.0 Hz, 1H), 4.07 (d, <i>J</i> = 6.0 Hz, 2H), 3.50-3.44 (m, 2H), 3.35-3.30 (m, 2H), 2.69 (t, <i>J</i> = 6.0 Hz, 2H), 2.59-2.51 (m, 1H), 2.49-2.40 (m, 4H), 0.68-0.62 (m, 2H), 0.45-0.41 (m, 2H). MS (m/z): 580.6 (M+1).

Cpd	Ex.	Structure	Characterization
313	171	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((5-(2-hydroxyacetyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H), 8.55 (bd, <i>J</i> = 1.2 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.73 (dd, <i>J</i> = 13.5, 2.3 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.65 (d, <i>J</i> = 5.3 Hz, 1H), 6.57 (bd, <i>J</i> = 2.3 Hz, 1H), 4.51 (t, <i>J</i> = 5.6 Hz, 1H), 4.06-3.92 (m, 2H), 3.64 (bs, 2H), 3.62-3.49 (m, 2H), 3.34-3.17 (m, 2H), 2.91-2.69 (m, 2H), 2.61-2.51 (m, 3H), 2.50-2.41 (m, 2H), 0.72-0.59 (m, 2H), 0.50-0.36 (m, 2H). MS (<i>m/z</i>): 603.7 (<i>M</i> +1).
314	172	 (<i>S</i>)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-hydroxypropanoyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.74 (s, 1H), 8.57 (bd, <i>J</i> = 1.4 Hz, 1H), 8.52 (d, <i>J</i> = 5.5 Hz, 1H), 8.34 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.88 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.73 (dd, <i>J</i> = 13.6, 2.4 Hz, 1H), 7.38 (t, <i>J</i> = 9.1 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.2 Hz, 1H), 6.65 (d, <i>J</i> = 5.3 Hz, 1H), 6.60 (bd, <i>J</i> = 2.3 Hz, 1H), 4.88 (d, <i>J</i> = 7.0 Hz, 1H), 4.40 (quint, <i>J</i> = 6.7 Hz, 1H), 3.59 (s, 2H), 3.59-3.39 (m, 4H), 2.59-2.51 (m, 1H), 2.47-2.30 (m, 4H), 1.16 (d, <i>J</i> = 6.5 Hz, 3H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H). MS (<i>m/z</i>): 591.7 (<i>M</i> +1).



Scheme 69







1H); 3.62 (s, 2H); 3.35-3.30 (m, 4H?, under water peak); 2.57-2.52 (m, 1H); 2.00-1.90 (m 2H); 0.67-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 554.6 (M+1).

Compound **317** (example **175**) and **318** (example **176**) were synthesized by following the procedures described above for the synthesis of compound **49** (scheme 15). Compounds **319** (example **177**) and **320** (example **178**) were prepared from compounds **317** and compound **318**, similarly to compound **31** (scheme 13). Compound **321** (example **179**) was obtained by following the procedure described above for the synthesis of compounds **315** and **316** (scheme 69). Compound **322** (example **180**) was synthesized from compound **308** (scheme 68) [alkylation by (2-bromoethoxy)(tert-butyl)dimethylsilane followed by a deprotection of the tert-butyl dimethylsilyloxy)ethyl)-intermediate with TBAF].




Table 24. Characterization of compounds **317-322** (examples **175-180**)





Cpd	Ex.	Structure	Characterization
317	175	 1-(4-(2-(5-(2,7-diazaspiro[4.4]nonan-2-ylmethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): mixture of rotamers, 8.87 (bs, 1H), 8.56 (bd, J = 1.6 Hz, 1H), 8.51 (d, J = 5.3 Hz, 1H), 8.32 (s, 1H), 8.23 (dd, J = 8.1, 0.7 Hz, 1H), 7.86 (dd, J = 8.0, 2.2 Hz, 1H), 7.73 (dd, J = 13.6, 2.5 Hz, 1H), 7.37 (t, J = 9.0 Hz, 1H), 7.21 (dd, J = 9.0, 1.4 Hz, 1H), 6.71 (bd, J = 2.5 Hz, 1H), 6.64 (dd, J = 5.3, 0.8 Hz, 1H), 3.67 (d, J = 13.7 Hz, 1H), 3.62 (d, J = 13.7 Hz, 1H), 2.88-2.77 (m, 2H), 2.76 (d, J = 10.4 Hz, 1H), 2.68-2.60 (m, 2H), 2.59-2.51 (m, 2H), one CH is masked by water peak, 2.32 (d, J = 9.0 Hz, 1H), 1.80-1.60 (m, 4H), 0.71-0.57 (m, 2H), 0.49-0.36 (m, 2H), one NH is missing. MS (m/z): 559.6 (M+1).
318	176	 1-(4-(2-(5-(3,9-diazaspiro[5.5]undecan-3-ylmethyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80 (bs, 1H), 8.56-8.48 (m, 2H), 8.31 (s, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.83 (dd, J = 8.2, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.21 (dd, J = 9.0, 1.2 Hz, 1H), 6.68-6.61 (m, 2H), 3.53 (s, 2H), 2.69-2.59 (m, 4H), 2.58-2.51 (m, 1H), 2.40-2.28 (m, 4H), 1.52-1.24 (m, 8H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H), one NH is missing. MS (m/z): 587.7 (MH) ⁺


Cpd	Ex.	Structure	Characterization
319	177	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((7-(2-hydroxyacetyl)-2,7-diazaspiro[4.4]nonan-2-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80 (s, 1H), 8.57 (s, 1H), 8.51 (d, J = 5.3 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.87 (dd, J = 8.1, 1.5 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.20 (dd, J = 8.8, 1.2 Hz, 1H), 6.64 (d, J = 5.3 Hz, 1H), 6.61 (bd, J = 2.5 Hz, 1H), 4.52 and 4.48 (2t, J = 5.6 Hz, 1H), 4.02-3.90 (m, 2H), 3.67 (bs, 2H), 3.36-3.18 (m, 4H), 2.74-2.34 (m, 5H), 1.96-1.66 (m, 4H), 0.72-0.58 (m, 2H), 0.49-0.36 (m, 2H). MS (m/z): 617.6 (M+1).
320	178	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((9-(2-hydroxyacetyl)-3,9-diazaspiro[5.5]undecan-3-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H), 8.54 (bd, J = 1.6 Hz, 1H), 8.52 (d, J = 5.5 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.85 (dd, J = 8.1, 2.1 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.1 Hz, 1H), 7.20 (dd, J = 9.0, 1.4 Hz, 1H), 6.64 (dd, J = 5.4, 0.7 Hz, 1H), 6.57 (bd, J = 2.3 Hz, 1H), 4.42 (t, J = 5.4 Hz, 1H), 4.04 (d, J = 5.3 Hz, 2H), 3.55 (s, 2H), 3.48-3.39 (m, 2H), 3.28-3.20 (m, 2H), 2.59-2.52 (m, 1H), 2.42-2.32 (m, 4H), 1.54-1.30 (m, 8H), 0.72-0.58 (m, 2H), 0.50-0.37 (m, 2H). MS (m/z): 645.8 (M+1).
321	179	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-fluoropiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.77 (s, 1H); 8.55 (d, J=1.6, 1H); 8.52 (d, J=5.5, 1H); 8.33 (s, 1H); 8.24 (d, J=8.0, 1H); 7.86 (dd, J=8.2, 2.2, 1H); 7.73 (dd, J=13.5, 2.5, 1H); 7.38 (t, J=9.0, 1H); 7.22-7.18 (m, 1H); 6.65-6.60 (m, 2H); 4.80-4.60 (m, 1H); 3.40 (s, 2H); 2.55-2.50 (m, 3H); 2.38-2.30 (m, 2H); 1.92-1.80 (m, 2H); 1.78-1.65 (m, 2H); 0.67-0.62 (m, 2H); 0.44-0.40 (m, 2H). MS (m/z): 536.6 (M+1).
322	180	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79(s, 1H), 8.42(d, J = 5.6 Hz, 1H), 7.90(s, 1H), 7.76(s, 1H), 7.72(dd, J = 2.4 and 13.6 Hz, 1H), 7.65(s, 1H), 7.35(t, J = 9.2 Hz, 1H), 7.22-7.16(m, 1H), 6.64(s, 1H), 6.54(d, J = 5.6 Hz, 1H), 4.37(bs, 1H), 4.13(t, J = 5.6 Hz, 2H), 3.47(bs, 2H), 2.65(t, J = 6.0 Hz, 2H), 2.59-2.51(m, 1H), 2.50-2.30(m, 8H), 2.36(t, J = 6.0 Hz, 2H), 0.68-0.61(m, 2H), 0.46-0.40(m, 2H). MS (m/z): 566.6 (M+1).

Compound **323** (example **181**) was synthesized by following the procedures described above for the synthesis of compound **315** (example **173**, scheme 69). Compounds **324-328** (examples **182-186**) and **330** (example **188**) were prepared in one step from compound **47** similarly to compound **48** (example **31**, scheme 15). Compound **329** (example **187**) was obtained by alkaline hydrolysis of compound **328** by following the procedure similar to the one described above for the synthesis of compound **31** (example **17**, scheme 13).


Table 25. Characterization of compounds **323-330** (examples **181-188**)

Cpd	Ex.	Structure	Characterization
323	181	 (S)-1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ(ppm): 8.71 (s, 1H); 8.57 (d, J=1.6 Hz, 1H); 8.52 (d, J=5.5 Hz, 1H); 8.33 (s, 1H); 8.25 (d, J=8.2 Hz, 1H); 7.88 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.5 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=8.4 Hz, 1H); 6.64 (d, J=5.5 Hz, 1H); 6.57 (d, J=2.3 Hz, 1H); 5.21 (dt, J= 54.6, 6.5 Hz, 1H); 3.70 (s, 2H); 2.86-2.52 (m, 4H); 2.39-2.34 (m, 1H); 2.22-2.10 (m, 1H); 1.94-1.87 (m, 1H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 522.7 (M+1).
324	182	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(pyridin-3-ylmethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ(ppm): 8.71 (s, 1H); 8.54-8.45 (m, 4H); 8.32 (s, 1H); 8.24 (dd, J=8.2, 0.6 Hz, 1H); 7.85 (dd, J=8.4, 2.2 Hz, 1H); 7.75-7.68 (m, 2H); 7.40-7.33 (m, 2H); 7.20 (dd, J=9.2 1.6 Hz, 1H); 6.64 (dd, J=5.5, 1.0 Hz, 1H); 6.57 (d, J=2.7 Hz, 1H); 3.55 (s, 2H); 3.50 (s, 2H); 2.57-2.54 (m, 1H); 2.41 (br. s, 8H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 610.8 (MH)+
325	183	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ(ppm): 8.71 (s, 1H); 8.55-8.49 (m, 4H); 8.32 (s, 1H); 8.24 (d, J=8.2, Hz, 1H); 7.85 (dd, J=8.0, 2.0 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.31 (dd, J= 5.7, 1.4 Hz, 2H); 7.20 (br d, J=8.8 Hz, 1H); 6.64 (dd, J=5.5, 0.8 Hz, 1H); 6.57 (d, J=2.7 Hz, 1H); 3.56 (s, 2H); 3.50 (s, 2H); 2.58-2.54 (m, 1H); 2.42 (br. s, 8H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 610.7 (M+1).

Cpd	Ex.	Structure	Characterization
326	184	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(pyridin-2-ylmethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ(ppm): 8.71 (s, 1H); 8.54 (d, J=1.4 Hz, 1H); 8.52 (d, J=5.5 Hz, 1H); 8.48 (d, J=4.1 Hz, 1H); 8.32 (s, 1H); 8.24 (d, J=8.0 Hz, 1H); 7.85 (dd, J=8.2, 2.0 Hz, 1H); 7.73-7.71 (dd, m, 2H); 7.43-7.36 (m, 2H); 7.26-7.19 (m, 2H); 6.64 (d, J=5.5 Hz, 1H); 6.57 (d, J=2.5 Hz, 1H); 3.57 (s, 2H); 3.56 (s, 2H); 2.57-2.53 (m, 1H); 2.45 (br. s, 8H); 0.67-0.64 (m, 2H); 0.45-0.42 (m, 2H). MS (m/z): 610.5 (M+1).
327	185	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.78 (s, 1H); 8.55 (br. s, 1H); 8.52 (d, J=5.3 Hz, 1H); 8.33 (s, 1H); 8.24 (d, J=8.0 Hz, 1H); 7.86 (dd, J=8.2, 2.0 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (br. d, J=9.0 Hz, 1H); 6.65 (d, J=5.3 Hz, 1H); 6.61 (d, J=2.3 Hz, 1H); 3.56-3.39 (m, 8H); 2.58-2.45 (m, 11H, overlaps with the residual signal of the solvent); 0.68-0.63 (m, 2H); 0.45-0.42 (m, 2H). [OH-proton is not seen]. MS (m/z): 607.6 (M+1).
328	186	 methyl 2-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yloxy)acetate	MS (m/z): 606.5 (M+1).
329	187	 2-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yloxy)acetic acid	MS (m/z): 592.5 (M+1).

Cpd	Ex.	Structure	Characterization
330	188	 3-(1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)propanoic acid	MS (m/z): 590.6 (M+1).

Scheme 70



WO 2009/109035 A1

Example 189




1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-morpholinoethoxy)phenylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (331)




To a solution of the aldehyde **47** (0.161 g, 0.359 mmol), 4-(2-morpholinoethoxy)aniline (0.120 g, 0.540 mmol), and dibutyltin dichloride (0.197 g, 0.648 mmol) in DMF (5 mL) was added a solution of phenylsilane (0.047 g, 0.434 mmol) in DMF (2 mL). The reaction mixture was stirred for 3 hours at RT and treated with a mixture of brine/sat. NaHCO₃ solution. A precipitate was formed which was collected by filtration, washed with water and dried. Crude material was purified by flash column chromatography, eluent a 10 to 20% gradient of MeOH in AcOEt - to afford the title compound **331** (139 mg, 59.1% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.72 (s, 1H); 8.62 (d, J=1.6 Hz, 1H); 8.51 (dd, J=5.5 Hz, 1H); 8.30 (s, 1H); 8.22 (d, J=8.2 Hz, 1H); 7.88 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.5 Hz, 1H); 7.38 (t, J=9.2 Hz, 1H); 7.20 (dd, J=8.8 1.2 Hz, 1H); 6.72-6.69 (m, 2H); 6.63 (dd, J=5.5, 0.8 Hz 1H); 6.58-6.54 (m, 3H); 5.95 (t, J=6.3 Hz, 1H); 4.30 (d, J=6.1 Hz, 2H); 3.82 (t, J=5.9 Hz, 2H); 3.55 (t, J=4.5 Hz, 4H); 2.60 (t, J=5.7 Hz, 2H); 2.57-2.62 (m, 1H); 2.42 (t, J= 4.5 Hz, 4H); 0.68-0.63 (m, 2H); 0.47-0.41 (m, 2H). MS (m/z): 655.6 (M+1)⁺


Compounds **332 - 335** and **339-341** (examples **190-193** and **197-199**, table 26) were synthesized by following the procedures similar to the one described above for the synthesis of compound **331** (example **190**, scheme 70).

5

Table 26. Characterization of compounds **332-341** (examples **190 -199**)


Cpd	Ex.	Structure	Characterization
332	190	 1-(4-(2-(5-((1H-Pyrazol-3-ylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 11.5 (br. s, 1H); 8.69 (s, 1H); 8.60 (d, J=1.4 Hz, 1H); 8.51 (d, J=5.5, 1H); 8.28 (s, 1H); 8.20 (d, J=8.0 Hz, 1H); 7.89 (dd, J=8.0, 2.2 Hz, 1H); 7.72 (dd, J=13.5, 2.5 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.35 (br. s, 1H); 7.20 (dd, J=8.6, 1.4 Hz, 1H); 6.63 (dd, J=5.5, 0.8 Hz, 1H); 6.56 (d, J=2.7 Hz, 1H); 5.83 (br. s, 1H); 5.50 (br. s, 1H); 4.30 (d, J= 6.3 Hz, 2H); 2.57-2.54 (m, 1H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 516.4 (M+1).
333	191	 1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((5-methyl-1H-pyrazol-3-ylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 11.19 (br. s, 1H); 8.70 (s, 1H); 8.58 (d, J=2.0 Hz, 1H); 8.51 (d, J=5.5, 1H); 8.28 (s, 1H); 8.20 (d, J=8.0 Hz, 1H); 7.88 (dd, J=8.0, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (dd, J=9.0, 1.4 Hz, 1H); 6.63 (d, J=5.5, Hz, 1H); 6.57 (d, J=2.5 Hz, 1H); 5.72 (br. s, 1H); 5.26 (s, 1H); 4.26 (d, J= 6.1 Hz, 2H); 2.58-2.52 (m, 1H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 530.5 (M+1)
334	192	 1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((1-methyl-1H-pyrazol-3-ylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.70 (s, 1H); 8.60 (d, J=2.0 Hz, 1H); 8.51 (d, J=5.5, 1H); 8.29 (s, 1H); 8.21 (d, J=8.0 Hz, 1H); 7.89 (dd, J=8.0, 2.2 Hz, 1H); 7.73 (dd, J=13.7, 2.5 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.31 (d, J=2.2 Hz, 1H); 7.20 (dd, J=8.8, 1.4 Hz, 1H); 6.63 (dd, J=5.5, 0.8 Hz, 1H); 6.57 (d, J=2.3 Hz, 1H); 5.83 (t, J=6.5 Hz, 1H); 5.45 (d, J=2.3 Hz, 1H); 4.28 (d, J= 6.3 Hz, 2H); 2.58-2.52 (m, 1H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 530.4 (M+1).

Cpd	Ex.	Structure	Characterization
335	193	 1-cyclopropyl-3-(4-(2-(5-((1,5-dimethyl-1H-pyrazol-3-ylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H); 8.58 (d, J=2.0 Hz, 1H); 8.51 (d, J=5.5, 1H); 8.29 (s, 1H); 8.20 (dd, J=8.0, 0.6 Hz, 1H); 7.88 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (dd, J=9.0, 1.4 Hz, 1H); 6.63 (dd, J=5.5, 0.8 Hz, 1H); 6.58 (d, J=2.5 Hz 1H); 5.71 (t, J=6.7 Hz, 1H); 5.29 (d, J=0.6 Hz, 1H); 4.24 (d, J=6.3 Hz, 2H); 3.46 (s, 3H); 2.58-2.52 (m, 1H); 2.09 (d, J=0.4 Hz, 3H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 544.3 (M+1).
339	197	 1-cyclopropyl-3-(4-(2-(5-((4-(3-(dimethylamino)propyl)phenylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79 (s, 1H); 8.62 (d, J=1.4 Hz, 1H); 8.51 (d, J=5.5 Hz, 1H); 8.30 (s, 1H); 8.23 (d, J=8.2 Hz, 1H); 7.89 (dd, J=8.2, 2.0 Hz, 1H); 7.73 (dd, J=13.7, 2.5 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (br. d, J=10.2 Hz, 1H); 6.89 (d, J=8.4 Hz, 2H); 6.64-6.61 (m, 2H); 6.54 (d, J=8.4 Hz, 2H); 6.20 (t, J=6.3 Hz, 1H); 4.33 (d, J=2.3 Hz, 2H); 2.57-2.53 (m, 1H); 2.42-2.32 (m, 4H); 2.26 (s, 6H); 1.68-1.60 (m, 2H); 0.67-0.63 (m, 2H); 0.44-0.41 (m, 2H). MS (m/z): 611.6 (M+1).
340	198	 4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methylamino)-N-(2-(diethylamino)ethyl)benzamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80 (s, 1H); 8.64 (d, J=1.6 Hz, 1H); 8.51 (d, J=5.5 Hz, 1H); 8.31 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.96 (br. t, 1H); 7.89 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.5 Hz, 1H); 7.59 (d, J=8.8 Hz, 2H); 7.38 (t, J=9.2 Hz, 1H); 7.20 (dd, J=9.0, 1.2 Hz, 1H); 6.87 (t, J=6.1 Hz, 1H); 6.64-6.61 (m, 4H); 4.42 (d, J=5.9 Hz, 2H); 3.30-3.23 (m, 2H), 2.57-2.52 (m, 3H); 0.98-0.67 (m, 6H); 0.66-0.63 (m, 2H); 0.44-0.41 (m, 2H). MS (m/z): 668.5 (M+1).


Cpd	Ex.	Structure	Characterization
341	199	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((3-(2-morpholinoethoxy)phenylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.81 (s, 1H); 8.62 (d, J=1.6 Hz, 1H); 8.51 (d, J=5.3 Hz, 1H); 8.30 (s, 1H); 8.22 (d, J=8.2 Hz, 1H); 7.88 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=16.0, 2.5 Hz, 1H); 7.37 (t, J=9.0 Hz, 1H); 7.20 (br. d, J=9.0 Hz, 1H); 6.94 (t, J=8.0 Hz, 1H); 6.66 (d, J=2.5 Hz, 2H); 6.63 (d, J=5.5, Hz 1H); 6.35 (t, J=6.3 Hz, 1H); 6.23 (dd, J=7.2, 1.4 Hz, 1H); 6.14-6.119 (m, 2H); 4.35 (d, J=6.1 Hz, 2H); 3.96 (t, J=5.9 Hz, 2H); 3.54 (t, J=4.7 Hz, 4H); 2.61 (t, J=5.9 Hz, 2H); 2.57-2.52 (m, 1H); 2.45-2.41 (t, J= 4.5 Hz, 4H); 0.67-0.63 (m, 2H); 0.44-0.41 (m, 2H). MS (m/z): 655.7 (M+1).

*For the synthesis of (2,5,8,11-Tetraoxatridecan-13-yloxy)anilines see scheme 99.

Scheme 71



WO 2009/109035 A1



343: Example 200

Example 200

1-(4-(2-(5-((4-Aminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (343)

Step 1. tert-Butyl 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-ylcarbamate (342)




tert-Butyl piperidin-4-ylcarbamate (1.34 g, 6.69 mmol) was added to a solution of the aldehyde **47** (2.0 g, 4.46 mmol) in a mixture of NMP (20 mL) and glacial AcOH (0.250 mL). The reaction mixture was stirred for 30 min. NaBH(OAc)₃ was then added and the reaction mixture was stirred for an additional 2.5 hours. The reaction mixture was then poured into a saturated aqueous NaHCO₃ solution. A precipitate was formed which was collected by filtration, washed with water and air-dried. The crude material was purified by column chromatography using a 5 to 20% gradient of MeOH in EtOAc as eluent to afford the title compound **343** (1.45 g, 51.4 % yield). MS (m/z): 633.6 (M+1)+.





Step 2. 1-(4-(2-(5-((4-Aminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (**343**).




A solution of the Boc-protected compound **342** in TFA (25 mL) was stirred at RT for 1.5 hours then evaporated. To the residue was added 3N aqueous NaOH solution and the suspension was stirred at RT overnight, collected by filtration, washed with water and dried to afford the title compound **343** (1.177 g, 96 % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ(ppm): 8.75 (s, 1H); 8.53-8.51 (m, 2H); 8.32 (s, 1H); 8.23 (d, J=8.2 Hz, 1H); 7.84 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (dd, J=8.8 1.2 Hz, 1H); 6.64 (d, J=5.5 Hz 1H); 6.61 (d, J=2.3 Hz, 1H); 3.52 (s, 2H); 2.74 (d, J=11.3 Hz, 2H); 2.58-2.52 (m, 1H); 1.99 (t, J=9.8 Hz, 2H); 1.66 (d, J=11.3 Hz, 2H); 1.29-1.20 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). [Signal of the NH₂-group is not seen; NH₂-CH-signal is obscured by the peak of residual water]. MS (m/z): 533.5 (M+1)+.




Compound **342-A** (example **199-A**) was synthesized similarly to compound **342** from the aldehyde **47** and *tert*-butyl methyl(piperidin-4-yl)carbamate. Compounds **344-350** (examples **201-207**) were synthesized starting from the compound **343** (scheme 71), by following the procedures similar to the described above for the synthesis of compounds **30** and **31** (scheme 13). Compounds **351-355** (examples **208-212**) were prepared in one step from compound **343** similarly to compound **128** (example 87, scheme 32).


Table 27. Characterization of compounds 342-A, 344-355 (examples 199-A, 201 -212)

Cpd	Ex.	Structure	Characterization
342-A	199-A	 tert-butyl 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl(methyl)carbamate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H), 8.55 (d, J = 1.6 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.86 (dd, J = 8.1, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.2 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.0 Hz, 1H), 6.58 (bd, J = 2.8 Hz, 1H), 3.55 (s, 2H), 3.35-3.28 (m, 1H), 2.93-2.85 (m, 2H), 2.67 (s, 3H), 2.60-2.52 (m, 1H), 2.07-1.97 (m, 2H), 1.75-1.62 (m, 2H), 1.55-1.44 (m, 2H), 1.39 (s, 9H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 647.6 (M+1).
344	201	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H); 8.54 (d, J=1.6 Hz, 1H); 8.52 (d, J=5.3, 1H); 8.32 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.85 (dd, J=8.2, 2.0 Hz, 1H); 7.77 (d, J=7.4 Hz, 1H); 7.73 (dd, J=13.7, 2.5 Hz, 1H); 7.38 (t, J=9.2 Hz, 1H); 7.20 (d, J=8.8 Hz, 1H); 6.64 (d, J=5.3 Hz 1H); 6.57 (d, J=2.3 Hz 1H); 3.53 (s, 2H); 3.50 (br. s, 1H); 2.77 (br. d, J=11.3 Hz, 2H); 2.58-2.51 (m, 1H); 2.04 (br. t, J=11.0 Hz, 2H); 1.77 (s, 3H); 1.71 (br. d, J=11.3 Hz, 2H); 1.42-1.37 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 575.5 (M+1).
345	202	 2-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-ylamino)-2-oxoethyl acetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H); 8.54 (d, J=1.6 Hz, 1H); 8.52 (d, J=5.5, 1H); 8.33 (s, 1H); 8.24 (d, J=8.0 Hz, 1H); 7.92 (d, J=7.8 Hz, 1H); 7.85 (dd, J=8.0, 2.0 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=8.8 Hz, 1H); 6.64 (d, J=5.1 Hz 1H); 6.57 (d, J=2.5 Hz 1H); 4.40 (s, 2H); 3.58 (br. s, 1H); 3.54 (s, 2H); 2.78 (br. d, J=11.5 Hz, 2H); 2.58-2.53 (m, 1H); 2.50-2.03 (m, 5H); 1.70 (br. d, J=10.2 Hz, 2H); 1.49-1.41 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 633.6 (M+1)

Cpd	Ex.	Structure	Characterization
346	203	 N-(1-((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-2-hydroxyacetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H); 8.54 (d, J=1.4 Hz, 1H); 8.52 (d, J=5.3, 1H); 8.32 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.85 (dd, J=8.0, 2.0 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.52 (d, J=8.2 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=8.8 Hz, 1H); 6.64 (d, J=5.3 Hz, 1H); 6.57 (d, J=2.3 Hz, 1H); 5.41 (t, J=5.9 Hz, 1H); 3.77 (d, J=5.9 Hz, 2H); 3.62-3.60 (m, 1H); 2.78 (br. d, J=11.3 Hz, 2H); 2.57-2.53 (m, 1H); 2.06 (br. t, J=11.0 Hz, 2H); 1.67 (br. d, J=9.8 Hz, 2H); 1.54-1.49 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 591.5 (M+1).
347	204	 N-(1-((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-3-(1H-1,2,4-triazol-1-yl)propanamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.73 (s, 1H); 8.54 (d, J=1.6 Hz, 1H); 8.52 (d, J=5.5, 1H); 8.39 (s, 1H); 8.32 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.93 (s, 1H); 7.88 (d, J=7.8 Hz, 1H); 7.84 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=9.0 Hz, 1H); 6.64 (d, J=5.5 Hz, 1H); 6.59 (d, J=2.5 Hz, 1H); 4.37 (t, J=6.7 Hz, 2H); 3.52 (br. s, 3H); 2.74 (br. d, J=11.5 Hz, 2H); 2.62 (t, J=6.8 Hz, 2H); 2.58-2.53 (m, 1H); 2.03 (br. t, J=10.8 Hz, 2H); 1.66 (br. d, J=9.6 Hz, 2H); 1.37-1.32 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 656.7 (M+1).
348	205	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-3-(pyridin-3-yl)propanamide	MS (m/z): 666.5 (M+1).
349	206	 N-(1-((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-3-hydroxypropanamide	MS (m/z): 605.4 (M+1).

Cpd	Ex.	Structure	Characterization
350	207	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)methanesulfonamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.70 (s, 1H); 8.54 (s, 1H); 8.52 (d, J=15.3 Hz, 1H); 8.32 (s, 1H); 8.24 (d, J=8.0 Hz, 1H); 7.85 (d, J=8.2, Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (dd, J=9.0, 1.2 Hz, 1H); 7.06 (d, J=7.2 Hz, 1H); 6.56 (dd, J=5.5, 0.8 Hz 1H); 6.56 (d, J=2.5 Hz 1H); 3.54 (s, 2H); 2.90 (s, 3H); 2.77 (br. d, J=10.6 Hz, 2H); 2.57-2.54 (m, 1H); 2.06 (br. t, Hz, 2H); 1.82 (br. d, J=9.4 Hz, 2H); 1.49-1.47 (m, 2H); 0.67-0.63 (m, 2H); 0.45-0.42 (m, 2H). [NH-CH ₂ -signal is probably obscured by the peak of residual water]. MS (m/z): 611.6 (M+1).
351	208	 Ethyl 1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-ylcarbamate	MS (m/z): 605.6 (M+1).
352	209	 1-(4-(2-(5-((4-Methylaminocarbonylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H); 8.54 (d, J=1.6 Hz, 1H); 8.52 (d, J=5.5 Hz, 1H); 8.32 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.85 (dd, J=8.2, 2.2 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (dd, J=9.0, 1.2 Hz, 1H); 6.65 (dd, J=5.3, 0.6 Hz, 1H); 6.57 (d, J=2.5 Hz, 1H); 5.80 (d, J=8.0 Hz 1H); 5.59 (dd, J=9.2, 4.3 Hz, 1H); 3.53 (s, 2H); 2.73-2.70 (m, 2H); 2.58-2.53 (m, 1H); 2.52 (s, 3H); 2.09-2.04 (m, 2H); 1.76-1.71 (m, 2H); 1.37-1.29 (m, 2H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). [The NH-CH ₂ -signal is probably obscured by the peak of residual water]. MS (m/z): 590.6 (M+1).

Cpd	Ex.	Structure	Characterization
353	210	 1-(4-(2-(5-((4-Ethylaminocarbonylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.70 (s, 1H); 8.54 (d, J=1.4 Hz, 1H); 8.52 (d, J=5.5 Hz, 1H); 8.32 (s, 1H); 8.23 (d, J=8.0 Hz, 1H); 7.85 (dd, J=8.0, 2.0 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=8.8 Hz, 1H); 6.65 (d, J=4.7 Hz, 1H); 6.56 (d, J=2.3 Hz, 1H); 5.72 (d, J=7.8 Hz, 1H); 5.65 (t, J=5.5 Hz, 1H); 3.53 (s, 2H); 3.01-2.94 (m, 2H); 2.72 (br. d, J=11.3 Hz, 2H); 2.57-2.54 (m, 1H); 2.07 (br. t, J=11.2 Hz, 2H); 1.73 (br. d, J=10.0 Hz, 2H); 1.36-1.31 (m, 2H); 0.96 (t, J=7.0 Hz, 3H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). MS (m/z): 604.6 (M+1).
354	211	 1-(4-(2-(5-((4-Propylaminocarbonylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H); 8.54 (br. s, 1H); 8.52 (d, J=5.5 Hz, 1H); 8.33 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.85 (dd, J=8.2, 1.8 Hz, 1H); 7.73 (dd, J=13.5, 2.3 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (br. d, J=8.6 Hz, 1H); 6.64 (d, J=5.5 Hz, 1H); 6.58 (d, J=2.0 Hz, 1H); 5.74-5.70 (m, 2H); 3.53 (s, 2H); 2.94-2.89 (m, 2H); 2.71 (br. d, J=11.2 Hz, 2H); 2.57-2.52 (m, 1H); 2.10-2.05 (m, 2H); 1.73 (br. d, J=9.8 Hz, 2H); 1.39-1.27 (m, 4H); 0.81 (t, J=7.4 Hz, 3H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). [The NH-CH-signal is probably obscured by the peak of residual water]. MS (m/z): 618.6 (M+1).
355	212	 1-(4-(2-(5-((4-Isopropylaminocarbonylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.72 (s, 1H); 8.54 (d, J=1.4 Hz, 1H); 8.52 (d, J=5.3 Hz, 1H); 8.33 (s, 1H); 8.24 (d, J=8.2 Hz, 1H); 7.85 (dd, J=8.0, 1.9 Hz, 1H); 7.73 (dd, J=16.0, 2.5 Hz, 1H); 7.38 (t, J=9.0 Hz, 1H); 7.20 (d, J=9.0 Hz, 1H); 6.65 (d, J=5.3 Hz, 1H); 6.58 (d, J=2.3 Hz, 1H); 5.64 (d, J=7.8 Hz, 1H); 5.56 (d, J=7.6 Hz, 1H); 3.65-3.60 (m, 1H); 3.53 (s, 2H); 2.70 (br. d, J=11.0 Hz, 2H); 2.57-2.52 (m, 1H); 2.10-2.05 (m, 2H); 1.73 (br. d, J=9.6 Hz, 2H); 1.31-1.29 (m, 2H); 1.00 (d, J=6.5 Hz, 6H); 0.68-0.63 (m, 2H); 0.45-0.41 (m, 2H). [One of NH-CH-signal is probably obscured by the peak of residual water]. MS (m/z): 618.6 (M+1).



Example 213

N-(1-(((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-4-methylpiperazine-1-carboxamide (357)

Step 1. Phenyl 1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)carbamate (356)

To a solution of the amine **343** (0.9 g, 1.69 mmol) in NMP (10 mL) at 0°C was added pyridine (0.3 mL, 3.71 mmol) followed by the chloroformate (0.3 mL, 2.38 mmol). The mixture was stirred for 40 min at 0°C then at room temperature for 120 min, quenched by addition of brine/ NaHCO₃ solution. A precipitate was formed which was collected by filtration and dried. The crude material was purified by flash column chromatography, eluent a 5 to 10% gradient of MeOH (containing 2% ammonia) in DCM, to afford the title compound **356** (0.528 g, 47.9 % yield). **MS (m/z): 653.6 (M+1)+.**

Step 2. N-(1-(((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-4-methylpiperazine-1-carboxamide (357).

To a solution of the phenylcarbamate **356** (0.11 g, 0.169 mmol) in DMF at RT was added the N-methylpiperazine (0.057 mL, 0.51 mmol). The reaction mixture was heated at 90-95°C for 2 hours, cooled to RT then treated with brine and saturated NaHCO₃ solution. A precipitate was formed which was collected by filtration and dried. The crude material was purified by flash column chromatography, eluent 12 to 30% MeOH (containing 2% ammonia) in DCM, to afford the title compound **357** (0.088 g, 79 % yield). ¹H NMR (400 MHz, CD₃OD-*d*₆) δ(ppm): 8.65 (d, J=1.4 Hz, 1H); 8.47 (d, J=5.5 Hz, 1H); 8.15-8.11 (m, 2H); 7.98 (dd, J=8.2, 2.0 Hz, 1H); 7.67 (dd, J=13.1, 2.3 Hz, 1H); 7.30 (t, J=9.0 Hz, 1H); 7.20 (br. d, J=9.0 Hz, 1H);

6.64 (d, J=5.5 Hz 1H); 3.94 (s, 2H); 3.68-3.65 (m, 1H); 3.57 (br. s, 4H); 3.18 (br. d, J=10.4 Hz, 2H); 2.89 (br. s, 4H); 2.65 (s, 3H); 2.63-2.58 (m, 3H); 1.98 (br. d, J=11.7 Hz, 2H); 1.69 (br. d, J=11.0 Hz, 2H); 0.79-0.74 (m, 2H); 0.55-0.52 (m, 2H). [Signals of NH-protons are not seen]. MS (m/z): 659.5 (M+1)+

5


Example 214

1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((4-((2-hydroxyethyl-methylamino)carbonylamino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (358)

10 Title compound **358** was obtained by following the procedure described above for the synthesis of compound 357 (example 214). ¹H NMR (400 MHz, CD₃OD-*d*₆) δ(ppm): 8.60 (d, J=1.6 Hz, 1H); 8.47 (d, J=5.7 Hz, 1H); 8.12-8.09 (m, 2H); 7.93 (dd, J=8.0, 2.2 Hz, 1H); 7.67 (dd, J=13.1, 2.5 Hz, 1H); 7.30 (t, J=8.8 Hz, 1H); 7.20 (dd, J=8.8, 1.4 Hz, 1H); 6.64 (dd, J=5.5, 1.0 Hz 1H); 3.72 (s, 2H); 3.66 (t, J=5.5 Hz, 2H); 3.63-3.57 (m, 1H); 3.37 (t, J=5.2 Hz, 2H); 2.98 (br. d, J=11.2 Hz, 2H); 2.93 (br. s, 3H); 2.63-2.58 (m, 1H); 2.33 (br. t, J=11.0 Hz, 2H); 1.92 (br. d, J=10.0 Hz, 2H); 1.65-1.55 (m, 2H); 0.90-0.74 (m, 2H); 0.55-0.52 (m, 2H). [Signals of OH- and NH-protons are not seen]. MS (m/z): 634.5 (M+1)+.

Scheme 73

20



Example 215

1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (362)

5 Step 1: 7-(2-Fluoro-4-nitrophenoxy)-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridine, (360)

To a solution of NaN₃ (49.6 mg, 0.764 mmol) in DMSO (5 mL) was added 1-(2-chloroethyl)pyrrolidine (102 mg, 1.2 eq, 0.764 mmol) and KI (127 mg, 1.2 eq, 0.764 mmol) and the reaction mixture was stirred for 12 hrs at RT. Compound **359** (200 mg, 0.636 mmol) and
10 Cu(OAc)₂·H₂O (34.7 mg, 0.3 eq, 0.191 mmol) were added and the deep red reaction mixture was allowed to stir at RT over 24 hrs. The mixture was then diluted with water and the precipitated solid was collected by filtration to afford the title compound **360** (150 mg, 52% yield) that was used in the next step with no additional purification. MS (m/z): 455.5 (M+H).

15 Step 2: 3-Fluoro-4-(2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)aniline (361)

To a solution of **360** (150 mg, 0.329 mmol) in MeOH (10 mL) was added ammonium chloride (35.3 mg, 2 eq, 0.660 mmol) in water (1 mL) and zinc powder (86 mg, 4 eq, 1.320 mmol) and the reaction mixture was heated to reflux for 3 hours. The mixture was cooled to RT then filtered and the filtrate was concentrated under reduced pressure. The residue was
20 dissolved in DCM and washed with water. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford the title compound **361** (98 mg, 70% yield) that was used in the next step with no additional purification. MS (m/z): 425.5 (M+H)



Step 3: 1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (362).




25 To a stirred solution of **361** (98 mg, 0.231 mmol) and pyridine (0.057 mL, 3 eq, 0.9 mmol) in DMF (5 mL) at 0°C under nitrogen was added phenyl chloroformate (0.072 mL, 2.5 eq, 0.577 mmol) and the reaction mixture was stirred at 0°C for 2 hrs. Cyclopropylamine (66 mg, 5 eq, 1.154 mmol) was added and the reaction mixture was heated at 55°C for 5 hrs. The reaction mixture was then diluted with EtOAc, washed sequentially with sodium bicarbonate solution,
30 saturated ammonium chloride solution and brine, then dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (eluent EtOAc to 30% MeOH in EtOAc) to afford the title compound **362** (50 mg, 42% yield) as a white solid after additional trituration with Et₂O. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.8 (s, 1H), 8.71 (s, 1H), 8.48 (d, J = 5.48 Hz, 1H), 7.91 (s, 1H), 7.70 (m, 1H), 7.36 (m, 1H), 7.18 (d, J = 8.99 Hz,


1H), 6.61 (d, J = 5.48 Hz, 1H), 6.55 (s, 1H), 4.55 (m, 2H), 2.93 (m, 2H), 2.50 (m, 1H), 1.67 (m, 4H), 0.65 (m, 2H), 0.41 (m, 2H). MS (m/z): 508.54.

Compounds **363-369** (examples **216-222**) were synthesized starting from the compound **359** (scheme 73) by following the procedures similar to the described above for the synthesis of compound **362** (example **215**, scheme 73).


Table 28. Characterization of compounds **363-369** (examples **216-222**)

Cpd	Ex.	Structure	Characterization
363	216	 1-cyclopropyl-3-(4-(2-(1-(2-(diethylamino)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.76 (s, 1H), 8.71 (s, 1H), 8.48 (d, J = 5.28 Hz, 1H), 7.89 (s, 1H), 7.71 (m, 1H), 7.36 (t, J = 8.99 Hz, 1H), 7.18 (m, 1H), 6.61 (d, J = 5.28 Hz, 1H), 6.56 (s, 1H), 4.46 (t, J = 6.26 Hz, 2H), 2.84 (t, J = 6.26 Hz, 2H), 2.53 (m, 4H), 1.08 (t, J = 7.04 Hz, 6H), 0.64 (m, 2H), 0.41 (m, 2H). MS (m/z): 510.15 (M+H).
364	217	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.94 (s, 1H), 7.72 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.63 (m, 1H), 6.57 (m, 1H), 4.58 (t, J = 6.26 Hz, 2H), 3.55 (m, 4H), 2.80 (t, J = 6.26 Hz, 2H), 2.52 (m, 1H), 2.45 (m, 4H), 0.65 (m, 2H), 0.42 (m, 2H). MS (m/z): 524.49 (M+H).

Cpd	Ex.	Structure	Characterization
365	218	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.0 (s, 1H), 8.67 (s, 1H), 8.45 (d, <i>J</i> = 5.49 Hz, 1H), 7.92 (s, 1H), 7.70 (m, 1H), 7.34 (t, <i>J</i> = 9.19 Hz, 1H), 6.89 (d, <i>J</i> = 5.47 Hz, 1H), 5.57 (s, 2H), 3.45 (m, 4H), 3.43 (m, 4H), 2.49 (m, 1H), 2.35 (m, 4H), 2.26 (m, 4H), 2.17 (s, 3H), 0.6 (m, 2H), 0.42 (m, 4H). MS (<i>m/z</i>): 551.53 (M+H)
367	220	 1-cyclopropyl-3-(4-(2-(1-(2-(dimethylamino)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80 (s, 1H), 8.50 (d, <i>J</i> = 5.28 Hz, 1H), 7.91 (s, 1H), 7.73 (m, 1H), 7.38 (t, <i>J</i> = 8.99 Hz, 1H), 7.20 (m, 1H), 6.63 (m, 2H), 4.54 (t, <i>J</i> = 6.07 Hz, 2H), 3.35 t, <i>J</i> = 6.07 Hz, 2H), 2.20 (s, 6H), 0.65 (m, 2H), 0.43 (m, 2H). MS (<i>m/z</i>): 482.43 (M+H)
368	221	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholino-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.79 (s, 1H) 8.71 (s, 1H), 8.50 (d, <i>J</i> = 5.48 Hz, 1H), 7.97 (s, 1H), 7.70 (m, 1H), 7.39 (t, <i>J</i> = 8.99 Hz, 1H), 7.38 (m, 1H), 6.64 (m, 2H), 5.62 (s, 2H), 3.69 (m, 2H), 3.61 (m, 2H), 3.55 (m, 2H), 3.48 (m, 2H), 0.65 (m, 2H), 0.42 (m, 2H). MS (<i>m/z</i>): 538.4 (M+H)

Cpd	Ex.	Structure	Characterization
369	222	 Methyl 3-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)propanoate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.82 (s, 1H), 8.70 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.91 (s, 1H), 7.72 (m, 1H), 7.38 (t, J = 9.20 Hz, 1H), 7.20 (m, 1H), 6.63 (d, J = 5.48 Hz, 1H), 6.56 (s, 1H), 4.68 (t, J = 6.65 Hz, 2H), 3.62 (s, 3H), 3.07 (t, J = 6.65 Hz, 2H), 2.55 (m, 1H), 0.64 (m, 2H), 0.43 (m, 2H). MS (m/z): 497.41 (M+H)

Scheme 74



5

Example 223

1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-oxo-2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea

10 Step 1: 4-(2-Ethynylthieno[3,2-b]pyridin-7-yloxy)-3-fluoroaniline (370)

To a solution of **359** (120 mg, 0.382 mmol) in EtOH (5 ml) was added SnCl₂.2H₂O (431 mg, 5 eq, 1.91 mmol) and the reaction mixture was heated to reflux for 30 min (Bellamy, F. D.; Ou, K. *Tetrahedron Lett.* **1984**, 25, 839). The mixture was cooled slightly and poured onto ice. A saturated solution of NaHCO₃ and DCM were added and the resultant cloudy mixture was stirred for 15 min. The mixture was then filtered and biphasic filtrate was allowed to separate.

15

The aqueous phase was extracted with additional DCM and the organic extracts were combined, dried over anhydrous MgSO₄, filtered and concentrated to afford the title compound **370** (102 mg, 94% yield) was used in the next step with no additional purification. MS (m/z): 285.17 (M+H).

5 Step 2: 1-Cyclopropyl-3-(4-(2-ethynylthieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea (**371**)




To a stirred solution of **370** (102 mg, 0.359 mmol) and pyridine (0.058 mL, 2 eq, 0.718 mmol) in THF (5 ml)/DMF (2 ml) at 0°C under nitrogen was added phenyl chloroformate (0.068 mL, 1.5 eq, 0.538 mmol) and the reaction mixture was stirred at 0°C for 1 hr. Cyclopropylamine (102 mg, 5 eq, 1.794 mmol) was added and the reaction mixture was heated
10 at 55°C for 3 hrs. The mixture was then cooled to RT, diluted with EtOAc then washed sequentially with saturated solutions of NH₄Cl, NaHCO₃ and brine. The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified *via* column chromatography (eluent EtOAc to 40% MeOH in EtOAc) to afford the title compound **371** (100 mg, 76% yield) as an off-white powder after trituration with Et₂O. MS (m/z): 368.23 (M+H)




15 Step 3: 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-oxo-2-(piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (**372**)




To a solution of the 2-chloro-1-(piperidin-1-yl)ethanone (106 mg, 2 eq, 0.653 mmol) in DMSO (2 ml) was added sodium azide (42.5 mg, 2 eq, 0.653 mmol) and KI (108 mg, 2 eq, 0.653 mmol) and the reaction mixture was stirred overnight at RT. The alkyne (120 mg, 0.0327
20 mmol), Cu(OAc)₂·2H₂O (17.8 mg, 0.3 eq, 0.098 mmol) and sodium ascorbate (38.8 mg, 0.6 eq, 0.196 mmol) were added and the pale orange mixture was allowed to stir at RT for 15 min. The mixture was then poured onto ice and a few drops of NH₄OH were added (~pH 10). The mixture was extracted with DCM and the organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated. Purification by column chromatography (EtOAc to 20%
25 MeOH in EtOAc) afforded an oil which was dissolved in a mixture of acetone/Et₂O. Additional Et₂O was added; a precipitate was formed which was collected by filtration to afford the title compound **372** (84 mg, 48% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.77 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.96 (s, 1H), 7.73 (m, 1H), 7.39 (t, J = 8.99 Hz, 1H), 7.38 (m, 1H), 6.64 (d, 1H), 6.63 (s, 1H), 5.58 (s, 2H), 3.38 (m, 4H), 2.55 (m, 1H), 1.61
30 (m, 4H), 1.48 (m, 2H), 0.64 (m, 2H), 0.43 (m, 2H). MS (m/z): 536.52 (M+H)




Compounds **373**, **375--388** (examples **224**, **226-239**) were synthesized starting from the compound **359** by following the procedures similar to the described above for the synthesis of compound **372** (example 223, scheme 74).




Table 29. Characterization of compounds 373-388 (examples 224-239)

Cpd	Ex.	Structure	Characterization
373	224	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (m, 2H), 8.52 (s, 1H), 7.98 (s, 1H), 7.73 (m, 1H), 7.39 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.64 (d, J = 5.086 Hz, 1H), 6.56 (s, 1H), 5.48 (s, 1H), 3.57 (t, J = 6.65 Hz, 2H), 3.35 (m, 2H, under H ₂ O peak), 2.54 (m, 2H), 0.65 (m, 2H), 0.43 (m, 2H). MS (m/z): 522.54 (M+H).
375	226	 ethyl 2-(2-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetamido)thiazol-4-yl)acetate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 12.78 (s, 1H), 8.86 (s, 1H), 8.71 (s, 1H), 8.51 (s, 1H), 7.99 (s, 1H), 7.73 (m, 1H), 7.40 (t, J = 8.99 Hz, 1H), 7.19 (m, 1H), 7.06 (s, 1H), 6.64 (d, J = 5.086 Hz, 1H), 6.56 (s, 1H), 5.57 (s, 2H), 4.10 (q, J = 7.043 Hz, 2H), 3.71 (s, 2H), 3.40 (m, 1H), 1.19 (t, J = 7.043 Hz, 3H), 0.64 (m, 2H), 0.43 (m, 2H). MS (m/z): 637.54 (M+H)
376	227	 (S)-1-cyclopropyl-3-(4-(2-(1-(2-(3-(dimethylamino)pyrrolidin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.97 (s, 1H), 7.73 (m, 1H), 7.39 (t, J = 9.19 Hz, 1H), 7.20 (m, 1H), 6.64 (d, J = 5.48 Hz, 1H), 6.56 (s, 1H), 5.59 (s, 2H, rotamer), 3.88 - 3.55 (m, 5 H, rotamers), 2.54 (m, 1H), 2.28 (s, 6H), 2.1-1.7 (m, 2H, rotamers), 0.65 (m, 2H), 0.43 (m, 2H). MS (m/z): 565.58 (M+H)


Cpd	Ex.	Structure	Characterization
377	228	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-morpholino-3-oxopropyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.8 (s, 1H), 8.71 (s, 1H), 7.91 (s, 1H), 7.72 (m, 1H), 7.37 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.64 (s, 1H), 6.57 (s, 1H), 4.66 (t, J = 4.89 Hz, 2H), 3.55 (m, 4H), 3.44 (m, 4H), 3.08 (t, J = 6.84 Hz, 2H), 2.54 (m, 1H), 0.65 (m, 2H), 0.43 (m, 2H). MS (m/z): 552.57 (M+H).
378	229	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-(4-methylpiperazin-1-yl)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.96 (s, 1H), 8.78 (s, 1H), 8.48 (d, J = 5.48 Hz, 1H), 7.89 (s, 1H), 7.72 (m, 1H), 7.35 (t, J = 8.99 Hz, 1H), 7.22 (m, 1H), 6.80 (m, 1H), 6.61 (d, J = 5.38 Hz, 1H), 4.63 (t, J = 6.45 Hz, 2H), 3.05 (t, J = 6.84 Hz, 2H), 2.53 (m, 1H), 2.24 (m, 4H), 2.13 (s, 3H), 0.62 (m, 2H), 0.41 (m, 2H). MS (m/z): 565.51 (M+H)
379	230	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-oxo-3-(piperidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.08 (s, 1H), 8.73 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.91 (s, 1H), 7.72 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.63 (d, J = 5.48 Hz, 1H), 4.64 (t, J = 6.65 Hz, 2H), 3.44 - 3.36 (m, 4 H), 3.05 (t, J = 6.84 Hz, 2H), 2.54 (m, 1H), 1.56 - 1.40 (m, 6H), 0.64 (m, 2H), 0.43 (m, 2H). MS (m/z): 550.57(M+H)

Cpd	Ex.	Structure	Characterization
380	231	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-oxo-3-(pyrrolidin-1-yl)propyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.80 (s, 1H), 8.78 (s, 1H), 8.50 (d, J = 5.47 Hz, 1H), 7.91 (s, 1H), 7.72 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.61 (m, 2H), 4.65 (t, J = 6.65 Hz, 2H), 3.39 (t, J = 6.85 Hz, 2H), 3.28 (t, J = 6.83 Hz, 2H), 2.98 (t, J = 6.65 Hz, 2H), 2.54 (m, 2H), 1.85 (m, 2H), 1.75 (m, 2H), 0.65 (m, 2H), 0.53 (m, 2H). MS (m/z): 536.56 (M+H)
381	232	 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)-N-(pyridin-3-ylmethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.97 (t, J = 5.86 Hz, 1H), 8.81 (s, 1H), 8.73 (s, 1H), 8.51 (m, 3H), 7.98 (s, 1H), 7.72 (m, 2H), 7.39 (m, 2H), 7.21 (m, 1H), 6.63 (d, J = 5.28 Hz, 1H), 6.59 (s, 1H), 5.31 (s, 2H), 4.38 (d, J = 5.67 Hz, 2H), 2.55 (m, 1H), 0.65 (m, 2H), 0.43 (m, 2H) MS (m/z): 559.41 (M+H).
382	233	 tert-butyl 1-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)pyrrolidin-3-ylcarbamate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (m, 2H), 8.48 (d, J = 5.49 Hz, 1H), 7.97 (m, 1H), 7.71 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 7.20 (m, 2H, rotamer), 6.62 (d, J = 5.48 Hz, 1H), 6.55 (s, 1H), 5.46 (m, rotamer, 2H), 4.11 - 3.99 (m, rotamers, 4H), 2.65-1.76 (m, rotamers, 2H), 1.38 (m, rotamers, 9H), 0.65 (m, 2H), 0.43 (m, 2H). MS (m/z): 537.59 (M+H)

Cpd	Ex.	Structure	Characterization
383	234	 2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)-N-(pyridin-2-ylmethyl)acetamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.04 (m, 1H), 8.82 (s, 1H), 8.71 (s, 1H), 8.54 (s, 1H), 7.99 (s, 1H), 7.79 (t, J = 7.43 Hz, 1H), 7.73 (m, 1H), 7.41 (m, 2H), 7.30 (m, 1H), 7.19 (m, 1H), 6.64 (m, 1H), 6.56 (m, 1H), 5.34 (s, 2H), 4.46 (d, J = 5.47 Hz, 2H), 2.54 (m, 1H), 0.65 (m, 2H), 0.42 (mn, 2H). MS (m/z): 559.47
384	235	 1-cyclopropyl-3-(4-(2-(1-(3-(dimethylamino)propyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.18 (s, 1H), 7.32 (s, 1H), 8.48 (d, J = 5.28 Hz, 1H), 7.89 (s, 1H), 7.72 (m, 1H), 7.37 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.61 (d, J = 5.47 Hz, 1H), 6.58 (s, 1H), 4.45 (t, J = 7.043, 2H), 3.35 (m, 1H), 2.23 (t, J = 6.8 Hz, 2H), 2.12 (s, 6H), 2.00 (m, 2H), 0.64 (m, 2H), 0.41 (m, 2H). MS (m/z): 496.43 (M+H)
385	236	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(3-morpholinopropyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.83 (s, 1H), 8.75 (s, 1H), 8.50 (d, J = 5.47 Hz, 1H), 7.90 (s, 1H), 7.72 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 6.63 (d, J = 5.48 Hz, 1H), 6.59 (s, 1H), 4.48 (t, J = 7.04 Hz, 2H), 3.55 (m, 4H), 2.55 (m, 1H), 2.29 (m, 6H), 2.08 (m, 2H), 0.65 (m, 2H), 0.42 (m, 2H). MS (m/z): 538.42 (M+H).

Cpd	Ex.	Structure	Characterization
386	237	 Ethyl 1-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)piperidine-4-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.61 (s, 1H), 8.45 (m, 1H), 7.91 (s, 1H), 7.65 (m, 1H), 7.33 (t, J = 8.99 Hz, 1H), 7.14 (m, 1H), 6.56 (d, J = 5.28 Hz, 1H), 6.52 (s, 1H), 5.56 (d, J = 8.61 Hz, 2H), 4.13 (m, 1H), 4.0 (q, J = 7.04, 2H), 3.82 (m, 1H), 3.54 (m, 1H), 3.14 (m, 1H), 2.77 (m, 2H), 2.61 (m, 2H), 2.50 (m, 1H), 1.83 (m, 2H), 1.68 (m, 1H), 1.21 (m, 1H), 1.13 (t, J = 7.04 Hz, 3H), 0.59 (m, 2H), 0.37 (m, 2H). MS (m/z): 538.42 (M+H)
387	238	 tert-butyl 4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)piperazine-1-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.74 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.96 (s, 1H), 7.72 (m, 1H), 7.39 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.98 (m, 1H), 6.62 (d, J = 5.09 Hz, 1H), 6.59 (s, 1H), 5.67 (d, J = 16.85 Hz, 1H), 5.56 (d, J = 16.62 Hz, 1H), 4.18 (m, 1H), 3.84 (m, 1H), 3.46 (m, 2H), 3.17 (m, 2H), 2.81 (m, 1H), 2.55 (m, 1H), 1.80 (m, 2H), 1.39 (s, 9H), 0.65 (m, 2H), 0.45 (m, 2H). MS (m/z): 651.58 (M+H)
388	239	 tert-butyl 4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)piperazine-1-carboxylate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.71 (s, 1H), 8.70 (s, 1H), 8.48 (s, d, J = 5.48 Hz, 1H), 7.95 (s, 1H), 7.71 (m, 1H), 7.38 (t, J = 8.99 Hz, 1H), 7.18 (m, 1H), 6.61 (d, J = 5.48 Hz, 1H), 6.57 (s, 1H), 5.62 (s, 1H), 3.52 (m, 2H), 3.44 (m, 4H), 3.35 (m, 2H), 2.55 (s, 1H), 1.41 (s, 9H), 0.64 (m, 2H), 8.41 (m, 2H). MS (m/z): 637.45 (M+H)

Scheme 75



5




Example 240




1-Cyclopropyl-3-(3-fluoro-4-(2-(1-(2-oxo-2-(piperazin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (389)

To a solution of **388** (800 mg, 1.256 mmol) in a solvent mixture of DCM (70 mL) and DMF (10 mL) was added HCl in dioxane (0.882 mL, 10 eq, 12.56 mmol, 4.0 M solution) and the reaction mixture was stirred for 24 hours. The mixture was poured into saturated NaHCO₃ solution and the resultant solid was collected by filtration then washed with water and dried to afford the title compound **389** (350 mg, 52% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 9.6 (m, 2H), 8.71 (d, *J* = 5.30 Hz, 1H), 8.49 (d, *J* = 4.05 Hz, 1H), 7.95 (m, 1H), 7.76 (d, *J* = 11.50 Hz, 1H), 7.45 (s, 1H), 7.35 (t, *J* = 9.1 Hz, 1H), 7.24 Hz (m, 1H), 6.62 (m, 1H), 4.43 (m, 1H), 4.30 (m, 5H), 2.75 (m, 1H), 2.66 (m, 1H), 2.53 (m, 1H), 1.21 (m, 1H), 0.61 (m, 2H), 0.42 (m, 2H). MS (*m/z*) = 537.4 (M+H).

Compounds **390-392** (examples **241-243**) were synthesized starting from the compound **389** (example **239**, scheme 75) by following the procedures similar to the ones described above for the synthesis of compounds **30** and **31** (scheme 13). Compound **393** (example **244**) was synthesized starting from the compound **392** by following the procedure similar to the one described above for the synthesis of compound **389** (example 240, scheme 75). Compound **394** (example 245) was synthesized starting from the compound **389** by following the procedure similar to the one described above for the synthesis of compound **128** (example **87**, scheme 32). Compound **395** (example **246**) was synthesized starting from the compound **387** by following the procedure similar to the one described above for the synthesis of compound **13** (example **10**, scheme 9).

Table 30. Characterization of compounds **390-395** (examples **241-246**)

Cpd	Ex.	Structure	Characterization
390	241	 4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)-N-ethylpiperazine-1-carboxamide	MS (m/z): 637.45 (M+H)
391	242	 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-(4-(2-hydroxyacetyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	MS (m/z): 594.35 (M+H)
392	243	 tert-butyl 2-(4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)piperazin-1-yl)-2-oxoethylcarbamate	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.47 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 5.48 Hz, 1H), 7.98 (s, 1H), 7.73 (m, 1H), 7.39 (t, J = 8.99 Hz, 1H), 7.20 (m, 1H), 6.82 (m, 1H), 6.64 (m, 2H), 5.56 (m, 1H), 3.83 (m, 2H), 3.39 (m, 7H), 2.54 (m, 1H), 0.65 (m, 2H), 0.42 (m, 2H). MS (m/z): 694.65 (M+H).




Cpd	Ex.	Structure	Characterization
293	244	 1-(4-(2-(1-(2-(4-(2-aminoacetyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 9.73 (s, 1H), 8.74 (s, 1H), 8.49 (d, <i>J</i> = 5.28 Hz, 1H), 7.97 (s, 1H), 7.72 (m, 1H), 7.37 (t, <i>J</i> = 9.19 Hz, 1H), 7.17 (m, 1H), 7.08 (m, 1H), 6.61 (d, <i>J</i> = 5.28 Hz, 1H), 5.57 (m, 1H), 3.57 (m, 9H), 2.54 (m, 1H), 1.98 (m, 1H), 1.88 (m, 1H), 0.65 (m, 2H), 0.40 (m, 2H). MS (<i>m/z</i>): 594.55 (M+H)
394	245	 4-(2-(4-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetyl)-N-ethylpiperazine-1-carboxamide	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.75 (s, 1H), 8.71 (s, 1H), 8.50 (d, <i>J</i> = 5.40 Hz, 1H), 7.97 (s, 1H), 7.74 (m, 1H), 7.41 (t, <i>J</i> = 9.05 Hz, 1H), 7.20 (m, 1H), 6.62 (m, 3H), 5.63 (s, 2H), 3.54 (m, 2H), 3.45 (m, 2H), 3.41 (m, 2H), 3.30 (m, 2H), 3.05 (m, 2H), 2.54 (m, 1H), 1.02 (t, <i>J</i> = 7.15 Hz, 3H), 0.65 (m, 2H), 0.42 (m, 2H). MS (<i>m/z</i>): 608.49 (M+H)
395	246	 1-(4-(2-(1-(2-(4-aminopiperidin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ (ppm): 8.74 (s, 1H), 8.71 (s, 1H), 8.50 (d, <i>J</i> = 5.48 Hz, 1H), 7.96 (s, 1H), 7.72 (m, 1H), 7.39 (t, <i>J</i> = 8.99 Hz, 1H), 7.20 (m, 1H), 6.98 (m, 1H), 6.62 (d, <i>J</i> = 5.09 Hz, 1H), 6.59 (s, 1H), 5.67 (d, <i>J</i> = 16.85 Hz, 1H), 5.56 (d, <i>J</i> = 16.62 Hz, 1H), 4.18 (m, 1H), 3.84 (m, 1H), 3.46 (m, 2H), 3.17 (m, 2H), 2.81 (m, 1H), 2.55 (m, 1H), 1.80 (m, 2H), 0.65 (m, 2H), 0.45 (m, 2H). MS (<i>m/z</i>): 551.42 (M+H).





Compounds **396-398** (examples **247-249**) were prepared similarly to compound **226** (example **127**, scheme 54). Compounds **399** and **400** (examples **249** and **250**) were prepared in one step by Boc-deprotection of compounds **397** and **398**, similarly to compound **72** (example

52, scheme 19). Compounds 401-402 (examples 252-253) were synthesized by following the procedures described above for the synthesis of compound 49 (scheme 15).


5

Table 31. Characterization of compounds 396-401 (examples 247-252)

Cpd	Ex.	Structure	Characterization
396	247	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(2-(2-hydroxyethoxy)ethyl)piperazine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	MS (m/z): 621.5 (M+H)
397	248	 tert-butyl 1-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperidin-4-yl(methyl)carbamate	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.73 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.02 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.8 Hz, 1H), 7.39 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.68 (d, J = 4.4 Hz, 1H), 6.58 (bd, J = 2.4 Hz, 1H), 4.65-4.53 (m, 1H), 3.70-3.60 (m, 1H), 3.40-3.29 (m, 1H), 3.24-3.10 (m, 1H), 2.85-2.73 (m, 1H), 2.70 (s, 3H), 2.59-2.51 (m, 1H), 1.80-1.60 (m, 3H), 1.59-1.43 (m, 1H), 1.40 (s, 9H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 661.48 (M+H).
398	249	 tert-butyl 1-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperidin-4-ylcarbamate	MS (m/z): 648.6 (M+H)

Cpd	Ex.	Structure	Characterization
399	250	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(methylamino)piperidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.75 (s, 1H), 8.66 (d, J = 0.8 Hz, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.45 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 7.97 (dd, J = 8.0, 2.0 Hz, 1H), 7.74 (dd, J = 13.6, 2.4 Hz, 1H), 7.39 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.68 (d, J = 5.2 Hz, 1H), 6.60 (bd, J = 2.4 Hz, 1H), 4.30-4.20 (m, 1H), 3.63-3.54 (m, 1H), 3.20-3.01 (m, 2H), 2.28 (s, 3H), 1.94-1.73 (m, 2H), 1.33-1.19 (m, 2H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 561.50 (M+H).
400	251	 1-(4-(2-(5-(4-aminopiperidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, CD ₃ OD-d ₆) δ(ppm): 8.71 (dd, J=2.2, 0.8 Hz, 1H); 8.51 (dd, J=5.5 Hz, 1H); 8.23 (dd, J=8.2, 0.8 Hz, 1H); 8.20 (s, 1H); 8.0 (dd, J=8.2, 2.2 Hz, 1H); 7.70 (dd, J=13.1, 2.5 Hz, 1H); 7.33 (t, J=9.0 Hz, 1H); 7.23 (dd, J=9.0, 1.4 Hz, 1H); 6.69 (dd, J=5.5, 0.8 Hz, 1H); 4.66 (br. s, 1H); 3.81 (br. d, J=8.6 Hz, 1H); 3.60 (br. s, 2H); 2.66-2.61 (m, 1H); 2.03 (br. s, 1H); 1.93 (br. s, 1H); 1.46 (br. s, 2H); 0.82-0.77 (m, 2H); 0.58-0.55 (m, 2H). [Signals of NH-protons are not seen; NH ₂ -CH ₂ -signal is probably, obscured by the peak of residual solvent]. MS (m/z): 547.5 (M+H)
401	252	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(methylamino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.74 (s, 1H), 8.53 (d, J = 1.2 Hz, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.84 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (dd, J = 5.6, 0.8 Hz, 1H), 6.60 (bd, J = 2.4 Hz, 1H), 3.52 (s, 2H), 2.80-2.72 (m, 2H), 2.60-2.50 (m, 1H), 2.30-2.20 (m, 1H), 2.24 (s, 3H), 2.05-1.96 (m, 2H), 1.80-1.72 (m, 2H), 1.38-1.16 (m, 2H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 547.44 (M+H).
402	253	 1-(4-(2-(5-((3-aminoazetidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.74 (s, 1H), 8.54-8.49 (m, 2H), 8.32 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.80 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.2, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.17 (m, 1H), 6.64 (dd, J = 5.2, 0.8 Hz, 1H), 6.60 (bd, J = 2.0 Hz, 1H), 3.59 (s, 2H), 3.52-3.45 (m, 2H), 3.45-3.30 (m, 1H), 2.69-2.64 (m, 2H), 2.59-2.51 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 505.50 (M+H).

Scheme 76



5

Example 254

1-(4-(2-(5-((Azetidin-3-yloxy)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (405)

10 Step 1. (6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl methanesulfonate (403)

To a solution of **64** (510 mg, 1.13 mmol, scheme 17) in DMF (15 mL) at 0°C were added TEA (0.79 mL, 5.65 mmol) and methanesulfonyl chloride (0.35 mL, 4.52 mmol). After 30 min, more TEA (0.48 mL, 3.39 mmol) and methanesulfonyl chloride (0.22 mL, 2.82 mmol) were added at 0°C. The reaction mixture was poured into water to form a precipitate that was collected by filtration, rinsed with water to give the title compound **403** (crude) as a beige powder which was used in the next step with no additional purification. MS (m/z): 529.39 (M+H).

Step 2. tert-butyl 3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methoxy)azetidine-1-carboxylate (404)

20 To a stirred suspension of NaH (271 mg, 60% dispersion in mineral oil, 6.72 mmol) in DMF (2 mL) at 0°C was added *tert*-butyl-3-hydroxyazetidine-1-carboxylate (1.0 g, 5.65 mmol). After 30 min, a solution of **403** (1.13 mmol) in DMF (6 mL) and KI (183 mg, 1.13 mmol) were added at 0°C. The reaction mixture was heated to 80°C for 30 min. The reaction was then quenched by addition of water and the mixture was extracted with AcOEt/MeOH. The organic phase was washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was purified via Biotage [linear gradient 0-10%,

25




(methanol/dichloromethane; SiliaFlash 25 g cartridge]. Title compound **404** was obtained as a beige solid (221 mg, 32 % yield for 2 steps). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.71 (s, 1H), 8.62 (d, J = 2.4 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.94 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.57 (brd, 1H), 4.53 (s, 2H), 4.42-4.36 (m, 1H), 4.09-4.00 (m, 2H), 3.77-3.68 (m, 2H), 2.59-2.50 (m, 1H), 1.37 (s, 9H), 0.68-0.62 (m, 2H), 0.47-0.41 (m, 2H). MS (m/z): 606.48 (M+H).



Step 3. 1-(4-(2-(5-((azetidin-3-yloxy)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea (**405**)

To a suspension of **404** (221 mg, 0.365 mmol) in DCM (5 mL) was added TFA (1 mL) and the reaction mixture was stirred for 4 h then concentrated, diluted with water and 1M NaOH to pH 11. The solid was collected by filtration, rinsed with water and dried. The residue was purified by Biotage (SNAP 25 g cartridge; 2% of ammonium hydroxide in MeOH/DCM: 10/90 to 30/70), to afford the title compound **405** (155 mg, 84% yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.77 (s, 1H), 8.55 (brd, J = 1.6 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.35 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 7.91 (dd, J = 8.0, 2.4 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.24-7.18 (m, 1H), 6.65 (d, J = 5.2 Hz, 1H), 6.62 (brd, J = 2.8 Hz, 1H), 4.48 (s, 2H), 4.40-4.41 (m, 1H), 3.56-3.49 (m, 2H), 3.47-3.50 (m, 2H), 2.58-2.51 (m, 1H), 0.68-0.62 (m, 2H), 0.47-0.41 (m, 2H). MS (m/z): 506.14 (M+H).

Compounds **406-409** (examples **255-258**) were prepared in one step by reacting the corresponding amine precursors **399**, **401**, **402** (table 31) and **405** (scheme 76) with ethyl isocyanate, similarly to compound **128** (example **87**, scheme 32). Compound **410** (example **259**) was prepared by reacting compound **401** (table 31) with methyl isocyanate instead of ethyl isocyanate.

Table 32. Characterization of compounds **406-410** (examples **255-259**)




Cpd	Ex.	Structure	Characterization
406	255	 Ethyl 1-(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)nicotinoyl)piperidin-4-yl(methyl)urea	¹ H NMR (500 MHz, DMSO-d ₆) δ (ppm): 8.78 (s, 1H), 8.69 (d, J = 2.0 Hz, 1H), 8.54 (d, J = 5.4 Hz, 1H), 8.44 (s, 1H), 8.34 (d, J = 8.2 Hz, 1H), 7.81 (dd, J = 8.1, 2.1 Hz, 1H), 7.72 (dd, J = 13.5, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.22-7.17 (m, 1H), 6.67 (d, J = 5.4 Hz, 1H), 6.55 (bd, J = 2.4 Hz, 1H), 6.22 (t, J = 5.4 Hz, 1H), 4.62-4.55 (m, 1H), 4.27-4.18 (m, 1H), 3.55 (s, 2H), 3.68-3.60 (m, 1H), 3.21-3.12 (m, 1H), 3.08-3.01 (m, 2H), 2.65 (s, 3H), 2.59-2.51 (m, 1H), 1.70-1.52 (m, 3H), 1.47-1.40 (m, 1H), 1.00 (t, J = 7.2 Hz, 3H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 632.40 (M+H).
407	256	 1-(4-(2-(5-((4-Ethylaminocarbonylmethylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.72 (s, 1H), 8.56 (d, J = 2.0 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.34 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.86 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.39 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.58 (bd, J = 2.0 Hz, 1H), 6.20 (t, J = 5.6 Hz, 1H), 3.96-3.87 (m, 1H), 3.55 (s, 2H), 3.07-2.98 (m, 2H), 2.90-2.83 (m, 2H), 2.59-2.51 (m, 1H), 2.09-2.00 (m, 2H), 1.70-1.59 (m, 1H), 1.47-1.39 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 618.58 (M+H).
408	257	 1-(4-(2-(5-((3-Ethylaminocarbonylamino)azetidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.74 (s, 1H), 8.54 (brd, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.33 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.88-7.80 (m, 1H), 7.73 (dd, J = 13.6, 2.8 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (dd, J = 5.2, 0.8 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 6.35-6.27 (m, 1H), 5.90-5.75 (m, 1H), 4.25-4.15 (m, 1H), 3.80-3.45 (m, 4H), 3.02-2.75 (m, 4H), 2.58-2.49 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H), 0.68-0.62 (m, 2H), 0.47-0.40 (m, 2H). MS (m/z): 576.50 (M+H).





Cpd	Ex.	Structure	Characterization
409	258	 3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methoxy)-N-ethylazetidine-1-carboxamide	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.71 (s, 1H), 8.62 (d, J = 1.6 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.94 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.57 (bd, J = 2.8 Hz, 1H), 6.31 (t, J = 5.6 Hz, 1H), 4.53 (s, 2H), 4.41-4.33 (m, 1H), 4.00-3.92 (m, 2H), 3.65-3.60 (m, 2H), 3.04-2.95 (m, 2H), 2.59-2.50 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H), 0.68-0.62 (m, 2H), 0.46-0.40 (m, 2H). MS (m/z): 577.28 (M+H).
410	259	 1-(4-(2-(5-((4-Methylaminocarbonyl-methylaminopiperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-3-cyclopropylurea	¹ H NMR (500 MHz, DMSO-d ₆) δ (ppm): 8.68 (s, 1H), 8.54 (d, J = 1.7 Hz, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.31 (s, 1H), 8.22 (d, J = 8.1 Hz, 1H), 7.85 (dd, J = 8.1, 2.0 Hz, 1H), 7.72 (dd, J = 13.5, 2.5 Hz, 1H), 7.37 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.4 Hz, 1H), 6.54 (bd, J = 2.2 Hz, 1H), 6.13 (d, J = 4.3 Hz, 1H), 3.95-3.86 (m, 1H), 3.54 (s, 2H), 2.89-2.83 (m, 2H), 2.62 (s, 3H), 2.59-2.51 (m, 1H), 2.54 (d, J = 4.3 Hz, 3H), 2.08-2.00 (m, 2H), 1.69-1.58 (m, 2H), 1.45-1.38 (m, 2H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 604.54 (M+H).


Compounds **411-412** (examples **260-261**) were prepared in one step by reacting the amine precursor **401** (table 31), similarly to compound **30** (scheme 13). Compound **413** (example **262**) was obtained similarly to compound **31** (scheme 13). Compounds **414-415** (examples **263-264**) were prepared in two steps by reacting the corresponding amine precursors **402** (table 31) and **405** (scheme 76), similarly to compound **31** (scheme 13).

Compounds **416-418** (examples **265-267**) were prepared in one step by reacting the amine precursor **401** (table 31), with the corresponding alkylating agent similarly to compound **275** (scheme 61).


Table 33. Characterization of compounds 411-418 (examples 255-267)

Cpd	Ex.	Structure	Characterization
411	260	 2-((1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)(methyl)amino)-2-oxoethyl acetate	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.73 (s, 1H), 8.56 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.34 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.39 (t, J = 9.0 Hz, 1H), 7.24-7.17 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.59 (bd, J = 2.0 Hz, 1H), 4.80 (s, 0.76H), 4.72 (s, 1.24H), 4.24-4.10 (m, 1H), 3.58 (s, 0.76H), 3.55 (s, 1.24H), 2.94-2.85 (m, 2H), 2.78 (s, 1.86H), 2.71 (s, 1.14H), 2.59-2.51 (m, 1H), 2.18-2.00 (m, 2H), 2.06 (s, 3H), 1.84-1.38 (m, 4H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 647.51 (M+H).
412	261	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-N-methylacrylamide	¹ H NMR (500 MHz, DMSO-d ₆) δ (ppm): 8.70 (s, 1H), 8.56 (brd, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.31 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.1, 1.9 Hz, 1H), 7.72 (dd, J = 13.6, 2.4 Hz, 1H), 7.37 (t, J = 9.0 Hz, 1H), 7.22-7.18 (m, 1H), 6.83-6.68 (m, 1H), 6.64 (d, J = 5.4 Hz, 1H), 6.55 (bd, J = 2.2 Hz, 1H), 6.05 (t, J = 17.0 Hz, 1H), 5.67-5.58 (m, 1H), 4.33-4.24 (m, 1H), 3.58-3.53 (m, 2H), 2.93-2.73 (m, 5H), 2.58-2.51 (m, 1H), 2.16-2.02 (m, 2H), 1.58-1.41 (m, 2H), 0.69-0.62 (m, 2H), 0.44-0.40 (m, 2H). MS (m/z): 601.48 (M+H).
413	262	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-2-hydroxy-N-methylacetamide	¹ H NMR (500 MHz, DMSO-d ₆) δ (ppm): 8.68 (s, 1H), 8.55 (d, J = 1.4 Hz, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.1, 1.9 Hz, 1H), 7.72 (dd, J = 13.5, 2.4 Hz, 1H), 7.37 (t, J = 9.0 Hz, 1H), 7.22-7.18 (m, 1H), 6.62 (d, J = 5.4 Hz, 1H), 6.54 (bd, J = 2.4 Hz, 1H), 4.41 (t, J = 5.2 Hz, 0.4H), 4.33 (t, J = 5.2 Hz, 0.6H), 4.27-4.18 (m, 1H), 4.10 (d, J = 5.1 Hz, 0.8H), 4.02 (d, J = 5.3 Hz, 1.2H), 3.59-3.54 (m, 2H), 2.94-2.83 (m, 2H), 2.74 (s, 1.2H), 2.72 (s, 1.8H), 2.58-2.51 (m, 1H), 2.12-2.03 (m, 2H), 1.84-1.65 (m, 2H), 1.59-1.41 (m, 2H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 605.37 (M+H).

Cpd	Ex.	Structure	Characterization
414	263	 N-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)azetidin-3-yl)-2-hydroxyacetamide	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.71 (s, 1H), 8.52 (brd, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.32 (s, 1H), 8.22 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 7.6 Hz, 1H), 7.82 (dd, J = 8.0, 2.0 Hz, 1H), 7.72 (dd, J = 13.6, 2.8 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (dd, J = 5.2, 0.8 Hz, 1H), 6.57 (d, J = 2.8 Hz, 1H), 5.46 (t, J = 2.0 Hz, 1H), 4.43-4.34 (m, 1H), 3.79 (d, J = 5.2 Hz, 2H), 3.66 (s, 2H), 3.52 (t, 7.2 Hz, 2H), 3.06 (t, J = 7.2 Hz, 2H), 2.58-2.50 (m, 1H), 0.69-0.62 (m, 2H), 0.47-0.40 (m, 2H). MS (m/z): 563.46 (M+H).
415	264	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((1-(2-hydroxyacetyl)azetidin-3-yloxy)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.81 (s, 1H), 8.63 (d, J = 1.6 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.37 (s, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.94 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.68-6.63 (m, 2H), 4.93 (t, J = 6.0 Hz, 1H), 4.55 (s, 2H), 4.50-4.44 (m, 1H), 4.40-4.34 (m, 1H), 4.13-4.04 (m, 2H), 3.90 (m, J = 6.0 Hz, 2H), 3.78-3.72 (m, 1H), 2.58-2.51 (m, 1H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 564.3 (M+H).
416	265	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-((2-methoxyethyl)(methyl)amino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): 8.72 (s, 1H), 8.54 (d, J = 1.6 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 8.0, 2.4 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (dd, J = 5.2, 0.8 Hz, 1H), 6.58 (bd, J = 2.4 Hz, 1H), 3.54 (s, 2H), 3.45-3.28 (m, 2H), 3.23 (s, 3H), 2.90-2.84 (m, 2H), 2.59-2.50 (m, 1H), 2.30-2.15 (m, 3H), 2.04-1.92 (m, 2H), 1.70-1.61 (m, 2H), 1.52-1.40 (m, 2H), 0.69-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 605.57 (M+H).
417	266	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-((2-hydroxyethyl)(methyl)amino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea	¹ H NMR (500 MHz, DMSO-d ₆) δ (ppm): 8.71 (s, 1H), 8.53 (d, J = 1. Hz, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.31 (s, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.84 (dd, J = 8.2, 1.9 Hz, 1H), 7.72 (dd, J = 13.5, 2.4 Hz, 1H), 7.37 (t, J = 9.0 Hz, 1H), 7.22-7.17 (m, 1H), 6.63 (d, J = 5.4 Hz, 1H), 6.68 (bd, J = 2.4 Hz, 1H), 3.53 (s, 2H), 3.49-3.41 (m, 2H), 2.89-2.83 (m, 2H), 2.59-2.50 (m, 2H), 2.30-2.20 (m, 3H), 2.01-1.93 (m, 2H), 1.72-1.65 (m, 2H), 1.53-1.40 (m, 2H), 0.67-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 591.54 (M+H).

Cpd	Ex.	Structure	Characterization
418	267	 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(methyl(2,5,8,11-tetraoxatridecan-13-yl)amino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.74 (s, 1H), 8.54 (d, J = 2.0 Hz, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 8.4, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.17 (m, 1H), 6.64 (dd, J = 5.2, 0.8 Hz, 1H), 3.54 (s, 2H), 3.52-3.36 (m, 17H), 3.22 (s, 3H), 2.91-2.82 (m, 2H), 2.58-2.51 (m, 1H), 2.35-2.15 (m, 3H), 2.04-1.92 (m, 2H), 1.74-1.60 (m, 2H), 1.51-1.40 (m, 2H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 737.83 (M+H).	

Scheme 77



5

Example 268

1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-fluoroethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (420)

10 Step 1. 2-Fluoroethyl methanesulfonate (419)

To a stirred solution of 2-fluoroethanol (0.100 mL, 1.72 mmol) in DCM (2 mL) at 0°C were added TEA (0.312 mL, 2.24 mmol) and methansulfonyl chloride (0.16 mL, 2.06 mmol). The reaction mixture was stirred at 0°C for 0.5 h, quenched with water and extracted with DCM. The organic phase was collected, dried over anhydrous Na₂SO₄, filtered and concentrated to afford the title compound **419** (140 mg, 57% yield) as an orange oil which was used in the next

15

step with no additional purification. ^1H NMR (400 MHz, CDCl_3) δ (ppm) : 4.75-4.72 (m, 1H), 4.63-4.60 (m, 1H), 4.52-4.49 (m, 1H), 4.45-4.42 (m, 1H), 3.08 (s, 3H).


Step 2. 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((4-(2-fluoroethyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (420)

5 To a solution of **49** (70 mg, 0.111 mmol, scheme 26) in DMF (2 mL) were added K_2CO_3 (77 mg, 0.555 mmol) and **419** (79 mg, 0.555 mmol). The mixture was heated to 80°C for 16 hours. Water was added to form a precipitate that was collected by filtration, rinsed with water and purified via Biotage [linear gradient 0-20%, (methanol/dichloromethane; SiliaFlash 10 g cartridge]. Title compound **420** was obtained as a white solid (38.9 mg, 62 % yield). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ (ppm) : 8.68 (s, 1H), 8.53 (d, $J = 1.7$ Hz, 1H), 8.51 (d, $J = 5.4$ Hz, 1H), 8.31 (s, 1H), 8.23 (d, $J = 8.2$ Hz, 1H), 7.85 (dd, $J = 8.1, 2.0$ Hz, 1H), 7.72 (dd, $J = 13.5, 2.4$ Hz, 1H), 7.37 (t, $J = 9.0$ Hz, 1H), 7.22-7.17 (m, 1H), 6.64 (d, $J = 5.4$ Hz, 1H), 6.54 (bd, $J = 2.3$ Hz, 1H), 4.55 (t, $J = 4.9$ Hz, 1H), 4.45 (t, $J = 4.9$ Hz, 1H), 3.54 (s, 2H), 2.89-2.83 (m, 2H), 2.62 (t, $J = 5.0$ Hz, 1H), 2.59-2.51 (m, 1H), 2.56 (t, $J = 5.1$ Hz, 1H), 2.50-2.32 (m, 8H), 0.68-0.62 (m, 15 2H), 0.45-0.40 (m, 2H). MS (m/z): 565.23 ($\text{M}+\text{H}$).

Example 269

1-Cyclopropyl-3-(3-fluoro-4-(2-(5-((4-((2-fluoroethyl)(methyl)amino)piperidin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea (421)

20




421 : Example 269

Compound **421** (example 269) was prepared in one step by reacting the amine precursor **401** (table 31) with compound **419**, similarly to compound **420** (example 268, scheme 77). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 8.73 (s, 1H), 8.54 (d, $J = 1.6$ Hz, 1H), 8.52 (d, $J = 5.6$ Hz, 1H), 8.33 (s, 1H), 8.24 (d, $J = 8.0$ Hz, 1H), 7.85 (dd, $J = 8.0, 2.0$ Hz, 1H), 7.73 (dd, $J = 13.6, 2.4$ Hz, 1H), 7.38 (t, $J = 9.0$ Hz, 1H), 7.22-7.18 (m, 1H), 6.64 (d, $J = 5.2$ Hz, 1H), 6.56 (bd, $J = 2.8$ Hz, 1H), 4.51 (t, $J = 5.2$ Hz, 1H), 4.39 (t, $J = 5.2$ Hz, 1H), 3.54 (s, 2H), 2.90-2.82 (m, 2H), 2.77-2.63 (m, 2H), 2.59-2.50 (m, 1H), 2.40-2.30 (m, 1H), 2.22 (s, 3H), 2.02-1.91 (m, 2H), 1.69-1.61 (m, 2H), 1.50-1.38 (m, 2H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 593.59 ($\text{M}+\text{H}$).

30

Scheme 78



5

Example 270

Ethyl 2-((1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)(methyl)amino)acetate (422)

- 10 To a suspension of **401** (109 mg, 0.20 mmol) in DMF (2 mL) were added K_2CO_3 (33 mg, 0.24 mmol) and Ethyl bromoacetate (33 mg, 0.22 mmol). The reaction mixture was stirred at RT for 1 h. Water was added to form a precipitate that was collected by filtration, rinsed with water and purified via Biotage [linear gradient 0-20%, (methanol/dichloromethane; SiliaFlash 10 g cartridge]. Title compound **422** was obtained as a beige solid (92 mg, 72 % yield). ^1H
- 15 NMR (500 MHz, $\text{DMSO}-d_6$) δ (ppm) : 8.71 (s, 1H), 8.54 (d, $J = 1.8$ Hz, 1H), 8.51 (d, $J = 5.4$ Hz, 1H), 8.32 (s, 1H), 8.24 (d, $J = 8.1$ Hz, 1H), 7.84 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.72 (dd, $J = 13.5, 2.5$ Hz, 1H), 7.38 (t, $J = 9.0$ Hz, 1H), 7.22-7.18 (m, 1H), 6.63 (d, $J = 5.4$ Hz, 1H), 6.56 (bd, $J = 2.0$ Hz, 1H), 4.05 (q, $J = 7.1$ Hz, 2H), 3.52 (s, 2H), 3.28 (s, 2H), 2.86-2.79 (m, 2H), 2.58-2.51 (m, 1H), 2.45-2.37 (m, 1H), 2.26 (s, 3H), 1.98-1.91 (m, 2H), 1.72-1.66 (m, 2H), 1.42-1.32 (m, 2H), 1.16 (t, $J = 7.1$ Hz, 3H), 1.45-1.38 (m, 2H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 633.45 (M+H).
- 20

Example 271

2-(((1-(((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)(methyl)amino)acetic acid (423)


5 To a suspension of **422** (78 mg, 0.12 mmol) in MeOH (3 mL) was added 1N NaOH (0.6 mL, 0.6 mmol). The reaction mixture was stirred at RT for 2 h. The reaction mixture was then concentrated, diluted with water and the pH was adjusted to 6-7 by addition of 1N HCl. The resulting suspension was stirred for 30 min, and the solid was collected by filtration, rinsed with water, air-dried and dried under high vacuum to afford the title compound **423** (50.3 mg, 67%
10 yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.81 (s, 1H), 8.55 (brd, 1H), 8.51 (d, J = 5.6 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 8.2, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.24-7.18 (m, 1H), 6.59-6.42 (m, 2H), 3.56 (s, 2H), 3.26 (s, 2H), 2.93-2.84 (m, 3H), 2.58-2.51 (m, 1H), 2.53 (s, 3H), 2.06-1.95 (m, 2H), 1.88-1.80 (m, 2H), 1.61-1.49 (m, 2H), 0.68-0.62 (m, 2H), 0.47-0.41 (m, 2H). MS (m/z):
15 605.59 (M+H).

Example 272

3-(((1-(((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)(methyl)amino)propanoic acid (424)

20 Compound **424** (example 272) was prepared in two steps starting from the amine precursor **401** (table 31), similarly to compound **423** (example 271, scheme 77). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.78 (s, 1H), 8.55 (brd, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.67-6.62 (m, 1H), 3.54 (s, 2H), 3.17 (s, 2H), 2.90-2.83 (m, 2H), 2.74 (t, J = 6.8 Hz, 2H), 2.58-2.45 (m, 2H), 2.30 (t, J = 6.8 Hz, 2H), 2.26 (s, 3H), 2.04-1.95 (m, 2H), 1.70-1.63 (m, 2H), 1.57-1.46 (m, 2H), 0.68-0.62 (m, 2H), 0.47-0.40 (m, 2H). MS (m/z): 619.54 (M+H).

Scheme 79



5

Example 273

Ethyl 2-(3-(1-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)ureido)acetate (425)

- 10 To a suspension of **343** (106 mg, 0.20 mmol, scheme 71) in THF (3 mL) was added ethoxycarbonylmethyl isocyanate (0.068 mL, 0.6 mmol) and stirred at RT for 3 h. To the mixture was added DMF (2 mL) and stirred for 1 h. The mixture was then concentrated, water was added to form a precipitate that was collected by filtration, rinsed with water and purified via Biotage [linear gradient 2-20%, (methanol/dichloromethane; SiliaFlash 10 g cartridge)]. Title
- 15 compound **425** was obtained as a white solid (79.5 mg, 60 % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.73 (s, 1H), 8.54 (brd, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.33 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.85 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.59 (bd, 1H), 6.15 (d, J = 8.0 Hz, 1H), 6.06 (t, J = 8.0 Hz, 1H), 4.06 (q, J = 6.4 Hz, 2H), 3.74 (d, J = 6.50 Hz, 2H), 3.54 (s, 2H), 2.77-
- 20 2.66 (m, 2H), 2.58-2.51 (m, 2H), 2.13-2.04 (m, 2H), 1.78-1.70 (m, 2H), 1.40-1.30 (m, 2H), 1.18 (t, J = 6.8 Hz, 3H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H). MS (m/z): 662.28 (M+H).

Example 274

2-(3-(1-((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)ureido)acetic acid (426)


5 To a suspension of **425** (78 mg, 0.12 mmol) in MeOH (3 mL) was added 1N NaOH (0.6 mL, 0.6 mmol). The reaction mixture was stirred at RT for 20 h. The reaction mixture was then concentrated, diluted with water and the pH was adjusted to 6-7 by addition of 1N HCl. To the resulting suspension was added MeOH to dissolve the mixture clearly, and purified via Biotage [KP-C18-HS 30 g, gradient 20-95% (methanol/water)]. Title compound **426** was obtained as a



10 white solid (79.5 mg, 60 % yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): one H of carboxylic acid is missing, 10.17 (brs, 1H), 8.53 (d, J = 1.6 Hz, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.29 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.02 (brs, 1H), 7.81 (dd, J = 8.0, 2.0 Hz, 1H), 7.76 (dd, J = 14.0, 2.4 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 7.28 (dd, J = 9.2, 2.0 Hz, 1H), 6.65 (d, J = 4.4 Hz, 1H), 6.25 (d, J = 7.6 Hz, 1H), 5.59 (t, J = 3.6 Hz, 1H), 4.15-4.09 (m, 1H), 3.51 (s, 2H), 3.28 (d, J = 4.4 Hz, 2H), 2.72-2.65 (m, 2H), 2.58-2.51 (m, 1H), 2.11-2.02 (m, 2H), 1.76-1.66 (m, 2H), 1.38-1.25 (m, 2H), 0.63-0.56 (m, 2H), 0.44-0.38 (m, 2H). MS (m/z): 634.5 (M+H).

Compounds **427–428** (examples **275–276**) were prepared in two steps starting from the corresponding amine precursors **401** and **402** (table 31), similarly to compound **426** (example


20 **274**, scheme 79). Compound **429** (example **277**) was prepared similarly to compound **426** (example **274**, scheme 79) using ethyl 3-isocyanatopropanoate instead of ethoxycarbonylmethyl isocyanate in the first step.

Table 34. Characterization of compounds **427-429** (examples **275–277**)

Cpd	Ex.	Structure	Characterization
427	275	 2-(3-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)-3-methylureido)acetic acid	¹ H NMR (400 MHz, DMSO-d ₆) δ (ppm): one H of carboxylic acid is missing, 10.21 (brs, 1H), 8.52 (d, J = 2.0 Hz, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.27 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.93 (brs, 1H), 7.79 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.32 (t, J = 9.0 Hz, 1H), 7.28 (dd, J = 8.8, 2.4 Hz, 1H), 6.62 (dd, J = 5.2, 0.8 Hz, 1H), 5.77 (t, J = 3.6 Hz, 1H), 3.93-3.82 (m, 1H), 3.50 (s, 2H), 3.29 (d, J = 3.6 Hz, 2H), 2.89-2.81 (m, 2H), 2.67 (s, 3H), 2.58-2.51 (m, 1H), 2.08-1.98 (m, 2H), 1.71-1.58 (m, 2H), 1.50-1.43 (m, 2H), 0.63-0.56 (m, 2H), 0.44-0.38 (m, 2H). MS (m/z): 648.37 (M+H).

Cpd	Ex.	Structure	Characterization
428	276	 2-(3-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)azetidin-3-yl)ureido)acetic acid ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): one H of carboxylic acid is missing, 10.03 (brs, 1H), 8.52-8.49 (m, 2H), 8.29 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.87 (brs, 1H), 7.81 (dd, J = 8.4, 2.0 Hz, 1H), 7.76 (dd, J = 14.0, 2.4 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 7.25 (dd, J = 9.0, 2.0 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 5.6 Hz, 1H), 5.65 (t, J = 4.0 Hz, 1H), 4.20-4.11 (m, 1H), 3.60 (s, 2H), 3.49 (t, J = 7.2 Hz, 2H), 3.26 (d, J = 4.0 Hz, 2H), 2.77 (t, J = 7.2 Hz, 2H), 2.58-2.51 (m, 1H), 0.64-0.56 (m, 2H), 0.44-0.38 (m, 2H). MS (m/z): 606.40 (M+H).	
429	277	 3-(3-(1-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperidin-4-yl)ureido)propanoic acid ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): (400 MHz, DMSO-d₆) d (ppm) : one H of carboxylic acid is missing, 9.79 (brs, 1H), 8.54-8.50 (m, 2H), 8.29 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.82 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.60 (brs, 1H), 7.34 (t, J = 9.0 Hz, 1H), 7.28-7.21 (m, 1H), 6.69 (d, J = 5.2 Hz, 1H), 6.02 (brd, J = 7.6 Hz, 1H), 5.78 (brs, 1H), 3.54 (s, 2H), 3.20-3.18 (m, 3H), 2.68-2.59 (m, 2H), 2.58-2.51 (m, 1H), 2.17 (t, J = 6.4 Hz, 2H), 2.14-2.05 (m, 2H), 1.75-1.66 (m, 2H), 1.38-1.25 (m, 2H), 0.64-0.58 (m, 2H), 0.43-0.39 (m, 2H). MS (m/z): 648.22 (M+H).	

Scheme 80



5 Example 278

2-(((6-(7-(4-(3-Cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(1-(ethylcarbamoyl)azetidin-3-yl)amino)acetic acid (434)

10 Step 1. tert-butyl 3-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methylamino)azetidine-1-carboxylate (430)

To a suspension of the aldehyde **47** (1.0 g, 2.25 mmol, scheme 15) in NMP (12 mL) were added 3-amino-1-N-Boc-azetidine (0.600 g, 3.38 mmol) and acetic acid (0.19 mL, 3.38 mmol) at RT and stirred for 30 min. Then NaBH(OAc)₃ (1.2 g, 5.63 mmol) was added and stirred for 3 days. The reaction mixture was poured into saturated aqueous solution of NaHCO₃ to form a precipitate that was collected by filtration, rinsed with water and purified via Biotage [linear gradient 2-20%, (methanol/dichloromethane; SiliaFlash 25 g cartridge)]. Title compound **430** was obtained as a beige solid (960 mg, 71 % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.71 (s, 1H), 8.56 (d, J = 1.2 Hz, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.32 (s, 1H), 8.23 (d, J =

8.0 Hz, 1H), 7.89 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.64 (dd, J = 5.2, 1.2 Hz, 1H), 6.56 (bd, J = 2.4 Hz, 1H), 3.98-3.83 (m, 2H), 3.69 (s, 2H), 3.62-3.47 (m, 3H), 2.58-2.51 (m, 1H), 1.36 (s, 9H), 0.68-0.62 (m, 2H), 0.45-0.40 (m, 2H), one NH is missing. MS (m/z): 605.46 (M+H).

5 Step 2. tert-butyl 3-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(2-ethoxy-2-oxoethyl)amino)azetidine-1-carboxylate (431)

To a solution of **430** (300 mg, 0.496 mmol) in DMF (6 mL) was added ethyl bromoacetate (0.06 mL, 0.546 mmol). The reaction mixture was stirred at RT for 3 days, quenched with water and extracted with DCM. The organic phase was collected, dried over
10 anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by Biotage (SNAP 10 g cartridge; MeOH/DCM: 0/100 to 10/90), to afford the title compound **431** (93 mg, 27% yield) as a beige solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.76 (s, 1H), 8.54 (brd, J = 1.6 Hz, 1H), 8.52 (d, J = 5.6 Hz, 1H), 8.35 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.88 (dd, J = 8.0, 2.0 Hz, 1H), 7.73 (dd, J = 13.6, 2.4 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.23-7.18 (m, 1H), 6.65 (dd, J =
15 5.2, 0.8 Hz, 1H), 6.61 (brd, J = 2.8 Hz, 1H), 4.05 (q, 7.2 Hz, 2H), 3.93-3.75 (m, 5H), 3.79 (s, 2H), 3.31 (s, 2H), 2.58-2.52 (m, 1H), 1.37 (s, 9H), 1.17 (t, J = 7.2 Hz, 3H), 0.68-0.62 (m, 2H), 0.47-0.41 (m, 2H). MS (m/z): 691.64 (M+H).

Step 3. ethyl 2-(azetidin-3-yl((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)amino)acetate (432)

20 To a solution of **431** (93 mg, 0.135 mmol) in DCM (5 mL) was added 4M HCl in 1,4-dioxane solution (0.17 mL, 0.675 mmol) and stirred at RT for 6 h. The mixture was then concentrated to afford the title compound **432** (presumably the hydrochloride salt) as beige solid which was used in the next step with no additional purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 9.13 (s, 1H), 8.98-8.86 (m, 1H), 8.78-8.66 (m, 1H), 8.69 (d, J = 6.0 Hz, 1H), 8.63 (d, J
25 = 1.2 Hz, 1H), 8.40 (s, 1H), 8.34 (d, J = 8.4 Hz, 1H), 7.94 (dd, J = 8.0, 2.0 Hz, 1H), 7.77 (dd, J = 13.6, 2.4 Hz, 1H), 7.44 (t, J = 9.0 Hz, 1H), 7.25-7.21 (m, 1H), 6.92 (d, J = 5.2 Hz, 1H), 6.77 (brs, 1H), 4.08 (q, J = 7.2 Hz, 2H), 4.15-3.80 (m, 7H), 3.16 (s, 2H), 2.58-2.51 (m, 1H), 1.19 (t, J = 7.2 Hz, 3H), 0.68-0.62 (m, 2H), 0.45-0.39 (m, 2H). MS (m/z): 591.58 (M+H).

30 Step 4. ethyl 2-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(1-(ethylcarbamoyl)azetidin-3-yl)amino)acetate (433)

To a suspension of **432** (0.135 mmol) in THF (5 mL) were added TEA (0.094 mL, 0.675 mmol) and ethyl isocyanate (0.032 mL, 0.405 mmol) and stirred at RT for 1 h. The mixture was then concentrated, water was added to form a precipitate that was collected by filtration, rinsed with water, air-dried to afford the title compound **433** (78 mg, 88% yield for 2steps) as a beige
35 solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) : 8.71 (s, 1H), 8.55 (d, J = 1.6 Hz, 1H), 8.52 (d,

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 307

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 307


NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

What is Claimed is:

1. A compound having the Formula (I):




including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of an aromatic, heteroaromatic, cycloalkyl or heterocyclic ring system, C₁-C₆alkyl-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-N(R⁶)-C(O)-, (R⁶)(R⁶)N-C(O)-O-heterocyclyl-C(O)-, heterocyclyl-C(O)-, PivO-heterocyclyl-C(O)-, C₁-C₆alkyl-O-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-N(R⁶)-heterocyclyl-C(O)-, (C₁-C₆alkyl)(Box)N-heterocyclyl-C(O)-, HO-heterocyclyl-C(O)-, HO-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-O-heterocyclyl-C(O)-, (R⁶)(R⁶)N-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C(O)- and (R⁶)(R⁶)N-heterocyclyl-C(O)-, wherein each of the aromatic, heteroaromatic, cycloalkyl and heterocyclic groups is optionally substituted with 1 or more independently selected R³⁸;

M is an optionally substituted fused heterocyclic moiety;

Z is selected from the group consisting of -O-, -S(O)₀₋₂- and -NR⁵-, wherein R⁵ is selected from the group consisting of H, optionally substituted C₁-C₅alkyl, an optionally substituted (C₁-C₅)acyl and C₁-C₆ alkyl-O-C(O), wherein C₁-C₆ alkyl is optionally substituted;

Ar is a group of the formula C,



C

wherein,

A⁴, A⁵, A⁶ and A⁷ are independently selected from the group consisting of N and -CH-, with the proviso that no more than two of A⁴, A⁵, A⁶ and A⁷ can be N, wherein Ar is optionally substituted; and

G is a group B-L-T, wherein

B is selected from the group consisting of a covalent bond, $-N(R^{13})-$, $-N(SO_2R^{13})-$, $-O-$, $-S(O)_{0-2}$ and $-C(=O)-$;

L is selected from the group consisting of a covalent bond, $-C(=S)N(R^{13})-$, $-C(=NR^{14})N(R^{13})-$, $-SO_2N(R^{13})-$, $-SO_2-$, $-C(=O)N(R^{13})-$, $-N(R^{13})-$, $-C(=O)C_{1-2}alkyl-N(R^{13})-$, $-N(R^{13})C_{1-2}alkyl-C(=O)-$, $-C(=O)C_{0-1}alkyl-C(=O)N(R^{13})-$, $-C_{0-4}alkylene-$, $-C(=O)C_{0-1}alkyl-C(=O)OR^3-$, $-C(=NR^{14})-C_{0-1}alkyl-C(=O)-$, $-C(=O)-$, $-C(=O)C_{0-1}alkyl-C(=O)-$ and an optionally substituted four to six-membered heterocyclyl containing between one and three annular heteroatoms including at least one nitrogen, wherein the alkyl and alkylene are optionally substituted; and

T is selected from the group consisting of $-H$, $-R^{13}$, $-C_{0-4}alkyl$, $-C_{0-4}alkyl-Q$, $-O-C_{0-4}alkyl-Q$, $-C_{0-4}alkyl-O-Q$, $-N(R^{13})C_{0-4}alkyl-Q$, $-SO_2C_{0-4}alkyl-Q$, $-C(=O)C_{0-4}alkyl-Q$, $-C_{0-4}alkyl-N(R^{13})Q$ and $-C(=O)N(R^{13})-C_{0-4}alkyl-Q$, wherein each $C_{0-4}alkyl$ is optionally substituted;

wherein

R^{38} is selected from the group consisting of

$C_2-C_6alkynyl-heterocyclyl$,

$H(O)C-$ and $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-$,

$R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,

$R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$,

$C_1-C_6alkyl-S(O)_2-(CH_2)_2-N(A)-CH_2-$,

$R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$,

$R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$,

$R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$,

$R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$,

$HOOC-C_1-C_6alkyl-N(A)-CH_2-$,

$(HOOC)(NR^9R^{10})-C_1-C_6alkyl-N(A)-CH_2-$,

$R^{37}O-C(O)-C_1-C_6alkyl-C(O)-$,

$(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$,

$cycloalkyl-N(R^{39})-C(O)-O-C_1-C_6alkyl-$,

$R^{37}-O-C_1-C_6alkyl-O-C_1-C_6alkyl-C(O)-$,

$(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$,

$(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-heterocyclyl-CH_2-$,

$NC-C_1-C_6alkyl-heterocyclyl-CH_2-$,

$\text{F}_3\text{C}-\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{CH}_2-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-(5 \text{ to } 10\text{-membered heterocyclyl})-\text{C}_1-\text{C}_6\text{alkyl}-$,
(optionally substituted 8- to 10-membered fused heterocyclyl)- $\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{F}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
heteroaryl- $\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{R}^{37}-\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{R}^{37}\text{O}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{R}^{37}\text{O}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
heterocyclyl- $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{aryl}-\text{N}(\text{R}^6)-\text{C}_1-\text{C}_6\text{alkyl}-$,
(heteroaryl substituted with one or more $\text{C}_1-\text{C}_6\text{alkyl}$)- $\text{N}(\text{R}^6)-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{C}_1-\text{C}_6\text{alkyl})_2\text{N}-\text{C}_1-\text{C}_6\text{alkyl}-\text{aryl}-\text{N}(\text{R}^6)-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{C}_1-\text{C}_6\text{alkyl})_2\text{N}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{aryl}-\text{N}(\text{R}^6)-\text{C}_1-\text{C}_6\text{alkyl}-$,
heterocyclyl- $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{aryl}-\text{N}(\text{R}^6)-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{R}^6)_2\text{N}-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{R}^{37}\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
heteroaryl- $\text{C}_1-\text{C}_6\text{alkyl}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{S}(\text{O})_2-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{R}^{37}\text{O}-\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{N}(\text{R}^6)-\text{heterocyclyl}-\text{C}_1-\text{C}_6\text{alkyl}-$,
(heterocyclyl optionally substituted with one or more $\text{C}_1-\text{C}_6\text{alkyl}$)- $\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{C}_1-\text{C}_6\text{alkyl})_2\text{N}-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{heterocyclyl}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
heterocyclyl- $\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-\text{heteroaryl}-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{C}_1-\text{C}_6\text{alkyl})_2\text{N}-\text{heterocyclyl}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
heteroaryl- $\text{C}_1-\text{C}_6\text{alkyl}-\text{N}(\text{R}^6)-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $(\text{Boc})(\text{H})\text{N}-\text{heterocyclyl}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{C}_1-\text{C}_6\text{alkyl}-\text{O}-\text{C}(\text{O})-\text{heterocyclyl}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,
 $\text{Boc}-\text{heterocyclyl}-\text{C}(\text{O})-\text{C}_1-\text{C}_6\text{alkyl}-$,

Ac-O-C₁-C₆alkyl-C(O)-heterocyclyl-C(O)-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-C(O)-C₁-C₆alkyl-,
 (Boc)(H)N-C₁-C₆alkyl-C(O)-heterocyclyl-C(O)-C₁-C₆alkyl-,
 NH₂-C₁-C₆alkyl-C(O)-heterocyclyl-C(O)-C₁-C₆alkyl-,
 (C₁-C₆alkyl)(H)N-C(O)-heterocyclyl-C(O)-C₁-C₆alkyl-,
 NH₂-heterocyclyl-C(O)-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-O-C₁-C₆alkyl-heterocyclyl-C(O)-,
 C₁-C₆alkyl-O-C(O)-N(R⁶)-heterocyclyl-C(O)-,
 (R⁶)(R⁶)N-heterocyclyl-C(O)-,
 (R⁶)(R⁶)N-heterocyclyl-C₁-C₆alkyl-,
 heterocyclyl-O-C₁-C₆alkyl-,
 C₁-C₆alkyl-N(R⁶)-C(O)-N(R⁶)-heterocyclyl-C(O)-,
 (R⁶)(R⁶)N-C(O)-heterocyclyl-O-C₁-C₆alkyl-,
 C₂-C₆alkenyl-C(O)-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-O-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-C₁-C₆alkyl-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 halo-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-,
 halo-C₁-C₆alkyl-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 R³⁷O-C(O)-C₁-C₆alkyl-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 R³⁷-O-C(O)-C₁-C₆alkyl-N(R⁶)-C(O)-N(R⁶)-heterocyclyl-C₁-C₆alkyl-,
 (C₁-C₆alkyl)(H)N-C(O)-heterocyclyl-N[C₁-C₆alkyl-C(O)-OH]-C₁-C₆alkyl-,
 C₁-C₆alkyl-O-C(O)-heterocyclyl-C₁-C₆alkyl-,
 HO-C(O)-heterocyclyl-C₁-C₆alkyl-,
 C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-,
 (R⁶)(R⁶)N-C₁-C₆alkyl-N(R⁶)-CO-heterocyclyl-C₁-C₆alkyl-,
 (C₁-C₆alkyl)(C₁-C₆alkyl)N-heterocyclyl-C₁-C₆alkyl-,
 R³⁷O-C₁-C₆alkyl-C(O)-[(C₁-C₆alkyl)(C₁-C₆alkyl)heterocyclyl]-C₁-C₆alkyl-,
 C₂-C₆alkenyl-C(O)-[(C₁-C₆alkyl)(C₁-C₆alkyl)heterocyclyl]-C₁-C₆alkyl-,
 R³⁷-O-C₁-C₆alkyl-[(C₁-C₆alkyl)(C₁-C₆alkyl)heterocyclyl]-C₁-C₆alkyl-,
 C₁-C₆alkyl-O-C₁-C₆alkyl-NR⁶-C₁-C₆alkyl-,
 C₁-C₆alkyl-O-C₁-C₆alkyl-N[C(O)-NH-C₁-C₆alkyl]-C₁-C₆alkyl-,
 C₁-C₆alkyl-O-C₁-C₆alkyl-N[C(O)-C₁-C₆alkyl]-C₁-C₆alkyl-,

$C_1-C_6alkyl-O-C_1-C_6alkyl-[C(O)-C_1-C_6alkyl-OH]-C_1-C_6alkyl-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-$,
 spiro-heterocyclyl- $C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-spiro-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-$,
 $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $heterocyclyl-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $heterocyclyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_2-C_6alkenyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $heterocyclyl-C_2-C_8alkenyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C_1-C_6alkyl-N(R^6)-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $heterocyclyl-C(O)-$,
 $(R^6)(R^6)N-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $C_2-C_6alkenyl-C(O)-O-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $(R^6)(R^6)N-C(O)-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-C_1-C_6alkyl-heterocyclyl-C_1-C_6alkyl-(heterocyclyl)-$,
 $R^{37}O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-heterocyclyl-C(O)-$,
 $R^{37}O-C_1-C_6alkyl-C(O)-heterocyclyl-C(O)-$,
 $C_1-C_6alkyl-O-C(O)-N(R^6)-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-(CH_2)_n[(CH_2)_iO]_x-C_1-C_6alkyl-N(R^6)-C(O)-heterocyclyl-C_1-C_6alkyl-$,
 $HO-heterocyclyl-C_1-C_6alkyl-$,
 $R^{37}O-cycloalkyl-C(O)-heterocyclyl-C_1-C_6alkyl-$

and

$R^{37}O-(CH_2)_n[(CH_2)_iO]_x-C_1-C_6alkyl-C(O)-N(R^6)-heterocyclyl-C_1-C_6alkyl-$;

A is selected from the group consisting of $-C(O)-C_1-C_6alkyl-N(R^{39})-C(O)-C_1-C_6alkyl-$,
 $N(R^9)(R^{10})$, $-C(O)-N(R^{39})-C_1-C_6alkyl$, $-C(=NR^{37})-C_1-C_6alkyl$, $-C(O)-(CH_2)_n-S(O)_2-C_1-$
 C_6alkyl , $-C(O)-N(R^{39})-cycloalkyl$, $-C(O)-N(R^9)(R^{10})$, $(R^{37}O)(R^{37a}O)P(O)O-C_1-C_6alkyl-$
 $C(O)-$, $-C(=NR^{37})-H$ and $-C_1-C_6alkyl-CF_3$;

each R^6 is independently H or C_1 - C_6 alkyl;

R^{37} is selected from the group consisting of H, C_1 - C_6 alkyl and C_3 - C_{10} cycloalkyl;

R^{37a} is selected from the group consisting of H, C_1 - C_6 alkyl and C_3 - C_{10} cycloalkyl;

j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

x is an integer ranging from 0 to 6, alternatively 2 or 3;

il is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2;

n is an integer ranging from 0 to 4;

R^{39} is selected from the group consisting of H, -OH, C_1 - C_6 alkyl, C_3 - C_{10} cycloalkyl, -
 $(CH_2)_{n2}(C_6$ - C_{10} aryl), $-(CH_2)_{n2}(C_5$ - C_{10} heteroaryl), $-(CH_2)_{n2}(5$ -10 membered heterocyclyl), -
 $(CH_2)_{n2}O(CH_2)_{i2}OR^{37}$ and $-(CH_2)_{n2}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
heterocyclyl moieties of the foregoing R^{39} groups are optionally substituted;

R^9 is selected from the group consisting of H, -OH, C_1 - C_6 alkyl, C_3 - C_{10} cycloalkyl, -
 $(CH_2)_{n3}(C_6$ - C_{10} aryl), $-(CH_2)_{n3}(C_5$ - C_{10} heteroaryl), $-(CH_2)_{n3}(5$ -10 membered heterocyclyl), -
 $(CH_2)_{n3}O(CH_2)_{i3}OR^{37}$ and $-(CH_2)_{n3}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
heterocyclyl moieties of the foregoing R^9 groups are optionally substituted;

R^{10} is selected from the group consisting of H, -OH, C_1 - C_6 alkyl, C_3 - C_{10} cycloalkyl, -
 $(CH_2)_{n4}(C_6$ - C_{10} aryl), $-(CH_2)_{n4}(C_5$ - C_{10} heteroaryl), $-(CH_2)_{n4}(5$ -10 membered heterocyclyl), -
 $(CH_2)_{n4}O(CH_2)_{i4}OR^{37}$ and $-(CH_2)_{n4}OR^{37}$, wherein the alkyl, aryl, heteroaryl and
heterocyclyl moieties of the foregoing R^{10} groups are optionally substituted;

n2 is an integer ranging from 0 to 6;

i2 is an integer ranging from 2 to 6;

n3 is an integer ranging from 0 to 6;

i3 is an integer ranging from 2 to 6;

n4 is an integer ranging from 0 to 6;

i4 is an integer ranging from 2 to 6;

R^2 at each occurrence is independently selected from the group consisting of -H, halogen,
trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -S(O)₂NR³R³, -C(O)OR³, -
C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, C_1 - C_4 alkoxy, C_1 - C_4
alkylthio, -O(CH₂)_naryl, -O(CH₂)_nheteroaryl, -(CH₂)₀₋₅(aryl), -(CH₂)₀₋₅(heteroaryl), C_1 - C_6
alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, -CH₂(CH₂)₀₋₄-T², wherein T² is selected from the
group consisting of -OH, -OMe, -OEt, -NH₂, -NHMe, -NMe₂, -NH₂Et and -NEt₂, and

wherein the aryl, heteroaryl, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl are optionally substituted; and

q is an integer from 0 to 4;

R¹³ is selected from the group consisting of -H, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -S(O)₂NR³R³, -C(O)OR³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, -C(O)SR³, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -O(CH₂)_{n5}aryl, -O(CH₂)_{n5}heteroaryl, -(CH₂)_{n5}(aryl), -(CH₂)_{n5}(heteroaryl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂(CH₂)₀₋₄-T², an optionally substituted C₁₋₄ alkylcarbonyl, and a saturated or unsaturated three- to seven-membered carboxylic or heterocyclic group, wherein T² is selected from the group consisting of -OH, -OMe, -OEt, -NH₂, -NHMe, -NMe₂, -NHET and -NEt₂, and wherein the aryl, heteroaryl, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl are optionally substituted;

two R¹³, together with the atom or atoms to which they are attached, can combine to form a heteroalicyclic optionally substituted with between one and four of R⁶⁰, wherein the heteroalicyclic can have up to four annular heteroatoms, and the heteroalicyclic can have an aryl or heteroaryl fused thereto, in which case the aryl or heteroaryl is optionally substituted with an additional one to four of R⁶⁰;

n₅ is an integer ranging from 0 to 6

R⁶⁰ is selected from the group consisting of -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -NR³R⁴, -S(O)₀₋₂R³, -SO₂NR³R³, -CO₂R³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, an optionally substituted (C₁-C₆)alkyl, an optionally substituted aryl, an optionally substituted heteroarylalkyl and an optionally substituted arylalkyl;

two R⁶⁰, when attached to a non-aromatic carbon, can be oxo;

each R³ is independently selected from the group consisting of -H and R⁴;

R⁴ is selected from the group consisting of a (C₁-C₆)alkyl, an aryl, a lower arylalkyl, a heterocyclyl and a lower heterocyclyl-alkyl, each of which is optionally substituted, or R³ and R⁴, taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, the optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional annular heteroatom selected from the group consisting of N, O, S and P;


R¹⁴ is selected from the group -H, -NO₂, -NH₂, -N(R³)R⁴, -CN, -OR³, an optionally substituted (C₁-C₆)alkyl, an optionally substituted heteroalicycyl-alkyl, an optionally substituted aryl, an optionally substituted arylalkyl and an optionally substituted heteroalicyclic,

Q is a three- to ten-membered ring system, optionally substituted with zero, one or more of R²⁰;

R^{20} is selected from the group consisting of -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂, -OR³, -OCF₃, -NR³R⁴, -S(O)₀₋₂R³, -S(O)₂NR³R³, -C(O)OR³, -C(O)NR³R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)C(O)OR³, -C(O)R³, -C(O)SR³, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -O(CH₂)_{n6}aryl, -O(CH₂)_{n6}heteroaryl, -(CH₂)_{n6}(aryl), -(CH₂)_{n6}(heteroaryl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂(CH₂)₀₋₄-T², an optionally substituted C₁₋₄ alkylcarbonyl, C₁₋₄ alkoxy, an amino optionally substituted by C₁₋₄ alkyl optionally substituted by C₁₋₄ alkoxy, -(CH₂)_{n6}P(=O)(C₁-C₆alkyl)₂, a saturated or unsaturated three- to seven-membered carboxylic or heterocyclic group, -SiMe₃ and -SbF₅; and

n₆ is an integer ranging from 0 to 6.

2. A compound having the Formula (Ia),



wherein D, M, Z, Ar and G are as defined in Formula (I), except that

R^{38} is selected from the group consisting of (R²³)(R²⁴)(O)P-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, (optionally substituted 7- or 8-membered heterocyclyl)-C₁-C₆alkyl-, (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl-, (optionally substituted spiro-heterocyclyl)-C₁-C₆alkyl-, (optionally substituted bridged bicyclic ring system)-C₁-C₆alkyl-, (substituted piperazine)-C₁-C₆alkyl-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, C₁-C₆alkyl-S(O)₀₋₂-C₁-C₆alkyl-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, R³⁷S(O)₀₋₂-aryl-C(O)-O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-, R³⁷O-C(O)-C₁-C₆alkyl-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (R⁹)(R¹⁰)N-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-, R^{37a}O-C(O)-C₁-C₆alkyl-N(R³⁷)-C(O)-C₁-C₆alkyl-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, R¹¹-C₁-C₆alkyl-C(O)-piperazine-C₁-C₆alkyl-, C₀-C₆alkyl-(5 or 6-membered heterocyclyl)-C₁-C₆alkyl-piperazine-C₁-C₆alkyl-, (5-10-membered optionally substituted heterocyclyl)-C₁-C₆alkyl-O-(oxo substituted 5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (5-10-membered optionally substituted heterocyclyl)-C₁-C₆alkyl-N(R¹)-(oxo substituted 5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (5-10-membered optionally substituted heterocyclyl)-C₁-C₆alkyl-S(O)₀₋₂-(oxo substituted 5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (R²³)(R²⁴)P(O)-C₁-C₆alkyl-C(O)-, (R²³)(R²⁴)(O)P-C₁-C₆alkyl-N(R³⁷)-C₁-C₆alkyl-, (R⁹)(R¹⁰)N-C(H)(R²⁸)-, R²⁹O-C(O)-C(H)(C(O)-

OR^{29a})-O-C₁-C₆alkyl-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, R²⁹O-C(O)-C(H)(C(O)-OR^{29a})-O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl- and (substituted piperidine)-C₁-C₆alkyl-;

wherein

R¹ is H or C₁-C₆alkyl;

R¹¹ is -OH, -O-C₁-C₆alkyl, optionally substituted 5 to 10-membered heterocyclyl, or -O-(amino acid);

R²³ is selected from the group consisting of H, -OH, C₁-C₆alkyl, C₁-C₆alkoxy, aryl, -O-aryl, cycloalkyl, -O-cycloalkyl, heteroaryl, -O-heteroaryl, 5 to 10-membered heterocyclyl, -O-(5 to 10-membered heterocyclyl), -C₁-C₆alkyl-aryl, -O-C₁-C₆alkyl-aryl, -C₁-C₆alkyl-heteroaryl, -O-C₁-C₆alkyl-heteroaryl, -C₁-C₆alkyl-cycloalkyl, -O-C₁-C₆alkyl-cycloalkyl, -C₁-C₆alkyl-(5 to 10-membered heterocyclyl) and -O-C₁-C₆alkyl-(5 to 10-membered heterocyclyl);


R²⁴ is selected from the group consisting of H, -OH, C₁-C₆alkyl, C₁-C₆alkoxy, aryl, -O-aryl, cycloalkyl, -O-cycloalkyl, heteroaryl, -O-heteroaryl, 5 to 10-membered heterocyclyl, -O-(5 to 10-membered heterocyclyl), -C₁-C₆alkyl-aryl, -O-C₁-C₆alkyl-aryl, -C₁-C₆alkyl-heteroaryl, -O-C₁-C₆alkyl-heteroaryl, -C₁-C₆alkyl-cycloalkyl, -O-C₁-C₆alkyl-cycloalkyl, -C₁-C₆alkyl-(5 to 10-membered heterocyclyl) and -O-C₁-C₆alkyl-(5 to 10-membered heterocyclyl);

R²⁸ is selected from the group consisting of H, -CF₃, -CHF₂, -CH₂F, CN, optionally substituted C₁-C₆alkyl and C₃-C₆cycloalkyl;


R²⁹ is selected from the group consisting of H, C₁-C₆alkyl and a cation; and

R^{29a} is selected from the group consisting of H, C₁-C₆alkyl and a cation.

3. A compound having the formulas Formula (II) or Formula (III):



(II)



(III)

including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of pyridine, phenyl, imidazole, pyrazole, and tetrahydropyridine, wherein the pyridine, phenyl, imidazole, pyrazole and tetrahydropyridine are substituted with one R^{38} , or D is unsubstituted tetrahydropyridine; R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, (oxo substituted heterocyclyl)- C_1-C_2 alkyl- (wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of $-N(R^9)(R^{10})$, C_1-C_6 alkyl, $-N(R^{37})(Ac)$, and $-OH$), $R^{37}O-(CH_2)_n-O-(CH_2)_nC(O)-N(R^{40})-CH_2-$, C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$, (heterocyclyl)- $C(O)-$ (wherein the heterocyclyl is optionally substituted with C_1-C_6 alkyl), C_1-C_6 alkyl- $S(O)_2-(CH_2)_2-N(A)-CH_2-$, C_0-C_6 alkyl-heterocyclyl- $(CH_2)_{1-3}-$, $HO-$ heterocyclyl- CH_2- , $(R^9)(R^{10})N-$ heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_0-C_6$ alkyl-heterocyclyl- $C(O)-$, $(C_1-C_6$ alkyl)- $C(O)-$ heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- $(CH_2)_{1-6}-$, C_0-C_6 alkyl-heterocyclyl- C_1-C_6 alkyl- $N(R^{39})-C(O)-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}-O-C(O)-C_1-C_6$ alkyl-heterocyclyl- $C(O)-$, $HOOC-C_1-C_6$ alkyl- $N(A)-CH_2-$, $(HOOC)(NR^9R^{10})-C_1-C_6$ alkyl- $N(A)-CH_2-$, $R^{37}-O-C(O)-$ heterocyclyl- $C(O)-$, C_0-C_6 alkyl-heterocyclyl- C_0-C_6 alkyl-heterocyclyl- $C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl- $C(O)-$, $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- CH_2- , cycloalkyl- $N(R^{39})-C(O)-O-C_1-C_6$ alkyl-, $R^{37}-O-C_1-C_6$ alkyl- $O-C_1-C_6$ alkyl- $C(O)-$, C_1-C_6 alkyl- SO_2- , $(R^9)(R^{10})N-C(O)-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , (HO- substituted C_1-C_6 alkyl- $N(R^{39})-C(O)-$, $NC-C_1-C_6$ alkyl-heterocyclyl- CH_2- , heterocyclyl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $F_3C-C_1-C_6$ alkyl-heterocyclyl- CH_2- , C_1-C_6 alkyl- $S(O)_2-$ heterocyclyl- CH_2- , heteroaryl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-, $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- CH_2- , C_1-C_6 alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)-(5\text{ to }10\text{-membered heterocyclyl})-C_1-C_6$ alkyl-, (optionally substituted 8- to 10-membered fused heterocyclyl)- C_1-C_6 alkyl-, (di-fluoro substituted heterocyclyl)- C_1-C_6 alkyl-, C_0-C_6 alkyl-(5 or 6-membered heterocyclyl)- C_1-C_6 alkyl-piperazine- C_1-C_6 alkyl-, $H(O)C-$ and C_1-C_6 alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)-$, $R^{37}O-C_1-C_6$ alkyl- $C(O)-$ heterocyclyl- C_1-C_6 alkyl-;

wherein when D is imidazole, the imidazole is further optionally substituted with C_1-C_6 alkyl;

R^{37} is H, C_1-C_6 alkyl;

R^{37a} is H, C_1-C_6 alkyl;

A is H, Ac, -C(O)-CH₂-OMe, -C(O)-CH(NH₂)-C(CH₃)₃, -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(O)-N(R³⁹)-C₁-C₆alkyl, -C(O)-H, -C(O)-C₁-C₆alkyl, -C₁-C₆alkyl-O-C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, -C(=NR³⁷)-C₁-C₆alkyl, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R³⁹)-cycloalkyl, -C(O)-N(R⁹)(R¹⁰), (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)-, C₁-C₆alkyl and -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)-C(O)-OBn;

j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

x is an integer ranging from 0 to 6, alternatively 2 or 3;

il is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2;

n is an integer ranging from 0 to 4;

n1 is an integer ranging from 0 to 4;

R³⁹ is H, C₁-C₆alkyl,

R⁴⁰ is C₁-C₆alkyl-OR⁴¹;

R⁴¹ is H, C₁-C₆alkyl;

R⁹ is H, C₁-C₆alkyl;

R¹⁰ is H, C₁-C₆alkyl;


R²³ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl and -O-(5 to 10-membered heterocyclyl);

R²⁴ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl);

R² is H or F;

R^{2a} is H, F, Cl;


G is selected from the group consisting of



R^{13} is H or C_1 - C_6 alkyl; and

each R^{20} is independently selected from the group consisting of H, halo, $-PO(C_1-C_6alkyl)_2$, $-S(O)_2-C_1-C_6alkyl$ and $-C(O)-NH_2$.

4. The compound according to claim 3, having the Formula (IV):




including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of pyridine, phenyl, imidazole and heterocycle- $C\equiv C$ -,


wherein said pyridine, phenyl and imidazole are each substituted with one R^{38} ;

R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-CH_2$ - (for example, $R^{37}O-$

$(CH_2)_2-N(A)-CH_2$ -), (oxo substituted heterocyclyl)- C_1-C_6alkyl - (for example



and (heterocyclyl)- $C(O)$ - (for example,



wherein when D is imidazole, the imidazole is further optionally substituted with C_1-C_6alkyl

(for example, $-CH_3$);

R^{37} is H or C_1-C_6alkyl ;


A is H or Ac;

R^2 is F;

R^{2a} is H; and

each R^{20} is independently selected from the group consisting of H, $-PO(C_1-C_6alkyl)_2$ (for example, $-PO(Me)_2$), $-S(O)_2-C_1-C_6alkyl$ (for example, $-S(O)_2Me$) and $-C(O)-NH_2$.

5. The compound according to claim 3, having the Formula (VI):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is selected from the group consisting of pyridine, phenyl, imidazole, pyrazole and tetrahydropyridine, each substituted with one R^{38} , or D is unsubstituted tetrahydropyridine; R^{38} is selected from the group consisting of $R^{37}O-(CH_2)_2-N(A)-(CH_2)_{1-2}-$, $R^{37}O-(CH_2)_n-O-(CH_2)_n-C(O)-N(R^{40})-CH_2-$, C_1-C_6 alkyl-heterocyclyl- $(CH_2)_{1-2}-$, (oxo substituted heterocyclyl)- C_1-C_6 alkyl- (wherein the oxo substituted heterocyclyl is further optionally substituted with a substituent selected from the group consisting of $-N(R^9)(R^{10})$, C_1-C_6 alkyl, $-N(R^{37})(Ac)$, $-OH$ and $(heterocyclyl)-C(O)-$, wherein the heterocyclyl is optionally substituted with C_1-C_6 alkyl), C_1-C_6 alkyl- $S(O)_2-(CH_2)_2-N(A)-CH_2-$, C_0-C_6 alkyl-heterocyclyl- $(CH_2)_{1-3}-$, $HO-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-heterocyclyl-CH_2-$, $(C_1-C_6$ alkyl)- $C(O)-heterocyclyl-CH_2-$, $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl- $C(O)-heterocyclyl-(CH)_{1-6}-$, C_0-C_6 alkyl-heterocyclyl- C_1-C_6 alkyl- $N(R^{39})-C(O)-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-heterocyclyl-C(O)-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl-heterocyclyl- $C(O)-$, $HOOC-C_1-C_6$ alkyl- $N(A)-CH_2-$, $(HOOC)(NR^9R^{10})-C_1-C_6$ alkyl- $N(A)-CH_2-$, $R^{37}-O-C(O)-heterocyclyl-C(O)-$, $(R^9)(R^{10})N-C_0-C_6$ alkyl-heterocyclyl- $C(O)-$, C_0-C_6 alkyl-heterocyclyl- C_0-C_6 alkyl-heterocyclyl- $C(O)-$, $R^{37}O-C(O)-C_1-C_6$ alkyl- $C(O)-$, $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-heterocyclyl-CH_2-$, cycloalkyl- $N(R^{39})-C(O)-O-C_1-C_6$ alkyl-, $R^{37}-O-C_1-C_6$ alkyl- $O-C_1-C_6$ alkyl- $C(O)-$, C_1-C_6 alkyl- SO_2- , $(R^9)(R^{10})N-C(O)-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-heterocyclyl- CH_2- , $(HO-$ substituted C_1-C_6 alkyl)- $N(R^{39})-C(O)-$, $NC-C_1-C_6$ alkyl-heterocyclyl- CH_2- , heterocyclyl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $F_3C-C_1-C_6$ alkyl-heterocyclyl- CH_2- , C_1-C_6 alkyl- $S(O)_2-heterocyclyl-CH_2-$, heteroaryl- C_1-C_6 alkyl-heterocyclyl- CH_2- , $R^{37}O-C_1-C_6$ alkyl-, $N(R^9)(R^{10})N-C_1-C_6$ alkyl- $C(O)-O-C_1-C_6$ alkyl- $C(O)-$

heterocyclyl-CH₂-, C₁-C₆alkyl-C(O)-O-C₁-C₆alkyl-C(O)-(5 to 10-membered heterocyclyl)-C₁-C₆alkyl-, (optionally substituted 8- to 10-membered fused heterocyclyl)-C₁-C₆alkyl- and (di-fluoro substituted heterocyclyl)-C₁-C₆alkyl-;

wherein when D is imidazole, the imidazole is further optionally substituted with C₁-C₆alkyl;

R³⁷ is H, C₁-C₆alkyl;

R^{37a} is H, C₁-C₆alkyl;

A is H, Ac, -C(O)-CH₂-OMe, -C(O)-CH(NH₂)-C(CH₃)₃, -C(O)-(CH₂)_n-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰)-C(O)-N(R³⁹)-C₁-C₆alkyl, -C(O)-H, -C(O)-C₁-C₆alkyl, -C₁-C₆alkyl-O-C₁-C₆alkyl, -C(O)-C₁-C₆alkyl-OH, -C(O)-C₁-C₆alkyl-N(R³⁹)-C(O)-C₁-C₆alkyl-N(R⁹)(R¹⁰), -C(=NH)-H, -C(O)-(CH₂)_n-S(O)₂-C₁-C₆alkyl, -C(O)-N(R³⁹)-cycloalkyl, -C(O)-N(R⁹)(R¹⁰), (R²³)(R²⁴)P(O)O-C₁-C₆alkyl-C(O)- and C₁-C₆alkyl,

j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

x is an integer ranging from 0 to 6, alternatively 2 or 3;

il is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2;

n is an integer ranging from 0 to 4;

n1 is an integer ranging from 0 to 4;

R³⁹ is H or C₁-C₆alkyl;

R⁴⁰ is -C₁-C₆alkyl-OR⁴¹;

R⁴¹ is H or C₁-C₆alkyl;

R⁹ is H or C₁-C₆alkyl;

R¹⁰ is H or C₁-C₆alkyl;


R²³ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl and -O-(5 to 10-membered heterocyclyl);

R²⁴ is selected from the group consisting of -OH, C₁-C₆alkoxy, -O-aryl, -O-cycloalkyl, -O-heteroaryl, -O-(5 to 10-membered heterocyclyl);

R² is H or F; and

R^{2a} is H, F or Cl.

6. The compound according to claim 3, having the Formula (VII)



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine or imidazole, wherein the pyridine and imidazole are substituted with one R^{38} ;

R^{38} is selected from the group consisting of (oxo substituted heterocyclyl)- C_1 - C_6 alkyl-,

(heterocyclyl)- $C(O)$ -, C_1 - C_6 alkyl, $R^{37}O-(CH_2)_2-N(A)-CH_2$ -, heterocyclyl- C_1 - C_6 alkyl- $N(R^{39})$ - $C(O)$ -, heterocyclyl- CH_2 -;

wherein when D is imidazole, the imidazole is further optionally substituted with C_1 - C_6 alkyl (for example, $-CH_3$);

R^{37} is H or C_1 - C_6 alkyl;


A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl or $-C(O)-C_1$ - C_6 alkyl;

R^{39} is H or C_1 - C_6 alkyl;

R^2 is F; and

R^{2a} is H.

7. The compound according to claim 3, having Formula (VIII)



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;

R^{38} is $R^{37}O-(CH_2)_2-N(A)-CH_2$ -, for example, $MeO-(CH_2)_2-N(A)-CH_2$;

A is H or $-C(O)-C_1$ - C_6 alkyl, for example $-C(O)-CH_3$;

R^{13} is H or C_1 - C_6 alkyl;


R^{37} is C_1 - C_6 alkyl;

R^2 is F;

R^{2a} is H; and

R^{20} is H or F.

8. The compound according to claim 3, having the Formula (IX):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;


R^{38} is $R^{37}O-(CH_2)_2-N(A)-CH_2-$, for example, $MeO-(CH_2)_2-N(A)-CH_2-$;

A is H or $-C(O)-C_1-C_6$ alkyl;

R^{37} is H or C_1-C_6 alkyl; and

R^2 is F.

9. The compound according to claim 3, having the Formula (X):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine, substituted with R^{38} ;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(A)-(CH_2)_{j1}-$, $R^{37}O-C(O)-C_0-C_6alkyl-heterocyclyl-CH_2-$, $R^{37}O-(CH_2)_j-[(CH_2)_iO]_x-(CH_2)_{i1}-N(R^{39})-C(O)-$, $R^{37}-O-C(O)-C_1-C_6alkyl-heterocyclyl-C(O)-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-C(O)-C_1-C_6alkyl-heterocyclyl-CH_2-$, $(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-heterocyclyl-CH_2-$, $F_3C-C_1-C_6alkyl-heterocyclyl-CH_2-$, $N(R^9)(R^{10})N-C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-heterocyclyl-CH_2-$ and $C_1-C_6alkyl-C(O)-O-C_1-C_6alkyl-C(O)-(5 \text{ to } 10\text{-membered heterocyclyl})-C_1-C_6alkyl-$;

R^{37} is H or C_1-C_6alkyl ;

A is selected from the group consisting of $-C(O)-C_1-C_6alkyl-N(R^{39})-C(O)-C_1-C_6alkyl-N(R^9)(R^{10})$, $-C(O)-N(R^{39})-C_1-C_6alkyl$, $-C(=NR^{37})-C_1-C_6alkyl$, $-C(O)-(CH_2)_n-S(O)_2-C_1-C_6alkyl$, $-C(O)-N(R^9)(R^{10})$ and $(R^{23})(R^{24})P(O)O-C_1-C_6alkyl-C(O)-$;

n is an integer ranging from 0 to 4;

R^{39} is H or C_1-C_6alkyl ;

R^9 is H or C_1-C_6alkyl ;

R^{10} is H or C_1-C_6alkyl ;

R^2 is F;

R^{2a} is H or F;

R^{23} is selected from the group consisting of $-OH$, $C_1-C_6alkoxy$, $-O-aryl$, $-O-cycloalkyl$, $-O-heteroaryl$ and $-O-(5 \text{ to } 10\text{-membered heterocyclyl})$;

R^{24} is selected from the group consisting of $-OH$, $C_1-C_6alkoxy$, $-O-aryl$, $-O-cycloalkyl$, $-O-heteroaryl$, $-O-(5 \text{ to } 10\text{-membered heterocyclyl})$;


j is an integer ranging from 0 to 4, alternatively 0 to 2;

i is 2 or 3;

x is an integer ranging from 0 to 6, alternatively 2 or 3;


i1 is 2 or 3;

j1 is an integer ranging from 0 to 4, alternatively 1 or 2; and



10. The compound according to claim 9, wherein R^{38} further includes $C_0-C_6alkyl-heterocyclyl-C_0-C_6alkyl-heterocyclyl-C(O)-$, alternatively $-C(O)-piperidine-piperazine-CH_3$.

11. The compound according to claim 3, having the Formula (XI):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

wherein

D is imidazole substituted with one R^{38} and further substituted with C_1 - C_6 alkyl;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$;


R^{37} is H or C_1 - C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1$ - C_6 alkyl,


R^{39} is H or C_1 - C_6 alkyl;

R^2 is F;

R^{2a} is H; and



12. The compound according to claim 3, having the Formula (XII):



wherein

including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is phenyl, substituted with R^{38} ;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$;


R^{37} is H or C_1-C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl, $-C(O)-N(R^{39})-$ cycloalkyl


R^{39} is H or C_1-C_6 alkyl;

R^2 is F;

R^{2a} is H; and



13. The compound according to claim 3, having Formula (XIII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is imidazole substituted with one R^{38} and further substituted with C_1-C_6 alkyl;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$;


R^{37} is H or C_1-C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl,


R^{39} is H or C^1-C^6 alkyl;

R^2 is F;

R^{2a} is H; and



14. The compound according to claim 3, having the Formula (XIV):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,


D is tetrahydropyridine substituted with R^{38} ;

R^{38} is $R^{37}O-C(O)-C_1-C_6\text{alkyl}-C(O)-$, $R^{37}-O-C_1-C_6\text{alkyl}-O-C_1-C_6\text{alkyl}-C(O)-$;


R^{37} is H or $C_1-C_6\text{alkyl}$;

R^2 is F;

R^{2a} is H; and



15. The compound according to claim 3, having the Formula (XV):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyrazole, substituted with R³⁸;


R³⁸ is cycloalkyl-N(R³⁹)-C(O)-O-C₁-C₆alkyl-, R³⁷O-(CH₂)₁₋₆-N(A)-(CH₂)₁₋₄-;

A is -C(O)-N(R³⁹)-C₁-C₆alkyl,


R³⁹ is H or C₁-C₆alkyl;

R² is F;

R^{2a} is H; and



16. The compound according to claim 3, having the Formula (XVI):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R³⁸;

R³⁸ is R³⁷O-(CH₂)₂-N(A)-CH₂;


A is selected from the group consisting of H, -C(O)-C₁-C₆alkyl, -C(O)-N(R³⁹)-C₁-C₆alkyl, and -C(O)-C₁-C₆alkyl-OH;

R³⁷ is H, C₁-C₆alkyl;

R³⁹ is H, C₁-C₆alkyl; and

R² is H.

17. The compound according to claim 3, having the Formula (XVII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine, substituted with R^{38} ;


R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$,

R^{37} is H or C_1-C_6 alkyl;


A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl,

R^{39} is H or C_1-C_6 alkyl;

R^2 is H; and



18. The compound according to claim 3, having the Formula (XVIII):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine or imidazole, each substituted with R^{38} , and wherein the imidazole is further substituted with $-C_1-C_6$ alkyl, for example $-CH_3$;

R^{38} is $R^{37}O-(CH_2)_{1-6}-N(A)-(CH_2)_{1-4}-$ or $R^{37}O-C_1-C_6$ alkyl- $C(O)$ -heterocyclyl- CH_2- ;


R^{37} is H or C_1-C_6 alkyl;

A is $-C(O)-N(R^{39})-C_1-C_6$ alkyl, $-C(O)-H$,


R^{39} is H or C_1-C_6 alkyl;

R^2 is H or F;

R^{2a} is H or F; and



19. A compound having the Formula (XIX):



including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein,

D is pyridine substituted with one R^{38} ;


R^{38} is $R^{37}O-(CH_2)_2-N(A)-(CH_2)_2-$;

R^{37} is C_1-C_6 alkyl;


A is H or C_1-C_6 alkyl,

R^2 is F;

R^{2a} is H; and





20. A compound selected from the group consisting of





including N-oxides, hydrates, solvates, tautomers, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof.

21. The compound according to claim 1 or claim 2, wherein G is



22. The compound according to any of claims 1, 2 and claim 21, wherein  is



23. The compound according to any of claims 1, 2, 21 and 22, wherein Ar is , wherein Ar is optionally substituted.

24. The compound according to any of claims 1, 2 and 21 to 23, wherein D is pyridinyl, imidazolyl or triazolyl, each of which is substituted with one R³⁸.

25. The compound according to any of claims 1, 2 and 21-24, wherein R³⁸ is selected from the group consisting of R³⁷O-C(O)-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, (R⁶)(R⁶)N-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-C(O)-heterocyclyl-C₁-C₆alkyl-, R³⁷O-C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl- and R³⁷O-(CH₂)_j-[(CH₂)_iO]_x-C₁-C₆alkyl-N(R⁶)-C(O)-heterocyclyl-C₁-C₆alkyl-, wherein each of said alkyl and heterocyclyl is optionally substituted.

26. The compound according to any of claims 1, 2 and 21 to 25, wherein D is pyridinyl substituted with one R³⁸.

27. The compound according to any of claims 1, 2 and 21 to 26, wherein when R³⁸ is attached to D by a C₁-C₆ alkyl, the C₁-C₆ alkyl is -CH₂-.

28. The compound according to any of claims 1, 2 and 21-23, wherein D is selected from the group consisting of C₁-C₆alkyl-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C₁-C₆alkyl-N(R⁶)-C(O)-, (R⁶)(R⁶)N-C(O)-O-heterocyclyl-C(O)-, heterocyclyl-C(O)-, PivO-heterocyclyl-C(O)-, C₁-C₆alkyl-O-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-C(O)-N(R⁶)-heterocyclyl-C(O)-, (C₁-C₆alkyl)(Box)N-heterocyclyl-C(O)-, HO-heterocyclyl-C(O)-, HO-C(O)-heterocyclyl-C(O)-,

C₁-C₆alkyl-C(O)-O-heterocyclyl-C(O)-, (R⁶)(R⁶)N-C₁-C₆alkyl -N(R⁶)-C(O)-heterocyclyl-C(O)-, C₁-C₆alkyl-heterocyclyl-C(O)-heterocyclyl-C(O)- and (R⁶)(R⁶)N-heterocyclyl-C(O)-, wherein said each of said alkyl and heterocyclyl is optionally substituted.

29. The compound according to any of claims 1, 2 and 21 to 28, wherein R⁶ is H.

30. A composition comprising a compound according to any of claims 1 to 29.

31. A method of inhibiting kinase activity, the method comprising contacting the kinase with a compound according to any of claims 1 to 29 or a composition thereof.

32. A method of inhibiting angiogenesis, the method comprising administering to a patient in need thereof an effective amount of a compound according to any of claims 1 to 29 or a composition thereof.

33. A method of treating a disease responsive to inhibition of kinase activity, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of claims 1 to 29 or a composition thereof.

34. A method of treating a cell proliferative disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of claims 1 to 29 or a composition thereof.

35. A method of treating an ophthalmic disease, condition or disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any of claims 1 to 29 or a composition thereof.

